The economics of diagnostic test: the cost-effectiveness of screening test for gestational diabetes mellitus in Scotland by Singweratham, Noppcha
Glasgow Theses Service 
http://theses.gla.ac.uk/ 
theses@gla.ac.uk 
 
 
 
 
 
Singweratham, Noppcha (2015) The economics of diagnostic test: the 
cost-effectiveness of screening test for gestational diabetes mellitus in 
Scotland. PhD thesis. 
 
http://theses.gla.ac.uk/5881/ 
 
 
 
Copyright and moral rights for this thesis are retained by the author 
 
A copy can be downloaded for personal non-commercial research or 
study, without prior permission or charge 
 
This thesis cannot be reproduced or quoted extensively from without first 
obtaining permission in writing from the Author 
 
The content must not be changed in any way or sold commercially in any 
format or medium without the formal permission of the Author 
 
When referring to this work, full bibliographic details including the 
author, title, awarding institution and date of the thesis must be given 
 
 The economics of diagnostic test: 
The cost-effectiveness of screening test  
for Gestational Diabetes Mellitus in Scotland 
 
 
 
 
 
 
 
 
 
 
 
 
Noppcha Singweratham 
 
 
 
 
 
 
 
 
 
Thesis submitted in fulfilment of the requirements for the degree of 
Doctor of Philosoply (PhD) 
 
 
 
 
 
 
 
 
 
 
 
Health Economics and Health Technology Assessment 
Institute of Health & Wellbeing 
 
University of Glasgow 
 
January 2015 
i 
 
Abstract 
Gestational diabetes mellitus (GDM) is the most common medical complication during 
pregnancy and is defined as carbohydrate intolerance with varying levels of severity, 
with the onset or first recognition occurring during pregnancy. A variety of different tests 
and guidelines have been used to screen for GDM over the past decade and due to this 
the prevalence’s for GDM that are reported in studies tend to vary considerably. 
However, in Scotland there has been controversy over the method for the screening and 
the diagnosis of GDM, reflecting the lack of consensus for the diagnosis of this 
condition. This thesis therefore undertakes a cost-effectiveness analysis that compares 
four screening test strategies that use various combinations of screening and diagnostic 
tests with a strategy that involves no screening. 
   The first objective was to explore the economic approach to evaluating 
diagnostic testing in GDM. In consultation with experts and informed by comparable 
diagnostic testing models, the thesis adapted a conceptual model to the practice of 
GDM detection. The thesis found that the most appropriate model makes use of a 
combination of tests as either “negative dominant strategy” (NDS) or “positive dominant 
strategy” (PDS), allowing the clinician to consider test results in terms of the differences 
in false negative (FN) and false positive (FP) test results, as combining the tests in 
terms of NDS and PDS involves a tread-off between sensitivity and specificity. 
    A key input parameter of the model was identified to be the disease prevalence. 
However, due to limited known evidence in Scotland, the second objective was to 
assess the evidence on this key parameter. A systematic review was conducted to 
evaluate the prevalence of GDM, considering not just screening test characteristics, but 
also population characteristics. The review explores the possibility that variations in over 
half of the studies can be explained by ethnicity and diagnostic screening strategies and 
whether 75g or 100g oral glucose tolerance test (OGTT) methods of testing for GDM 
can cause variations in the results. Mothers with risk factors are prone to testing positive 
which in turn leads to higher prevalence rates compared to other populations and 
screening ethnic groups that have a high risk of developing GDM can indeed result in 
high prevalence estimates, ranging from 8.5% to 12.8%. 
   Decision making in healthcare over the past decade has increasingly been 
based on considerations of cost effectiveness, including national guidelines for GDM 
screening. The third objective was to summarize and appraise the present economic 
evaluation literature. Thus, a systematic review of economic evaluations, as outlined in 
the various cost and cost-effectiveness studies that have been published in recent 
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years, was performed to critically appraise the current analytical methods used to 
measure the cost-effectiveness of screening tests in order to develop a standardised 
economic model. Costs associated with the screening and management of GDM vary 
widely by country, ranging approximately from £2.42 to £50.9 per case detection, and 
are dependent on the tests used, the screening approach, how the costs are calculated 
and the prevalence of GDM in the population. The review of the CEA studies has 
significant implications for future research and policy making and as such long term 
consequences are appropriate outcomes for the CEA of screening tests for GDM in 
order to capture all long term adverse health outcomes for GDM. Therefore, the 
economic evaluation for GDM should account for the effectiveness of postpartum 
screening for type 2 DM.  
   The aforementioned conceptual model and the results of the systematic reviews 
of diabetes prevalence and GDM screening cost-effectiveness have been synthesised 
into a model to estimate the cost-effectiveness of screening for GDM based on four 
screening guidelines that include 1) SIGN 2001 (random plasma glucose followed by 
75g OGTT) , 2) NICE 2008 (risk factors screening followed by fasting plasma glucose 
and 75g OGTT) , 3) Consensus 2010 (75g OGTT) and 4) SIGN 2010 (risk factors 
screening followed by 75g OGTT) versus 5) no screening. This probabilistic model was 
used to estimate and compare the costs and quality adjusted life years (QALYs) of 
screening tests for GDM. Three independent decision trees, for case detections, short 
term complications in the first year and long term complications over the lifetime, 
explored and considered the combinations of screening and diagnostic tests in terms of 
NDS and PDS. Independent decision trees would allow policy makers to focus on each 
part of the model separately. The primary outcomes of the analysis were the incremental 
cost per case identification, one year QALYs for short term complications and lifetime 
QALYs for type 2 diabetes mellitus for long term complications. Case identification was 
insufficient for policy makers because it fails to take account of the consequence of false 
positive and false negative results of tests. 
For short term complications, the incremental cost-effectiveness ratio was 
£46,760 per QALY for the two-step approach with SIGN 2001 (NDS) using 75g OGTT to 
confirm any positive random plasma glucose (RPG) before treatment compared with no 
screening. At willingness to pay £30,000/QALY, this strategy has 64% probability of 
being cost-effective for short term complications. The cost effectiveness of screening 
tests for GDM, to prevent short term complications, is dependent on the probability of 
GDM being undiagnosed. Additionally, treatments during gestation are important as they 
reduce additional costs that may be required to treat serious adverse complications. 
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   PDS screening where all pregnant women with one or more high risk factors are 
requested to undertake 75g OGTT diagnostic test, proposed by SIGN 2010, is the most 
cost-effective strategy in long term complications. SIGN 2010 (PDS) has higher QALY 
(80.9736) and is less expensive (£4,088) than the other strategies and dominates the 
other screening test strategies for long term complications. At a threshold of 
£30,000/QALY, the CEA illustrates that the probability that SIGN 2010 (PDS) will be 
cost-effective is approximately 55.8%. The cost effectiveness of screening tests for 
GDM, to prevent long term complications, is dependent on the probability of GDM being 
over diagnosed. If mothers have received previous diagnoses of GDM, this should 
trigger regular screening for type 2 DM so that it is discovered early on, before the onset 
of symptoms or the development of complications associated with type 2 DM. 
Postpartum screening and the subsequent treatment of GDM presents an important 
opportunity to reduce type 2 DM.  
   This thesis provides the first economic model of a screening test using 
independent decision trees, split by NDS and PDS. By using NDS and PDS, decision 
makers can interpret the combination of test results. This better presents the 
consequences of false positive and false negatives and a trade-off between sensitive 
and specificity. The thesis finds novel value of applying this methodology to GDM 
screening. By using independent decision trees for NDS and PDS, the model was able 
to identify long term complications as the most important factors affecting the results of 
screening test strategies. Currently, all guidelines for GDM screening tests which also 
included two Scottish guidelines SIGN 2001 and SIGN 2010 are performed as NDS with 
regard to both screening tests and postpartum screening. Thus, in Scotland, policy 
makers or clinicians should consider SIGN 2010 with PDS for screening tests for GDM 
in order to prevent long term complications. Lastly, this work is also the first to apply the 
expected value of information (EVPI) to the area of GDM screening. The population 
EVPPI of £784,042 for long term complications shows that there is greater uncertainty 
with respect to long term complications and that collecting information on long term 
complications is likely to be worthwhile.  Thus, it captures the long time horizons in 
screening programmes required for decisions about the value of further research and 
the expected payoff of conducting further research to resolve the model uncertainties.  
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Chapter 1 Introduction 
1.1 Introduction 
Increasing costs of health care relative to other sectors, due to the labour intensive 
nature of health care provision, has lead to pressures on health care budgets.  
Moreover, health care resources are limited by total funds available, as well as through 
competition with other areas, such as housing, education and finance. This raises the 
question of how to make decisions about the proper allocation of funds (Hine, 1999). 
Nowadays, governments in many countries are faced with rising health care costs due 
to rapidly growing populations, increasing demands for health care services, and the 
introduction of new health technology. As a result, governments are under pressure to 
justify their resource allocation. Many countries around the world apply economic 
evaluation to the decision-making process for health, including Australia, Canada, the 
United States of America and many European countries. Each year more than £100 
billion is spent by the UK National Health Service (NHS) on health care in the UK 
(Department of Health, 2010). With new technologies in health care continually being 
discovered, there is a need for decision making strategies and prioritization of health 
care when faced with limited budgets. Rising expenditure in health care is often 
associated with new technologies and health care programmes (Cunningham, 2001). 
Given the limitations in health care resources, there is increased interest in assessing 
the value for money, or economic efficiency of health care programmes. This is 
achieved through economic evaluation, where the costs and consequences of 
alternative intervention strategies are compared (Drummond, 2005b). Therefore, 
economic evaluation has become part of modern health care evaluation. 
   Diagnostic tests can monitor the benefits and/or side effects of appropriate 
treatment. An error in diagnostic test results may result in over or mis-diagnosis, also 
referred to as false positive and false negative results, respectively. Over diagnosis 
refers to the situation where screening programmes detect disease which is not in fact 
present (Moynihan et al., 2012). People without disease symptoms can then be 
diagnosed and treated for a disease which may in turn lead to unnecessary and possibly 
harmful treatment, and resulting in disutility for these patients. On the other hand, miss 
diagnosis refers to patients that have disease but test negative during screening which 
may delay access to beneficial treatment.  Diagnostic tests come with costs and 
consequences both of which are appropriate subjects for economic analysis. Because of 
increasing health care costs and limited resources, obstetricians must pay attention to 
the cost-effectiveness of the diagnosis and treatment programmes. In addition, 
obstetricians should be concerned with several important factors in the cost analysis of 
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health care. Diagnostics consist of using the tests to categorise the population into two 
groups or help physicians revise disease probability for their patients. A test may be 
performed to prove that a person is free from disease.  Additionally, the aim of all 
diagnostic testing is to refine this probability to the point where the clinicians can 
confidently assign a treatment to the correct patient. Each diagnostic test, whether it is a 
symptom, sign, laboratory or radiological examination, results in a change in the 
clinician’s probability of disease in their patients.  
   Gestational diabetes mellitus (GDM) is the most common medical complication 
of the pregnancy period. GDM is defined as carbohydrate intolerance of variable 
severity, with onset or first recognition during pregnancy, whether or not insulin is used, 
and regardless of whether diabetes persists after pregnancy (WHO, 1999a). The 
prevalence of women with GDM has increased over time, impacting between 1% - 16% 
of women, depending on the diagnostic criteria and population studies (King, 1998). 
There are three main reasons for screening for GDM. First of all, GDM is a significant 
complication and metabolic disorder of pregnancy, and disappears after delivery 
(Koukkou et al., 1995) (Carpenter and Coustan, 1982).  Secondly, GDM is associated 
with adverse effects for both mother and child.  These include fetal macrosomia and 
perinatal mortality in children, hypertension disorders, pre-eclampsia, and cesarean 
section in mothers, and future diabetes in both (Persson and Hanson, 1998) (Greco et 
al., 1994). Thirdly, identifying this group of women can not only prevent perinatal 
morbidity but also reduce risks to health through diet and lifestyle management, oral 
medication programmes and insulin therapy (Jovanovic, 1998). 
   Screening tests for GDM are performed by either selective or universal 
screening. Normally, screening and diagnostic tests are performed between 24 and 28 
weeks gestation because the diabetogenic effect takes place at this time in pregnancy 
(Naylor et al., 1997) and there is sufficient time during pregnancy to start treatment or 
therapy programmes (Greene, 1997). Screening tests are a controversial topic in terms 
of the appropriate screening approach of pregnant women with GDM (Greene, 1997) 
(Jarrett et al., 1997) (Soares J de AC, 1997) and  screening test strategies for GDM are 
still debated with no consensus having been established yet (Metzger and Coustan, 
1998). These strategies are widespread screening of the population, the timing of 
screening, screening test techniques and the threshold of diagnosis. Moreover, in 
screening for GDM there is also controversy regarding the use of universal or selective 
screening (Vogel et al., 2000). The Australasian Diabetes in Pregnancy Society (ADIPS) 
Management Guidelines for GDM strongly recommends that screening tests for GDM 
should be used to screen all pregnant women. If the resources are restricted, high risk 
factor groups will be screened (Hoffman et al., 1998). Common risk factors for GDM 
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include advanced maternal age (women > 40 years), a family history of diabetes, 
obesity, previous adverse pregnancy outcome, non-white ethic origin and being a 
current smoker (Santini and Ales, 1990) (Sacks et al., 1987). However, testing by 
universal screening, which tests every woman in every pregnancy, comes at a cost, and 
in addition those women who are diagnosed with GDM will use further health care 
resources, with cost implications.  
   In terms of the management of GDM, effective treatment demonstrates that 
diagnosis and treatment of GDM results in a reduction in adverse effects for both mother 
and child. Two randomised control trials have shown that interventions in women 
diagnosed with GDM using dietary advice, monitoring and management of blood 
glucose, are effective in reducing birth weight, the rate of growth for gestational age 
infants, and perinatal morbidity. Treatment of GDM reduces serious perinatal 
complications and may also improve women’s health-related quality of life during 
pregnancy and after delivery. Two studies found that treatment of women with GDM, 
including dietary advice, blood glucose monitoring, and insulin therapy, reduced the rate 
of serious adverse outcomes (defined by one or more of the following: death, shoulder 
dystocia, bone fracture, and nerve palsy) from 4 percent to 1 percent (Crowther et al., 
2005) (Landon et al., 2009) 
   In the past, convenient screening tests such as glycosuria, the measurement of 
blood Glycosylated hemoglobin A1c (HbA1c) and random plasma glucose tests (RPG) 
were used to classify GDM, which were not adequately sensitive to measure glucose 
levels. At present, the test most used internationally is a 2h 75g oral glucose tolerance 
test (OGTT) and 3h 100g oral glucose tolerance test (OGTT). The 2h 75g OGTT is 
recommended by the World Health Organisation (WHO) and is widely used outside the 
United States of America, especially in Europe and Japan (Alberti and Zimmet, 1998). 
On the other hand, The American Diabetic Association (ADA) recommends screening 
for gestational diabetes with the 3-hour 100g oral glucose tolerance test, it is commonly 
used in the United States of America (Martine et al., 2007). However, in the UK, two 
national surveys of UK obstetric units have shown a lack of consensus on screen tests 
for GDM, with some health care centres using the ADA guidelines and others 
implementing the WHO guidelines. Moreover, screening and diagnostic tests, cut-off 
values, timings, and subsequent management programmes vary widely in the UK (Mires 
et al., 1999) (Hanna et al., 2008). The national survey of the Association of British 
Clinical Diabetologists (ABCD) reported 82 percent of centres in the UK providing 
routine screening for GDM, half of those centres using universal screening and half 
selective screening. This survey reports a widely varied prevalence of GDM from 0.1-
10% (Median 1.5%) (Hanna et al., 2008).  
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   In Scotland, there has been controversy over the best method of screening and 
specific diagnostic criteria for the detection and definition of GDM, with no accepted 
international consensus to this day. The Scottish Intercollegiate Guidelines Network 
(SIGN) published two guidelines in 2001 and 2010 called “Management of Diabetes - A 
National Clinical Guideline” each with different screening test methods (SIGN, 2001) 
(SIGN, 2010). There is very limited information available about the cost of screening and 
diagnostic tests for GDM, and the utilisation of resources involved. However, it is 
commonly accepted that detection of GDM is of great importance in implementing a 
proper strategy for reducing maternal and perinatal complications. With the limitations in 
health care and budgets, economic evaluation can help to determine the most cost-
effective screening and diagnostic tests among numerous intervention options available. 
This evidence can help policy decision-makers set priorities in terms of  budget 
allocation (Singh et al., 2001). The decision analysis method has been applied to 
evaluate screening and diagnostic tests in terms of possible clinical consequences. 
There is no study, however, on the economic evaluation of screening and diagnostic 
tests for GDM in Scotland. This study compares different strategies, of screening for 
GDM in Scotland.  
1.2 Objectives of this thesis 
The overall aim of this thesis is to study the cost-effectiveness of screening and 
diagnostic tests for GDM in Scotland. To estimate GDM detection rates and the 
proportion of women identified for subsequent testing involves modelling a relationship 
between prevalence and the positive and negative predictive value of testing. This study 
aims to inform policy makers on this important issue by establishing the optimal mix of 
cost-effective screening and diagnostic tests of GDM. This study compares four 
strategies of screening for GDM against no screening in different organisations in 
Scotland. 
1.2.1 Objective 1: To explore the economic approach to 
evaluating diagnostic tests 
The first objective is to describe the combination of the test approaches in evaluating 
diagnostic tests. The combination of the tests as either “negative rule” or “negative 
dominant strategy” and either “positive rule” or “positive dominant strategy” are 
described and illustrated. Positive and negative dominant strategies may help the 
clinician to interpret the combination of test results and illustrate this new technique for 
economic test evaluation.  
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1.2.2 Objective 2: To obtain disease prevalence, diagnostic test 
accuracy and health benefits of outcomes of GDM by 
systematic review 
The second objective is to ascertain data for the input parameters by means of a 
systematic review. All economic evaluation studies are obliged to include all parameters 
in the economic model.  This study also requires many parameters to populate the 
model, such as GDM prevalence, sensitivity and specificity of the screening test and 
proportion of adverse outcomes in both mother and offspring. This paper includes a 
systematic review to reassess the prevalence and incidence of gestational diabetes 
mellitus in the general pregnancy population.  
1.2.3 Objective 3: To review the economic evaluation of 
screening tests for GDM 
Screening tests for GDM are widely reported to be cost-effective interventions. 
Therefore, the third objective aims to review systematically and critically an economic 
evaluation of screening tests for GDM.  The review assesses the evidence for the cost-
effectiveness of different approaches to screening tests, taking into account the 
appropriateness of the model, and assesses the data requirements used to derive cost 
and effectiveness of screening tests for GDM. The findings for this review should help to 
provide more reliable information about the economic evaluation of screening tests of 
GDM and develop a new and appropriate model for GDM screening tests.   
1.2.4 Objective 4: Estimate the cost-effectiveness of screening 
test for GDM 
The fourth objective is to compare the cost-effectiveness of both universal and selective 
screening tests for GDM in Scotland. A basic decision tree structure is used in 
developing the model, based on five strategies of both universal and selective screening 
used to identify glucose intolerance during pregnancy. This part of the analysis focuses 
on the health outcomes of GDM. Quality adjusted life years (QALY) in both mothers and 
offspring are split into short and long term complications. The most appropriate 
assessment for effective comparison across disease states include health-related quality 
of life year (HRQoL) measures such as EuroQol and the 5 dimensional (EQ-5D), which 
can be employed to derive QALY.  This paper will assume a willingness to pay £30,000 
per QALY.  
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1.2.5 Objective 5: Impact of uncertainty  
This objective will address the issues of impact of uncertainty during every stage of the 
economic evaluation of GDM. Probabilistic sensitivity analysis is used to estimate the 
probability that each strategy will be cost-effective at a given willingness to pay for each 
additional unit of benefit.  
1.3 Structure of the thesis  
The structure of this thesis is as follows: 
Chapter 2 summarises a narrative of the grounds for economic evaluation of health care 
intervention. This chapter introduces two important frameworks of economic evaluation 
and decision analytic modelling. In the first framework, the key concepts for economic 
analysis in health care are introduced before exploring the health economic evaluation 
technique. The chapter briefly describes a general overview of health economic 
evaluation; perspectives and comparators of study; costing and time horizons are 
discussed. The second framework is based on decision modelling for health economic 
evaluation, which describes cost-effectiveness analysis based on cohort modelling; such 
as decision tree modelling and Markov modelling. The finer details of the rules 
governing cost-effectiveness analysis are also examined. 
Chapter 3 mainly describes the fundamental terminology of diagnostic test evaluation to 
support the methodology of this thesis. In order to present the diseases present and 
absent in the population, the accuracy of the test are also introduced. This chapter will 
focus on Bayesian inference by giving an introduction to the theorem and demonstrating 
an example of how positive and negative predictive values from sensitivity and 
specificity are calculated and to show how to apply this technique to the economic 
evaluation of diagnostic tests.  The two component tests under either the positive 
dominant strategy or the negative dominant strategy are discussed.  
Chapter 4 provides a background review of the literature regarding GDM by means of a 
systematic review.  This chapter begins by outlining the natural history of GDM and the 
treatment for the disease in order to start the conceptualisation around and economic 
evaluation for GDM. Generally, before developing an economic evaluation, it is essential 
to fully understand the nature of the disease under scrutiny, including how the disease 
presents itself, how the disease propagates and how treatment affects the disease. The 
short and long term complications that occur in both mothers and offspring are briefly 
reviewed. The testing techniques, the various screening and diagnostic tests in current 
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use are also discussed. The systematic review of GDM will provide all relevant data for 
the input parameters to populate the economic model for GDM screening tests. 
Chapter 5 conducts a comprehensive systematic review of the prevalence of GDM. This 
chapter reviews an article which reports on the prevalence of GDM in the general 
population. The selected articles are presented and prevalence is estimated. The 
prevalence estimates will be discussed and synthesised in this chapter, and are used as 
input parameters in the model. This addresses objective two.   
Chapter 6 presents and critiques a review of the relevant published literature on cost 
analysis and  economic evaluation of GDM screening by means of a systematic review. 
The key concepts of economic evaluation identified in chapter 2 such as perspective, 
patient group, comparators, outcome measures, extrapolation, and the results of the 
evaluations and the handling of uncertainty are criticised in this particular paper. 
Following this is a comparison of all papers discussed in which important methodological 
issues and gaps are highlighted. The result of this review provides a new economic 
evaluation model of GDM in Scotland. This chapter supports objective 3. 
Chapter 7 aims to construct a model of cost-effectiveness for GDM by integrating the 
natural history of GDM, diagnostic test evaluation and health economic evaluation. This 
chapter assesses the relative costs and effectiveness of single outcomes (case 
identification). The two components of the tests from chapter 3 are applied to construct 
the decision tree model. The results from the cost-effectiveness analysis of case 
identification are then presented.  
Chapter 8 develops and presents the results of a decision analysis model of GDM 
screening tests in terms of short and long term adverse complications. The 
developments of the decision tree models in both short and long term adverse 
complications are detailed. The outcome measures of effectiveness were QALY in both 
short and long term complications.  In order to determine QALY in both mothers and 
offspring in short term complications, this chapter calculates the QALY over 1 year from 
health-related quality of life scores. With respect to long term adverse complications in 
both mothers and offspring with diabetes mellitus life tables, life expectancy and quality-
adjusted life expectancy are calculated. This addresses objective four.     
Chapter 9 conducts a cost-effectiveness analysis to compare four screening test 
strategies and a strategy that involves no screening test, following the development of 
the decision tree in chapters 6 and 7. This chapter explores uncertainty in the model 
result and demonstrates that using a cost-effective acceptability curve, where results 
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can be examined in terms of decision uncertainty, is recommended. The Value of 
Information (VOI) technique is presented to give meaningful recommendations to 
funding organisations and decision making bodies. VOI can eliminate the possibility of 
making the wrong decision and can also present the expected opportunity loss 
surrounding the decisions.  
Chapter 10 summarises and discusses the main findings from analyses in the empirical 
chapters. Beside this, recommendations based on the findings are also provided, in 
order to demonstrate the knowledge gained from the literature and past research. This 
chapter also explains how the overall aim of the project was accomplished through the 
work undertaken. Limitations of the thesis are discussed and the scope for future 
research is carried out.   
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Chapter 2 Economic evaluation and health 
decision making  
  
2.1 Introduction 
This chapter aims to explore the grounds for economic evaluation of health care 
interventions. This chapter is split into two halves; the economic evaluation framework 
and the decision analysis modelling framework. 
   The first section of the first half discusses an eight step framework for conducting 
economic evaluations. This section introduces the key concepts for economic analysis in 
health care before exploring health economic evaluation techniques. The subsequent 
section further describes the components of health economic evaluation, including 
perspectives and comparators of study, costs and the time horizon. Then, the different 
types of outcome measures are followed by a discussion of the time horizon, discount 
rate and sensitivity analysis. Following this, descriptions of the various models of 
economic evaluation techniques that are commonly employed are discussed. It 
describes the cohort model, the main type of decision model used in the field. 
   The second half of the chapter begins by discussing the six steps of the 
framework for decision analytical modelling. Firstly the decision problem is outlined and 
then the decision model itself is structured before identifying and synthesising the 
available evidence. The systematic review and meta-analysis in this section are 
discussed in terms of how to access appropriate information for using an input 
parameter in an economic model. The following section examines the structure of the 
model for decision-making in detail, the deciding factors and cost-effectiveness analysis. 
Cost-effectiveness analysis and the deciding factors are described to decision makers 
using methods such as incremental cost-effectiveness ratio, net benefit and net 
monetary benefit. Following this, there is a discussion of the methods for handling 
uncertainty and heterogeneity in models for decision-making, in particular the use of 
probabilistic sensitivity analysis to reflect parameter uncertainties. Then, the value of 
information methods are explored and used to look at how future research studies may 
be efficiently designed.   
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2.2 Economic evaluation 
In 1948, the National Health Service (NHS) published three core principles: the NHS 
would aim to meet the needs of everyone, be free at the point of delivery and be based 
on clinical need, not ability to pay (National Health Service, 1948). Currently, those three 
components are being applied. Difficult decisions are constantly being made because 
resources are limited, and include such issues as which new treatments and procedures 
to finance (and for whom) and which older treatments should be replaced.  
  Academic researchers and others, especially economists, can support and guide 
the policy maker with these difficult decisions by conducting health economic 
evaluations on the value of pharmaceutical products, devices and other interventions. 
The value of one treatment in terms of its costs and effects is compared to the costs and 
effects of other treatments, currently in practice.  The main purpose of providing 
information to health care decision makers is to allocate resources efficiently in terms of 
costs and quality of life, within the health care sector (Evans et al., 2004). Economists 
attempt to make explicit one set of criteria that can be used to decide between different 
uses of resources in short-supply (Drummond, 2005b). Thus the choices of which 
treatment or intervention should be accepted and/or eliminated are made based on 
economic value and health related quality adjusted life years.  
   Nowadays, many countries around the world incorporate economic evidence into 
the decision making process for health and reimbursement decisions in health care. This 
includes many European countries, Australia and Canada (CADTH, 2006)  (Andronis et 
al., 2009)  (NICE, 2013). For example, NICE is an organisation independent from the 
government, which is the relevant decision making agency in England & Wales, 
responsible for providing guidance on the use of health technologies and the 
implementation of public health programmes. In 2008, NICE proposed guidelines for 
methods of technology appraisal (NICE, 2008c). These guidelines were revised and 
proposed in a new version in 2013 (NICE, 2013). In both versions cost- effectiveness 
analysis (CEA) is recommended as a highly integrated component of the technology 
appraisal process by NICE. NICE brings together all evidence in order to decide whether 
the adoption of a technology (treatment or drug) represents good value for the NHS 
during the process of developing guidelines (NICE, 2005).  NICE has defined a 
‘reference case’ in which submission to the institute should follow to ensure consistency 
of health technology assessment (NICE, 2008c) (NICE, 2013). The reference case 
suggested by NICE recommends the use of current practice as the best comparator for 
economic evaluation. Also the cost of treatment or procedures should include all costs 
pertaining to the NHS or personal social services and all health effects should be 
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considered. The outcome is measured in terms of the quality adjusted life year (QALYs) 
which enables comparison across studies and is normally required by NICE. The source 
of valuing QALYs should be that of the general population as opposed to a patient 
population since the NHS is acting on behalf of the general population in distributing 
resources. A discount rate of 3.5% should be applied to costs and consequences (NICE, 
2008c) (NICE, 2013).   
   In Scotland, the Scottish Medicine Consortium (SMC) and Scottish 
Intercollegiate Guidelines Network (SIGN) both have a national and international 
reputation for the quality of their output, and provide guidance that is central to the 
provision of high quality, evidence based health care in Scotland (NHS Scotland, 2013).  
Unlike SIGN, SMC carries out an evaluation of the clinical and cost effectiveness of all 
newly licensed drugs that represent good value for money to NHS Scotland and offers 
advice to health boards and their area drug and therapeutic committees. As the NHS 
has limited resources, the SMC work to confirm that those drugs which represent good 
value for money are accepted for routine use so that they can benefit patients. 
Moreover, SMC also analyses information supplied by the drug manufacturer on the 
health benefits of drugs.    
2.2.1 Rationale for economic evaluation 
The increasing cost of health care relative to other sectors, due to the labour intensive 
nature of health care provision, has led to pressure on health care budgets.  Moreover, 
health care resources are limited by total funds available, as well as through competition 
with other areas, such as housing, education and finance. This raises the question of 
how to decide to allocate the money properly (Hine, 1999). Is this health care scheme 
worth implementing compared with other ways to use the same resources? Are we 
satisfied that health care resources are spent in one way rather than some other way? 
(Drummond, 1987). Economic evaluation sets out to answer these questions. 
2.2.2 Principles of economic evaluation 
Economic evaluation has become necessary a part of modern health care evaluation. 
New technologies in health care contribute to rising expenditure in health care programs 
(Alcocer and Cueto, 2008) (Drummond, 1987). Dummond defines economic evaluation 
as “the comparative analysis of alternative courses of action in terms of both their costs 
and consequences”. Therefore, the basic principle of any economic evaluation is not just 
dealing with costs but also in the way that the consequences of health care programs 
are measured and valued. In fact, both costs (inputs) and consequences (outputs) of 
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economic analysis may be employed to distinguish and label several evaluation 
situations commonly encountered in the health care evaluation literature (Drummond, 
1987). The distinguishing of characteristics of health care evaluations are discussed 
based on Drummond and colleagues work (Drummond, 2005b).  In not comparing 
alternatives (where only a single service or programmes is being evaluated), there can 
be only the consequences of the programs that are evaluated; it can be labeled as an 
outcome description. On the other hand, cost description deals only with costs, but not 
full economic evaluations because alternatives are not compared (Drummond, 2005b). If 
both costs and consequence of a single program are examined, the evaluation is called 
a cost-outcome & description.  
  In the comparison of alternative programs, if only the consequences of the 
alternatives are compared, then the study is called an efficacy or effectiveness 
evaluation. Cost analysis examines the costs of the alternative programs. However, 
none of above-mentioned entirely fulfils the requirements of an economic evaluation. 
Drummond and colleagues named and designated those studies as partial evaluations. 
These analyses may not represent full economic evaluations but remain important 
nonetheless as they provide an understanding of either costs or consequences even if 
they do not provide a full economic evaluations. The four techniques used in a full 
economic evaluation include the following; cost-minimisation, cost-benefit analysis, cost-
effectiveness analysis and cost-utility analysis. They involve the identification, 
measurement, and followed by the comparison of the costs (input) and consequences 
(outcome) of two or more alternative programs. Different types of economic evaluations 
are discussed in Section 2.10.  
2.2.3 A framework for conducting economic evaluation 
   The most well-known and popular classification framework in health economics 
is given by Drummond and colleagues (Drummond, 1987). They introduced an eight 
step framework for conducting economics, as shown in Table 2.1. This framework is 
admirable for its simplicity and transparency. This section is discussed only step 1 to 
step 6. 
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Table 2.1 Drummond’s framework for economic evaluations 
Step Framework 
Step 1 Define the health intervention & Study perspective 
Step 2 Identify & Describe the Alternative 
Step 3 Identify, Measure & Value all Relevant costs 
Step 4 Identify, Measure & Value all Relevant Benefits 
Step 5 Discount Future Costs and Benefits 
Step 6 Perform a sensitivity analysis 
Step 7 Perform a Marginal analysis 
Step 8 Make recommendations 
Source: Adapted from Drummond et al (2007) 
2.3 Study Perspective 
A well-designed health economic evaluation should clearly state the study perspective 
and the interventions under study (Shih and Halpern, 2008).  The perspective of an 
economic evaluation is the viewpoint from which the study is conducted. There are a 
number of alternative perspectives, including societal, third-party payer, patients, 
employers, or health care providers. These can be classified into two groups. First, a 
health sector perspective concerns the healthcare-related cost and impact on the 
government. Second, a societal sector perspective focuses all impacts inside and 
outside the health sector. These impacts all have related costs in terms of resource 
usage, which should be taken into account (Drummond and McGuire, 2007). According 
to the US Panel on Cost-effectiveness in Health and Medicine, economic evaluations in 
social perspective should include all the cost and consequence of health care 
interventions, which concern the health-related costs and impact on the government and 
on the private sector(such as third-party payers, clients and their families or caregiver) 
(Russell et al., 1996). Although the societal perspective is recommended in many text 
books of economic evaluation, the choice of perspective depends on the aim of the 
evaluation.  
2.4 Comparators 
Economic evaluation is always structured to compare alternatives. Choosing suitable 
comparators for analyses is important, as their selection is crucial in order to determine 
the cost effectiveness of the intervention and the study’s relevance. Generally, it can be 
found that the alternative expected to be replaced if an intervention is adopted will be 
the comparator.   
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In the reference case, the most widely used comparator is “current practice”, also 
referred to as “base case” and “standard of care”. However another common 
comparator is, “do nothing”, outlined in the Generalized Cost-Effectiveness Analysis 
(GCEA) framework (WHO, 2003). According to the GCEA guidelines, the appropriate 
comparator for optimal intervention is a hypothetical “back-calculation” of “what if current 
practice is eliminated”. This is namely the “null comparator” (WHO, 2003).   
Hay and Jackson, however, have stated that a comparator should not just be the current 
standard of care as a single standard may not exist (Hay and Jackson, 1999). Moreover, 
the choice of option should include evidence from local guidelines and treatment 
patterns and may perhaps be based on the review of literature and expert opinion. In 
other words, in the analysis, a comparison should be made first of all with standard 
therapy. If standard therapy is not appropriate as a comparator, the most frequent 
therapy or the most effective therapy can also be chosen. The comparator should not be 
constrained by the immediate concern of the decision maker, data available or 
restrictions of current practices. There should be justification provided for the exclusion 
of any possible options. If good practice is to anticipate future comparators, particularly 
lower cost intervention, it may lead to an underestimation of the incremental cost-
effectiveness ratio (ICER) of the new intervention. 
2.5  Costs 
Drummond and colleagues state that the cost of heath intervention or treatment can be 
categorised into four main groups (Drummond, 2005b). 
- C1 are costs arising from the use of resources within the health sector 
such as medical visits, pharmaceuticals, hospitalisation etc; 
- C2 are costs forming the use of resources by patients and their 
families such as travel costs, co-payments for medical services or 
drugs, expenditure on home modifications specifically related to the 
illness and its treatment, time cost and other out-of-pocket expenses; 
- C3 are costs related to resource use in other sector such as welfare 
organizations, forensic service, educational services etc; and 
- C4 are productivity losses  
 
 Furthermore, costs can be divided into direct and indirect costs (Shih and 
Halpern, 2008). Direct costs focus on the resource consumed, related to medical care 
cost interventions. On the other hand, indirect costs consider the time consumed or 
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saved by patients and their families who look after the patients as a result of treatment 
and intervention. Sometimes, indirect costs measure the long-term labour market 
consequence of disease or interventions (Shih and Halpern, 2008).   
   Costing in health economic evaluations are dependent on the perspective of a 
health economic evaluation and the different types of costs are further outlined in Table 
2.2. The type of costs to be included in an analysis depends on the aim and perspective 
of study design. Health economic analyses performed in the health care providers 
perspective or public programme tend to focus on direct costs only, C1, which might 
include inventory carrying cost, pharmacy time to compound or dispense, nursing time 
to administer and even allocated hospital overhead costs. Other perspectives, including 
third-party payers, businesses, clients and their families or caregivers might be 
considered in C2 + C3. Analysis done for an employer might consider only costs that 
affect the employees, for example an intervention that results in productivity loss of 
workers is classed as C4. In health economics a more complete model, “societal” 
perspective, which captures the full economic impact of new treatments and 
interventions is sometimes used, and requires both direct and indirect cost; C1 + C2 + 
C3 + C4. However, while preferable as an economic theory point of view, this 
perspective is more complex and time-consuming than the health sector perspective. 
Table 2.2 The relation between perspectives of economic evaluations and cost  
Perspective Costs types  Example  
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C1 Medical visits 
Pharmaceuticals and medical devices 
Hospital services 
Medical services 
Community base service such as home care 
Health care providers and other staff 
Equipment, space , building and associated overhead costs 
  C2 Travel costs 
Co-payments for medical services or drugs 
Expenditure on home modifications specifically related to the Illness 
and its treatment 
Time cost and other out-of-pocket expenses 
  C3 Welfare organizations 
Forensic service 
Educational services 
  
E
m
p
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y
e
r 
C4 Productivity losses 
Short-term and long-term absences from work 
Cost to employer to hire and train replacement worker 
Based on page 19, table 2 in Guidelines for the economic evaluation of health technologies: 
Canada. (CADTH, 2006) 
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2.6 Outcome measurement 
The choice of outcome measure is dependent on the study question and the type of 
economic evaluation that is being undertaken (Lorgelly et al., 2010). In valuing health 
outcomes, NICE advises that all health effects should be accounted for within an 
economic evaluation. If other non-utility based measures capture health effects that are 
not captured within the utility measure, the effectiveness of treatment on these 
measures can also be presented (Lorgelly et al., 2010).  
2.6.1 Types of outcome measurement 
Gold and colleagues state that the most important factors a researcher should consider 
while choosing the appropriate outcomes are the beneficial outcomes and adverse 
effects affecting individuals, for instance patients, families, health care personnel or 
decision makers and society (Gold et al., 1996). This section describes different types of 
outcome measures that have been used in health economic evaluation. Table 2.3 
categorises health outcomes into three different types including clinical outcomes, 
quality of life outcomes and monetary outcomes.  
Table 2.3 Types and outcome measurement in economic evaluations 
Types  Outcome measures 
Clinical outcome   
 -Morbidity (intermediate outcome) Health endpoints, other clinical measures, prevalence 
or event, generally expressed in natural units such as 
number of cancers detected and episode free days 
 -Mortality  
(final outcome single dimension) 
Estimate life years gained, survival rate and life year 
saved 
Quality of life outcome (Final outcome with multiple dimensions) 
 - Disease specific instrument EORTC QLC-C30 (cancer) ,Arthritis impact 
measurement scale 
 - Generic health questionnaire based Short Form 36 (SF-36), Short Form 12  (AF-12), 
Sinkness Impact Profile 
 - Generic health preference based The EuroQol 5D (EQ-5D), Short Form (SF-6D) and 
Health Utility index (HUI) 
Monetary  As measured in a contingent valuation excise to elicit 
an individual’s willingness-to-pay for an intervention 
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2.6.2 Clinical outcomes 
Morbidity: Intermediate outcome 
The first type of effectiveness unit in cost-effectiveness analysis is the intermediate 
outcomes, such as the number of heart attacks prevented, the number of ulcer 
prevented and number of cases detected. Some health endpoints can be classified as 
binary outcomes, which occur or do not occur. An advantage point of using endpoint 
prevention as the effectiveness measure is that it is closely related to clinical objective. 
On the other hand, a disadvantage of using the number of endpoints prevented is that, 
with an intertemporal model(Johannesson et al., 1996).   
 Mortality: Final outcome single dimension 
 A saved life is one type of event that is sometimes used as an effectiveness measure. 
Survival analysis is a statistical method used to analyse data that can be used to 
estimate the probability distribution of the expected time to an event, which is often 
mortality but can be a nonfatal event as well (Drummond and McGuire, 2007).  The 
analysis compares all the different activities that reduce the risk of mortality by using 
lives saved as an effectiveness measure. In the medical area, one, three, five and ten 
year’s survival is often used in this respect. Similarly, using survival may result in similar 
problems to the morbidity endpoint measure. For example, if five year survival is used, 
patients may live for 8 or 10 years after treatment, and is an obvious weak point of such 
an outcome measure.  However, at least in the medical area it has been common to use 
the number of life-years gained rather than lives saved as the effectiveness measure for 
programmes that reduce the mortality risk. The advantage of this measure is that it 
takes into account the number of life-years at risk when mortality risk is reduced.  
Additionally, life-years gained only focuses on survival and does not incorporate quality 
of life. Comparisons of health programmes that affect both the quality and quantity of life 
are considered. Effectiveness measures need to incorporate changes in both the quality 
and quantity of life (Johannesson et al., 1996).    
2.6.3 Quality of life: Final outcome with multiple dimensions 
Since the World Health Organisation (WHO) defines health as being not only the 
absence of disease and infirmity but also the presence of physical, mental and social 
well-being, in health care research and economic evaluation, quality of life has become 
ever more important (WHO, 1952) . “Quality of life” and more specifically health related 
quality of life (HRQoL) refer to the physical, psychological, and social domains of health, 
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which reflects the definition defined by the WHO (Marcia and Donald, 1996). There are 
three main approaches to describe and measure HRQol which include disease-specific 
instruments, generic health questionnaire based instruments and generic health 
preference based instruments.  
Disease-specific scales  
Disease-specific scales mainly focus on reference values for individual diseases with 
specific population and specific medical conditions such as the European organisation 
for research and treatment of Cancer (EORT) Quality of Life Core 30 (QLC-C30), the 
Rotterdam Symptom Checklist (RSCL), the Functional living index cancer (FLIC), and 
the Functional Assessment of Cancer Therapy scale (FACT). For instance, EORT QLC-
C30 is frequently used to assess HRQoL in various groups of cancer patients (Aaronson 
et al., 1993). The strength of disease specific scales is that it is good at assessing 
specific diseases and is typically better accepted by clinicians and patients. On the other 
hand, it cannot provide a comprehensive measure of health and quality of life, and it is 
not possible to make comparisons between conditions.  
Generic health questionnaires based instruments 
Generic health questionnaire based instruments were developed to attempt to capture 
the HRQol. The concept of HRQoL takes into account patient well-being as expressed 
by both the physical and psychological (or mental) domains of health.  Generic 
questionnaires include SF-36, SF-12, and Sickness Impact Profiles. For example SF-36 
or its reduced version SF-12 is the most widely used instrument for assessing HRQol in 
individuals with chronic disease. The SF-36 is a generic multi dimensional instrument for 
capturing quality of life with 8 dimensions that can be broken down into two broader 
classes applicable to different populations and comparisons can be made across 
conditions or programmes; physical and mental (Ware et al., 1993). The eight aspects of 
health status include: general mental health, physical and social functioning, physical 
and emotional role, bodily pain, vitality, and general health perception. Scores on each 
scale range from 0 (worst) to 100 (best) (Brazier et al., 2002). Generic measures can be 
used on a variety of disease areas or health problems and can be used to compare 
HRQoL across diseases (Valderrabano et al., 2001). This instrument may not however 
pick up slight changes in HRQoL which are of importance to the patient.   
Generic preference based instruments 
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Several generic preference based measures have been developed and commonly use 
questionnaires including the EuroQol 5D (EQ-5D), Short Form 6D (SF-6D) and the 
Health Utilities Index (HUI)(Whitehead and Ali, 2010). Those values are translated into a 
zero to one scale where zero denotes death status and one with perfect health. For 
instance, EQ-5D is a popular method usually used in CUA studies (Richardson and 
Manca, 2004). The EQ-5D questionnaire has five dimensions including mobility, self-
care, usual activities, pain/discomfort and anxiety/depression. These dimensions include 
three levels which individuals are asked to respond to; whether they have no problems, 
some problems or severe problems (King, 1996). These preference based instruments 
also differ in terms of the valuation method:  time trade-off (TTO) is used to value EQ-
5D, whereas SF-6D and HUI use the standard gamble (SG), and the visual analogues 
scale (VAS) is also used in HUI (Whitehead and Ali, 2010). Each technique is discussed 
in greater detail in the next section.   
2.6.4  Measuring preferences 
The three most widely used techniques to measure the preferences of individuals for 
health outcomes, and so derive QALY weights are the rating scale, also called the visual 
analogues scale (VAS), the time trade-off (TTO) and the standard gamble (SG). Those 
methods are described below.  
Visual analogues scale (VAS) 
VAS is the simplest approach in which people are asked to rate health states on a scale 
(ranged between 0 and 100). The 0 represents the worst possible state, assumed to be 
equivalent to death, and 100 is the best possible state, or perfect health. The SF-6D 
questionnaires are used to derive utilities. The questionnaires are comparatively easy to 
administer and the results are easy to generalise across disease areas (Bravo Vergel 
and Sculpher, 2008). However, when compared with preferences measured by TTO and 
SG, this technique may not act as an interval scale of preferences (Bleichrodt and 
Johannesson, 1997).  
The time trade-off (TTO)  
The second method of measuring quality weights is TTO. It was developed by Torrance 
and colleagues (Torrance et al., 1972). In the TTO approach, respondents are asked to 
choose how many years of full health they would trade off against living 10 years with 
their current health state. They are given two choices between living the rest of their life 
(t) in a given health state (i) or a shorter period of time (x) living in perfect health. The 
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time (x) is varied until the subject is indifferent between the two alternatives, at which 
point the required preference score for state (i) is (x/t) (Bravo Vergel and Sculpher, 
2008).  
The standard gamble (SG).  
In the SG technique, participants are asked to choose between the certainties of an 
intermediated health state (such as current health state with a chronic disease) and the 
uncertainty of treatment. Treatment offers two possible outcomes, one is more attractive 
than the certain outcome (e.g. curable outcome) and another outcome is less attractive 
(e.g. death).  The quality weight of a health state is assessed by comparing a specific 
number of years in the health state to a gamble with a probability (p) of achieving full 
health for the same number of years and a complementary probability (1-p) of 
immediate death. The probability of full health (p) is varied until the individual is 
indifferent between the alternative, and the quality weight of the assessed health state is 
equal to (p) (Johannesson et al., 1996).  
   Drummomd and colleague stated that future health outcomes are clearly 
uncertain in the real world. Therefore, the preferences measured under uncertainty 
(utilities) are the more appropriate (Drummond and McGuire, 2007). The three different 
methods result in different scores. The SG generally produces higher utility values than 
the TTO (Bravo Vergel and Sculpher, 2008). The SG usually gives the highest weight 
followed by TTO and VAS.    
2.6.5 Valuing life years: the concept of a QALY 
The outcomes from treatment and other health programs have two fundamental 
components, the quality and the quantity of life (Whitehead and Ali, 2010). The quality of 
life will result in a number of dimensions relating to both physical and mental capacity. 
The quantity of life is expressed in terms of survival or life expectancy (Phillips and 
Thompson, 2009). A Quality adjusted life year (QALY) takes into account both the 
quantity and quality of life generated by health care interventions and treatments. It is 
the arithmetic product of life expectancy and measure of the quality of the remaining life-
years. Moreover, a QALY combines both mortality and morbidity measures of health by 
weighing a year of life by the quality of life (that is utility) experience. QALYs are 
estimated by assigning every life-year a weight between 0 and 1. A weight of zero 
reflects a health status that is valued to be equal to death and one reflects full health. 
There are also disability adjusted life years (DALYs) as an outcome measure (Lorgelly 
et al., 2010). DALYs are years of healthy life lost, 1 represents the greatest amount of 
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disability (equivalent to death) and 0 represents  no disability (full health) (Gold et al., 
2002).   
   The concept of QALYs is to combine the survival of an individual with their 
HRQoL, as shown in figure 2.1.  This demonstrates the QALYs that can be gained by an 
individual by comparing one treatment and without treatment.  The QALY shows a 
concept of how many extra months of years of life of a reasonable quality a person 
might gain as a result of treatment or interventions (particularly important when 
considering treatments for chronic disease). Consider an individual suffering from a 
particular disease without treatment, the lower line shows the health profile if no 
treatment is received, where the HRQol reduces over a period of time until death (Death 
A). In treatment groups, their HRQol remains at a higher level for longer. However, the 
subject would experience side effects during treatment and then be without disease until 
they die (Death B).  
 
Figure 2.1 QALY gained from an intervention 
Based on fig 6.6 chapter 6 in Methods for the Economic Evaluation of Health care 
Programmes (Drummond, 1987) 
 For example, The QALY is calculated simply by multiply the duration of time 
spent in a health state by the HRQoL weight (utility score). The QALYs calculation 
based on this figure is as follows. Without treatment the estimated QALYs are 0.25 year 
at 0.9 + 1.5 years at 0.5 = 0.98 QALYs.  With treatment the estimated QALYs are 0.75 
year at 0.7 + 1.5 year at 0.8 + 0.25 year at 0.6 = 1.88 QALYs.  Therefore, 0.9 QALYs are 
gained with treatment.  
   Traditionally, the impact of health care has been measured in terms of its effects 
on mortality.  Since, health is much more than just being alive, its effects on morbidity 
are increasingly being taken into account. Moreover, mortality and morbidity data says 
nothing about what the priority weights given to one condition relative to another ought 
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to be. Therefore, to quantify the health effects of therapy, it is necessary to measure 
something about their effects on life expectancy and health related quality of life. CEA 
expresses the outcomes (effectiveness, benefits or consequences) in terms of natural 
units, which include survival, cost per exacerbation avoided, improvement in health 
status, years of life gained or clinical parameter (e.g. response or remission rates, 
reduction in blood pressure etc). The results are usually expressed as a cost per unit of 
effect. However, in any one program there is often more than one outcome of interest, 
some outcomes are more important or more valued than others.  Intermediate outputs 
are unsuitable because they cannot directly be converted into an outcome measurement 
like QALYs gained, which is required for CUA.  
2.7 Time Horizon 
The time horizon should be sufficient in length to include all major clinical and economic 
outcomes and is distinct from the length of treatment effect (Gold et al., 1996) 
(Husereau et al., 2013). However extending the time horizon beyond the period after 
which there are no meaningful differences is unnecessary and to maintain consistency, 
costs and outcomes should have the same time horizon applied to them.  
   The time horizon essentially depends on the clinical area being considered, 
however lifetime horizons are suitable for most models, and for decision tree models this 
would normally be from the onset of treatment until a recovery or death (Hay and 
Jackson, 1999). Shorter time horizons can be considered for acute conditions, for 
example; however this should only be done if there are no long term complications 
associated with the disease process or intervention . Finally, in certain circumstances 
multiple time horizons may be justified, for example trivial data can be collected for short 
term analysis in order to complement more important patient data collected over the 
long term (NICE, 2013).  
2.8 Discount Rate 
   Economic evaluation combines total costs and health outcomes over time. 
However if such costs and outcomes occur beyond one year in the future they should be 
discounted to present values to adjust for time preference. A standard method for 
discounting should be adopted across evaluations, and the discount rate clearly stated, 
as discount rates are not universal across all guidelines, with differences depending on 
setting, location and perspective of an analysis. For example, NICE set the discount rate 
at 3.5% for both costs and outcomes (NICE, 2008c) (NICE, 2013). 
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2.9 Sensitivity analysis 
Sensitivity analysis is an essential tool to investigate outcomes that are obtained from 
health economic models. The tool is employed to estimate the effect of uncertain 
variables on the robustness of model results, and indeed Adronis (2009) argues that 
sensitivity analysis is an appropriate method for handling uncertainty (Andronis et al., 
2009) 
  There are several ways of undertaking sensitivity analysis, such as one–way and 
multi-way sensitivity analysis and probabilistic sensitivity analysis, each of which is 
discussed below (Briggs et al., 1994). Together these complementary tools offer a 
collection of techniques for dealing with uncertainty, and are best used together to help 
clarify the level of uncertainty in the results of a model, and consequently of the model 
robustness and its recommendations.  
2.9.1 Univariate (one-way) sensitivity analysis  
This is the simplest form of sensitivity analysis and involves simply varying one value in 
the model by a given amount, and examining the impact that the change has on the 
results in the model. One-way analysis can be performed using a number of different 
approaches, each of which is useful for different purposes (Briggs et al., 1994). For 
example, each parameter of a model can be changed individually by a certain amount to 
find out which parameters have the greatest effect on the results of the model. 
Additionally another approach would be to individually vary every parameter in the 
model to their greatest and least possible values, based on the data confidence 
intervals, in situations where the decision maker has little confidence in the models 
inputs. The limitations of one-way sensitivity analyses should be noted. The examination 
of one parameter at a time creates a incomplete picture of uncertainty and may 
underestimate how uncertain the results of the model actually are. Finally, a more 
detailed approach to univariate sensitivity analysis, called ‘threshold analysis’, is to 
examine the impact of varying the size of a single input parameter over a range of 
values. This helps the analyst to understand the relationship between the model’s 
results and the input values (Briggs et al., 1994). 
2.9.2 Multivariate (multi-way) sensitivity analysis  
This is an extension of one-way sensitivity analysis, which involves changing two or 
more key parameters at the same time and studying the combined effect on the results 
of the evaluation (Briggs et al., 1994).  This type of analysis takes into consideration the 
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probability that more than one parameter value in a model is uncertain, however it 
becomes increasingly more complex and difficult as the number of inputs involved 
increase (Taylor, 2009). One advantage of multivariate sensitivity analysis over one-way 
sensitivity analysis is that its results are more realistic; one-way analysis can be difficult 
to interpret as it only presents a partial picture of uncertainty.  
A specific form of multivariate sensitivity analysis is ‘scenario analysis’, of which there a 
number of approaches. For example extreme case analysis, also known as ‘worst/best’ 
case analysis looks at a set of extreme values across parameters; the most optimistic 
and pessimistic values chosen from the perspective of the intervention being assesse 
(Briggs et al., 1994)d. If an intervention is preferred under base-case assumptions, high 
cost/ low effectiveness (pessimistic) assumption, low cost high effectiveness (optimistic) 
assumptions, the analyst can be confident in the conclusion of the study (Briggs and 
Gray, 1999). 
2.9.3 Probabilistic sensitivity analysis 
The final form of sensitivity analysis that is considered is probabilistic sensitivity analysis 
(PSA). This method assigns a specific distribution to each input parameter in the model 
rather than a single value and, and by drawing randomly from those distributions using 
computer software, a large number of mean cost and effectiveness estimates are 
generated that can then be used to form a joint distribution of the differences in cost and 
effectiveness between interventions (Briggs et al., 2006). This sensitivity analysis 
method can provide a more complete assessment of the uncertainty associated with all 
inputs in a model.  However, Although PSA is similar to univariate and multivariate 
sensitivity analysis as parameter values are still substituted with different values, it 
should complement not replace these sensitivity analyses as PSA does not allow for the 
consideration of each type of uncertainty (Briggs et al., 1994).  
2.10 Type of Economic Evaluation 
The aim of economic evaluation is to present a methodology, which can be employed to 
certify that the efficient deployment of scarce health care resources in the absence of 
the price signals a free market would produce. Economic evaluation is essentially a 
comparative technique that examines alternative courses of action in terms of both their 
costs and health outcome  consequences (Drummond, 1987). The selection of a type of 
economic evaluation depends on the purpose of the study or the question to be 
addressed and may also influence by factors such as data or target audience. 
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   There are several different types of economic appraisal. There are different ways 
in which these types can be classified and presented. The first method is to classify 
them according to efficiency. The second is to classify them according to cost and 
benefits measured and how this is done. Lastly, economic appraisal can be classified by 
the type of decision that they apply to.  The most well-known and popular classifications 
in health economics are given by Drummond and colleague (Drummond, 1987) 
(Drummond, 2005b). Drummond et al classified using both the measurement and 
decision type principles which include cost-benefit analysis (CBA), cost-effectiveness 
analysis (CEA) and cost-utility analysis (CUA). Similarly, four different types of economic 
evaluation are often discussed in the literature;  cost-minimization analysis (CMA), cost-
benefit analysis (CBA), cost-effectiveness analysis (CEA) and cost-utility analysis (CUA) 
(Cunningham, 2001) (Shih and Halpern, 2008). Furthermore, the possible fifth approach 
is cost-consequence analysis (CCA) has been employed by other commentators 
(Drummond, 1987). 
   This thesis presents the types of economic evaluation in two broad 
classifications, distinguished by whether or not health outcomes are measured in the 
same units as resource consequences. Hence CBA describes the situation where all 
coast and benefit are measured in the same units (usually monetary). CEA is used to 
explain the general class of approach where costs are measured in terms of money, but 
that health outcome is measured in units other than money. CUA is considered as a 
special case of CEA characterised by a generic measure of health outcome. 
Subsequently, this section briefly discusses types of economic evaluations and the 
criteria used to select the types. 
2.10.1 Cost-minimisation analysis 
Cost-minimisation analysis (CMA) is a method of economic evaluation in which two or 
more therapeutic alternatives are compared in terms of net cost, which chooses the 
least total cost alternative interventions. CMA is applied when the evidence is shown to 
have equivalent clinical outcomes of two alternative programmes. Moreover, the 
transparent and intelligible equivalence of comparators in terms of efficacy must be 
presented. 
2.10.2 Cost-benefit analysis 
The second analytical type is cost-benefit analysis (CBA). CBA is an evaluation 
technique that quantifies both costs and outcomes, compares alternative interventions 
using in monetary units such as the Dollar or the Euro. Subtracting the costs of an 
Chapter 2  26 
 
intervention from the value of outcomes of the intervention can calculate the net benefit. 
The choice criteria as to whether or not to accept the intervention or technology is 
considered whether the benefits are greater than the costs subject to budget limit.  
   The main advantage of CBA as an analytic technique is that is has an 
uncomplicated decision rule which is consistent with economic theory and will lead to an 
efficient distribution of health care resources. Since resources and health outcomes are 
valued in the same units, if the health outcome benefits are greater than the resource 
use cost then the health care programme in question should be implemented. If, on the 
other hand, the costs outweigh the benefits, the programme should not be implemented. 
The drawback of the CBA is that a monetary assessment of clinical results must be 
made even though methodologically this is difficult to present. Because of those 
methodological difficulties, this method of analysis is not used for NICE decision making 
(NICE, 2013).  
2.10.3 Cost-effectiveness analysis 
The main purpose of CEA is to maximise the health effects obtained for a given budget 
(Karlsson and Johannesson, 1996).The definition of cost-effectiveness analysis (CEA) is 
taken to be the analysis of alternative courses of action in terms of their resource costs, 
evaluated in monetary terms and health outcome effects evaluated in natural 
units(NICE, 2008c). The more useful of CEA is a full economic evaluation where both 
costs and outcomes of health programmes or treatments are analysed. CEA expresses 
the consequences (effectiveness, benefits or outcomes) in terms of natural units, which 
include survival, cost per exacerbation avoided,  improvement in health status, year of 
life gained or clinical parameter (e.g. response or remission rates, reduction in blood 
pressure etc) (Oostenbrink et al., 2005) (Shih and Halpern, 2008). CBA is appropriated 
for answering questions about whether or not health programmes or treatment are an 
efficient use of resources, while CEA presents which of the possible ways of providing 
those is the most efficient. However, CEA is a handy technique for comparing alternative 
intervention whose effects are in similar units but can not be used to measure an 
isolated single programme and cannot evaluate interventions which have several types 
of clinical effects. In this problem are drawbacks that lead to development of cost-utility 
analysis (CUA).  
2.10.4 Cost-utility analysis 
The final type of economic evaluation is cost-utility analysis (CUA) where costs are 
measured in monetary units and the benefit is assessed as a not-monetary but utility-
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adjusted outcome, the quality adjusted life year (QALY).  On the other word, the benefit 
measurement is an extension of CEA that identifies the change in health status measure 
known as the QALY.  Information from QALY along with cost can be applied to guide 
resource allocation. Such an approach allows decision to be made concerning the 
suitable level of resources to be devoted to different health care programmes. Hence, 
CUA analysis can be seen as addressing allocative efficiency concerns within the health 
service budget. The implicit goal of CUA is the maximisation of health gain from a fixed 
budget. CEA and CUA are similar methods of economic evaluation, particularly in the 
USA and some authors do not distinguish (Gold et al., 1996). 
2.11 Using decision analytic modelling for economics 
evaluation  
Over the last two decades, decision modelling has been widely used in many countries 
around the world to evaluate alternative health care interventions (Hunking et al., 2001) 
(Taylor et al., 2004). In the health care field, modelling is usually applied to scheduling 
budgets, the workforce and the location of facilities (Brennan and Akehurst, 2000). In 
addition, decision analysis is an established framework used to inform decision making 
under conditions of uncertainty. Policy making involves choosing an action after 
weighing the costs, benefits and risk factors of the information of individual patients or 
the patient population (Siebert, 2003). The purpose of decision modelling is mainly to 
allow for the variability and uncertainty associated with all decisions (Briggs et al., 2006). 
Subsequently, the results of decision analysis can inform a decision both for an 
individual and for health care policy (Eddy, 1990) (Richardson and Detsky, 1995). 
Models for the economic evaluation of health technologies make valuable information 
available to policy makers and are a useful tool for demonstrating the detailed and 
complex “real world” with a more simple and understandable structure (Taylor, 2009), 
represented by a series of numbers, mathematics and statistical relationships. Several 
definitions have been presented for the term “model” as it applies to the context of 
health care. The International Society for Pharmacoeconomics and Out-comes 
Research (ISPOR) Task Force on Good Research Practice defines Modelling Studies 
as “an analytic methodology that accounts for events over time and across populations, 
that is based on data drawn from primary and/or secondary sources, and whose 
purpose is to estimate the effects of an intervention on values of health consequence 
and cost” (Weinstein et al., 2003). However, it is unlikely that a model will ever include 
all the possible ramifications of a particular option under consideration (Briggs et al., 
2006).  
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   Decision analysis is applied flexibly to the evaluation of health care, where 
alternatives are judged upon the basis of expected costs and health outcomes. Decision 
analysis is a systematic approach that uses explicit and quantitative methods to analyze 
decisions under conditions of uncertainty (Pauker and Kassirer, 1975). It uses 
mathematical relationships to define a series of possible consequences and result in a 
set of alternative options being evaluated. Based on the inputs, the likelihood of each 
consequence is expressed in terms of probabilities where each consequence has an 
outcome and a cost. The technique can calculate the expected cost and outcome of 
each option under evaluation. The purpose modeling in economic evaluations is to 
synthesise data for the purpose of making a decision.  
2.12 A framework incorporating decision analytical 
modelling into economic evaluations 
There are many stages in developing a decision model for economic evaluation (Briggs 
et al., 2006). In 1976, Shepard and Thompson suggested measuring costs in monetary 
units and health benefits in non-monetary units, consisting of five major analytical steps 
(Shepard and Thompson, 1979). However, the most prevalent framework that 
incorporates decision analytical modelling for economic evaluations was proposed by 
Biggs and colleagues (Briggs et al., 2006). The six distinctive stages of this framework, 
presented in Table 2.4, indicate how to develop a decision model when conducting an 
economic evaluation. The first step begins with defining the programme or intervention, 
which focus on processes and limits. Secondly, both net monetary cost for the 
prevention and treatment of the illness under the proposed programme or intervention, 
based on the cost of current practice, as well as the discounted present value are 
computed. The third step is to compute the respective health effects or benefits, 
followed by a sensitivity analysis, which is performed in steps four and five. The final 
step is then to complete a Value of Information analysis. This framework does not 
however quantify the decision uncertainty associated with the mean health outcome and 
mean cost in the model.  
Table 2.4 Briggs’s framework for decision analytical modelling  
Step Framework 
Step 1 Specifying the decision problem 
Step 2 Structure the decision model 
Step 3 Identify and Synthesis evidence 
Step 4 Deal with Uncertainty and Heterogeneity 
Step 5 Presenting Uncertainty in cost, effects and cost-effectiveness 
Step 6 Value of additional research 
Source: Adapted from Briggs et al (2006) 
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2.13 Specifying the decision problem 
This step entails clearly identifying the question that needs to be addressed in the 
analysis (CADTH, 2006). The perspective, comparators of study, and time horizon of the 
model, in terms of which cost and consequence are considered relevant, should be 
stated clearly (Philips et al., 2006). Moreover, disease states should be selected to 
reflect the underling biological process of the disease in question and the impact of 
interventions and therapies (Philips et al., 2006).   
2.14  Structure the decision model 
   Economic evaluation can take different structures including formalised 
approaches such as decision tree, Markov analysis, and discrete event simulation. 
Models are useful tools for simulating real-world situation in health economic 
evaluations. The choice of structures depends on the nature of disease, the impact of 
technology and the availability of data for its assessment (Brennan et al., 2006) 
(Brennan and Akehurst, 2000).  Briggs and colleagues also suggested that choices have 
to be made to structure the model based on the nature of the interventions themselves 
and the natural history of a particular condition and the impact of the options on that 
process (Briggs et al., 2006).  There are two main approaches in the construction of a 
model for the CEA, namely deterministic and stochastic approaches. Where decision 
tree and Markov analysis is deterministic approach, and discrete event simulation (DES) 
and Monte Carlo simulations is stochastic approach. The majority of the health care 
models use a deterministic approach (Drummond, 2005b) (Drummond et al., 2005). On 
the other hand, Briggs and colleagues consider the two forms of the cohort model. First, 
whether the model should seek to characterise the experience of the “average” patient 
from a population sharing the same characteristics, such as decision tree and Markov 
models. The other form of the model should explicitly consider the individual patient and 
allow for variability between patients, which use the micro simulations model (Briggs et 
al., 2006).  This thesis present the decision analysis based on Briggs and colleagues.   
2.14.1 Decision trees  
The decision tree is probably the most common structure that describes a clinical 
decision and possible outcomes (Drummond, 1987) (Briggs et al., 2006) . A decision 
tree is a graphical model that shows the consequence for each possible outcome. A 
decision tree is included with three types of nodes: decision nodes, chance nodes and 
terminal nodes, shown as squares, circles and triangles respectively. Typically, the 
decision tree is drawn by starting at the far left with decision nodes and moving from left 
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to right through a consequence decision and chance nodes. The decision tree diagram 
begins with the decision node, which represents the alternative options or interventions 
of the decision in the model. Chance nodes may come out of the decision nodes, 
showing the range of possible pathways. Similarly, the pathways are built up through a 
series of branches showing each pathway. A branch of chance nodes will illustrate the 
probability of a particular pathway occurring. Probabilities show the likelihood of a 
particular event at the chance node. Moving from left to right, the probabilities in each 
branch of those following events relate to those patients who have undergone particular 
previous occurrences. Each pathway ends in the terminal node which represents the 
average outcome of this event. The expected value probabilities are calculated by 
multiplying along the pathway probabilities of subsequent events, which is the joint 
probability.  Expected values are based on the summing up of the pathway values 
weighted by the pathway probabilities. For economic evaluation, the costs and health 
benefits are shown in the final outcomes in each partway. Another way of working out 
the expected costs and effectiveness is by ‘rolling back’ the tree for given option in a 
decision tree. This will give exactly the same answer as the approach mentioned above.  
   However, simple decision tree is usually appropriated with situation which time 
frame is short and the mortality of patients does not differ across strategies (Barton et 
al., 2004). The tree is not suitable in chronic disease and can become very bushy in 
modelling, making them unwieldy and complex to programme and analyse (Drummond, 
1987) (Drummond and McGuire, 2007).  
2.14.2 Markov Model 
Markov models have been frequency applied for published decision analyses (Barton et 
al., 2004). The limitation of decision trees models are resolved by Markov models but 
certainly not all. Particularly, Markov models are functional when the decision problem 
involves a risk that is ongoing over a period time. Markov models can deal with the 
pattern of recurring –remitting disease over a period of time and of competing clinical 
risks characteristic of many chronic diseases, which is needed to reflect a large number 
of possible outcomes over time (Briggs et al., 2006). A cohort-based Markov matrix uses 
a transition probability per unit time for individuals in the cohort to change to another 
state, with related costs and utilities. Subjects in cohorts are designed to be in one of a 
finite number of health states and a patient in each state can only make one state 
transition during a cycle. The cycle of models have durations, depending on the nature 
of the disease, which might last one day, one week, one month or one year. Subjects 
move through the model starting at the beginning, middle or end of each cycle. The 
patients in the modelling move through the models in a number of ways, either stay in 
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the same state, or travel to a worse state (or a state in which a specific event occurs), or 
they move to death state. The transition probabilities determine the proportion moving 
between states at fixed time periods or cycles (Glasziou and Sanders, 2002). Cost and 
effects are typically incorporated into these models as a mean value per state per cycle. 
Adding the cost and effectiveness over the states and then weighting them in 
accordance with the time the patient will be in each state gives expected values 
   Markov models are applied to estimate the clinical and economic consequences 
for disease with recurrent events. The limitation of Markov modelling is that the model 
lacks memory (Briggs et al., 2006). Using the Markov model on a patient in a certain 
state, the model cannot make a distinction between someone who has just entered a 
state and someone who has been in the state for some time and remains in the same 
state. A problem with this is that time is frequently correlated to worsening disease, 
especially with chronic disease and this correlation is ignored in this model. In addition, 
decision trees are used within Markov model as call Markov cycle trees (Vos et al., 
2005). One form of this is when transitions between Markov states are characterise in 
term of a tree  (Briggs et al., 2006). 
2.14.3 Discrete Event Simulation 
Discrete Event Simulation (DES) is unlike Markov Modelling in several aspects. DES 
can resolve the problem associated with the Markov model where there is no memory of 
previous events. The three components included in DES are entities, event and time. 
Entities usually incorporate personal characteristics into modelling. Individuals’ attributes 
such as age, sex, previous history of illness of subject can be taken into account and 
tracked over the modelling period through the natural history of disease. An event is 
anything that occurs during the simulation, such as an exacerbation, and events can 
occur sequentially, simultaneously or both. This idea extends well beyond the transitions 
in Markov model because the event need not imply a change in the patient’s state. In 
terms of time, it is an explicit element of DES models and the model can be run for as 
long as is necessary are more flexible than Markov models (Le Lay et al., 2006). The 
DES is not restricted to the use of equal cycle length, but when using Markov modelling 
a fixed cycle length is required. Also, the time to the next event may derive from either a 
parametric or an empirical distribution to characterize the variability of time to next event 
between individuals in the population (Karnon, 2003). DES is most successfully applied 
to processes such as modelling the introduction of new equipment within the setting of a 
GP clinic or for queuing. Furthermore, two main interactions between individual patients 
should be taken into account in two main circumstances. First, when modelling of 
infectious disease, where the risk of an individual catching the disease depends on how 
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many other people already have it. Second, when restrictions on resources mean that 
the choice of treatment for one patient affects what can be given to another. Methods 
such as DES and system dynamics (SD) are required when interaction is a significant 
issue in modelling. DES works at an individual level, where as SD works on an 
aggregated level (Barton et al., 2004).  
2.15 Identifying and synthesizing evidence 
For economic evaluation it is important to use all relevant evidence. In the context of 
parameter relating to the effectiveness of intervention, this is consistent with evidence-
based medicine. Ideally, evidence on outcome should come from a randomised 
controlled clinical trial. If a clinical trial is unavailable, then evidence should be obtained 
from a meta-analysis, or an indirect treatment comparison analysis. In the UK, the NICE 
demand a systematic review, evidence-based analysis of input parameters in the model. 
This framework is required to synthesise this range of evidence (NICE, 2008c) (NICE, 
2013) . Moreover, this also requires synthesis of evidence in a computer-based 
mathematical model. The role of decision analysis is a methodology for synthesising 
evidence on different parameters to inform estimates of net cost and net effectiveness 
from different sources (Karnon and Brown, 1998).  Clinicians, health care managers, 
policy makers and consumers have wide-ranging information needs. They require high-
quality information on the effectiveness, meaningfulness, and appropriateness of a large 
number of healthcare interventions. Moreover, economic evaluation also needs 
appropriate information for using as an input parameter in an economic model. Data can 
be chosen based on the principle of systematic review and meta-analysis 
2.16 Making decision models probabilistic  
Economic evaluation models, as mentioned in section 2.12, are a useful tool to aid 
policy makers to make decisions in health care programmes. Economic evaluation of 
interventions or therapy often relies on mathematical models to account for relevant 
clinical, biological, epidemiological, and economic factors. The key point of decision 
modelling is to permit for the variability and uncertainty linked with all decisions (Briggs 
et al., 2006).     
2.16.1 The role of probabilistic models 
The aim of probabilistic modelling is to be a sign of the uncertainty in the input 
parameters of the decision model and explain what this means for uncertainty over the 
outputs of interest such as measures of cost, effect and cost-effectiveness, in both 
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incremental cost-effectiveness ratios and net-benefit measure (Briggs et al., 2006) 
(Claxton et al., 2002).  There will never be complete information on all the possible 
consequences of a particular intervention in a given population.  This uncertainty needs 
to exist in order for decisions to be made according to the best available evidence and 
best practices in decision analytic modelling (Bilcke et al., 2011) . Briggs and co-workers 
propose three main reasons why it is important to consider uncertainty, even if the 
concern of decision maker is expected values. Firstly, most models relate to combining 
input parameters in ways that are additive and also multiplicative as power functions, 
resulting in models that have non-linear input and output parameters. Secondly, 
uncertainty over the results of an analysis implies the possibility of incorrect decision 
making which impose a cost in terms of benefits forgone, such that there may be value 
of obtaining more information even in a world where our only interest is in expected 
values. Lastly, policy changes are rarely costless exercises and decision reversal may 
be problematic, such that there may exist value associated with delaying a decision that 
may be impossible, or problematic to reverse (Palmer and Smith, 2000) (Briggs et al., 
2006). This section will describe how models can be made probabilistic in order to 
capture parameter uncertainty. 
2.16.2 Variability, heterogeneity and uncertainty 
Uncertainty exists in all economic evaluation. There are three concepts commonly 
referred to in relation to uncertainty in economic evaluation; variability, heterogeneity 
and decision uncertainty.  
   Variability refers to the differences that are found amongst patients by chance, 
and in some of the medical literature, is referred to as first order uncertainty. On the 
other hand heterogeneity refers to the differences amongst patients that can mostly be 
explained, such as age and sex. As heterogeneity is not a source of uncertainty though, 
it is quite distinct from variability.  
   Additionally, rather than variability or heterogeneity, it is uncertainty that decision 
models aim to capture.  A number of guidelines for economic evaluation discuss the 
importance of considering different types of decision uncertainty and specific 
frameworks for quantifying uncertainty have emerged (Briggs and Gray, 1999) (Briggs, 
2000). Two forms of uncertainty can be identified, the first of which is parameter 
uncertainty. Economic models require information to populate them, and these 
information requirements are often referred to as the parameters of the model (Briggs, 
2000). The level of uncertainty surrounding a parameter is dependent on the extent to 
which its value has been estimated and has been referred to as second order 
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uncertainty to differentiate it from variability (Briggs et al., 2006). The second form of 
uncertainty is model uncertainty, is considered to be external to the decision model and 
does not relate to the parameters but to the assumptions formulated by modelling 
framework (Drummond, 2005b) (Kim et al., 2010) (Bilcke et al., 2011). In other words, it 
refers to uncertainty about the extent to which the structure of the model adequately 
captures the relevant characteristics of the disease and intervention being investigated  
(Gold et al., 1996). 
   Stinnet and Paltiel refer to the categorisation of uncertainty in terms of first and 
second order (Stinnett and Paltiel, 1997). They explain that first order uncertainty (or 
variability) is random error, which reflects the inherent stochastic natural of a trial. This 
uncertainty persists even when the probability distribution of an outcome is known with 
certainty. Second order uncertainty is systematic error that corresponds to uncertainty in 
the parameters of the probability distribution of the outcome. In CEA, second order 
uncertainty is often considered. There is usually a lot of uncertainty in the estimation of 
expected health costs and outcomes, which leads to uncertainty around estimates of 
intervention respective, ICER.   
2.16.3 Distributions for probability parameters 
In probability sensitivity analysis, inputs are defined as probability distributions to reflect 
their full uncertainty.  In capturing parameter uncertainty in the estimation of expected 
values of a parameter, the model needs to represent the sampling distribution of the 
mean. This has important implications for the choice of distribution for any of the 
parameters to represent the uncertainty in any parameter of the model, which vary 
depending on the family or from of distribution (Briggs et al., 2006). However, the 
probability distribution that represents uncertainty in a decision analytic model is not 
chosen randomly but decided based on the type of data, the parameter type and 
estimation process (Claxton et al., 2005b) (Briggs et al., 2006). Briggs and Claxton and 
colleagues discuss the types of distribution as follows: 
   Normal distribution: The normal distribution is a very important statistical data 
distribution pattern. When graphed as a histogram it creates a bell shaped curve known 
as a normal curve. The curve is symmetrical about a single central peak at the mean ( ) 
(average of the data), so fifty percent of the distribution lies to the left of the mean and 
fifty percent lies to the right. Therefore, a random variable (parameter) on the normal 
distribution is of any value between negative and positive infinity (-    . Because of the 
central limit theorem, such distributions are considered to be a good choice to represent 
uncertainty. The standard deviation (   describes the amount of variation of the normal 
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distribution. The mean value of a parameter and its standard deviation are required to 
calculate normal distribution.  
   Log normal distribution: The log normal distribution is a continuous probability 
distribution that ranges from zero to positive infinity (0,   and is positively skewed. This 
distribution does not cover any negative values and this distribution is suitable for 
parameters that are non-negative as well as highly skewed or are multiplicative, such as 
ratios. A normal distribution is generated if the natural logarithms of the parameters of 
such a distrirbution are calculated.  
   Beta distribution: In probability theory and statistics, the beta distribution is 
employed to model the proportion of successes (n) in a binomial trial and define the 
interval (0,1). Two positive shape parameters that appear as exponents of the random 
variable and control the shape of the distribution are α and β.  α is the number of events 
that occur  and β is the number of non-events. 
    Dirichlet distribution: The Dirichlet distribution, being multivariate in nature, is 
generally considered to be the multinomial extension of the beta distribution with one 
parameter per category. It is thought of as flexible and convenient, computationally, as 
its components take values (0,1) 
   Gramma distribution: The gamma distribution is useful for continuous 
variables, particularly those considered to be highly skewed. It is constrained within the 
interval zero to positive infinity (0,  . Gamma distribution is represented by α and β. 
2.16.4 Choosing distributions for parameters 
This section discusses how to choose distributions for parameters of decision models. 
Assigning the probability distribution is the first step in making a probabilistic model.  
The common distributions in PSA are Normal, Log-normal, Beta and Gramma 
distributions. Table 2.5 shows the common types of distributions and distributional forms 
of parameters (Briggs et al., 2006).  
   Probability parameters can only take values between zero and one (0,1). Beta 
distributions are commonly representative of such parameters as prevalence, diagnostic 
test accuracy, and the probabilities exclusive events must some to one. Uncertainty in 
this probability can be presented by two parameters, α and β, as mention in the previous 
section, β = (sample size (n) – the number of events occurring (α)).  Normally, α and n 
are reported in publications, and these are used to calculate the β for the beta 
Chapter 2  36 
 
distribution. On the other hand, as opposed to binomial data, multinomial data with 
numerous categories, each represented by proportions that sum to one, are appropriate 
for the Dirichlet distribution. If the overall sample size and the number of events of 
interest for each category are reported in a publication, the data can then be used to 
calculate proportions for each category to fit the Dirichlet distribution.  
   Costs data are calculated from resource usage, weighted by unit costs. 
Therefore, cost parameters should not be lower than zero, as it is not possible to have a 
negative result, although they can range up to infinity.  When considering which 
distribution best fits the costs parameter, gamma distribution can be selected as it is 
constrained to value zero and upward to infinity, (0,  . If cost estimates of a suitably 
large sample are found to be symmetric around the mean, it can be assumed that the 
central limit theorem applies and a normal distribution fitted to the data. However if the 
data is highly skewed, a more characteristic situation for cost data, both log-normal and 
gamma distribution are used to fit the distribution. 
   Utility can be suited to the Beta distribution only if it is appropriate to assume that 
the utility range is between close to zero and close to one. However, in cases of severe 
life-threatening illness, the utility can be very low or negative utility and so utility ranges 
between negative infinity and one (     . Therefore, the beta distribution should be 
avoided in such cases.  When the transformation of UD = 1 - utility, where UD is a utility 
decrement, the distribution is constrained on the scale zero to infinity (0,    and is 
better fitted to a Gamma or Log-normal distribution.  
   Where publications only report the mean and standard deviation (SD) for a 
parameter point estimate,  the Method of Moments can be applied to obtain α and β 
from the known values of the mean and SD in order to fit the Beta distribution. In 
situations where publications report the mean without standard error (SE), an assumed 
standard error that is of sufficient size to reflect a broad enough uncertainty range can 
be adopted. However if rather than a specified SE, a 95% confidence interval is 
reported, then the SE can be calculated using the confidence limits.  
Table 2.5 Distribution parameters and the distributional forms 
 
Distribution Scale Cost Utility Relative risk Prevalence Mortality Treatment probability 
Normal (continous) (-∞,∞)
Lognormal (interval) (0,∞)
Gramma (continous) (0,∞)
Beta  (binomial) (0,1)
Dirichlet (multinominal) (0,1)
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2.16.5 Assessing parameter uncertainty 
Parameters represent the point estimate (mean values) for a particular population or 
subgroup, but they are estimated with uncertainty from sample data.  In order to handle 
this parameter uncertainty in the decision model, there needs to be an assessment of 
how it impacts the result on the analysis. Cost-effectiveness analysis based on the 
mean value is called deterministic analysis. In probabilistic models, the uncertainties 
around individual parameters are represented using an appropriate distribution for each 
parameter and by drawing a random estimate of the distribution to represent the point 
estimate. By propagating this uncertainty though the model, a measurement of the 
uncertainty in the outcome statistic is derived. A parameter simulation technique (Monte 
Carlo simulation) is used to assess the implication of the results of the study of 
uncertainty in all of the inputs. Using simulation techniques allows propagating 
parameter uncertainty through the model.   
   Once the simulation process has been undertaken for propagating the 
uncertainty, the situation is comparable to one where sample data is available and 
provides an estimation of mean overall parameters such as cost and effectiveness of 
therapy. The average of cost, effect and cost-effectiveness are used to present the 
probability outcomes of uncertainty in the input parameters by drawing randomly from 
the parameters numerous times. In the best practical guidelines (e.g. the BMJ, NICE 
and US Panel), it is recommended that the uncertainty surrounding estimates of cost-
effectiveness needs to be explored when presenting economic evaluation results (NICE, 
2008c). Using any number of iterations greater than 1,000 times is acceptable (Briggs et 
al., 2006). The next section will discuss how to present the cost effective results.   
  
2.17 Presenting the results 
This section reviews in detail the cost-effectiveness plane (CE plane), followed by a 
discussion of the decision rules for cost-effectiveness analysis. Once the relevant 
parameters in a decision model are determined and the appropriate distributions 
applied, probabilistic sensitivity analysis can be performed. Random values form each 
parameter distribution are sampled randomly using Monte Carlo simulations with 1,000 
iterations as mentioned in the previous section in order to provide different cost, effect 
and cost-effectiveness outcomes for each vector of the input parameters. NICE 
guidelines for methods of technology appraisal 2013 suggest standard deciding factors 
should be followed when combining costs and QALY, these should reflect when 
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dominance or extended dominance exists, and present a thorough incremental cost-
effectiveness ratio (ICERs) (NICE, 2013).   
Cost-effectiveness analysis on the CE plane 
The purpose of cost-effectiveness analysis is to compare the cost and health outcomes 
of one treatment compared to some relevant alternatives (O'Brien et al., 1994a) 
(Shepard and Thompson, 1979) (Sculpher et al., 1997). In other words, a new 
experimental therapy (or treatment group) may be compared with and some current 
practice (or control). In terms of costs, the true costs of the new therapy (Ct) versus the 
control therapy (Cc) are presented and the true effectiveness of the new therapy (Et) 
versus the control therapy (Ec) are also illustrated, as shown in Table 2.6. Four 
situations have been identified by O’Brien and colleagues that can occur with regard to 
the incremental cost and effectiveness of therapies, as outlined in (O'Brien et al., 1994b) 
(Drummond and McGuire, 2007).  
   Table 2.6 Characteristics of cost-effectiveness and not-cost-effectiveness regions in the 
cost-effectiveness plane (CE) 
Situations Interpretation CE plane 
quadrants 
1. Ct – Cc > 0; Et – Ec < 0 dominance – reject experimental therapy as it is 
both more expensive and less effective than 
existing therapy 
NW 
2. Ct – Cc > 0; Et – Ec > 0 trade-off consider magnitude of the additional cost 
of the new therapy relative to its additional cost 
NE 
3. Ct – Cc < 0; Et – Ec < 0 Trade-off consider magnitude of the cost-saving of 
the new therapy relative to its reduced effectiveness 
SW 
4. Ct – Cc < 0; Et – Ec > 0 dominance – accept experimental therapy as it is 
both cheaper and more effective than existing 
therapy 
SE 
Base on page 174, chapter 8 of economic evaluation in health care (Drummond and 
McGuire, 2007) 
 Four situations in are equivalent to the four quadrants of the CE plane. This 
plane has been advocated for the analysis of cost-effectiveness results (Anderson et al., 
1986). The difference in cost and the different in health outcome between two therapies 
can fall into one of four quadrants of the CE plane.  There are a lot of authors discussed 
and presented the CE plane in different way.   The four situations are presented in 
different ways. The most popular used is compass direction which shown in north, 
south, east and west (Hoch et al., 2002) (Fenwick et al., 2006) (Briggs, 2007). Another 
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way to present the result in different quadrants of the cost-effectiveness plane is Roman 
numbers (Black, 1990) (Briggs, 1998) (Drummond, 2005b).  
   This thesis presents the cost-effectiveness plane by compass direction. Figure 
2.2 illustrates the cost-effectiveness plane. In the diagram, the horizontal axis represents 
the difference in effect between the therapies of interest, and the vertical axis represents 
the difference in costs. A therapy can be placed anywhere on this diagram according to 
its incremental costs and effectiveness.  In the SE and NW quadrants one intervention is 
simultaneously cheaper and more effective than the other (situation 1&4). However, 
quadrants NE and SW (situation 2&3) on the CE plane represent where an intervention 
is both more effective and more costly. A trade-off must then be made between the 
additional health outcomes and the additional resources required.  Or, in other words, a 
judgement needs to be made concerning whether the additional cost of the more 
expensive therapy is justified by the additional effectiveness associated with that 
therapy. 
     In order to summarise this trade-off, an incremental effectiveness ratio (ICER) is 
calculated. If this ICER is less than the maximum acceptable cost-effectiveness ratio 
then the treatment is considered cost-effective. The ICER is discussed below. A straight 
line is drawn across the NE and SW quadrants and through the origin (as shown in 
Figure 2.2) and represents the maximum acceptable cost-effectiveness ratio. The line 
divides the CE plane into two parts; cost-effective and non-cost-effective. The right side 
of the line indicates that therapies are cost-effective, while the other side indicates cost-
ineffective therapies. 
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Figure 2.2 The cost-effectiveness plane 
Based upon figure 2.3, Uncertainty in cost-effectiveness of health care intervention 
(Briggs, 1998) 
Incremental cost effectiveness ratio 
 The results of CEA are summarised in a cost-effective ratio (CER) (Phillips, 2009). 
According to the individual programme, the result may be an average cost-effectiveness 
ratio (ACER). An independent programme requiring ACER is calculated for each 
programme, by comparing total costs and total outcomes. The ACER can be calculated 
by equation below.  However, ACER does not provide guidance in decision making and 
is  inappropriate to maximise the health effects for a specific share of resources 
(Karlsson and Johannesson, 1996). Therefore, ACER is inconsistent with the underlying 
decision rules of cost-effectiveness analysis.  
      
Ct Cc
ACER= and
Et Ec
   
 
   It is likely that choices will normally have to be made between different therapy 
options for the same condition, different dosages/treatment compared with prophylaxis. 
What must be questioned however is the amount of benefit that can be achieved from a 
new therapy and what cost it is associated with? To answer this question incremental 
cost-effectiveness ratios (ICER) are used. ICER can be calculated, which obtains a 
summary of the cost-effectiveness of one intervention compared to the other. Similarly, 
ICER is the difference in costs between the two interventions divided by the difference in 
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their consequences, and can be described as the incremental price of a health unit 
outcome from the intervention, compared to the other. The interventions that have a low 
cost-effectiveness ratio are good value and would be the preferred option. Alternatively, 
where the costs and benefits of each alternative are calculated and compared with their 
next best alternative, rather than with a common alternative. The ICER can be 
calculated by the following equation. 
Ct Cc Ct-Cc
ICER= -
Et Ec Et-Ec
   
 
   The ICER determines the appropriate measure of cost-effectiveness rather than 
the ACER. The difference of two average ratios is not equal to ratio of the differences 
(Briggs et al., 2006).  The first problem with ACER, in order to make the judgement 
concerning whether therapy represents good value for money, decision-makers need to 
consider the additional cost of new therapy, as treatment A, over the control therapy, as 
treatment B, in comparison to the additional effect, that is the ICER. Suppose that we 
are comparing treatment A versus treatment B. If Treatment B gives the lowest cost per 
unit effect, treatment A shows the greatest overall effect. It could be that society wishes 
to provide treatment A rather than treatment B even though its average cost per unit 
effect is higher. Another problem with ACERs is that they give no information on the 
relative position of the two treatments in the cost-effectiveness space. 
Incremental net benefit  
In this section, two methods for developing point estimates for the difference in cost and 
effect, the cost-effectiveness ratio and net monetary benefit (NMB) are described. If both 
cost and effectiveness are higher with the new intervention, the question will come up 
with will decision maker, should a new intervention be accepted as cost effective or not. 
To answer this question, the decision rule is applied. Decision rule requires the decision 
maker to know the maximum amount that the payer would be willing to spend for and 
additional benefit or maximum acceptable cost-effectiveness ratio. In the other words, 
the maximum willingness to pay for a benefit is known as the cost-effectiveness ceiling 
ratio, which can be plotted as a line through the origin on the CE plane, as demonstrated 
in figure 2.3.  The ICER remains the most popular method of presenting the result of 
CEA and CUA (Drummond, 1987). Interpretation of ICER requires the choice of a cost-
effectiveness ceiling where representing the maximum that society would be willing to 
pay for an incremental health benefit, and the development of the decision rule based on 
this maximum. If the estimated ICER is below some maximum willingness to pay for 
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health gain then that intervention represents good value for money. For example, if the 
ceiling ratio was £ 30,000 per QALY gained, then an intervention which presents 
incremental costs of £10,000 and increased QALY by 0.4. Thereby, it would have an 
ICER at £ 25,000 per QALY and would be considered to be cost-effective in comparison 
to the alternative. If the ceiling ratio presents at £20,000 per QALY, then an ICER of 
£25,000 per QALY would not be considered cost-effective. The cost-effectiveness 
decision rule rearrangement by ICER can be calculated by equation 2.3. The maximum 
acceptable willingness to pay or ceiling ratio is denoted by λ.  
Ct-Cc
Decision-rule= <λ
Et-Ec
   
 
   One of the most major drawbacks of the ICER relates to the mathematical 
difficulty in creating confident intervals for a ratio (McFarlane and Bayoumi, 2004). The 
net benefit approach employs a simple re-arrangement of the cost-effectiveness 
decision rule of equation 3 in order to overcome the problems with cost-effectiveness 
ratios. The limitation of ICER  have led some authors to prefer the incremental net 
monetary benefit (INMB) (Hoch et al., 2002) (McFarlane and Bayoumi, 2004). The INMB 
is calculated by the increase in effectiveness multiplied by the amount of the maximum 
acceptable willingness to pay and subtracting from this the incremental cost of achieving 
the benefit, as shown in equation below.  Using the NMB approach, a therapy is deemed 
to be cost-effective if a positive incremental net-benefit suggests that the therapy 
represents good value for money, while a negative side suggests the intervention is 
cost-ineffective (Drummond, 2005b). > 
   INMB= Ct-Cc λ- Et-Ec 0   
  
     The INMB expression is probably most familiar to economists, and is the one 
most often referred to as “net benefit” in the literature, as mention above. Thus, one 
potential advantage of INMB compared with cost-effectiveness ratios is that we can 
directly compare the difference in arithmetic mean monetary benefits between treatment 
groups to determine NMB by use of the same types of univariate and multivariable 
methods. Moreover, using the net benefit approach, it is also possible to re-arrange the 
inequality in another way to define the net health benefit (NHB), as shown in equation 
below.  
Chapter 2  43 
 
 
(Et-Ec)
NHB= Et-Ec - >0
λ
   
   For both expressions, a positive incremental net benefit presents the health gain 
greater than that from investing the same resources in an alternative therapy. A negative 
incremental net benefit suggests the intervention is cost-ineffective.  
 
2.18 Decision making, uncertainty and the value of 
information  
The previous section described how models can be made probabilistic in order to 
capture parameter uncertainty. In recent years there has been considerable emphasis 
on the development of an appropriate method for handling uncertainty in mathematical 
models, with a trend to move from univariate sensitivity analysis towards a fuller 
probabilistic description of uncertainty, e.g. cost-effectiveness planes, cost-effectiveness 
acceptability curves (CEAC) and distribution of incremental net benefits (Tappenden et 
al., 2004). This section will briefly address how the results of probabilistic modelling 
should be interpreted by decision makers, and how to address the question of whether 
more evidence is required. 
2.18.1 Decision making with uncertainty 
Once distributions have been applied to each of the appropriated parameters in decision 
model, the probabilistic sensitivity analysis can be performed. The probabilistic analysis 
explores uncertainty in cost-effectiveness outcomes by using Monte Carlo simulation 
(1000 iterations) in order to determine expected costs, outcomes and cost-effectiveness. 
The minimum of 1,000 iterations of Monte Carlo simulation is used to sample random 
values from each parameter distribution simultaneously to provide different cost, 
outcome and cost-effectiveness for each vector of input parameters. Those outcomes 
across all 1,000 iterations represent the probability outcomes. Incremental cost and 
incremental effectiveness for each of the 1,000 iterations can be represented visually 
using a cost-effectiveness plane (CE plane). The joint distribution of the costs and 
effectiveness from the Monte Carlo simulations (1000 iterations) are plotted on a cost-
effectiveness plane in order to show the impact of uncertainty in the model parameters 
on the model outcomes in both expected incremental costs and effects (Briggs, 2000). 
95% confident intervals (uncertainty intervals) can be calculated by using the lower 
percentiles (0.025) and upper (0.975) percentiles from the simulations results using the 
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percentile method (Briggs et al., 2006). Uncertainty in the incremental outcomes is 
demonstrated when the results cross over the y-axis, representing both QALY gains (in 
the eastern quadrants) and QALY losses (in the western quadrants), as shown in Figure 
2.3. Similarly, a spread through the origin passing through the x-axis represents 
uncertainty in the incremental costs of the intervention.  The size of the spread also 
shows the extent of uncertainty in the costs. 
   
 
Figure 2.3 The CE plane 
 
The uncertainty surrounding the cost-effectiveness of a technology, for a range of 
thresholds for cost-effectiveness, can be resulted as a cost-effectiveness acceptability 
curve (CEAC), which illustrate the uncertainty surrounding the estimate of cost-
effectiveness and were developed as a result of considerable debate regarding the best 
way to deal with such uncertainty (Briggs and Fenn, 1998) (Fenwick and Byford, 2005).  
The information from a CEAC should not be used to make statements about the 
implementation of the intervention or therapy (Fenwick and Byford, 2005). The 
uncertainty around the cost-effectiveness estimate is illustrated in Figure 2.4. 
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Figure 2.4 The CEAC 
 
 Figure 2.4 illustrates a hypothetical CEAC to demonstrate the probability that each 
intervention is cost-effective at different thresholds. At a threshold of £10,000 there is a 
95% probability that the new treatment is cost-effective and an only 5% probability that 
old treatment is cost-effective. The new intervention presents as the greatest expected 
net benefit, therefore it would be considered the optimal choice at this ceiling ratio. At a 
threshold at £5,000, new and old interventions are cost-effective with 50%. There 
remains a 50% probability that new and old treatments are the wrong choice, which is 
the uncertainty in the decision.   
   The CEAC is straightforward to calculate and interpret and is therefore an ideal 
technique for presenting uncertainty in the cost-effectiveness outcome from a 
probabilistic sensitivity analysis to decision makers who have to make the choice of 
whether to adopt or reject a new intervention, based on the current evidence. 
Uncertainty over the results of analysis leads to the likelihood of incorrect decision 
making. In order to adequately address that the new treatment is cost-effective that old 
treatment, it is necessary to consider two issues, namely, knowing the decision 
uncertainty and current evidence, should the technology be adopted or not and is 
additional research essential in order to support the decision (Briggs et al., 2006). 
Presenting the probability sensitivity analysis with CEAC can be considered to be the 
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first question (the technology should be adopted or not), in addressing the second 
question, further techniques are required.  
2.18.2 Value of information  
Having constructed a decision analytic model, subsequently undertaken probabilistic 
sensitivity analysis and then considered decision uncertainty, the results of the 
probabilistic sensitivity analysis can, in addition, be used to perform a value of 
information analysis (VOI).  
Bayesian decision theory and the value of information method provides an analytic 
structure which can address both whether a technology should be adopted based on 
current evidence and whether more evidence is required to support this decision in the 
future (Claxton et al., 2002) (Briggs et al., 2006). Likewise, value of information (VOI) 
analysis has been suggested as a systematic  decision analytic approach for aiding 
decision makers in assessing whether there is enough evidence to support and adopt 
new therapies, and setting research priorities for health technology assessment (HTA) 
(Eckermann et al., 2010). VOI is based on the reasoning that decisions based on 
information that already exists will be uncertain, with this uncertainty there is therefore a 
chance that a wrong decision is made, presenting a cost in terms of implications for the 
health of patients who receive less than optimal care and less than efficient use of 
health care resources.  
   Decisions based on existing information will be uncertain, and there will 
constantly be an opportunity that the mistaken decision will be made. Although, decision 
makers make the right choice based on our current estimate of expected net benefit, 
there is a chance that another therapy would have had high net benefit once our current 
uncertainties are resolved. For example, at threshold of £10,000 there is a 95% 
probability of being cost-effective in new intervention as shown in Figure 2.4. New 
intervention would be considered the optimal choice as it has the greatest expected net 
benefit [ENBt >ENBc].  While control intervention is the optimal choice, 5% of the time it 
would have been the wrong decision and this represent uncertainty in the decision to 
adopt the new treatment. The probabilistic sensitivity analysis results have been 
presented in previous sections and the decision uncertainties for each of the analyses 
have also been explored, however to demonstrate the probability that each intervention 
is cost-effective at different thresholds it is necessary to consider two issues, namely, 
knowing the decision uncertainty and current evidence, should the intervention be 
adopted or not and is additional research essential in order to support the decision 
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(Briggs et al., 2006). If such questions are left unanswered, it may be the case that 
decision makers attempt to interpret the cost effectiveness results in terms of how to 
make the decision to adopt or reject the intervention given the uncertainty. Uncertainty 
about the results of an analysis can lead to incorrect decisions, and this can have a cost 
in terms of the correct decision that was not acted upon. (Claxton, 1999). Decision 
makers wish to evade incorrect decisions, and so there is a value in obtaining more 
information, if it can reduce uncertainty.  
In the UK, the application of the value of information approach was demonstrated for 
health technology assessment (HTA) programme and for the UK reimbursement 
decision body by NICE, however, practical application of EVPI in publish literature are 
limited (Claxton et al., 2004) (Claxton et al., 2005a). 
EVPI per decision/patient 
In the ideal world in which there is perfect information, the most favourable intervention 
(and the most cost-effective) would be the chosen each time. On the other hand, in a 
non ideal world where there is uncertainty, on choosing an intervention ordinarily 
thought to be optimal there is a strong possibility that it will be a less favorable one. The 
expected opportunity loss associated with this uncertainty can be interpreted as the 
expected value of perfect information (EVPI), as the perfect information can get rid of 
the probability of making the incorrect decision or it is the amount the decision maker 
should be willing to pay to eliminate all uncertainty in the decision. With estimates of the 
probability of error and the opportunity cost of error, the expected cost of uncertainty or 
the expected opportunity loss surrounding the decision can be calculated (Briggs et al., 
2006).  
   The EVPI was calculated using the probability of cost-effectiveness for each 
strategy, and were generated in the CEAC calculation within a range of values at 
intervals of £500 from zero to £100,000/QALY. As discussed in the previous section, net 
benefit can be determined for each of the interventions for every one of the thousand 
iterations of the Monte Carlo simulation (Treatment (NBt) and Control (NBc)). The 
average is then taken in order to calculate the expected net benefit for each iteration, so 
that the optimal strategy can be determined. With existing evidence, the optimal 
intervention is that which has the greatest expected net benefit for all 1000 Monte Carlo 
iterations [max(ENBt : ENBc)]. The expected net benefit for the optimal strategy is the 
value that is assigned to the decision made based on current information. Given perfect 
information, the optimal strategy would be the decision of choice each time, and by 
choosing the strategy that maximizes net benefit for each iteration of the Monte Carlo 
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simulation, this can be accounted for: from iteration one through to iteration 1000: 
[max(NBt1 :NBc1],[max(NBt2 : NBc2)] and ….[max(NBt1000 : NBc1000)]. The Mean of 
the 1000 optimal net benefit choices is the expected value of the decision based on 
perfect information [E[max(NBt : NBc)]]. The expected value of perfect information is 
therefore the difference between the value of a decision with perfect information and 
without perfect information.  
   EVPI= E max NBt:NBc -max ENBt:ENBc    
EVPI population level 
Having estimated EVPI per patient, the population EVPI for one year is calculated using 
population estimates. In order to determine the population value for EVPI, the patient 
population over the lifetime of the technology must be taken into account in terms of the 
relevant patient population who would benefit from the screening tests. Representing the 
EVPI per decision in terms of the patient population, the population value for EVPI, gives 
an idea of the upper limit for expenditure on future research into the decision question. It 
is calculated by multiplying the patient population (both present and future) that is able 
to benefit from the information, by the difference between a decisions expected value 
(the greatest net benefit expected) with current information and with perfect information 
(Briggs et al., 2006).  
   The process of calculating the EVPI follows on from calculating the EVPI per 
decision. Firstly, the annual patient incidence (I) for the specific disease is used to 
represent the annual patient population. The expected timeframe of the intervention can 
then be estimated in years (t) and a discount rate applied. For example, the annual 
pregnancy population is estimated to be 60,000 mothers (NHS, 2013). With regard to 
screening tests for GDM, this study assumes an effective technology life of 10 years 
with new patients eligible for treatment each year. An appropriate timeframe for the 
intervention should be used for which estimates of the the effectiveness of the 
technology used in the model are unlikely to change and are relevant. Given an annual 
disease incidence in population (I) and the intervention lifetime of T years (t), then the 
effective population can be calculated by applying a discount rate (r) for patients in 
future years, and summing the population across the years (t). Consequently, the 
effective population is multiplied by the EVPI per decision to give the population level 
EVPI (EVPIpop). The EVPI pop equation is detailed below. 
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 
tt=1,2,...t
It
EVPIpop= EVPI*
1+r
  
   The EVPI can be used to point out whether future research is likely to be 
worthwhile. However, it does not take into account the cost of future research. This may 
be construed as a drawback to EVPI, however it is still useful in providing an indication 
of whether future research is worthwhile or not and is an important part of VOI analysis.  
EVPI for parameters (EVPPI) 
Where the EVPI analysis indicates further research is worthwhile, the next step involves 
identifying what type of research should be performed. In order to reduce uncertainty in 
the cost effectiveness decision, it is necessary to consider what parameters are driving 
uncertainties in the model. In this respect, the expected value of perfect parameter 
information (EVPPI) is used to distinguish parameters for which it would be valuable to 
have more accurate estimates. Briggs and colleague use EVPPI as an abbreviation for 
the expected value of perfect information for a parameter (Briggs et al., 2006). Similarly, 
Ades and colleague denote EVPPI as expected value of partial perfect information 
(Ades et al., 2004).  Those addressed in the same meaning of the difference between 
expected value with perfect and current information about the parameter.  
   The EVPPI is calculated from the difference between the maximum net benefit 
calculated from current estimates that involve some uncertainty and the expected net 
benefit that is calculated from partial perfect information. This provides the proportion of 
general uncertainty furnished by any single or group of parameters and gives a guide to 
where research should be focused for greatest efficiency. The equation of EVPPI is 
detailed below. The EVPPI algorithm with the parameters of the model denote by ( θ ) 
including the perfect parameter of interest and the other parameters which keep their 
distribution from the probabilistic sensitivity analysis. The net benefit of an intervention 
(t) if the parameters of the model take the value (θ ) is denoted by NB (t,θ ). 
    θ θ θEVPPI= E  maxt E NB t,θ -max E NB t,θ       
The various steps in the EVPPI process are detailed as follows: 
1. Firstly, a parameter of interest is chosen for which perfect information is required, 
then a random value is taken from its probabilistic distribution and held constant, 
to represent ‘perfect’ information for the parameter of interest. 
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2. The Monte Carlo simulation is run once more maintaining the ‘perfect’ parameter 
as a constant but allowing the probabilistic draws from all other parameters to 
run.  
3. Then the average NB under treatment and control (average NBt) (average NBc) 
from the 1000 iteration Monte Carlo simulation is subsequently recorded in 
addition to the intervention identity that gives the maximum expected net benefit  
[max(NBt :NBc)]. 
4. Following the Monte Carlo simulation a second random draw is made for the 
‘perfect’ parameter of interest, so that a new ‘perfect’ value can be held constant. 
Step 1 through to 3 are repeated 1000 items, each time holding a different value 
for the perfect parameter estimate constant while the other parameters in the 
Monte Carlo simulation are allowed to vary. For each Monte Carlo simulation the 
mean net benefit for treatment and control is recorded along with the intervention 
identity that gives the maximum net benefit.  
5. Once the process has been completed, the 1000 stored mean NBs for treatment 
and control and maximum intervention identities are used to calculated the 
expected net benefit (ENB) for each intervention [ENBt , ENBc] and the expected 
maximum net benefit [E[max(NBt:NBc)]] across the 1000 Monte Carlo 
simulations outcomes 
6. The intervention with the greatest ENB [max(ENBt :ENBc)] is the expected value 
of a decision based on current information; the intervention which has the 
greatest ENB and would therefore be the optimal (cost-effective) choice. 
7. The expected maximum benefit [E[max(NBt:NBc)]] is the average of the 1000 
maximum net benefit interventions from each of the Monte Carlo simulations. 
This is the expected value of perfect parameter information.  
8. The final stage in the EVPI process is to subtract the ENB of the decision under 
current information from the ENB of the decision with perfect parameter 
information which gives the expected value of perfect parameter information 
(Briggs et al., 2006).  
In terms of which parameters would add the most value in this additional information and 
how it should be collected, the expected value of perfect parameter information (EVPPI) 
is used; understanding what drives the uncertainty is necessary to establish the type 
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and perhaps the scale of future research. The EVPPI analysis reports results in terms of 
the value per patient and these are presented in terms of the pertinent patient population 
that may benefit from this supplementary information. Parameter uncertainty for one or a 
group of parameters can be eliminated instead of the EVPI for all parameters being 
estimated at once. 
EVSI  
    Alternatively, expected value of sample information (EVSI) is related with 
predicting the expected reduction in uncertainty resulting from the collection of data from 
an additional finite sample (Tappenden et al., 2004). In other words, EVSI represents 
the reduction in uncertainty that may be expected to result from further information from 
studies with predetermined sample size.  As mentioned previously, the expected value 
of perfect information (EVPI) places an upper limit on the returns to further research. 
This deals with a necessary condition for carrying out future research, where more 
research about the problem as a whole, or about particular parameters or parameters 
groups, may be worthwhile if the EVPI or EVPPI is more than the cost of conducting 
more research. Nonetheless, to establish an adequate research design, we need to 
consider the marginal benefits and marginal costs of sample information (Briggs et al., 
2006). EVSI, the net of the costs of sampling provides the expected net benefit of 
sampling or the societal pay off to proposed research.   
2.19 Conclusion 
This chapter addresses the introduction to the subject of Health Economic Evaluations 
with a focus on details of Economic Evaluations. Key concepts of economic evaluations 
have been given in terms of the cost, study perspective, time horizon and discounting 
rate. In the economic evaluation it is crucial to select the appropriate comparators of the 
analysis.  The time horizon should be long enough to capture all important difference in 
cost and consequence in both the comparator and interventions. In the cost process, all 
relevant costs should be considered. From a UK perspective, this should represent all 
costs to the NHS and social services. The measuring of utility is a vital component of 
economic evaluation and the QALYs are proposed as the measure of HRQoL for valuing 
intervention and treatment. The QALYs is preferred because of simplicity, clarity, ease 
of application, and face validity. Cost and consequence (QALYs) in two different 
interventions can be compared in order to create a cost utility value, ICER. There is 
different structure modelling in economic evaluation including formalised approaches 
such as the decision tree, Markov analysis, and discrete event systems. The majority of 
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cost-effectiveness studies are based on cohort modelling. Cohort modelling provides a 
flexible framework which can be programmed relatively easily and evaluated rapidly. 
The decision tree and Markov model are the two basic types of decision model that 
predominate in health economic evaluation. Decision analysis allows different strategies 
to be compared in terms of expected outcome. All relevant events and possible 
complications are considered along with their probabilities and relevant clinical 
outcomes and costs are compared.  In a situation where information is plentifully, 
decision analysis can be used to synthesise the best available data from various 
sources, in order to present results which are as unbiased and realistic as possible.   
   Cost-effectiveness analysis has become wildly used in evaluation technique, 
which relates costs and health outcome effects in different units in terms of a ratio. It is 
important to select a structure that is appropriate for the disease under study and the 
question or purpose of the economic evaluation study. The CE plane is a useful device 
for clarifying the concept of cost-effectiveness. The CEAC indicates the probability that 
the intervention is cost-effective compared with the alternative, given the data and for a 
given value of the maximum acceptable ratio (λ). Uncertainty should be considered in 
every stage of economic evaluation, if at all possible, using probabilistic sensitivity 
analysis. It is not just parameter uncertainty that is important, however, the importance 
of model uncertainty should be considered at the same time. Use of cost-effectiveness 
acceptability curves is a method for summarising information on uncertainty in cost-
effectiveness. Furthermore, the analysis is on estimating expected value of parameters, 
the normal distribution is always a candidate distribution because of the central limit 
theorem. The choice of distribution should be informed by the logical constraints on the 
parameter and the form of the data/estimation process.  Expected value of information 
(EVI) analysis should be incorporated into the decision problem because it provides an 
important framework for determining the expected payoff of conducting further research 
to resolve the model uncertainties.  
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Chapter 3.The diagnostic test evaluation and 
application of Bayes’ theorem to diagnostic test 
evaluation 
3.1 Introduction 
The aim of this chapter is to introduce a general overview of diagnostic test evaluations 
and consider the approach of Bayes’ theorem to diagnostic test evaluation.  The chapter 
begins by describing the fundamental terminology of diagnostic test evaluations. Next, the 
difference between screening and diagnostic tests are discussed, in terms of purpose, 
target population, test methods, positive results and costs. The following section 
discusses the clinical performance of laboratory tests, distribution of the tests and cut-off 
points. After that, sensitivity, specificity, predictive values, and likelihood ratios are also 
discussed. Diagnostic tests produce test results, which can divide patients into two 
groups, disease present and disease absent. Likewise, clinicians can measure sensitivity 
and specificity and how often specific symptoms occur with disease and without disease, 
but cannot directly measure the predictive value of a set of symptoms (positive predictive 
value and negative predictive value). Consequently, this chapter gives an introduction to 
the theorem of Bayesian inference which can address this problem and in relation to this 
discusses how clinicians can use sensitivity and specificity, the quantities that a clinician 
can estimate to calculate predictive values, and which clinicians need to make appropriate 
diagnoses or decisions. The final section will discuss and introduce the combination of 
test results.  
3.2 Diagnostic tests 
This section provides a brief description of diagnostic characteristics. First, the principles 
of diagnostic test evaluations and their basic notation are demonstrated. This is followed 
by a discussion of test performance and test accuracy and then a demonstration of 
moving the cut-off point is given. Finally, the trade-off between maximising sensitivity and 
specificity is briefly discussed.  
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3.2.1 Characteristics of diagnostic tests 
Screening tests are a medical strategy used to detect a disease in individuals in the 
general population without clinical signs or symptoms of that disease, and who are at 
sufficient risk of the disease. Diagnostic tests are medical procedures used to confirm 
positive screening tests and distinguish healthy individuals from people who have the 
disease (Public Health Action Support Team 2010). Some of the key differences such as 
purpose, target population and positive result threshold are shown in Table 3.1. The five 
main purposes of screening and diagnostic tests are as follows: to verify a diagnosis in 
symptomatic patients; to screen for disease in asymptomatic patients; to provide 
prognostic information on patients established to have the disease, to monitor the benefits 
and side effects of therapy; to confirm disease absent patients (Jyoti and Richard, 2009)  
(Edgar. et al., 1999).  In this way, early intervention and management might reduce 
complications and mortality from a disease.  Although screening may result in an earlier 
diagnosis, not all screening tests have been shown to benefit the person being screened. 
Over-diagnosis, misdiagnosis, and the creation of a false sense of security are some 
potential adverse effects of screening and diagnosis (Laking et al., 2006). 
Table 3.1 Differences between screening and diagnostic tests 
 Screening Tests Diagnostic tests 
Purpose To detect potential disease indicators To verify presence/ absence of disease 
Target 
Population 
Large numbers of asymptomatic but 
potentially at risk individuals, or personal 
history, race/ ethnicity, disease state, or 
other factors 
Symptomatic individuals to establish 
diagnosis, or asymptomatic individuals with 
a positive screening test 
Test method Simple, acceptable to patients and staff Invasive, expensive but justifiable as 
necessary to verify diagnosis 
Positive result 
threshold 
Chosen towards high sensitivity not to 
miss potential disease 
Chosen towards high specificity (true 
negative) and high sensitivity (true positive). 
More weight given to accuracy and 
precision than to patient acceptability 
Positive result Essentially indicates suspicion of disease 
(often used in combination with other risk 
factors) that warrants confirmation 
Result provides a definite diagnosis 
Cost Cheap, benefit should justify the cost 
since large numbers of people will need to 
be screened to identify a small number of 
potential cases 
Higher costs associated with diagnostic test 
may be justified to establish diagnosis 
Based on table 3.3.1 in diagnosis and screening: differences between screening and 
diagnostic tests, case finding (Ruf M. and Morgan O., 2008). 
Test results may help physicians to make a diagnosis in a symptomatic patient (diagnostic 
testing), or identify disease in an asymptomatic patient (screen testing) (Jyoti and Richard, 
2009) The most common tests provide results along a continuous or quantitative scale 
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(eg. blood glucose level, white blood cell count). The clinicians often use these ranges to 
diagnose a condition by classifying them as positive or negative and disease present or 
absent, based on the criteria or cut-off point. (Laking et al., 2006) Diagnostic techniques 
allow clinicians to allocate the right treatment to the right patient. However, the errors of 
diagnostic tests or misdiagnosis may risk useless and possibly harmful treatment, or 
prevent or delay access to beneficial treatment (Laking et al., 2006). 
3.2.2 Diagnostic test performance 
To show the performance of the screening test and diagnostic test, the fundamental 
element is the test result which is often used to evaluate the accuracy of the outcome. 
Screening and diagnostic test results are shown by classifying patients into two groups: 
one population with disease (or conditional), the other without disease. (Khamis, 1987)  
   The clinical performance of a laboratory test can be described in terms of 
diagnostic accuracy. The four outcomes of the test performance are shown, according to 
the test results, as positive (T+) or negative (T-), and according to whether the disease 
was truly present (D+) or absent (D-). Table 3.2 displays the status of the person being 
tested in the columns and the test results in the rows. For example, in cases where there 
is disease and the test is positive, the outcome is classified as true positive (TP).  In cases 
without disease, but where the test result claims that disease is present, the outcome is 
classified as false positive (FP). On the other hand, cases without disease where the test 
confirms its absence are classified as true negative (TN). In cases where the patient has 
disease, but the test indicates that they don’t, the outcomes are classified as false 
negative (FN).  Information on the accuracy of screening and diagnostic tests can be put 
into a two way table. A two by two table is the easiest and clearest way to calculate and 
summarize all the information about diagnostic tests.  
Table 3.2 Two way classifications of results according to tests and disease status 
 Disease      
Test Present D+ n Absent D- n Total n 
Positive  T+ True Positive (TP) a False Positive (FP) b All positive a + b 
Negative T- False Negative (FN) c True Negative (TN) d All negative c + d 
Total All diseased 
persons 
a + c All non – diseased  b + d All tested persons a + b+ c+ d 
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3.2.3 Distributions of test results 
The test results can be used to allocate people in the population into two groups: those 
suspected of having the disease, and those thought to be without it. Typically, the test 
results include quantitative results (e.g., white blood cell count in cases of suspected 
infection) followed by some type of distribution curve.  Test results are random variables 
and hence are subject to a distribution, which can be, but are not necessarily, a normal 
distribution.  The distribution of test results shows a different mean for patients with or 
without disease. The variation in results for patients with the disease is quite large, but a 
high proportion of test results are close to the mean value. A very similar pattern exists for 
patients without the disease, although the mean value differs.  
   There is some overlap in test results for the two patient groups, as can be seen in 
Figure 3.1.  Patients with the disease are represented in the distribution to the right, and 
patients without disease are represented in the distribution to the left. Those patients with 
the disease and test values to the right of the cut-off point are TP, and those with results 
below the cut-off are FN; that is to say, they are wrongly identified as free from the 
disease. Similarly, those without the disease and with test results lower than the cut-off 
point are TN, and those with values above the cut-off point are FP; that is, they are 
wrongly identified as having the disease. The extent to which the two distributions overlap, 
that is the false positive and false negative rates, change when the cut-off point changes.  
 
Figure 3.1 Distribution of the biomarker among disease and disease free in population 
 
Disease free Diseased
Cut-off Point
Test Negative Test Positive
True Negative (TN) True Positive (TP)
False Negative (FN) False Positive (FP)
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3.2.4 Cut-off point 
Diagnostic test results produce two types of data, qualitative data from clinical symptoms 
and quantitative data from diagnostic tests. The qualitative data identify patients as being 
with or without disease according to the presence or absence of clinical signs or 
symptoms. The quantitative results classify patients as diseased or disease free on the 
basis of whether they fall above or below the cut-off point. The cut-off point determines 
how many subjects are considered to have the disease. For continuous and ordinal tests, 
when the disease test result is above the cut-off level, the patient is assumed to have the 
disease. Similarly, when the test result drops below the cut-off point, the patient is 
assumed to be without the disease (McMaster University Health and Sciences Centre, 
1981)  (Edgar. et al., 1999) (Peter., 2007). Ideally, the test should not overlap in results 
between those with and without disease. The test would have perfect predictive accuracy 
and there would be no false positives or false negatives (perfect sensitivity and specificity) 
(Edgar. et al., 1999). A perfect test should have high sensitivity and high specificity. 
However, in reality most test results do not meet these standards, as in the case 
considered here. For most tests, the results will overlap between patients with and without 
disease. These relationships are demonstrated in the Figure 3.2. 
    Each cut-off point is related with a specific probability of true positive and false 
positive results. Line “A” indicates test results for high sensitivity and low specificity of 
about 90% and 60% respectively. All values that fall to the left are negative; those to the 
right are positive. This cut-off point criterion decreases the number of false negatives 
(increased sensitivity) but also increases the number of false positives (decreased 
specificity). Tests with a high sensitivity are often used to screen for disease, and tests 
with low sensitivity fail to identify many patients with disease. Screening tests tend to cast 
a wide net in order to pick up all cases of disease and not miss anyone, but they include 
some accidental positive results in people who do not actually have the disease. Moving 
the cut-off point may affect the sensitivity and specificity of the test result. Cut-off point “B” 
is intermediate between the two (sensitivity 80%, specificity 80%). This cut-off point shows 
high sensitivity and high specificity in screening tests, but still produces false positives and 
false negatives. Cut-off point “C” shows hypothetical test results with high specificity at 
about 95%, but limited sensitivity at about 60%. All values that fall to the right of “C” are 
considered positive; those to the left are negative. This cut-off point criterion increases the 
number of FN (increased specificity) but also decreases the number of FP (decreased 
sensitivity).  Tests with a high specificity are appropriate to confirm a suspected diagnosis, 
but cannot be used to exclude the presence of disease because it shows low sensitivity. 
Patients who produce positive results on a very sensitive screening test may produce 
negative results on a specific confirmation test.If a test is designed to confirm a disease in 
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a population, a cut-off point with greater specificity and low sensitivity is selected. On the 
other hand, if a test is designed to screen in a general population without clinical signs or 
symptoms of that disease, a cut-off point with greater sensitivity and low specificity is 
selected. 
 
Figure 3.2 Distribution of the biomarker of results with different cut-off points 
 
3.2.5 Test accuracy 
Diagnostic accuracy relates to the ability of a test to discriminate between people with and 
without the disease. Sensitivity, specificity, predictive values, and likelihood are also 
discussed in this section. Different measurements of diagnostic accuracy relate to the 
different aspects of the diagnostic procedure. Some measures assess the discriminatory 
power of the tests; others are used to estimate the predictive ability of the test. Some 
results of the test relate to the background characteristics of the population to which they 
are applied. Sensitivity, specificity, positive predictive value and negative predictive value 
can all be represented as probabilities. A summary of all terms, calculation methods and 
definitions related to test accuracy are shown in Table 3.4 and are denoted the same as in 
Table 3.2. 
Sensitivity and specificity 
Sensitivity and specificity are two critical components that reflect the accuracy of 
diagnostic tests (Altman and Bland, 1994b, NCSSM Statistics Leadership Institute, 1999)  
(NCSSM Statistics Leadership Institute, 1999). The sensitivity of a test is the probability 
that a test provides a positive result when the subject does in fact have the disease, and 
Disease free Diseased
Cut-off Point
Test Negative Test Positive
A B C
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specificity is the probability that the test result is negative given that the individual tested is 
free from the disease. Sensitivity and specificity relate only to the characteristics of the 
test and are unaffected by population characteristics, such as the prevalence of a disease, 
and so can be applied to a variety of populations (Šimundić, 2008) (Altman and Bland, 
1994b). 
   Sensitivity and specificity are of considerable importance for a clinician. Ideally, 
good test results should provide high sensitivity and specificity. For example, screening 
and diagnostic tests can cause a test to have very high sensitivity, but sometimes these 
test results have low specificity. The clinicians are able to keep both specificity and 
sensitivity high in the test, but the tests still produce FP and FN. In a large population it is 
impossible to avoid FP and FN. FP are especially undesirable when screening a serious 
disease in a population. The clinicians do not want to tell patients that they have a serious 
disease when they do not actually have it (NCSSM Statistics Leadership Institute, 1999). 
   Both sensitivity and specificity are closely related to the concepts of type I and type 
II errors, as shown in Table 3.3. In the ideal test, perfect test prediction can achieve 100% 
sensitivity, predicting that all people from the sick group are sick, and 100% specificity, not 
predicting that anyone from the health group is sick. The upper left corner relates to the 
correct decision to reject null hypothesis when the alternative is really true. The lower right 
corner corresponds to the correct decision not to reject the null hypothesis when it should 
not be rejected. A type I error is a FP result during diagnostic testing, while a test with a 
high specificity has a low type I error rate. The upper right corner relates to a test result 
that causes clinicians to reject the null hypothesis when it is actually true.  A type II error is 
a FN result during diagnostic testing, while a test with a high sensitivity has a low type II 
error rate. The lower left corner corresponds to a test result that causes clinicians not to 
reject the null hypothesis when it is not true. 
Table 3.3 Relationships among type I error and type II error with diagnostic test  
 Disease  
Test Present (D+) Absent (D-) 
Positive  (T+) True Positive (TP) False Positive (FP) 
(Type I error)  
Negative (T-) False Negative (FN) 
(Type II error) 
True Negative (TN) 
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Predictive values 
Other statistical relationships between test results and the disease outcome are positive 
predictive value and negative predictive value. Positive predictive value (PPV) gives the 
probability that a patient has the disease given that they test positive, and negative 
predictive value (NPV) gives the probability of a patient not having the disease given that 
they test negative (Parmigiani, 2002). Unlike sensitivity and specificity, predictive values 
are highly dependent on the prevalence of the disease in the population. The PPV and 
NPV should only be used if the prevalence ratio of patients in the disease group is the 
same. With high prevalence the positive predictive value will be high for disease. The NPV 
moves in the opposite direction. For example, if a clinician uses a diagnostic test in a high 
prevalence population, the positive test result will be more likely to be truly positive than in 
a low prevalence population. Therefore, neither predictive value from one study should be 
applied to another setting in which prevalence differs (Šimundić, 2008) (Altman and Bland, 
1994a). To overcome the problem of two populations having equal prevalence, positive 
and the negative likelihood ratio should be reported instead of PPV and NPV, as likelihood 
ratios do not depend on prevalence. 
Likelihood ratio 
Likelihood ratio (LR) is a very crucial measure of diagnostic accuracy. The likelihood ratio 
for positive test results (LR+) tell a clinician how likely it is that a patient has disease when 
there is a positive test result.  It is usually higher than 1 because it is more likely that the 
positive test result will occur in subjects with the disease than in disease-free subjects. 
Likelihood ratio for negative test results (LR-) tell a clinician how much more likely a 
negative result is to be found in subjects without disease than in subjects with disease.  It 
is usually less than 1 because it is less likely that a negative test result will occur in 
subjects with disease than in subjects without disease (Greenhalgh, 1997)  (Šimundić, 
2008). Both specificity and sensitivity are used to calculate the likelihood ratio. LR+ and 
LR- are unaffected by prevalence of disease. Therefore, the likelihood ratio from one 
study can be applied in other settings, as long as the definition of the disease is not 
changed (Šimundić, 2008) (Jyoti and Richard, 2009). 
Prevalence  
The prevalence of disease in the population can be denoted by P(D+), the prior probability 
of a randomly selected individual from the population having the disease.  
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Table 3.4 Definition of terms related to test accuracy  
Term Calculation Definitions 
Sensitivity or True 
positive rate (TPR) 
P (T+│D+) =  
a
a+c
 
 
Sensitivity is defined as the proportion of patients with the 
disease who have a positive test result. This is P (T+│D+) = 
true positive divided by the sum of true positive plus false 
negative. 
False positive rate 
(FPR) 
P (D-│T+) =
b
b+d
 
1- Specificity
 
The false positive rate is defined as the proportion of patients 
without the disease who have a positive test result. This is P 
(T+│D-) = false positive divided by the sum of false positive 
plus true negative. 
Specificity or True 
negative rate(TNR) 
P (T-│D-) = 
d
b+d
 
Specificity is defined as the proportion of patients without the 
disease who have a negative result. This is P (T-│D-) = true 
negative divided by the sum of true negative plus false 
positive. 
False negative rate 
(FNR) 
P (D+│T-) = 
c
c+a
 
1- Sensitivity    
  
The false negative rate is defined as the proportion of 
patients with disease who have a negative test result. This is 
P (T+│D-) = false negative divided by the sum of true positive 
plus false negative 
Positive predictive value 
(PPV) or post-test 
probability of a positive 
test 
P (D+│T+) = 
a
a+b
 
The positive predictive value is defined as the likelihood of 
patients with a positive test result will have the disease. This 
is P (D+│T+) = true positive divided by the sum of true 
positive plus false positive. 
Negative predictive 
value (NVP)  or post-
test probability of a 
negative test 
P (D-│T-) = 
d
c+d
 
The negative predictive value is defined as the likelihood of 
patients with a negative test result will not have disease. This 
is P (D-│T-) = true negative divided by the sum of true 
negative plus false negative.  
Positive likelihood ratio 
LR+ = 
 
sensitivity
1-specificity
 
The positive likelihood ratio is defined as the increase in the 
odds of having the disease after a positive test result. This is 
LR+ = true positive rate(sensitivity) divided by the false 
positive rate(1-specificity) 
Negative likelihood ratio 
LR- = 
 1-sensitivity
specificity
 
The negative likelihood ratio is defined the decrease in the 
odds of having the disease after a negative test result. This is 
LR- = false negative rate(1-sensitivity) divided by the true 
negative rate(specificity) 
Accuracy Accuracy  =  
a+d
a+b+c+d
 
Accuracy is defined as the proportion of all tests that give a 
correct result. This is  true positive plus true negative divided 
by the sum of true positive, true negative, false positive and 
false negative. 
Prevalence P (D+)  Prevalence is defined as the proportion of patients who have 
the disease (McMaster University Health and Sciences 
Centre, 1981).  
 
The ideal test is one that has very high sensitivity and specificity, so that the most true 
disease cases are identified and most non disease cases are excluded. Sometimes a test 
result can be positive in patients who do not actually have the disease, which is called the 
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false positive rate (1 – sensitivity), and can be negative in patients who do actually have 
the disease, which is called false negative rate (1-specificity). However, sensitivity and 
specificity change in opposite directions when the cut-off point of tests change, this is due 
to a trade-off between maximising sensitivity and specificity, as mentioned in section 
3.2.3.  This occurs because tests generally do not have a 100% TPR or a 100% TNR. For 
example, as the cut-off point for positivity is high, specificity will increase and sensitivity 
will decrease. Diabetes is diagnosed based on a fasting blood sugar >126 mg/dl, however 
If a clinician moves the cut-off point to 170mg/dl, it makes it more difficult to detect positive 
cases. This makes the test less sensitive (some true diabetic cases don’t have such high 
blood sugar levels) and more specific (people without diabetes may at times have blood 
sugar levels higher than 126mg/dl, but it is unlikely to be as high as 170 mg/dl). On the 
other hand, when lowering the cut-off point, the test becomes more sensitive but less 
specific. The score that is chosen as the cut-off point is determined by maximising 
sensitivity (true positive rate) and 1- specificity (false positive rate) across a series of cut-
off points. Sensitivity and specificity always have this inverse relationship and the plot of 
the trade-off between sensitivity and the false negative rate is known as the ROC curve, 
which highlights the covariation between the two outcomes  (Warner, 2004). The best 
diagnostic tests will be those that maximize both sensitivity and specificity.  
    If the detection or diagnosis of disease involves the use of more than one 
diagnostic or screening device, the evaluation of the diagnostic strategy entails a 
combination of two or more diagnostic and screening tests. Decision trees are an ideal 
tool for such evaluations. The standard decision tree for a diagnostic test begins with the 
disease prevalence at the first chance node and is followed by the diagnosis testing  
(Phelps and Mushlin, 1988). The reason why decision trees for diagnostic tests should 
start with disease prevalence and then be followed by the accuracy of the tests is 
explained at the end of section 3.3.3. Diagnostic testing is undertaken in order to identify 
the disease, and the accuracy of the test depends on how well the technology or test 
correctly indentifies the disease. The standard approach for measuring correct and 
incorrect identification is through diagnostic test accuracy, that is to say, sensitivity and 
specificity. Therefore, the test characteristics of sensitivity that can correctly identify TP 
and of specificity that can correctly indentify TN are important in the evaluation of 
diagnostic technologies. Moreover, neither sensitivity and specificity change with the 
prevalence of a disease, unlike PPV and NPV (Warner, 2004).     
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3.3 Bayesian methods for test accuracy 
This section will introduce an application of Bayes’ Rule in the evaluation of diagnostic 
tests, and show how Bayes’ Rule can be used to switch between conditional and 
unconditional test accuracy.   
3.3.1 Fundamentals of Bayesian 
Bayes’ theorem, is a logical consequence of the product rule of probability (Khamis, 
1990). The theory of conditional probability and Bayes’ theorem are found in various 
applications in formulating mathematical models in all sciences (Hardeo, 1992).  Bayes’ 
rule in medical diagnosis is applied and discussed in various texts, including Lusted 
(1968) and Sox et al (1998) (Parmigiani, 2002). Furthermore, to evaluate laboratory tests 
and the principles and techniques of medical decision analysis, Bayes’ rule is commonly 
applied. 
   Bayes’ Rule is a way of calculating conditional probabilities. Bayes was the first to 
use probability theory inductively, which developed the mathematical basis for probability 
inference (Lesaffre et al., 2007). The concept of conditional probability provides 
information about how the occurrence of one event predicts the probability of another 
event. The essential fundamentals of the Bayesian method are their estimated unknown 
probability, and making decisions on the basis of new (sample) information (Okeh and 
Ugwu, 2008). In other words, Bayesian data analysis is a practical method for making 
inferences from data, using probability models for quantities we observe and for quantities 
about which we wish to learn.  
3.3.2 Simple statement of theorem 
Conditional probability is a very helpful method and is used in many ways. Bayes’ theorem 
associates the conditional and marginal probabilities of event A and B. Bayes’ theorem in 
this form indicates a mathematical representation of how the conditional probability of 
event A given B is associated with the converse conditional probability of B given A.  We 
symbolize conditionality by using a vertical slash ‘│’ , which can be referred to as ‘ given’.  
                                              
   
 
P B A P A
P A B =
P B
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  Each term in Bayes’ theorem states: 
 
P(A│B) Shows the conditional probability of A given B. It is also 
called the posterior probability because it is derived from 
or depends upon the specified value of B. 
P(B│A) States the conditional probability of B given A. It is also 
called the likelihood. 
P(A) Indicates the prior probability or marginal probability of A. 
It is “prior” in the sense that it does not take into account 
any information about B. 
P(B) Indicates the prior or marginal probability of B, and acts 
as a normalizing constant. 
 
                                               
   
 
P A B P B
P B A =
P A
     
  Each term in Bayes’ theorem states: 
 
P(B│A) Shows the conditional probability of B given A. It is also 
called the posterior probability because it is derived from 
or depends upon the specified value of A. 
P(A│B) States the conditional probability of A given B. It is also 
called the likelihood. 
P(B) Indicates the prior probability or marginal probability of B. 
It is “prior” in the sense that it does not take into account 
any information about A. 
  
P(A) Indicates the prior or marginal probability of A, and acts 
as a normalizing constant. 
 
3.3.3 An application of Bayes’ Rule to screening and diagnostic 
test evaluation 
The function of a diagnostic test is to make a diagnosis. Clinicians have to know the 
probability that the test results will give the correct diagnosis. In fact, medical diagnosis 
tests commonly yield mathematic test results such as sensitivity and specificity. However, 
the sensitivity and specificity of test results alone do not provide strong enough guidance 
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to make clinical decisions. They cannot be converted into clinically relevant quantities 
without information on disease prevalence. On the other hand, probabilities related to 
screening and diagnosis tests are based on Bayes’ theorem, and is applied to diagnostic 
test evaluation.  Bayes’ rule shows that positive and negative predictive values can be 
calculated from the sensitivity and specificity of diagnostic tests, which are values that a 
clinician needs in order to make appropriate diagnoses or decisions. (Khamis, 1990) 
(Anthony, 2007) (Okeh and Ugwu, 2008). Suppose you test positive for a disease.  What 
is the probability that you actually have the disease?  It depends on the accuracy and 
sensitivity of the test, and on the background (prior) probability of the disease.  Let “D+“ 
stand for “disease present” and “D-” stand for “disease absent”. Let “T” indicate test 
results and “+” the event of a positive test and “-“ the event of a negative test. In particular, 
the prevalence rate in the population is represented as P(D+), the sensitivity as P(T+│D+) 
and the specificity as P(T-│D-).  
   There are two possible decision tree maps which involve diagnostic tests. Firstly, 
the initial branching of the decision tree starts with testing. According to a decision tree 
map, a patient visiting the clinic undergoes tests and examinations to distinguish whether 
the patient is with or without disease.  Treatment or further tests will be offered according 
to those test results. The final results represent whether disease is present or absent in 
the patient. Such, Bayes theory uses conditional probability to assess decision making 
under uncertainty and is particularly applicable to decision trees. Bayes’ rule is therefore 
applied to determine the probability of a particular diagnosis, given the appearance of 
specific signs, symptoms and test outcomes (MedicineNet, 2004). Figure 3.3 presents a 
common example involving one diagnostic test where treatment is given following the test 
result. The beginning of the decision tree map starts with receiving a positive or negative 
test result. The probabilities are denoted by P(T+) and P(T-). The disease outcomes must 
be shown in the right hand of the test results as the disease status. The subsequent 
branching probabilities are the likelihood of disease in each outcome. The probabilities are 
denoted by P(D+│T+), P(D-│T+), P(D+│T-), and P(D-│T-). 
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Figure 3.3 Tests approach to decision problem with testing 
 
The four possible final outcomes associated with this decision tree are then calculated 
 True Positive    = P(T+) * P(D+│T+)  
   False Negative   = P(T+) * P(D-│T+) 
   False Positive   = P(T-) * P(D+│T-) 
   True Negative   = P(T-) * P(D-│T-) 
 
We can compute the posterior probability P(D+│T+) of a patient who tested positive while 
actually having the disease.  In this context, Bayes’ rule takes the from 
Positive predictive value = P(D+│T+) =  
   
 
P T+ D+ P D+
P T+
    
Positive predictive value = P(D+│T+) = 
   
       
P T+ D+ P D+
P T+ D+ P D+ +P T+ D- P D-
 
Positive Predictive Value =   
  
     
Sensitivity Prevalence
Sensitivity Prevalence + 1-Specificity 1-Prevalence
 
 
P(D+) The probability that the disease is present in the patient, 
regardless of any other information. This is the prior 
probability of D. 
P(T+) The probability of a positive event, which is found by 
adding the probability that a true positive result will 
appear with the probability that a false positive will 
Disease T+   D+   True Positive (TP)
P(D+│T+)
Test Positive
P(T+)
No Disease T+    D- False Positive (FP)
Test P(D- │T+)
Disease T-    D+ False Negative (FN)
P(D+│T-)
Test Negative
P(T-)
No Disease T-    D- True Negative (TN)
P(D-│T-)
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appear. 
P(T+│D+) This is the probability of true positive rate, that is, that the 
test is positive and the disease present. 
P(T+│D-) This is the probability of false positive rate, that is, that 
the test is positive, though the disease is absent. The 
prior probability of P(T+│D-) is 1 - P(T+│D+). 
   
Similarly, we can also compute the posterior probability P(D-│T-) of a patient who tests 
negative while actually being without the disease, from Bayes’s theorem. 
Negative predictive value = P(D-│T-) = 
   
 
P T- D- P D-
P T-
    
Negative predictive value = P(D-│T-) = 
   
       
P T- D- P D-
P T- D- P D- +P T- D+ P D+
 
Negative Predictive Value=   
  
     
Specificity 1-Prevalence
Sepcificity 1-Prevalence + 1-Sencitivity Prevalence
 
P(D-) The probability that the disease is absent in the patient. 
The prior probability of D- is 1- P(D). 
P(T-) The probability of a negative event, which is found by 
adding the probability that a true negative result will 
appear with the probability that a false negative will 
appear. 
P (T-│D-) This is the probability of true negative rate, that is, that 
the test is negative and the disease absent. 
P(T-│D+) This is the probability of false negative rate, that is, that 
the test is negative, though the disease is present. The 
prior probability of P(T-│D+) is 1 - P(T-│D-). 
 
Secondly, the other method of constructing the decision tree commences with branches of 
disease status. The subsequent branching states the test outcomes.  The primary 
branching probability shows the likelihood of outcomes for the patient within the specific 
population, in terms of presence or absence of disease. In each branch, the incidence or 
prevalence within the specific population are indicated.  The probabilities are denoted by 
P(D+) and P(D-). The test outcomes must be shown in the right hand branch of the 
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disease status. The subsequent branching probabilities are the likelihood of tests in each 
outcome. The probabilities are denoted by P(T+│D+), P(T+│D-), P(T-│D+), and P(T-│D-). 
In particular, subsequent pathways for the probabilities of sensitivity and specificity are 
indicated. These probabilities are indicated by the test results, which are routinely 
calculated and reported, as shown in Figure 3.4. 
  
Figure 3.4 Test approaches to decision problems with disease status 
 
The four possible outcomes associated with this decision tree are than calculated: 
  True Positive    = P(D+) * P(T+│D+)  
   False Negative   = P(D+) * P(T-│D+) 
   False Positive   = P(D-) * P(T+│D-) 
   True Negative   = P(D-) * P(T-│D-) 
 
The actual chorological method used in the second method of constructing the decision 
tree, whereby the initial chance node separates the population according to the disease 
status involves the same information as the first method, and it can be illustrated that the 
probabilities associated with each pathway are equivalent in the two methods.  
True positive from the first method = P(T+)*P(D+ T+)  
       = 
P(T+ D+)*P(D+)
P(T+)*
P(T+)
 
         = P(D+ T+)*P(D+)  
Test Positive T+   D+   True Positive (TP)
 P(T+│D+)
Disease
P(D+)
Test Negative T-    D+ False Negative (FN)
Disease  P(T-│D+)
Test Positive T+    D- False Positive (FP)
 P(T+│D+)
No Disease
 P(D-)
Test Negative T-    D- True Negative (TN)
(P(T-│D-)
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True positive from the second method = P(D+ T+)*P(D+)  
 True positive from first method = true positive from second method 
 Whilst it is not possible to indentify the actual disease status for an individual patient 
consulting with the doctor, using prevalence and incident data it is possible to calculate 
the expected numbers with and without disease for a given population. Hence, when 
modelling a health policy decision affecting a population, the second approach can be 
used, enabling the direct application of conditional probabilities to the following branches. 
Given that most medical information that is provided is conditional upon the disease 
present and absent, the second method provides an easier method by which to examine a 
population based decision problem. In light of this, applications of decision analysis to 
economic evaluations of health care commonly employ the second method. 
3.4 Combinations of the test results  
 Combinations of the tests are usually applied to many diagnostic, health-certification, and 
disease-surveillance situations. Multiple tests might be applied to all subjects or the tests 
might be used on a subset of a population. Decision rules are then used to test the results 
and to classify individuals as disease positive or negative (Gardner et al., 2000).  In these 
cases, clinicians can combine two component tests under either the “negative rule” or 
“negative dominant strategy” and either the “positive rule” or “positive dominant strategy”  
(Tang, 2004). Positive and negative dominant strategies may help the clinician to interpret 
the combination of test results. Before introducing the positive and negative dominant 
strategies, discussions of the differences in characteristics of screening tests (Test 1) and 
diagnostic tests (Test 2) which divide people into the two groups are provided. Normally, 
in order to classify disease in a population, a two step approach is used. The population is 
initially screened by means of a screening test. Patients that test positive for the screening 
test undergo a diagnostic test to confirm the results (Public Health Action Support Team 
2010). In a two step approach, the initial clinical performance of the laboratory is shown as 
four outcomes, namely TP, FN, FP and TN, as introduced in the previous section. 
Similarly, diagnostic tests are shown as four outcomes, according to the test results.  
   The following section illustrates an example using two binary tests to explain the 
concept of negative and positive dominant strategies. There is an example with a basic 
branch of a decision tree for intervention A to represent the dominant strategy, as shown 
in Figure 3.5 and Figure 3.6. The decision tree initially starts with the probability of disease 
being present (prevalence) or absent (1 – prevalence). Branches of decision nodes 
present possible outcomes of probability for the prevalence. Subsequently, each point 
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where there is a chance node indicates the screening test (Test 1) and diagnostic test 
(Test 2) strategies. Branches of the chance nodes illustrate the possible positive (T+) or 
negative (T-) test results. Those branches apply the probability of sensitivity and 
specificity of screening and diagnostic tests. The diagnostic test accuracy (sensitivity and 
specificity) for Test 1 is initially applied indentifying TP (sensitivity 1) and TN (specificity 1) 
for correct diagnoses, whereas FN (1 – sensitivity 1) and FP (1- specificity 1) are for 
incorrect diagnoses. Following test 1, test 2 is performed and likewise the diagnostic test 
accuracy for test 2 is applied identifying TP (sensitivity 2), FN (1 – sensitivity 2), FP (1 – 
specificity 2) and TN (1 – specificity 2). 
3.4.1 Negative dominant strategy  
The negative dominant strategy (NDS) represents a test strategy in which negative test 
results dominate. Figure 3.5 demonstrates an example of a decision tree for the NDS. A 
two step approach that uses screening test and diagnostic tests is used to demonstrate 
the NDS. In the negative dominant strategy, if screening tests (Test 1) show negative 
results, patients will not receive a second test to confirm the results. On the other hand, 
diagnostic tests (Test 2) are used to confirm the results if the screening tests (Test 1) are 
positive. NDS accepts positive outcomes over negative results. For example, positive 
results (TP) are only obtained if Test 1 and Test 2 are both positive. If either Test 1 or Test 
2 is negative a negative result is obtained. There are a greater proportion of TN and FN 
outcomes in the NDS where screening and diagnostic tests involve negative results. 
Therefore, NDS benefits from the specificity of both tests, at the expense of lower overall 
sensitivity, and a greater proportion of FN identifications. Positive test results are 
dominated by negative test results, which are significant as all patients who have disease 
but test negative, are likely to not receive treatment or have delayed treatment. Moreover, 
in order to calculate the sensitivity and specificity of the strategy, the values for the 
sensitivity and specificity of each test can be combined using the formulae below. The 
sensitivity of Test 1 and Test 2 are denoted by Sen_t1 and Sen_t2, respectively, and the 
specificity of both tests are denoted by Spe_t1 and Spe_t2, respectively. 
        Sensitivity  = Sen_t1*Sen_t2  
     Specificity = Spe_t1+ Spe_t2-(Sen_t1*Spe_t2)  
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Figure 3.5 Decision tree for the negative dominant strategy (NDS) 
 
3.4.2 Positive dominant strategy  
The positive dominant strategy (PDS) represents a test strategy in which positive test 
results dominate. As the two step approach demonstrates, in the P(D+) pathway if a 
screening test (Test 1) is over the threshold all patients who test positive directly receive 
treatment without further testing, as shown in Figure 3.6. In the other pathway P(D+), 
patients that are negative for the screening test (Test 1) undergo an additional diagnostic 
test (Test 2). In other words, PDS would accept positive outcomes over negative results. 
For example, if a patient has a negative screening test result and a positive diagnostic test 
the strategy treats this as a positive result. In contrast, only if the results of both Test 1 
and Test 2 are negative will the outcome for the strategy be treated as negative. 
Consequently positive test results in the PDS dominate negative test results. Sensitivity of 
both of the tests benefits PDS, and may result in a larger proportion of TP being identified 
than could be done through either test alone, this is because in this strategy FN results 
from Test 1 are countered by positive outcomes in Test 2. However the PDS presents with 
few FN and a larger proportion of FP, which means trading-off specificity for greater 
sensitivity. In terms of patient management, PDS may result in more FP which is likely to 
lead to over-diagnoses. It means that people who do not have the disease may be treated 
unnecessarily. Moreover, to calculate the sensitivity and specificity of the strategy, as in 
the previous section, a formula that combines the values for each test can be used.  
        Sensitivity  = Sen_t1+Sen_t2-(Spe_t1*Sen_t2)  
     Specificity = Spe_t1*Spe_t2  
 
Screening test(Test 1) Diagnostic test (Test 2)
Positive  (T2+│D+) TP
Sensitivity 2
Positive  (T1+│D+)
Sensitivity 1
P(D+) Negative  (T2 -│D+) FN
1- Sensitivity 2
Negative  (T1 -│D+) FN
1 - Sensitivity 1 Positive  (T2+│D-) FP
1 - Specif icity 2
Positive  (T1+│D-)
1 - Specif icity 1
P(D-) Negative  (T2-│D-) TN
Specif icity 2
Negative (T1-│D-) TN
Specif icity 1
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Figure 3.6 Decision tree for the positive dominant strategy (PDS) 
 
However, most diagnostic technologies have adopted NDS. All screening and diagnostic 
test devices classify patients with some error, clinicians must select from a variety of 
methods to interpret the test results, trading-off the risk of FP and FN (Phelps and 
Mushlin, 1988). The NDS and PDS approaches allow the clinician to consider test results 
in terms of the differences in FN and FP test results. The trade-off between sensitivity and 
specificity or detection and unnecessary testing is at the heart of screening and diagnostic 
tests and the accuracy of the tests in terms of sensitivity and specificity is an important 
consideration for clinicians. 
   Moreover, combining the tests, NDS and PDS give alternative sensitivity and 
specificity trade offs compared to individual tests.  In individual tests, even if clinicians are 
able to keep both specificity and sensitivity high, FP and FN outcomes will still persist. The 
individual tests involve diagnostic tests without prior screening. Consequently, the 
accuracy of the individual tests, in terms of sensitivity and specificity, always have this 
inverse relationship, and the plot of the trade-off between sensitivity and the false negative 
rate presents as the optimal point in the ROC curve. However, on combining the tests, 
when the second test is performed to confirm the first test, there is a trade-off between the 
sensitivity and specificity of the tests. The two-step approach it consider better than using 
individual tests.   
3.4.3 Positive and negative dominant strategies in various 
screening test approaches 
Screening and diagnostic tests are medical procedures used to detect a disease in 
individuals in the general population without clinical signs or symptoms of that disease. 
Screening test(Test 1) Diagnostic test (Test 2)
Positive  (T1+│D+) TP
Sensitivity 1
P(D+) Positive  (T2+│D+) TP
Sensitivity 2
Negative  (T1 -│D+)
1 - Sensitivity 1
Negative  (T2 -│D+) FN
1 - Sensitivity 2
Positive  (T1+│D-) FP
1 - Specif icity 1
P(D-) Positive  (T2+│D+) FP
1 - Specif icity 2
Negative (T1-│D-)
Specif icity 1
Negative  (T2 -│D+) TN
Specif icity 2
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Screening and diagnostic tests involve controversial issues that include who should be 
screened, whether a one-step or two-step approach should be employed and whether 
screening should be universal or selective. This section discusses how to apply NDS and 
PDS to all screening and diagnostic approaches, as shown in Figure 3.7.  
Treatment options 
There are two different treatment decisions for screening tests outlined in Figure 3.7, 
whether to treat all patients or not to treat all patients.  If none of the patients are given 
treatment by the clinician, all classifications are either TN or FN for treatment. Patients 
without disease that do not receive treatment classify as TN (negative for the receipt of 
treatment and true as the patients do not require treatment due to the lack of disease). 
Likewise, patients with disease that have not received treatment identify as FN (negative 
for the receipt of treatment and false as the patients should have received treatment due 
to the presence of disease).  
If on the other hand the whole population receives treatment irrespective of 
disease state, all patients are then classified as either TP or FP. In this instance TP is 
indicative of patients with disease that received treatment and FP represents patients 
without disease that receive treatment.  
One step approach option 
The one step approach is a diagnostic test performed without prior screening. Results for 
both positive and negative dominant strategies are listed. For both strategies however, 
patients that test positive classify as TP whereas those that test negative display as FN.  
Likewise patients without disease that test positive present as FN, while TN is 
representative of patients without disease who test negative.  
Two step approach option 
In this approach, a diagnostic test is performed to confirm the results of a positive 
screening test. Outcomes of both positive and negative dominant strategies for the two 
step approach are similar to those discussed in sections 3.4.1 and 3.4.2.   
Universal screening option 
Universal screening refers to the screening of all pregnant women in the population and 
so this strategy ignores the risk factor pathway at the beginning of the decision tree. In this 
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option, positive and negative dominant strategies are applied to universal screening tests 
for GDM. It is assumed that all patients receive both screening tests (Test 1) and 
diagnostic tests (Test 2).  
   For the positive dominant strategy, patients with disease that test positive for either 
Test 1 or Test 2 are classified as TP, and those that are negative in both Test 1 and Test 
2 present as FN. For patients that do not have disease but test positive in either Test 1 or 
Test 2, the results are FP, whereas those that test positive in both Test 1 and Test 2 are 
TN.  
   On the other hand, with regard to the negative dominant strategy, patients with 
disease that test positive in both Test 1 and Test 2 have TP outcomes, while a negative 
result in either Test 1 or Test 2 gives a FN outcome. For patients without disease, those 
that have positive results for both Test 1 and Test 2 are FP, while those with either a 
negative result in Test 1 or Test 2 are TN.  
Selective screening option 
This strategy assumes that at first visit, all patients are only screened for risk factors. In 
this model risk factor screening is considered to be a selective screening tool. Patients 
with risk factors may present with disease or without disease. For patients with risk 
factors, those that have disease are TP, whereas patients who are disease absent classify 
as FP. On the other hand, for patients without risk factors, if disease is present they are 
TN and if absent they are FN.  
Selective screening and other two tests options 
As in the previous strategy, all patients are screened for risk factors at the first visit, 
however in this option all women that test positive for risk factors receive further tests. The 
outcomes for both positive and negative dominant strategies, combining the risk factor 
screening test and Tests 1 and Test 2, are listed in Figure 3.7.  
   For patients that are positive for risk factors in the PDS, if they are positive for 
either Test 1 or Test 2 and have disease the outcome is TP for risk factors, whereas 
patients that do not have disease and are negative in either Test 1 or Test 2 are FN for 
risk factors. On the other hand for patients that are negative for risk factors, but have 
disease and are positive for either Test 1 or Test 2, the outcome is FP for risk factors. 
When all three tests are negative and the patient has no disease the outcome is TN.  
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   In the NDS, if all tests are positive and disease is present, the outcome is TP. 
Additionally for patients that test positive for risk factors, if there is no disease or for those 
that have disease and either Test 1 or Test 2 is negative the outcome is FN. In the group 
with no risk factors, for those patients that have disease and who test positive in both Test 
1 and Test 2, the outcome is FP. Also for patients without disease or those that have 
disease but are negative for either Test 1 or Test 2 the outcome is TN.  
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Figure 3.7 The different strategies of screening test for GDM 
Risk factor Risk factor + test 
No All PD ND PD ND PD ND PD ND
P o sit ive  (T2+│D+) FN TP TP TP TP TP TP TP TP TP TP
P o sit ive  (T1+│D+)
N egative  (T2 -│D+) FN TP TP FN TP TP TP FN TP TP FN
D is   (P+│Rf+)
P o sit ive  (T2+│D+) FN TP TP FN FN FN TP FN TP TP FN
N egative  (T1 -│D+)
N egative  (T2 -│D+) FN TP FN FN FN FN FN FN TP TP FN
R isk facto r P(R+) 
P o sit ive  (T2+│D-) TN FP FP FP FP FP FP FP FP TP FN
P o sit ive  (T1+│D-)
N egative  (T2-│D-) TN FP FP TN FP FP FP TN FP TP FN
N o  D is  (P-│Rf+)
P o sit ive  (T2+│D-) TN FP FP TN TN TN FP TN FP TP FN
N egative (T1-│D-)
N egative  (T2-│D-) TN FP TN TN TN TN TN TN FP FN FN
P o sit ive  (T2+│D+)
FN TP TP TP TP TP TP TP FN FP FP
P o sit ive  (T1+│D+)
N egative  (T2 -│D+) FN TP TP FN TP TP TP FN FN FP TN
D is (P+│Rf-)
P o sit ive  (T2+│D+) FN TP TP FN FN FN TP FN FN FP TN
N egative  (T1 -│D+)
N egative  (T2 -│D+) FN TP FN FN FN FN FN FN FN FP TN
N o R isk facto r P(R-) 
P o sit ive  (T2+│D-) TN FP FP FP FP FP FP FP TN FP TN
P o sit ive  (T1+│D-)
N egative  (T2-│D-) TN FP FP TN FP FP FP TN TN FP TN
N o  D is  (P-│Rf-)
P o sit ive  (T2+│D-) TN FP FP TN TN TN FP TN TN FP TN
N egative (T1-│D-)
N egative  (T2-│D-) TN FP TN TN TN TN TN TN TN TN TN
Dis = Disease; PD = Postive dominate; ND = Negative dominate: TP = True positive; FP = False positive: FN = False negative; TN = Treu negative
D isease T est  1 T est  2R isk F acto rs Two step approachTreatment Universal One step approach
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3.5 The economics of diagnosis 
Economic assessments of diagnostic tests are necessary for health technology 
assessments (HTA) (Sanghera et al., 2013). There are however two main reasons why 
the economic assessment of diagnostic tests can be difficult.  Firstly, difficulties can 
arise because of doubts about the relationship between diagnosis and health outcomes. 
Secondly, because of the increasing importance of diagnostic technology in healthcare, 
only with economic assessments will the most value be gained from restricted medical 
resources (Mushlin et al., 2001). Diagnostic technologies make it possible for clinicians 
to make decisions that allocate the right therapy to the right patient. The outcomes of 
diagnostics tests are more usually measured in terms of case detection and the 
sensitivity and specificity of test results. To translate this information into an economic 
evaluation it is necessary to perform a cost-effectiveness analysis (CEA). Moreover, 
new diagnostic technologies could potentially incur substantial additional expense, 
creating the need for comparative economic and clinical analysis.  
3.6   Conclusion  
Screening and diagnostic tests relate to the ability of a test to discriminate between the 
target condition and health. In other words, they identify between the presence or 
absence of disease in patients. The discriminative potential of disease can be quantified 
by the measure of diagnostic accuracy. Diagnostic accuracy can be measured in 
different ways, such as sensitivity, specificity, predictive values and likelihood ratios.  To 
use the results of test accuracy, a clinician should consider the prevalence in the 
population, as positive and negative predictive values are highly dependent on the 
disease prevalence in the population. Bayes’ rule is a useful theorem, which can be 
applied in the diagnostician’s inference.  It illustrates the sensitivity and specificity of 
diagnostic tests and can calculate positive and negative predictive values, which are 
quantities that a clinician needs in order to make appropriate diagnoses or decisions. 
Laboratory tests are imperfect and may identify some healthy people as diseased (false 
positive result) or identify some diseased patients as disease-free (false negative result). 
Although screening tests and diagnostic tests are a critical contributor to clinical decision 
making, test results may have unwanted and unintended consequences. Test results 
may interfere with clinical decisions if the tests poorly identify between people with and 
without disease. All tests must be chosen properly and used with deliberation and 
purpose with the expectation that the test results will decrease ambiguity surrounding 
patient problems and contribute to their health.  
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Chapter 4 Gestational Diabetes Mellitus (GDM) 
  
4.1 Introduction 
In developing an economic evaluation, it is important to fully understand the disease 
including how the disease presents itself, how the disease changes over time and how 
treatment affects the disease. The purpose of this chapter is to provide a review of the 
literature regarding Gestational diabetes mellitus (GDM). The chapter is divided into 6 
main sections and begins with a definition of the disease area. In the next section, a 
brief review is given of the short and long term maternal and perinatal complications. At 
the end of this section, the burden to both the health care system and finances will be 
demonstrated. Next, the clinical management of GDM are described where treatments 
fall into two main groups, namely pharmacological and non-pharmacological. In the 
following section, numerous guidelines, which have been developed and published in 
Europe and UK, are described by year, testing, threshold values and type of screening 
test. After this, the various screening and diagnostic tests in current use, based on these 
guidelines, are then described. In the last section, an account is then given of different 
screening and diagnostic test guidelines in current use and newly published in the UK 
and Scotland. 
4.2 Search strategy 
The aim of this chapter is to provide a literature review of screening tests for GDM. The 
following electronic databases were searched from 1996 to December 2013: Medline, 
Embase, and Web of Science. Specific searches were performed covering five main 
areas (screening test, burden of disease, guidelines, management or treatment, adverse 
complications) for each of the databases, as detailed in Appendix 1. Inclusion criteria 
were applied to include relevant publications that provided information on screening 
tests for GDM in terms of the management or treatment of GDM, burden of disease, 
guidelines, adverse complications, diagnostic tests for GDM, quality of life related to 
GDM and type 2 DM. In addition, the prevalence of GDM and economic evaluations of 
screening tests of GDM are presented in a systematic review in Chapter 5 and Chapter 
6, respectively and the search strategies of those systematic reviews are therefore not 
included in the results of this Chapter. The search outputs are detailed in Figure 4.1. 
After assessment, 104 studies remained for final review. Information from the review 
was then used to design the economic evaluation model to identify appropriate 
comparators, and parameter estimates for the model.      
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Figure 4.1 Flowchart of article selection 
 
4.3 The disease 
Diabetes mellitus (DM) is a disease that has been recognised for thousands of years 
(Sattley, 2008). There are two major forms of maternal diabetes which may occur during 
pregnancy: GDM and pre-existing  diabetes (NHS., 2011). Firstly, GDM is the most 
common medical complication of the pregnancy period.  In 1999, the World Health 
Organisation (WHO) defined GDM “as carbohydrate intolerance of variable severity with 
onset or first recognition during pregnancy, whether or not insulin is used, and 
regardless of whether diabetes persists after pregnancy”. Women who become pregnant 
and who are known to have DM which antedates pregnancy do not have gestational 
diabetes but have “diabetes mellitus and pregnancy” and should be treated accordingly 
before and after the pregnancy (WHO, 1999a). GDM is a relatively new condition that 
has only been recognized in modern times, since the nineteenth century. In the 1940 – 
1950s it was recognized that women developing type 2 DM had excess perinatal 
mortality and that their babies were born with excessive weight (Kitzmiller, 2010).  
Secondly, GDM is different in pregnant women with pre-existing diabetes, including 
mothers that have type 1 and type 2 diabetes mellitus before pregnancy. Type 1 DM is 
marked by the body’s inability to produce insulin on the one hand, and type 2 DM is 
actually caused by the body’s resistance to insulin (NHS., 2011). Care and treatment for 
Sources indentified in MEDLINE, 
EMBASE and Web of Science 
(n= 3,350) 
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Duplicates removed 
(n=591) 
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Excluded after full text 
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these must be different from that for GDM. Women who become pregnant and who have 
either  type 1 and type 2 DM before pregnancy are not said to have GDM, but are said 
to have pre-existing diabetes mellitus, and should be treated before, during and after the 
gestation period (American Diabetes Association, 2006) (NHS., 2011). GDM resolves 
after delivery in approximately 90% of the cases reported by Kjos and colleagues (Kjos 
et al., 1990).  Patients who had GDM in previous pregnancies may also get GDM again 
in subsequent pregnancies.  
4.3.1 Pathophysiology 
GDM is a particular type of diabetes developed by some women during pregnancy. 
GDM is a condition in which the patient suffers from glucose intolerance as it occurs in 
patients with type I and type II diabetes. Pregnant women, in particular, are vulnerable to 
transient glucose intolerance because, during pregnancy, the hormones make it harder 
for the body to respond to insulin. The metabolism is changed in normal pregnancy to 
ensure adequate nutrition of the foetus. Levels of maternal estrogen and progesterone 
hormones increase at the beginning of pregnancy, and promote pancreatic β-cell 
hyperplasia and increased insulin release. GDM is a group of diseases that are caused 
by deficiencies in insulin secretion and/or insulin action that occurs when pancreatic 
function is not sufficient to overcome the insulin resistance created by a change in 
diabetogenic hormones during pregnancy (Jovanovic, 2010). As pregnancy is 
characterised by insulin resistance and hyperinsulinemia, it may predispose some 
women to develop diabetes. In pregnancy, the placenta normally produces diabetogenic 
hormones, such as growth hormone, corticotrophin-releasing hormone, placental 
lactogen and progesterone which induce maternal insulin resistance and compensatory 
hyperinsulinemia. Pregnancy hormones and other factors result in interference with the 
action of the insulin receptor.  These and other endocrinologic and metabolic changes 
ensure that the foetus has an adequate supply of energy and nutrients at all times. In 
some pregnancies, pancreatic insulin production cannot compensate for this insulin 
resistance, and carbohydrate intolerance develops (Kennedy et al., 2006). Two forms of 
insulin resistance occur in women who develop GDM. The first of these is the 
physiological insulin resistance of late pregnancy. The second is a chronic form that is 
present before pregnancy and becomes worse because of the physiological changes 
that exacerbate insulin resistance during pregnancy (Metzger et al., 2007).  
   The placenta is a foetal organ with widespread functions that contains a common 
boundary between mother and foetus. The functions of the placenta are transport of 
maternal nutrients to sustain foetal growth, synthesis of hormones and growth factors to 
facilitate maternal adaptation to pregnancy, provision of an immunologic barrier, and 
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dissipation of heat energy from foetal metabolism (Hiden and Desoye, 2010). Women 
with GDM have elevated blood glucose levels in spite of higher insulin levels. Pancreatic 
secretion of insulin is increased, but insulin does not reduce blood glucose levels. 
Subsequently, extra blood glucose passes through the placenta, resulting in high foetal 
levels. This, in turn, causes the baby’s pancreas to produce extra insulin to eliminate the 
blood glucose. Since the infant is getting more energy than it needs to grow and 
develop, the extra energy is stored as fat (Jones, 2001). 
4.3.2 Symptoms 
DM commonly presents during pregnancy because the process of gestation in the non-
diabetic women makes significant demands on insulin-producing cells (Fox and 
Pickering, 1995). Most mothers with GDM do not have any symptoms and the condition 
is detected by screening. Sometimes, pregnant women with GDM may have symptoms 
of high blood sugar, including increased thirst, polyuria and tiredness. However, those 
are also common symptoms of pregnancy. 
4.4 Burden of gestational diabetes mellitus 
This section presents a review of the published literature on burden of GDM. The burden 
of GDM can be categorised into both health and financial aspects. The major health 
burden of GDM is the prevalence of maternal and infant morbidity. On the other hand, 
the financial burden is very much the cost of screening and treatments in order to 
complete full diagnostic and medical procedures required for both the mother and infant.  
4.4.1 Health burden 
Reports from many sources indicate that type 2 DM is increasing rapidly throughout 
developed and developing countries. For example, Hilary King and co-workers have 
carefully analysed a number of reports and published their findings, in which 
adjustments for age were included, to develop the most comprehensive estimates of the 
prevalence of diabetes (King et al., 1998). In the same study, predictions were made of 
the numbers of people with diabetes who would be aged 20 years or more in three 
different time periods, 1995, 2000 and 2025. Worldwide, the prevalence of diabetes in 
adults was estimated to be 4.0% of the population (135 million adults) in 1995 and it is 
estimated that in 2025 the prevalence of diabetic adults will increase to 5.4% of the 
population (300 million adults) In 2004, the revised projections of the prevalence of 
diabetes for year 2000 and 2030 were published by Wild and colleagues. The 
prevalence of diabetes for all age groups worldwide in 2000 and 2030 was estimated at 
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2.8% and 4.4% respectively. The total number of people with diabetes is predicted to 
increase from 171 million in 2000 to 366 million by 2030 (Wild et al., 2004). Moreover, 
Type 2 diabetes and obesity are frequently diagnosed in children and young adults in 
many countries. In the UK, 2.6 million people have been diagnosed with diabetes 
mellitus in 2009.  The prevalence of diabetes in adults across the UK varies, from 5.1 % 
in England, 4.5 % in Northern Ireland, 4.6 % in Wales and 3.9 % in Scotland (Diabetes 
UK, 2010).  
   The global increase in incidence of diabetes has been accompanied by an 
increase in incidence of GDM in many countries. There are differences in the results of 
prevalence studies. The prevalence of women with GDM has increased over time, 
affecting between 1%-16% of women, depending on the diagnostic criteria and 
population studies (King, 1998). A recent international survey of 47 countries estimated 
a prevalence range of <1% - 28%, with data derived from expert analysis and national 
prevalence estimates (Jiwani et al., 2012). Moreover, GDM has been found to be more 
prevalent in African Americans, Hispanic/Latino and American Indians (National Institute 
of Diabetes and Digestive and Kidney Diseases, 2008). The prevalence is often 
significantly different in populations of different size and diversity, reflecting differences 
in geographic diversity (states, regions, and countries) and the definition used to identify 
women with GDM.  The magnitude of the risk varied in different ethnic groups, ranging 
from 9% in Caucasians, 11.9% in Latinos, and 25% in women of Mediterranean or east-
Asian descent (Berger et al., 2002). Moreover, approximately 650,000 women give birth 
in England and Wales each year, and 2-5% of them have diabetes (NICE, 2008b). As 
mentioned above, the prevalence of GDM has not yet been fully quantified. Additionally, 
the prevalence of pregnancy with GDM has increased over time. This study therefore 
conducted a comprehensive systematic review to assess the prevalence of GDM and is 
presented in chapter 5.  
   Increased maternal morbidity because of GDM may occur during pregnancy or in 
the longer term (Barry and Gabbe, 1998). In many studies, an increased risk was 
reported for preeclampsia, polyhydramnios, and cesarean section in women with GDM 
(Sermer et al., 1995)  (de Veciana et al., 1995). Despite the fact that GDM occurs during 
pregnancy, a relatively short period of time in a woman’s life, it may cause type 2 DM in 
the long term. Postpartum, women with GDM have a significantly increased risk of type 
2 diabetes. The National Institute of diabetes and digestive and kidney disease in 2008 
stated that the risk of developing diabetes in women with GDM was about 5-10%, and 
that the risk slightly increased at 40%-60% in the next 5 to 10 years. Coustan and 
colleagues studied former gestational diabetic women, and found diabetes or impaired 
glucose tolerance (IGT) in 6% at 0–2 years, 13% at 3-4 years, 15% at 5-6 years, and 
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30% at 7-10 years postpartum (Coustan et al., 1993). In the case of postpartum 
impaired glucose tolerance and high body mass index (BMI) in adult females, they are 
predicted to develop type 2 diabetes after GDM occurrence. 
   Previous estimates of perinatal mortality have been based on results of older 
studies. Evidence to support increases in perinatal mortality related to GDM was 
confirmed in a more recent literature review of these older studies (Martine et al., 2007).  
Perinatal mortality rates of 49-198 per 1,000 births have been observed to occur in 
women receiving GDM treatments (Coustan and Lewis, 1978). The perinatal mortality 
rate in infants of diabetic mothers has declined sharply from 250 per 1,000 live births in 
1960 to a near-normal 20 per 1,000 live births in 1980 (Weintrob et al., 1996).  Infants 
born to diabetic mothers have a risk of perinatal morbidity and mortality, resulting from 
hyperbilirubinemia, macrosomia, birth trauma, hypoglycaemia and neonatal respiratory 
distress syndrome (Crowther et al., 2005).  
   In terms of health-related quality of life (HRQoL) in women with GDM, there have 
been only a few studies that have investigated the effects of GDM on women’s HRQoL. 
A randomised control trial (RCT) in Australia measured maternal health status by the 
Short-Form 36 (SF-36) at 6 weeks and 3 months postpartum, and stated that treatment 
of GDM improved the mother’s HRQoL (Crowther et al., 2005). The results of Crowther 
and colleagues were used to estimate QALY in a cost-effectiveness analysis for GDM in 
the UK (Round et al., 2011). In Finland, the HRQoL after pregnancy of 100 women 
sampled from the birth register at a University hospital was measured using the 15D 
instrument.  This study showed insignificant difference in the median and mean level 
values of 15D between the GDM group and the control group (Halkoaho et al., 2010). In 
addition, another report showed that Type 2 DM after GDM may reduce life expectancy 
up to 10 years on average (Diabetes UK, 2012). No studies have been conducted in 
terms of Disability adjusted life years (DALY) for GDM yet. However, two cost-
effectiveness analysis (CEA) studies for GDM screening tests reported results in terms 
of DALY Adverse in order to present the long term adverse complications for mothers 
who have both GDM and type 2 DM (Lohse et al., 2011) (Marseille et al., 2013).  
4.4.2 Financial burden 
It is estimated that 10% of the entire National Health Service budget is accounted for by 
diabetes, approximately £9 billion a year (based on the 2007/2008 budget for the NHS) 
(Diabetes UK, 2010). GDM management involves initial screening and diagnostic tests, 
treatments (dietary therapy, self-monitoring blood glucose level, pharmacotherapy and 
insulin programme), management of maternal medical complications (maternal trauma, 
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preeclampsia and operative deliveries), monitoring blood glucose level 
(pharmacotherapy and insulin programme), and management of neonatal complications 
(macrosomia, brachial plexus injury (BPI), jaundice and birth trauma).  All of these 
account for parts of the financial budget.  
   In the UK, the NHS reported national costs for antenatal care and diabetes in 
pregnancy in 2008 (NICE, 2008a). The cost of a random blood test was £3.37 and the 
cost of a diagnostic test by 75g oral glucose tolerance test was £17.58.  It was estimated 
that the net costs of screening and testing for GDM in England were £2,150,000 per 
year, which included all pregnant women with risk factors tested by the biochemical test 
and diagnostic test. The estimated costs of treatment of blood glucose monitoring, oral 
medication and regular insulin or analogue insulin were £704,000, £4,000 and £55,000 
respectively.  The costs of implementation of treatment for GDM by year 1, 2 and 3 in 
England were estimated at £840,000, £897,000 and £953,000, respectively  (National 
Health Service, 2008b). In 2007, Chen and colleagues estimated the national medical 
costs associated with GDM by analysing National Hospital Discharge data in the USA.  
They showed that the total estimated cost attributable to GDM nationally was $596 
million (approximately $3,305 per woman with GDM) for mothers, $40 million for 
newborn babies (approximately $209 per newborn of mothers with GDM), and $320 
million for medical care costs (Chen et al., 2009).  Maternal GDM can be managed in 
various ways. Approximately 65% (cost  £114.82 per course/person) of the cases will 
undergo dietary therapy with constant monitoring of blood glucose levels, approximately 
20% (cost £3.09 per course/person) will receive oral hypoglycaemia therapy, and 
approximately 15% (cost £59.57 per course/person) will be treated with insulin (National 
health service, 2008a). In 2007, The University Hospitals of Coventry and Warwickshire 
estimated that the cost of each case of OGTT to the NHS was £12.13 (Wilson et al., 
2008).   
4.5 Adverse complications of GDM for mother and 
offspring 
GDM is associated with substantial increases in rates of maternal and prenatal 
complications. During gestation and after delivery, both mother and offspring are at risk 
of developing short and long term complications. In a meta-analysis conducted by 
Marine and colleagues in 2007,  strong associations were reported between GDM and 
adverse outcomes for mother and children including hypertensive disorder, caesarean 
section, macrosomia, infant respiratory distress syndrome and hypoglycemia  (Martine 
et al., 2007).   
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   When a mother has metabolic aberrations during pregnancy complicated by 
diabetes, there are serious implications for the foetus, newborn baby, child and young 
adult (Weintrob et al., 1996). According to the “Pederson hypothesis”, maternal diabetes 
is characterized by high concentrations of glucose that result in increased nutrient 
transfer to the foetus. Maternal glucose crosses to the placenta easily, which results in 
intrauterine hyperglycemia, foetal hyperinsulinemia and possible modification of growth 
and development of the foetus. (Pedersen, 1954). GDM during pregnancy can have 
multiple adverse outcomes for the mother and offspring, which can be divided into short 
and long term, shown in Table 4.1. This review will present these adverse outcomes by 
dividing them into short and long term impacts.  
Table 4.1 Short and long term complications in mothers and offspring 
 Age at Expression Period of Exposure Complications 
Mother with GDM   
Short term Gestation 3
rd
  trimester Hypertension, Preeclampsia 
  Delivery Cesarean section, Instrumental delivery 
(forceps and ventouse deliveries), Vaginal 
injuries or Uterine hemorrhage 
Long term After delivery  Obesity ,  GDM in next gestation, type 2 DM 
Offspring in mother with GDM  
Short term Fetus 2
nd
 trimester Macrosomia, Nervous system development 
delay 
  3
rd
 trimester Chronic hypoxemia, Stillbirth 
 Newborn Deliver Birth injury, Respiratory distress syndrome, 
Polycythemia and Hyperbilirubinemia, 
Neonatal metabolic problems (Hypoglycemia, 
Hypocalcemia, Hypomagnesemia 
,Hyperbilirubinemia) 
Long term Child/adult  Obesity, Impaired glucose tolerance, DM 
 
The details of short and long term complications in both mothers and offspring in Table 
4.1 have been simplified and shown in diagrammatic form in Figure 4.2.  The figure is 
divided into 4 sections. The upper two sections show short term complications in both 
mothers and offspring. In mothers, hypertension and preeclampsia are presented as 
direct complications which occur during the gestation period. Whereas, cesarean 
section, instrument deliveries and vaginal injuries are presented as indirect adverse 
complications which occur in mothers who have macrosomic babies, shown by broken 
arrow lines in the figure. Moreover, offspring with macrosomia can produce indirect 
complications not only for mothers but also for themselves. Long term adverse 
complications in both mothers and offspring are shown in the two lower sections of this 
figure.  Obesity and type 2 DM are the main long term complications.   
   The design of the diagram in Figure 4.2 of short and long term complications 
does not taken into account perinatal mortality. Perinatal mortality refers to the death of 
a foetus or neonate and is considered to be the most important complication of GDM. 
Martine and co-workers found in their meta-analysis that the main evidence for an 
increased risk of perinatal mortality associated with GDM stemmed only from older 
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studies (Martine et al., 2007). Additionally, in a current systematic review and meta-
analysis of the effects of treatment in women with GDM, zero cases of perinatal mortal 
were reported. Because of this, pinatal mortality is not taken into account in the 
presentation of short term complications in Figure 4.2.  
 
Figure 4.2 Short and long term complications in both mother and offspring 
 
4.6 Management of gestational diabetes mellitus 
The goal of treatment in women with GDM is to achieve blood glucose level control. 
Diabetic control in pregnancy and obstetric management will be associated with a 
reduction in the severity of neonatal complications and improve the adverse outcomes 
for the mother. In terms of the management of GDM, effective treatment demonstrates 
that diagnosis and treatment of GDM results in a reduction in adverse effects for both 
mother and child. In two randomized control trials, it has been shown that interventions 
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in women diagnosed with GDM using dietary advice, monitoring and management of 
blood glucose, are effective in reducing birth weight, the rate of growth for gestational 
age infants, and perinatal morbidity. The authors of the Australian Carbohydrate 
Intolerance Study in Pregnant Women (ACHOIS), a large randomized control trial (RCT) 
of treatment for GDM, concluded that treatment of GDM reduced the risk of serious 
perinatal complications and may also improve women’s health-related quality of life 
during pregnancy and after delivery (Crowther et al., 2005). The authors of another RCT 
in 2009, The Maternal Foetal Medicine Units network (MFMU) study, found that 
treatment of mild GDM did not significantly reduce the frequency of a composite 
outcome that included stillbirth or perinatal death and several neonatal complications but 
did reduce the risk of foetal overgrowth, shoulder dystocia, caesarean section, and 
hypertensive disorders  (Landon et al., 2009). In the ACHOIS, a significant decreased 
risk in the composite outcome was demonstrated, but in the MFMU study the risk of 
composite outcome was not significantly different. The authors of a systematic review of 
treatment of women with GDM stated that treatment for GDM, including treatment to 
control blood glucose alone or with other specific treatment, seems to lower the risk for 
some perinatal complications in both mother and child (Horvath et al., 2010). In addition, 
untreated carbohydrate intolerance during pregnancy was associated with increased risk 
of maternal and perinatal morbidity (Pettitt et al., 1980).  Bellamy and colleagues found 
that proper tests and management such as dietary, lifestyle and pharmacological 
intervention, might prevent or delay the onset of type 2 diabetes in women with GDM 
(Bellamy et al., 2009). 
   There are a substantial number of treatments for GDM. This review divides these 
into two main groups, non-pharmacological and pharmacological, based on the Scottish 
Intercollegiate Guidelines Network for the management of diabetes (SIGN) and the 
National Institute for Health and Clinical Excellent (NICE) guidelines for antenatal care 
diabetes in pregnancy (SIGN, 2010) (NICE, 2008d). Management of GDM in these 
guidelines are the same, including dietary therapy and blood glucose monitoring on the 
one hand, and pharmacotherapy (Glibenclamide and Metformin) or insulin therapy 
(Regular insulin, Insulin aspart and Insulin lispro). 
4.6.1 Dietary therapy 
Dietary therapy is the primary GDM treatment strategy for controlling glucose levels and 
ensuring appropriate maternal weight gain. A good diet is important for women during 
pregnancy, as food provides the mother’s energy requirement and supplies the foetus 
with the nutrients it needs to develop.  All women should receive nutritional advice from 
an appropriately skilled dietician. For women with diabetes before pregnancy, pre-
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pregnancy nutritional assessment and care from a dietician may improve the patient’s 
chance of achieving the best possible diabetes control before conception. Dietary 
programmes need to conform to the principles of dietary management of diabetes in 
general and meet the nutritional requirements of pregnancy. In addition, dietary therapy 
should be individually tailored for each woman with GDM and take account of maternal 
weight and body mass index. The dietary recommendations generally include avoiding 
sugar, convenience foods and junk foods.  Small frequent meals and a very small 
breakfast should be eaten and fat intake reduced.  Generally, daily calorie needs for 
women of normal weight in the second half of pregnancy are 30 – 32 kcal per kilogram 
of body weight. Dietary therapy plans control blood sugar by controlling the amount of 
carbohydrate food consumed during a day. Eating less carbohydrate may decrease 
blood sugar level. Some carbohydrates are digested more slowly and raise blood  sugar 
level more than others (Diabetes prevention and control program, 2007).  
   Carbohydrate counting for meals and snacks are considered in most dietary 
programme recommendations. The American Diabetic Association (ADA) recommends 
an intake of calories and nutrients sufficient to decrease maternal hyperglycemia. The 
dietary programme recommended a 30-33% reduction of calories for those pregnant 
with diabetes, with at least 40% daily carbohydrate intake.  The ideal allocation would be 
50-60% carbohydrates (complex and high fiber), 10 -20 % protein, and 25 - 30 % fat (< 
10% saturated). In 2003, the British Diabetic Association recommended not less than 
45% carbohydrates with a low glycaemic index, and a limited proportion of dietary fats. 
The Fifth Workshop Conference on GDM in Chicago in November 2005 suggested an 
optimal carbohydrate content in pregnancy of 175 g/day including 140g for the mother 
and 35g for foetal brain metabolism (Cianni D G et al., 2008).  
   Major and co-workers found that women with GDM who received dietary 
treatment and who obtained less than 40 percent of their total calories from 
carbohydrates, had babies with lower birth weights and had lower risk of caesarean 
delivery than women with higher intakes(Major et al., 1998). Magee and colleagues, who 
performed a randomized control trial in obese women with GDM, stated that restriction 
of carbohydrates by 50% (1,200 kcal/day) improved glycaemic control but, significantly 
increased the risk of ketonemia and ketonuria (Magee et al., 1990). The authors of a 
systematic review of the evidence for screening for GDM found that more than 70% of 
patients with GDM have mild hyperglycemia and are usually treated with diet alone 
(Brody et al., 2003).  
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4.6.2 Blood glucose Monitoring 
Once patients with GDM start a dietary programme, it is important to monitor capillary 
blood glucose levels. Patients and health care providers have to increase the frequency 
of the monitoring of daily blood glucose levels. Monitoring the blood glucose is important 
in evaluating the efficacy of the exercise and eating programme by testing blood sugar 
levels at the proper times during each day. In the self-monitoring of blood glucose, a 
drop of blood is tested for blood glucose levels by using a special device. Patients 
should do this test three times a day, as shown in Table 4.2. Occasionally, some 
patients may ask to test more frequently during a day or at night. 
   The Australasian Diabetes in Pregnancy Society (ADIPS) recommends self-
monitoring of blood glucose, obtaining at least one fasting and one 1 or 2 hour 
postprandial (5.5, 8.0 and 7.8 mmol/L respectively) tests daily (Hoffman et al., 1998). 
The Fourth International Workshop Conference on Gestational Diabetes Mellitus 
suggested maintaining fasting blood glucose concentrations at less than 5.3 mmol/L, 
and for one or two hours after a meal at less than 7.8 and 6.7 mmol/L respectively, 
glucose levels which are lower than ADIPS (Metzger and Coustan, 1998). The clinical 
practice recommendation of the American Diabetes Association (ADA) on GDM is to 
perform fasting glucose 5.8 mmol/L and 2-hour postprandial plasma glucose 6.7 mmol/L 
tests. Self-monitoring of blood glucose in glycaemic control is a controversial issue 
(American Diabetes Association, 1997). Several studies had shown that more frequent 
self-monitoring improved glycaemic control. Postprandial hyperglycemia is more closely 
related to fetal macrosomia than preprandial hyperglycemia in pregnancy with diabetes. 
In one randomised study of postprandial and preprandial blood glucose monitoring in 
women with GDM who required insulin treatment, patients who measured their glucose 
levels after a meal had infants with lower birth weight, and had fewer caesarean 
deliveries (de Veciana et al., 1995). 
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Table 4.2 Treatment targets for women with gestational diabetes mellitus 
Test Glucose levels mmol/L 
 The American 
Diabetes 
Association 
The Australasian 
Diabetes in 
Pregnancy 
Society (ADIPS) 
The Fourth 
International 
Workshop 
Conference on 
Gestational 
diabetes mellitus 
Fasting capillary (venous 
plasma) 
< 5.8 < 5.5 < 5.3 
1 hour postprandial capillary 
(venous plasma) 
- < 8.0 < 7.8 
2 hour postprandial capillary 
(venous plasma) 
< 6.7 < 7.8 < 6.7 
 
4.6.3 Insulin therapy 
Insulin therapy is used when capillary blood glucose levels exceed the threshold, 
according to the guidelines for self-monitoring blood glucose levels, because of a lack of 
effectiveness of dietary therapy in controlling these levels. The decision regarding 
starting insulin therapy differs greatly from centre to centre and is based on many 
factors, including effectiveness of screening, local incidence, mode of surveillance, 
individual obstetrical, medical and psychosocial factors, and local resources (Firth, 
1996).  
   Various criteria have been proposed for starting insulin therapy in women with 
GDM.  The American College of Obstetricians and Gynaecologists Committee (ACOG) 
recommends insulin therapy for women whose fasting glucose level is over 5.2 mmol/L, 
whose one-hour postprandial glucose level is over 7.1 to 7.7 mmol/L, or whose two-hour 
postprandial glucose level is over 6.6 mmol/L (ACOG 2001). The ADA recommends a 
higher glucose level for starting insulin therapy: between 5.0 to 5.5 mmol/L in the fasting 
state, less than 7.7 mmol/L at one hour after eating, and less than 6.65 to 7.05 mmol/l at 
two hours after eating (Metzger et al., 2007).  Buchanan and colleagues recommend 
initial insulin therapy to reduce risk of macrosomia when abdominal circumference (AC) 
measured by ultrasound is higher than the 75th percentile for gestational age  (Buchanan 
et al., 1994).  
   Insulin is the first-line pharmacologic therapy for GDM. Human insulin has 
several theoretical and practical advantages for GDM.  It does not cross the placenta 
and is highly effective. In gestational diabetes, mothers require insulin for the duration of 
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the pregnancy period (Firth, 1996). Regular insulin, which is used in pregnancy for 
treatment of diabetes, has some limitations: it becomes effective from 30 – 60 minutes 
after subcutaneous injection, the effect peaks after 2 – 3 hours and the duration of the 
effect is too great (about 8 – 10 hours). Currently available insulin analogues include 
rapid-action mealtime insulins Lispro (Humalog) and Aspart (Novolog), and long-acting 
basal insulin Glargine (Lantus). Mealtime insulins (Lispro, Aspart) are used to control 
post-meal blood glucose level. For controlling between-meal and overnight blood 
glucose levels a basal insulin is used (NPH, Glargine, Lente and Ultralente). Lispro and 
Aspart are categorised as class B drugs in The United States of America. However, 
ACOG and the ADA have not yet officially recommended their use. In contrast to Lispro 
and Aspart, there is little information on the use of the long-acting insulin analogues 
Glargine (Lantus) and Detemir (Levemir) in pregnancy. HPN is the intermediate-acting 
option of choice for those who require pharmacologic treatment. 
   Initially, the insulin dose can be calculated on the basis of the patient’s weight. 
The first doses depend on gestational age, capillary blood glucose monitoring levels, 
current body weight at the start of therapy, further adjustments, base activity, meal plan 
and other factors, as shown in Table 4.3. Most gestational diabetic patients require an 
insulin dose of 0.6 U/kg body weight or more. Patients may safely be given an initial total 
daily dose of 0.4 U/kg by giving two-thirds of it in the morning and one-third in the 
evening (Firth, 1996). The normal dose for diabetes patients is 0.8 U/kg, and 0.9 -1.0 
U/kg for overweight and obese women. 
Table 4.3 Total suggested daily insulin during pregnancy 
 
Gestational weeks Total daily insulin 
Week 1-18 0.7 U/kg actual body weight 
Week 18 – 26 0.8 U/kg actual body weight 
Week 26 – 36 0.9 U/kg actual body weight 
Week 36 – 40 1.0 U/kg actual body weight 
 
   In most, but not all, prospective trials of insulin therapy in women with GDM, a 
reduction has been shown in the risk of neonatal macrosomia (Turok et al., 2003). 
Coustan and Lewis reported that treatment of women with diabetes with insulin (20 units 
NPH and 10 Units regular) was effective in reducing the incidence of foetal macrosomia 
(Coustan and Lewis, 1978). Similarly, the authors of a study in Alabama in 1990 using 
the same insulin dose reported a successfully reduced mean birth weight, macrosomia 
rate, and ponderal index (Thompson et al., 1990). In contrast, little effect on birth weight, 
birth trauma, operative delivery, or neonatal metabolic disorder was found in a 
randomised controlled trial of intensive treatment of GDM  (Garner et al., 1997). 
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4.6.4 Pharmacotherapy 
   Oral hypoglycaemic agents are not currently used in treating GDM because 
these medications cross the placenta and could stimulate the foetal pancreas.  For this 
reason, tolbutamide, chloropropamide, and other sulfonylureas are not used in 
pregnancy (Langer, 1993) (Hoffman et al., 1998). Nevertheless, glyburide therapy is an 
alternative for women who are unable or unwilling to take insulin, and is recommended 
in several practices as a first-line therapy (Serlin and Lash, 2009). Glyburide, an oral 
glucose lowering agent often used in the treatment for type 2 Diabetes mellitus, has 
been shown not to cross the placenta and has been studied for use in pregnant women 
(Elliott et al., 1994). Moore stated that the safety of glyburide is difficult to establish 
because of the relatively small number of patients with GDM in the study (Moore, 2007). 
201 glyburide-treated women were compared to 203 insulin-treated women. The study 
showed gyburide to be a clinically effective alternative to insulin therapy in women with 
GDM (Langer et al., 2000). In a secondary analysis of a previous paper by Langer and 
co-workers, it was also found that glyburide and insulin are equally efficient in the 
treatment of GDM at all levels of disease severity (Langer et al., 2005).  In addition, 
metformin (Glucophage) may be another option for treatment of GDM. In a randomised 
controlled trial of 751 women with diabetes in urban obstetrical hospitals in New Zealand 
and Australia, in which treatment with metformin (plus insulin, if needed) and treatment 
with insulin alone were compared, neither were associated with an increase in perinatal 
complications (Rowan et al., 2008). In another randomised study, metformin was 
compared with insulin treatment in patients with GDM. Rowan and colleagues reported 
that glycaemic control in patients with GDM treated with metfomin and/or insulin was 
strongly related to pregnancy outcomes (Rowan et al., 2010).  
   During pregnancy, the NICE and SIGN guidelines recommend that women with 
GDM receive interventions that include dietary control, home glucose monitoring and 
pharmacotherapy, as well as insulin therapy when needed (SIGN, 2010) (NICE, 2008d). 
Pharmacotherapy or insulin should be considered when dietary therapy results are 
ineffective in controlling blood glucose levels, when there is a lack of expected weight 
loss following calorie restriction, or when patients are consistently hungry  (Serlin and 
Lash, 2009). GDM treatment should be focused on the prevention of both mother and 
foetal complications (Kjos and Buchanan, 1999). A team focused treatment for 
managing GDM in women is ideal, if possible. The teams would usually include an 
obstetrician, diabetes physician, a diabetes educator (diabetes midwifery educator), 
dietician, midwife and paediatrician. The number of maternal care visits per mother is 
significant in confirming whether GDM is being managed properly. Bryson and colleague 
stated that where the number of maternity clinic visits were 80% less than expected, 
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women with GDM were found to have a higher risk of both eclampsia (convulsions from 
high blood pressure) and preeclampsia (swelling of kidney problems from high blood 
pressure) than women with GDM who complete prenatal care (Bryson et al., 2003). 
Women with GDM should be closely monitored until the early postpartum period. 
4.7 Guidelines: screening and diagnostic test thresholds 
for GDM  
The purpose of screening for GDM as early as possible is to diagnose and treat 
pregnant women with GDM (Martine et al., 2007). There are three main reasons for 
screening for GDM. Firstly, GDM is a significant complication and metabolic disorder of 
pregnancy, and disappears after delivery (Koukkou et al., 1995) (Carpenter and 
Coustan, 1982).  Secondly, GDM is associated with increased risk of adverse effects for 
both mother and child.  These include foetal macrosomia and perinatal mortality in 
children, hypertension disorders, pre-eclampsia, and caesarean section in mothers, and 
future diabetes in both (Persson and Hanson, 1998) (Greco et al., 1994). Thirdly, 
identifying this group of women may not only prevent perinatal morbidity but also reduce 
the risk of complications through diet and lifestyle management, oral medication 
programmes and insulin therapy  (Jovanovic, 1998).  In addition, Kristina and colleagues 
stated that unrecognized GDM increases risks of large gestational-age infants, 
macrosomia, shoulder dystocia and birth trauma independent of maternal obesity 
(Adams et al., 1998).   
   Numerous screening test guidelines for GDM have been developed and 
published. Most countries have their own diabetes associations, these societies often 
publish guidelines for GDM, which may differ slightly (National Diabetes Data Group, 
1979) (American Diabetes Association, 1998) (WHO, 1999a) (Metzger and Coustan, 
1998). The screening test strategies for GDM are still debated, and no consensus has 
been established yet. (Metzger and Coustan, 1998)  Agreeing on the diagnostic 
threshold for GDM remains problematic (Ryan, 2011). A summary of recommendations 
from reviewed guidelines of the tests and criteria commonly used to diagnose GDM 
ordered by year of recommendation are shown in Appendix 2. In this section, the 
guidelines focus on guidelines published in Europe and the UK, as shown in Table 4.4.    
   In 1991, The European Association for the Study of Diabetes (EASD) first 
published the guidelines for GDM by using fasting plasma glucose for screening tests, 
50g GCT and 75g OGTT for screening (Lind and Phillips, 1991).The most used oral 
glucose tolerance test internationally was a 2-hour 75g glucose solution test 
recommended by World Health Organization (WHO) in 1998 (WHO, 1999a).  The 75g 
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OGTT involves one-step and two-step approaches to screening and diagnosis for GDM 
in all pregnant women during 24 – 28 weeks of gestation. All pregnant women have 
random or fasting plasma glucose tests followed by a 75g OGTT. 
   In 2001 The Management of Diabetes National Clinical Guidelines were 
published by The Scottish Intercollegiate Guidelines Network (SIGN 55) (SIGN, 2001). 
SIGN 55 endorsed using universal screening for GDM.  In the same year, The Clinical 
Resource Efficiency Support Team (CREST) published the Management of Diabetes in 
Pregnancy. CREST is a team of health care professionals in Northern Ireland, whose 
guidelines recommend universal screening. The screening test suggested was RBG at 
28 weeks of gestation and the recommended diagnostic test was 75g OGTT, using the 
same threshold as EADS in 1991(Clinical Resource Efficiency Support Team, 2001).  
   In 2002, Health Technology Assessment (HTA) UK concluded that while some 
women with very high levels of glucose should be treated, there was uncertainty over 
the benefits of screening across the population. 50g GCT is used in these guidelines by 
selective screening (Scott et al., 2002). 
   In 2008, the National Institute for Health and Clinical Excellence (NICE) 
published the Diabetes in Pregnancy Clinical Guideline 63. NICE is the relevant 
decision-making agency in England & Wales, independent of the government. They 
recommended that the 75g OGTT should be used to screen and diagnose using the 
criteria defined by The World Health Organization (NICE, 2008d). Subsequently, the 
March 2010 SIGN guidelines publication recommend a widening of diagnostic criteria 
and an increase in glucose tolerance testing in pregnancy (SIGN, 2010). Additional new 
consensus criteria for GDM reported in 2010 recommended screening tests using 75 g 
OGTT which based on HAPO study as outlined Diabetes Care  (Moses, 2010) (Metzger 
et al., 2010a).  
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Table 4.4 Guidelines and recommendations for screening tests for GDM 
 
Organisation Year Diagnostic 
method 
Threshold  values (mmol/l) Type of 
screening 
Remark 
   0h 1h 2h 3h   
EADS 1991 FPG ≥4.8    Universal  
  50g GCT  ≥8.2     
  75g OGTT ≥6.0  ≥9.0    
WHO 1998 50g GCT  ≥7.8   Universal One-step approach to 
screening 
  75g OGTT ≥7.0  ≥7.8   and diagnosis, one or more 
criteria must be met or 
exceeded  and one step 
approach 
SIGN 2001 RPG ≥5.5    Universal Urine for screening for every  
  FPG ≥5.5     visit 
  75g OGTT ≥7.0  ≥9.0    
CREST 2001 RPG ≥5.5    Universal Urine for screening for every  
  75g OGTT ≥6.0  ≥9.0   visit and 28 weeks gestation 
HTA UK 2002 50g GCT  ≥7.8   Selective Very selective screening 
based on age, obesity and 
ethnic origin 
NICE 2008 FPG ≥7.0    Selective Women with on of risk factor  
  75g OGTT ≥7.0  ≥7.8   should be offer screening 
test 
Consensus 2010 75g OGTT ≥7.0  ≥7.8  Universal   
SIGN 2010 FPG ≥5.1    Selective one or more value must  
  75g OGTT ≥10.0  ≥8.5   be met or exceeded 
Organisation (C&C) Indicated Carpenter and Constant, (WHO) World Health Organisation, (EASD) European Association for 
the Study of Diabetes. (SIGN) The Scottish Intercollegiate Guidelines Network, (SOGC) The Society of Obstetricians and 
Gynaecologists of Canada (NICE) The National Institute for Health and Clinical Excellence : Tests (OGTT) Oral Glucose 
tolerance Test, (GCT) Glucose challenge test, ( FPG) Fasting Plasma Glucose, (RPG) Random Plasma Glucose : Threshold 
Now, if you want to convert mg/dl of glucose to mmol/l, you can divide the result in mg/dl by 18 or multiply by 0.055 but, if you 
want to convert mmol/l of glucose to mg/dl, just multiply by 18. 
 
In summary, over the past decade, many tests and various thresholds for GDM have 
been developed, not only across America, but also within Europe and the UK. The 
OGTT remains the foundation for the diagnosis of GDM. All expert panels such as the 
WHO, NICE, EADS, and SIGN recommend OGTT as the “gold standard” for the 
diagnosis of diabetes in pregnancy. The 100g OGTT is popular In North America, while 
the 75g OGTT version is used more in Europe and UK. In the UK, two national surveys 
of UK obstetric units have shown a lack of consensus on screening tests for GDM, with 
some health care centres using the ADA guidelines and others implementing the WHO 
guidelines. Moreover, screening and diagnostic tests, cut-off values, timings, and 
subsequent management programmes vary widely in the UK  (Mires et al., 1999)  
(Hanna et al., 2008). The national survey of the Association of British Clinical 
Diabetologists (ABCD) reported 82 percent of centres in the UK provide routine 
screening for GDM, half of those centres using universal screening and half selective 
screening. This survey reports a widely varied prevalence of GDM from 0.1-10% 
(Median 1.5%) (Hanna et al., 2008). Consequently, the prevalence of GDM is 
significantly related to the screening test used in its detection and the cut-off point.  
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4.8   Guidelines: screening and diagnostic test thresholds 
for postpartum screening for type 2 DM in women 
with a history of GDM.  
Many guidelines suggest postpartum follow up glucose tolerance tests for mothers with 
GDM (WHO, 1999a) (ACOG, 2000) (American Diabetes, 2004) (NICE, 2008d) (SIGN, 
2010). The WHO recommends postpartum screening for type 2 DM by 75g OGTT at 6 
weeks or more after delivery but does not recommend it for follow-up after this time 
(WHO, 1999a). The ACOG proposed that the postpartum screening for type 2 DM 
should be performed at the time of the postpartum visit by FPG or 75g OGTT.  
According to the ADA guidelines, GDM mothers should have their blood glucose tested 
by RPG or FPG within 1-3 days post-delivery (American Diabetes, 2004). If the test is 
negative, the next test should be delayed until 6-12 weeks after delivery in GDM women 
who do not have DM immediately postpartum. Then, mothers should receive a 
confirmation test again around their early postpartum visit using 75g OGTT. If glucose 
levels are normal on all previous follow ups, reassessment of glycemia should be 
undertaken at a minimum of 3 year intervals. NICE proposed using RPG (but not an 
OGTT) at 6 weeks postpartum and annually thereafter (NICE, 2008d). The variable 
recommendations for postpartum screening and continued monitoring for type 2 DM in 
women with history of GDM is shown in Table 4.5.  
Table 4.5 Guidelines and Recommendations for postpartum screening for type 2 DM in 
women with history of GDM 
 
Organisation Time Diagnostic 
method 
Threshold  values (mmol/l) Remarks 
   0h 1h 2h 3h  
ADA Post-delivery (1-3 days) RPG ≥5.2 ≥9.9 ≥8.5 ≥7.7  
  FPG      
 Early postpartum visit 75g OGTT ≥6.0  ≥9.0  Two or more value must 
be met or exceeded 
 1 year postpartum 75g OGTT ≥6.0  ≥9.0  Two or more value must 
be met or exceeded 
 Tri-annually 75g OGTT ≥6.0  ≥9.0  Two or more value must 
be met or exceeded 
WHO 6 weeks or more after  FPG ≥6.1 ≥9.9 ≥11.1 ≥7.7  
 delivery 75g OGTT ≥6.0  ≥9.0   
ACOG No specific 
recommendation, but 
should be the first 
postpartum visit 
75g OGTT ≥6.0  ≥9.0  FPG can be used in 
subsequent testing if both 
FPG and OGTT are 
normal postpartum 
        
NICE 1 year postpartum RPG ≥5.1    Offer lifestyle advice 
 2 year postpartum RPG ≥5.1     
 3 year postpartum RPG ≥5.1     
SING 6 weeks postpartum FPG ≥5.1    With 75g OGTT if clinically 
indicated 
 
The postpartum screening for type 2 DM is a controversial issue in terms of the 
appropriate time and methods for screening (Bentley-Lewis et al., 2008). Most 
guidelines for the postpartum screening of type 2 DM in women with history of GDM 
Chapter 4  97 
 
recommend screening witthin different time frames. Ketzmiller and co-workers 
conducted a systematic review of mostly European studies, and found the prevalence of 
type 2 DM, 1-10 years after delivery, to be 2.3% – 9.3% (Kitzmiller et al., 2007). Kim and 
colleagues estimated the efficacy and cost of postpartum screening for diabetes among 
women with GDM. Screening tests for diabetes with FPG, OGTT, HbA1c, annually, 
every 2 years and every 3 years over a period of 12 years were simulated and 
compared and the in the outcomes of the study it was stated that screening women with 
a history of GDM using OGTT every 3 years had the lowest costs per case of detected 
diabetes (Kim et al., 2007b). Therefore, an appropriate time frame for postpartum 
screening should be longer than 6 years but not shorter than 10 years to mitigate 
against the risk developing type 2 DM and it is recommended that an annual test using 
OGTT be repeated every 2 or 3 years. 
4.9 Screening and diagnostic methods for gestational 
diabetes mellitus  
   The usual test for detecting GDM is screening of all pregnant women by 
measurement of plasma glucose between the 24th and 28th week of gestation. (Naylor 
et al., 1997).  In a recent survey reaching 173 countries, 47 countries responded and 
reported that they have GDM testing and treatment guidelines. Many countries use a 
variety of screening approaches, including universal screening (routine screening of all 
pregnant women), selective screening (based on risk factors) or a mixed approach. In 
this survey, the most commonly used screening and diagnostic tests were the FPG, the 
50g GCT, the 75g OGTT and the 100g OGTT, dependant on the guidelines (Jiwani et 
al., 2012). This section presents screening procedures, screening tests and diagnostic 
tests based on UK and European guidelines, as mentioned in a previous section.  
4.9.1 Screening procedures 
Screening and diagnostic tests are a controversial topic in terms of the appropriate 
screening of pregnant women with GDM. (Greene, 1997) (Jarrett et al., 1997) (Soares J 
de AC, 1997). Other controversial issues include who should be screened, whether a 
one-step or two step approach should be employed and whether screening should be 
universal or selective.  
Universal and selective screening  
A screening test can be applied universally or selectively. In screening for GDM there is 
controversy regarding the use of universal or selective screening (Vogel et al., 2000) 
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(Coustan, 1991). Normally, screening and diagnostic tests are performed between 24 
and 28 weeks because at this time in gestation the diabetogenic effect occurs in 
pregnancy. There is sufficient time during pregnancy to start treatment or therapy 
programmes (Greene, 1997). The Universal screening strategy is to screen all pregnant 
women by measurement of plasma glucose between 24 and 28 weeks using different 
test techniques. On the other hand, the selective screening strategy is to screen initially 
all pregnant women with risk factors. In the next stage, women who show positive risk 
factors undergo further screening. Both universal and selective screening may operate 
by one-step or two-step protocols, depending on the screening criteria. In the two-step 
protocol, women who have exceeded the threshold for screening tests have to continue 
with diagnostic tests. Confirmation of GDM is made diagnostically after a positive 
screening test.  
   Selective screening (Risk factors) is the most widely used screening strategy for 
GDM (American Diabetes Association, 1998) (Metzger and Coustan, 1998). Risk factors 
may be found to be present during the first interview or visit at clinic.  The main risk 
factors in screening for GDM include obesity, age greater than 25 years, family history of 
diabetes, history of previous GDM and ethnic group, depending on the criteria. Factors 
suggested in many guidelines include obesity, age, family history of DM and previous 
GDM. Various ethnic groupings have been recommended as high-risk for GDM in 
different guidelines. For instance, the current National Institute for Clinical Excellence 
(NICE) recommended only three ethnic groups, namely South Asian, Black Caribbean 
and Middle Eastern (National Health Service, 2008b). The Fourth International 
Workshop-Conference on Gestational Diabetes Mellitus and The Australasian Diabetes 
in Pregnancy Society suggested more high-risk ethnic groups, including Hispanic, 
African, Native American, South or East Asian , Pacific Islands and Indigenous 
Australian ancestry (Metzger and Coustan, 1998) (Hoffman et al., 1998). All common 
risk factors and various ethnic high risk groups are shown in Table 4.6. Kim and co-
workers conducted a systematic review of risk factors associated with recurrence of 
GDM. The significant risk factor was ethnicity where the recurrence rate varied between 
30% - 84%.  Lower rates were found in non-Hispanic white groups, about 30% - 37%, 
and higher rates were found in minority groups, approximately 52% - 69% (Kim et al., 
2007a).  
   In 2002, Scott and co-workers carried out a systematic review of risk factor 
screening tests for GDM. They found that the use of risk factor screening tests alone 
were associated with low sensitivity and specificity (Scott et al., 2002). In another  
systematic review,  it was found that the use of risk factors alone as a screening test 
was associated with a low positive likelihood ratio of about 1.75 (women with risk factors 
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are only 1.75 times more likely to have GDM than those without). In other words, a 
diagnostic test only in women with positive risk factors will miss many women with GDM 
(Martine et al., 2007).  For example, Marquette and colleagues reported about 50% 
sensitivity, 55% specificity, positive predictive values (PPV) of only 3% and negative 
predictive values (NPV) of risk factors screening (Marquette et al., 1985). In a study in 
North Carolina, Heltona and colleagues showed low sensitivity, specificity, PPV and 
NPV of about 69%, 68%, 5%, 55% respectively (Helton et al., 1997). 
Table 4.6 Clinical risk factors for gestational diabetes mellitus  
 
 Clinical Risk Factors for Gestational diabetes mellitus 
• body mass index (BMI) above 30 kg/m
2 
 
• previous macrosomia baby weighing 4.5 kg or above  
• previous gestational diabetes  
• family history of diabetes (first-degree relative with diabetes)  
• family origin with a high prevalence of diabetes:  
– South Asian (specifically women whose country of family origin is India, Pakistan or 
Bangladesh) 
– Black Caribbean  
– Middle Eastern (specifically women whose country of family origin is Saudi Arabia, 
United Arab Emirates, Iraq, Jordan, Syria, Oman, Qatar, Kuwait, Lebanon or Egypt). 
– South-east Asian 
– Aborigine  
– Hispanic 
– African 
– Pacific Islands and Indigenous Australian ancestry 
 
On the other hand, approximately 40% – 60% of mothers with GDM have an invisible 
risk factor. The implication of this is that all pregnant women should be screened 
(ACOG, 1994). Another reason for screening all pregnant women is that women with 
GDM may exhibit no symptoms. In the systematic review, it was concluded that 50% of 
women with GDM would be indentified by using historic and clinical risk factors to detect 
those at risk from GDM (Scott et al., 2002). Weeks and colleagues stated that 43% of  
women with GDM remained undiagnosed after selective screening of patients using risk 
factors of obesity glycosuria, family history of DM, previous macorsomis and stillborn or 
anomalous foetus (Weeks et al., 1994).  Poyhomen-Alho and co-workers reported 47% 
of cases were missed by selective screening when using 50g glucose challenge test 
(GCT) combined with risk factors (Poyhonen-Alho et al., 2005). Therefore, selective 
Chapter 4  100 
 
screening should be used with another diagnostic test to confirm if disease is actually 
present.  
One step and two step protocols 
In general, the tests can be divided into screening tests and diagnostic tests. Screening 
and diagnostic tests are further divided into one-step and two-step. There has been 
debate about one-step and two-step protocols for the diagnosis of GDM (Ferrara and 
Kim, 2009).  In the first case, in the one step strategy, a diagnostic test such as 50g 
GCT, 75g oral glucose tolerance test (OGTT) and 100g oral glucose tolerance test 
(OGTT) is performed without prior screening. In the second case, in the two step 
strategy, a diagnostic test is performed to confirm a positive screening test such as a 
random plasma glucose test, fasting plasma glucose test or glycosuria (American 
Diabetes Association, 2003) (Rey, 1999). For example, the one step approach by 50g 
GCT requires women to be tested in the morning after a 12 hour fast, following 3 days of 
a diet with at least 150g of carbohydrate per day. In the two step approach, only women 
with abnormal results in the initial screening are required to proceed to diagnostic 
screening, depending on the strategy.    
4.9.2 Test techniques for the screening of gestational diabetes 
mellitus 
Many test techniques for GDM have been described over the past decades. The 
screening and diagnostic test techniques have been developed to detect high levels of 
glucose or serum in defined circumstances. The test techniques for GDM can be divided 
into screening and diagnosis tests. Table 4.7 shows the list of test techniques that are 
used to identify GDM in pregnancy based on the guideline as discussed in previous 
section.  
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Table 4.7 Test techniques for the screening of gestational diabetes mellitus 
  Test 
technique 
Fasting : 
without 
food and 
drink 
(except for 
water) 
Drink 
contains  
glucose 
(g) 
 
Blood test drawn Test Suggestion 
       0h 1h 2h 3h screening diagnostic   
1 Random Plasma 
Glucose Test 
(RPG) 
    √       √     
2 Fasting Plasma 
Glucose Test 
(FPG) 
Overnight, for 
10-16 hours 
before the test 
 √       √     
3 50g Glucose 
Challenge Test 
(50 GCT) 
  50   √     √ √ No food or 
drink during 
time collecting 
of blood 
sample 
4 50g Oral Glucose 
Tolerance Test 
(50g OGCT) 
Overnight, for 
10-16 hours 
before the test 
50   √     √ √ No food or 
drink during 
time collecting 
of blood 
sample 
5 75g Oral Glucose 
Tolerance Test 
(75 OGTT) 
Overnight, for 
10-16 hours 
before the test 
75 √ √ √     √ No food or 
drink during 
time collecting 
of blood 
sample 
6 100g Oral 
Glucose 
Tolerance Test 
(100 OGTT) 
Overnight, for 
10-16 hours 
before the test 
100 √ √ √ √   √ No food or 
drink during 
time collecting 
of blood 
sample 
 
4.9.3 Screening test techniques for GDM 
Screening tests for GDM include risk factors, random blood glucose (RBG), fasting 
blood glucose (FBG), and other tests. Abnormally high levels of glucose in a screening 
test may indicate GDM. However, a patient will probably be asked to undergo further 
diagnostic testing to confirm a diagnosis. 
Random blood glucose (RBG) 
Random blood glucose (RBG) is a simple, fast and inexpensive test for DM and GDM. 
The RBG is a measure of non-fasting glucose level.  No glucose load need be given and 
the measurement is made randomly. Either random plasma glucose (RPG) or whole 
blood glucose (WBG) may be measured (Scott et al., 2002). In a national survey from 
the UK by Hanna and co-workers, it was shown that 25% of the respondents used a 
random glucose measurement to test for GDM (Hanna et al., 2008). Van and 
colleagues, in a systematic review of accuracy of the random glucose test as a 
screening tool for GDM, stated that random glucose measurement was inadequate as a 
screening tool for GDM based on limited studies. They reported of the accuracy of RBG, 
due to the small number of studies, when specificity approached 100%, sensitivity 
dropped to 20% – 30% (van Leeuwen et al., 2010).  
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Fasting Blood Glucose (FPG) 
Fasting blood glucose (FPG) became popular for screening GDM after the greater 
acceptance of ADA and WHO guidelines for detecting DM. The FPG is a measure of 
blood glucose in a patient who has not eaten anything for at least 8 hours. The FPG test 
is most reliable when done in the morning. The risk of GDM is increased in patients who 
have positive FPG tests. The test is easy to perform and not very demanding for the 
subjects. In a study in a United Arab Emirates population, Agarwal and co-workers 
found the FPG using a threshold of ≥ 5.3 mmol/l had 48% sensitivity and 97.5% 
specificity and a threshold of equal to or lower than 4.3 mmol/l had 93% sensitivity and 
38.5% specificity (Agarwal et al., 2000). Perucchini and co-workers concluded that the 
best threshold for FPG was 4.8 mmol/l, which give a sensitivity of 81% and specificity of 
76% (Perucchini et al., 1999). The authors of the systematic review of screening for 
GDM stated that there is no conclusive data regarding the reproducibility of the 
sensitivity and specificity of the test. In addition, use of fasting glucose as a screening 
test is known to be unreliable for predicting a risk of macrosomia in a mother with either 
GDM or  type 2 DM (Martine et al., 2007). 
Other screening test techniques 
However, other test techniques that are not so commonly used as screening tests for 
GDM are HbA1c, capillary blood glucose measurement with a hemocue, breakfast test, 
lunch test, glycosuria, blood fructosamine, and foetal abdominal circumference (Martine 
et al., 2007)  In the past, convenient screening tests such as glycosuria, glycosylated 
hemoglobin A1c (HbA1c) and random plasma glucose (RPG) test were used to identify 
GDM. These were found to be not sensitive enough to measure the glucose level. 
Glycosylated hemoglobin showed low sensitivity to detect women with GDM and was 
not being recommended (Cousins et al., 1984). The breakfast and lunch tests have an 
advantage of using a standard test meal rather than an artificial glucose solution. This 
technique is not widely used worldwide and has limited research (Martine et al., 2007).   
The systematic review of screening for GDM and economic evaluation by Scott and co-
workers stated that glycosuria is common in pregnancy unaffected by GDM. Glycosuria 
is routinely collected during pregnancy for other purposes than for detecting of GDM in 
pregnancy (Scott et al., 2002). One advantage is that screening for GDM as glycosuria 
is a cheap, convenient and standard nursing procedure (Hanna and Peters, 2002). 
Blood fructosamine showed very low sensitivity and seem to have little value as a 
screening test for GDM (Martine et al., 2007).    
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4.9.4 Diagnostic test techniques for GDM 
The “gold standard” for diagnosis of GDM is 75g OGTT and 100g OGTT (Martine et al., 
2007). The diagnostic test is more time-consuming and complicated than the screening 
test. This section focuses on 75g OGTT because the 100g OGTT is popular In North 
America, while the 75g OGTT version is used more in Europe and Asia.  The 75g OGTT 
has been the international standard for the diagnosis of diabetes in the general 
population for several decades and has been endorsed by WHO in 1999 for use during 
pregnancy (WHO, 1999a)  (Pettitt, 2001). The 75g OGTT is a measure of blood glucose 
after an overnight fast or fast for at least 8 to 12 hours (water only permitted). Before the 
three day period of the test, patients should maintain an adequate carbohydrate intake 
(150 - 200). Patients drink a glucose-containing beverage of 75g concentrate, finishing 
this within 5 minutes.  This test involved 3 blood collections over 2 hours. Blood samples 
will be drawn at various intervals to measure glucose levels, while fasting, one and two 
hours after glucose intake. Table 4.8 provides a summary of the thresholds of 75g 
OGTT by different strategies commonly used to diagnose GDM.  
Table 4.8  Gestational diabetes mellitus threshold on the 2 hour 75g OGTT test (mmol/l) 
 
Interval time EASD WHO CDA ADIPS SIGN NICE ICG SIGN 
Fasting  ≥6 ≥7 ≥5.3 ≥5.5 ≥7 ≥7 ≥10 ≥10 
2 h ≥9 ≥7.8 ≥8.9 ≥9.0 ≥9 ≥7.8 ≥8.5 ≥8.5 
Organisation  (WHO) World Health Organisation, (ADIPS) The Australasian Diabetes in Pregnancy Society,(ADA) 
American Diabetes Association, (CDA) Canadian Diabetes Association, (AGOG) American College of Obstetricians and 
Gynecologists ,( EASD) European Association for the Study of Diabetes, (SIGN) The Scottish Intercollegiate Guidelines 
Network,(NICE) the National Institute for Health and Clinical Excellence ,(ICG) International Consensus Guideline. 
 
   Different thresholds for the diagnosis of GDM are widely used, which can have 
an impact on the prevalence and case detection of GDM, as mentioned in section 3.2.3. 
No studies comparing the different cut-off points used in the 75g OGTT were found in 
this review, however studies are available that report the difference in cut-off points with 
the 100g GOTT and how they relate to changes in prevalence, as discussed below. 
Table 4.9 provides a summary of 100g OGTT and the strategies which are commonly 
used to diagnose GDM. 
 
 
 
Chapter 4  104 
 
Table 4.9  Gestational diabetes mellitus threshold on the 3 hour 100g OGTT test (mmol/l) 
 
Interval time O’Sullivan-
Mahan 
NDDG C&C ADA AGOG 
Fasting  ≥ 5.9 ≥ 5.9 ≥ 5.3 ≥ 5.3 ≥ 5.3 
1 h ≥ 9.9 ≥ 10.6  ≥ 10.0 ≥ 10.0 ≥ 10.0 
2 h ≥ 8.5  ≥ 9.2 ≥ 8.7 ≥ 8.6 ≥ 8.6 
3 h ≥ 7.7  ≥ 8.1  ≥ 7.8 ≥ 7.8 ≥ 7.8 
Organisation (C&C) Indicated Carpenter and Constant, (NDDG) National Diabetes Data Group, (ADA) American 
Diabetes Association, (CDA)Canadian Diabetes Association, (AGOG) American College of Obstetricians and 
Gynecologists  
 
The prevalence of GDM was estimated in three studies using the C&C criteria and 
reported comparisons with NDDG criteria. A similar trend was outlined in the three 
studies such that prevalence’s derived from C&C criteria were found to be greater than 
those from NDDG (Ferrara et al., 2002) (Karcaaltincaba et al., 2009) (Hadaegh et al., 
2005). Schmidt and colleagues reported that 22 women (2.4%, 95% CI 2.0 – 2.9) were 
present with GDM by the ADA criteria alone and 260 women (7.2%, 95% CI 6.5 – 7.9) 
were diagnosed by WHO criteria (Schmidt et al., 2001). However, a study in Thailand, 
Soonthornpun and colleagues found that the 75g OGTT gave a significantly lower 
diagnostic yield of GDM than the 100g OGTT. Using the ADA criteria when the same 
threshold levels were measured, the results of prevalence were approximately 7.1% and 
21.4% respectively (Soonthornpun et al., 2003). 
   The different screening and diagnostic thresholds also present with different 
outcome risks. In a Californian study, Ferrara and co-workers investigated whether 
woman who did not meet the NDDG criteria (Capenter and Coustan plasma Glucose 
thresholds) for GDM, but who exceed the ADA criteria are at risk of neonatal adverse 
outcomes. The results showed lower thresholds in ADA, in comparison to the NDDG 
criteria, which leads to a risk of complications, such as the risk of delivering an infant 
with macrosomia, hypoglycemia or hyperbilirubinemia (Ferrara et al., 2007). In 2003, 
Savona - Ventura and Chircop found a significantly increased risk of developing 
hypertensive disorders during pregnancy and caesarean section by using WHO criteria 
(Savona-Ventura and Chircop, 2003). 
4.10 Current screening and diagnostic tests in Scotland 
In Scotland, historically, there has been controversy over the best method of screening 
and specific diagnostic criteria for the detection and definition of GDM, with no accepted 
international consensus to this day. The Scottish Intercollegiate Guidelines Network 
produced guidelines in two different years, SIGN 2001 and SIGN 2010 (SIGN, 2001) 
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(SIGN, 2010). Although these two guidelines were published by the same organisation, 
they recommend different screening test methods and procedures.  
   Various screening test strategies have been proposed and discussed in section 
4.7. Of these, four screening tests have been selected for further study, including SIGN 
2001, SIGN 2010, NICE 2010 and Consensus 2010, each being developed by different 
organizations and employing different screening test techniques. Furthermore, the four 
screening test strategies include either a one or two step approach as well as either 
universal or selective screening procedures. Further details of this selection strategy are 
presented in chapter 7. 
4.11 Conclusion 
GDM is the most common medical complication found during pregnancy, with a large 
prevalence and imposing cost burden. GDM is defined as any degree of glucose 
intolerance with an onset or first recognition during the period of pregnancy. The high 
risk of maternal and neonatal adverse outcomes brought about by maternal 
hyperglycemia make it crucial to diagnose GDM during 24-28 weeks of gestation. Early 
diagnosis and appropriate treatment aim to control maternal glucose levels and may 
positively influence short and long term maternal and perinatal outcomes.   
   A variety of tests and thresholds for GDM have been proposed. Screening tests 
that are inadequate can result in missed cases of GDM and improper testing strategies 
may result in false positive results. Women may have less insulin resistance earlier in 
gestation and may show a false negative in screening, although screening at an 
inappropriate time may detect undiagnosed type 2 DM. This can lead to avoidable 
health care costs and cases of preventable maternal and neonatal morbidity. 
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Chapter 5 Prevalence of gestational diabetes 
mellitus: A systematic review by characteristic of 
screening tests 
5.1 Introduction 
Commensurate with the global increase in diabetes, generally the prevalence of GDM has 
increased in many countries associated with the rising prevalence of obesity and older 
age mothers. It is commonly perceived that the prevalence of GDM cannot be measured 
well by means of a systematic review. A problem with assessing the prevalence of GDM is 
that epidemiological data is captured with different test techniques. Numerous screening 
tests and guidelines for GDM have been developed and published over the last decade. A 
variety of different tests and guidelines are used to screen for GDM, and due to this the 
prevalence’s for GDM that are reported in studies tend to vary considerably. In order to 
understand this variance, it is necessary to pay close attention to the characteristics of the 
screening tests and the population, such as test procedures, test guidelines and risk 
factors (e.g. ethnicity and age). Thus, the purpose of this chapter is to perform a 
systematic review to reassess the prevalence of gestational diabetes mellitus (GDM) 
considering not just screening test characteristics but also population characteristics. 
Systematic reviews are characterised by a clearly stated set of objectives and 
methodology, a systematic search that attempts to identify all articles to be included into 
the study, an assessment of the validity of the findings of the included studies, and a 
systematic presentation and synthesis of the characteristics and findings of the studies. 
    Accurate prevalence information required for health-care planning is important for 
several reasons as it provides essential knowledge in order to assess the burden of a 
condition within a population. Furthermore, accurate decision models require accurate 
estimates of prevalence and decision model outputs are highly sensitive to the 
prevalence. Additionally, in economic evaluations of screening tests prevalence is 
required as a probability in the construction of decision trees. Using prevalence and 
incident data it is possible to calculate expected numbers with and without disease for a 
given population. Hence, when modelling a health policy decision affecting a population, a 
decision tree that commences with branches for disease status can be used, enabling the 
direct application of conditional probabilities to the following branches, as mentioned in 
section 3.3.3.  
 The review begins with the search strategy as well as inclusion and exclusion 
criteria. The key words are detailed in this section. The next section looks at the quality 
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assessment of the prevalence studies included in this review. Following this there is a 
discussion of how the studies are selected and shown in the accompanying flowchart. The 
results of the review are discussed in terms of the various screening tests used in each 
study, the prevalence reports from the studies, and limitations and recommendations for 
future research. The final section offers a summary and conclusions.  
5.2 Methodology  
5.2.1 Search strategy  
The two electronic databases, MEDLINE and EMBASE were used to search the literature 
on prevalence of GDM from January 1996 through July 2013. All reference lists from the 
main reports and relevant reviews were hand-searched. In addition, the following subject 
headings and text words, and their combinations were included in electronic database 
search strategy (incidence or epidemiolog* and prevalence and gestation* diabet* or GDM 
or pregnan* and diabet* and burden), as detailed in Appendix 1.  
  All retrieved studies were initially screened by title and abstract, then the 
exclusion/ inclusion criteria were applied. If it was concluded that an article should be 
included for systematic review, the full text of the article was obtained. Based on the full 
text manuscripts, studies were selected according to whether they matched predefined 
criteria. 
5.2.2 Eligibility criteria 
The newly published, Preferred Reporting Items for Systematic reviews and Meta-
Analysed (PRISMA), provides guidelines for conducting systematic reviews, and suggests 
framing questions with five components to help facilitate the systematic review and meta-
analysis process. Inclusion criteria are presented as five PICOS components namely, the 
patient population or the disease being addressed (P), the intervention or exposure (I), the 
comparator group (C), the outcome or endpoint (O), and the study design chosen (S) 
(Liberati et al., 2009). Predefined criteria were applied to choose the final list of papers to 
be included in the review based on the inclusion criteria presented as five PICOS 
components, as shown in Table 5.1.  
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Table 5.1 Eligibility criteria in PICOS components 
PICOS components Inclusion criteria 
Populations(P) Participants of any age of pregnancy. GDM was described as carbohydrate 
intolerance of varying degrees of severity, with onset or first recognition 
during pregnancy. 
Intervention(I) All screening test techniques and procedure  
Comparative (C) - 
Outcome (O) Papers which attempted to identity the prevalence of GDM as their primary 
objective were included, a subject has been identified for GDM papers 
provided a prevalent number (usually shown as a percentage) and 95% 
confident interval for the whole population or sub-populations of gestational 
diabetes mellitus were included 
Study design chosen (S) Cross-sectional study design or cohort studies.  
 
  Exclusion criteria included papers not in the English language, case studies based 
on a single case and prevalence numbers where patients were already known to have 
diabetes mellitus before pregnancy. Studies that report only prevalence trends for GDM 
over a number of years were also omitted. Additionally, papers consisting of abstracts 
only were omitted. However the potential for selection bias is recognised particularly with 
regard to English language and abstract exclusion.  
5.2.3 Data collection process 
All information about the methodology and results from each study were extracted using a 
data extraction collection form. Abstracted information included study characteristics and 
study results as well as other items; the study’s location and population, PICOS, study’s 
design, screening test criteria and threshold, and prevalence.  
5.2.4 Methodological quality assessment 
No generally accepted criteria for the quality assessment of prevalence studies were 
available. This systematic review applied and adopted the quality assessment list of 
previous systematic reviews of prevalence (Bishop et al., 2010) (Prins et al., 2002). 
Regarding the methodological quality of those studies, two aspects of validity are 
important: external validity and internal validity. External validity relates to the applicability 
of study results to other populations, whereas internal validity implies accurate 
measurement apart from random error. This quality assessment covers all aspects of the 
prevalence article including items deemed essential for the transparent reporting of a 
systematic review of prevalence studies. A checklist was designed that consists of 15 
items: six items on internal validity; six items on external validity and; three items on 
informativity, as shown in Appendix 3. The quality assessments were scored for each item 
as positive (Yes) or Negative (No) and were not weighted for importance. If an item was 
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yes, its score equals one, whereas if an item was no, its score equals zero. The scores of 
the 15 items were summed up and presented as a total score for each study.  
5.2.5 Statistical analysis methods 
Descriptive statistics were used to summarise the quality of papers and the characteristics 
of the studies in accordance with the guidelines in the PRISMA statement (Liberati et al., 
2009). The prevalence and its confidence interval (CI) were plotted for each study in a 
forest plot-type chart. Prevalence’s were then grouped according to the characteristics of 
the respective screening tests and population, as detailed in Table 5.2; screening test 
procedures, risk factor (ethnic group) and screening test guidelines.  
   The screening procedures groups were broken down into two groups, universal 
and selective screening. Selective screening initially screens all pregnant women with risk 
factors. The studies were then grouped according to the main risk factors detailed in the 
work by National Institute for Clinical Excellence (NICE) and The Fourth International 
Workshop-Conference on Gestational Diabetes Mellitus (National Health Service, 2008b) 
(Metzger and Coustan, 1998). The risk factors are obesity, age greater than 25 years, 
family history of diabetes, history of previous GDM and ethnic group. Ethnic background 
was divided into two groups related to a high and low risk for GDM, based on the 
guidelines. The difference in screening test guidelines used may play a major part in the 
different incidences of GDM as well as screening procedures. However, if appropriate 
results were obtained from individual studies it was planned to estimate the overall 
prevalence of GDM using meta-analysis. Many systematic reviews contain meta-
analyses, but not all.  
Table 5.2 The characteristics of screening tests for GDM 
Characteristics  Details 
Screening procedure  Universal screening: screen all pregnant women by measurement of plasma 
glucose between 24 and 28 weeks using different test techniques 
 Selective screening: screen initially all pregnant women with risk factors. In 
the next stage, women who show positive risk factors undergo further 
screening 
Ethnicity group High risk groups of GDM: South Asian, Back Caribbean, Middle Eastern, 
South-East Asian, Aborigine, Hispanic, African and Pacific Islands. 
 Low risk groups of GDM: Other nationalities 
Screening test guideline Based on the guidelines used in the study 
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5.3 Study selection 
The primary search by MEDLINE and EMBASE produced 366 papers. Removing 
duplicates and English language limitations, a total of 155 papers remained. Figure 5.1 
illustrates the process of literature identification and study selection. Thus, 188 articles 
were reviewed for eligibility. Of those, 67 papers were excluded after screening title and 
abstract. 88 abstracts were accepted for further reading. 74 other studies were excluded 
for the following reasons: study population (n=9) outcome measurement (n=47), and study 
type (n=18). There were many reasons to exclude papers such as study population 
(included women with pre-existing DM and GDM or type 1 and type 2 diabetes), outcome 
measurement (the prevalence in postpartum diabetes and data not shown properly) and 
study type (report, review, and litter to edit paper). Only two articles were included 
following a hand search. Finally, 16 studies remained for final review. A PRISMA flowchart 
illustrates the process of study inclusion.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.1 PRISMA flowchart of article selection  
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5.4 Methodological quality assessment 
Table 5.3 displays the results of the quality assessment. On external validity, the average 
score was 4.6 (range 3-6), on internal validity the average score was 4.1 (range 3-6), and 
on informativity the average score was 2.4 (range 1-3). The quality assessment showed 
slightly high scores in all of the selected papers with more than half presenting with scores 
above 10. However some of the papers had lowers scores due to the effect of specific 
criteria. For example, external validity, the checklist items with the lowest scores were due 
to a lack of important population characteristics being specified and a response rate 
>70%. Regarding internal validity, the criterion with the lowest score was data collection, 
and thus was the most frequent reason for downgrading. Most of the studies used 
secondary data such as from medical records or databases. The last aspect of the quality 
assessment is informativity, and the item that scored the least was due to data collection 
not being properly described. It is recognised however that as scores are not weighted 
there may be an element of unreliability in the results.  
Table 5.3 Year of published and quality assessment of selection studies  
Reference  External validity Internal validity Informatively  
Number Year a b c d e f Sum g h I j k l sum m n o Sum  
(Yue et al., 1996) 1996 + + - - - + 3 - + + + - - 3 + + - 2 8 
(Godwin et al., 1999) 1999 + + + + + + 6 - + + + + - 4 + + + 3 13 
(Rodrigues et al., 1999) 1999 + + + + + + 6 - + + + - - 3 + - + 2 11 
(Seyoum et al., 1999) 1999 + + + + - - 4 - + + + - + 4 - - + 1 9 
(Schmidt et al., 2000) 2000 + + + + + - 5 - + + + - + 4 - + + 2 11 
(Ferrara et al., 2002) 2002 + + + + + + 6 - + + + + - 4 + + + 3 13 
(Jimenez-Moleon et al., 
2002) 
2002 + + + + + - 5 - + + + - + 4 + + + 3 12 
(Chanprapaph and 
Sutjarit, 2004) 
2004 + + - - + + 4 + + + + - + 5 + + + 3 12 
(Hadaegh et al., 2005) 2005 + + + + + - 5 + + + + + - 5 + + + 3 13 
(Janghorbani et al., 2006) 2006 + + - + + + 5 + + + + + + 6 - + + 2 13 
(Hossein-Nezhad et al., 
2007) 
2007 + + + - - + 4 - + + + + - 4 - + + 2 10 
(Karcaaltincaba et al., 
2009) 
2009 + + + - + - 4 - + + + - + 4 + + + 3 11 
(Pedersen et al., 2010) 2010 + - + + + + 5 - + + + - + 4 + + + 3 12 
(Karcaaltincaba et al., 
2011) 
2011 + + - - + - 3 - + + + - - 3 + - + 2 8 
(Moses et al., 2011) 2011 + - + + + + 5 + + + + - - 5 + + + 3 12 
(Anzaku and Musa, 2013) 2012 + - + - + - 4 - + + + - + 4 + + + 3 10 
Items a-o refer to table 1 
 
5.5 Description of selected study populations 
Descriptions of the populations included in the selected studies are given in Table 5.5. 
Five studies were conducted in general prenatal care clinic. Nine articles used secondary 
data including medical charts, computerised hospitalisation recorded and birth 
registration. Of the 16 studies, three were conducted in North America (Godwin et al., 
1999) (Rodrigues et al., 1999) (Ferrara et al., 2002) and five Studies were conducted in 
Europe (Jimenez-Moleon et al., 2002) (Janghorbani et al., 2006) (Karcaaltincaba et al., 
2009) (Pedersen et al., 2010). The remaining eight studies were conducted in Australia 
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(Yue et al., 1996) (Moses et al., 2011), Ethiopia (Seyoum et al., 1999), Thailand 
(Chanprapaph and Sutjarit, 2004), Brazil (Schmidt et al., 2000), Iran (Hadaegh et al., 
2005) (Hossein-Nezhad et al., 2007) and Nigeria (Anzaku and Musa, 2013). Clinical 
prevalence was measured during 20 – 28 weeks of gestation. There was only one paper 
that reported the age range of subjects; teenage pregnancies age ≤ 19 in Ankara Turkey 
were studied by Karcaaltincaba and colleagues (Karcaaltincaba et al., 2011). 
5.5.1 Diagnostic criteria for case inclusion 
The criteria and test methods of screening for GDM are shown in Table 5.4. First, National 
Diabetes Data Group (NDDG) criteria were used in four studies (Rodrigues et al., 1999) 
(Ferrara et al., 2002) (Hadaegh et al., 2005) (Karcaaltincaba et al., 2009). The NDDG 
criteria screen by 1 hour, 50g GCT with cut-off point of ≥ 7.8 mmol/l and 3 hour 100g oral 
glucose tolerance test (OGTT); fasting, ≥5.8 mmol/l; 1 hour, ≥10.5 mmol/l ; 2 hour, ≥9.2 
mmol/l; 3 hour, ≥8.1 mmol/l. Two studies from Iran and Turkey screened pregnant women 
by Carpenter and Coustan (C&C) criteria which proposed all women were screened for 
GDM by a 1 hour, 50g GCT, with cut-off point of ≥ 7.8 mmol/l (Hossein-Nezhad et al., 
2007) (Karcaaltincaba et al., 2011). All women with positive screening test results 
underwent a 3 hour OGTT with 100g of glucose, with cutoff points of ≥ 5.8, ≥10.0, ≥ 8.6 
and ≥7.8 mmol/l, respectively. A study in Canada used the screening strategy by The 
Third international work shop conference on GDM (Godwin et al., 1999). Four studies 
used World Health Organisation (WHO) guidelines to diagnose women with GDM 
(Seyoum et al., 1999) (Schmidt et al., 2000) (Janghorbani et al., 2006) (Pedersen et al., 
2010) (Anzaku and Musa, 2013). WHO has recommended that all pregnant women have 
fasting plasma glucose tests exceeding ≥ 7.8 mmol/l, then followed by 2-hour 75g glucose 
solution tests with cutoff point; fasting ≥ 7.0 mmol/l; 2 hour, ≥ 7.8 mmol/l. Next criteria, 
from the Fourth international workshop conference on GDM, were used to screen patient 
with GDM in Granada, Spain (Jimenez-Moleon et al., 2002). This criterion has a cutoff 
point and screening test technique, which is from The Third International Work Shop 
Conference on GDM. In Australia a study used the criteria of The Australian Diabetes in 
Pregnancy Society (ADIPS) (Yue et al., 1996) (Moses et al., 2011). ADIPS was performed 
with 50g GCT. If the 1 hour blood glucose level exceeded ≥ 7.7 mmol/l, then a diagnostic 
2 hour 75g OGTT was performed with ≥ 8.0 mmol/l. Lastly, a study in Thailand adopted 
the criteria of The Expert Committee on The Diagnosis and Classification of Diabetes 
mellitus to screen for GDM (Chanprapaph and Sutjarit, 2004). All women screened with 
50g GCT and patients with result ≥ 7.8 mmol/l underwent 3 hour 100-g OGTT, with cutoff 
points of ≥ 5.3, ≥10.0, ≥ 8.6 and ≥7.8 mmol/l, respectively. Screening tests in this study 
can be applied either selectively or through universal screening. The Universal screening 
strategy is to screen all pregnant women by measuring their plasma glucose between 24 
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and 28 weeks by different test techniques. Conversely, selective screening strategy 
screens begin with all pregnant women by risk factors. Thus, women who have positive 
risk factors undergo further screening tests.  
Table 5.4 Diagnostic test criteria and test methods of screening for GDM 
Paper Strategy 
screening 
Year of 
published 
guideline 
Test methods Threshold values (mmol/l) Screening 
procedure 
    0 h 1h 2h 3h  
(Rodrigues et al., 1999, 
Ferrara et al., 2002),  
NDDG 1979 50g GCT   ≥7.8    
(Hadaegh et al., 2005, 
Karcaaltincaba et al., 
2009),  
  100gOGTT ≥5.8 ≥10.5 ≥9.2 ≥8.1  
(Hossein-Nezhad et al., 
2007),(Karcaaltincaba et 
al., 2011) 
C&C 1982 50g GCT   ≥7.8   Selective 
   100g OGTT ≥5.3 ≥10.0 ≥8.6 ≥7.8  
(Godwin et al., 1999) 3th 1991 50g GCT   ≥ 7.8   Universal 
   100g OGTT ≥5.3 ≥10.0 ≥8.6 ≥7.8  
(Seyoum et al., 
1999),(Schmidt et al., 
2000)  
WHO 1998 50g GCT,   ≥7.8   Universal 
(Janghorbani et al., 
2006),(Pedersen et al., 
2010), (Anzaku and Musa, 
2013) 
  75g OGTT ≥7.0  ≥7.8   
(Jimenez-Moleon et al., 
2002) 
4th 1998 50g GCT   ≥ 7.8   Selective 
   100gOGTT ≥5.3 ≥10.0 ≥8.6 ≥7.8  
(Yue et al., 1996) (Moses 
et al., 2011) 
ADIPS 1998 50g GCT   ≥7.8   Universal 
    75g OGTT ≥5.5  ≥8.0 
≥9.0 
  
(Chanprapaph and 
Sutjarit, 2004) 
ECDC 2002 50g GCT  ≥ 7.8   Universal  
   100gOGTT ≥5.3 ≥10.0 ≥8.6 ≥7.8  
Organisation (C&C) Indicated Carpenter and Constant, (NDDG) National Diabetes Data Group, (WHO) World Health 
Organisation, (ADIPS) The Australasian Diabetes in Pregnancy Society, ( 3
rd
)Third International work shop Conference on 
GDM, (4
th
) Forth International Workshop Conference on GDM, (ECDC) The Expert Committee on the Diagnosis and 
Classification of DM in USA 
 
5.5.2 Prevalence of gestational diabetes mellitus 
Studies were published between January 1966 and July 2013 and the prevalence 
estimates for GDM in the systematic review reveal that the pregnancies of 76,312 women 
ranged from 1.35% to 12.80%. However, the present analysis identified considerable 
heterogeneity in the prevalence of GDM and so refrained from calculating pooled 
estimates. Therefore, the individual articles are discussed.  
   There are slightly different populations in 16 studies. When comparing screening 
protocols, universal screening shows lower prevalence than selective screening. Four 
studies used selective screening which shows a prevalence range from 4.7% to 12.8% 
(Godwin et al., 1999) (Rodrigues et al., 1999) (Chanprapaph and Sutjarit, 2004) 
(Pedersen et al., 2010), as shown in Figure 5.2.  
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Figure 5.2 Prevalence of GDM groups by screening protocol characteristic 
 
   Ethnicity is a particularly important factor determining the prevalence of GDM. 
Figure 5.3 shows the distribution of GDM prevalence according to the different ethnic 
groups with both high and low risk factors for GDM. Ethnic groups with a high risk factor 
include South Asian, Back Caribbean, Middle Eastern, South-East Asia, Aborigine, 
Hispanic, African and Pacific Islands, while ethnic groups with a low risk factor include all 
other nationalities, as mentioned in Table 5.2. Prevalence of GDM when ethnicity is a low 
risk factor presented from 1.35% to 9.6 %. Whereas, the prevalence when ethnicity is a 
high risk factor of GDM varied between 4.7% and 12.8 %. Two of the studies conducted in 
Canada that determined the prevalence of GDM in Cree people, a Native American ethnic 
group, varied between 8.5% and 12.8 % (Godwin et al., 1999) (Rodrigues et al., 1999). 
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Figure 5.3 Prevalence of GDM group by ethnicity characteristic 
 
  There are four main screening guidelines in the review, namely Carpenter and 
Constant (C&C), World Health Organisation (WHO), National Diabetes Data Group 
(NDDG) as well as other guidelines. Prevalence varies widely amongst the screening 
guidelines and prevalence showed disassociation in the different screening strategies, as 
showed in Figure 5.4. Three studies report both NDDG and C&C strategies (Ferrara et al., 
2002) (Hadaegh et al., 2005) (Karcaaltincaba et al., 2009). The prevalence of GDM for 
NDDG in the 3 studies was selected for analyses as the prevalence from the C&C 
guideline ranged from 4.8% to 8.9%, which is slightly higher than the NDDG guideline 
which ranged from 3.2% to 6.3%. Moreover, only one of the 16 studies presented two 
estimates of GDM prevalence: observed prevalence (number of confirmed cases among 
the total study) and expected prevalence (number of GDM cases among those women 
who had not been screened) (Jimenez-Moleon et al., 2002). 
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Figure 5.4 Prevalence of GDM group by guideline of screening test characteristic 
 
5.6 Discussion 
This is a systematic review of the literature focussing on the prevalence of GDM. 
Previously, available data in this field of research was summarised unsystematically or 
without a focus on a population based study and characteristic of screening test. There 
were 16 population-based studies of prevalence of GDM identified. Prevalence estimates 
for GDM depending on screening protocol and population ranged from 1.35% to 12.80%.  
5.6.1 Selection of studies and data extraction 
The prevalence rate reported for GDM is based on population-based studies that screen 
all pregnant women without GDM. Studies that reported trends to predict prevalence and 
those that reported prevalence in order to measure the accuracy of tests were omitted 
from this review. As one of the inclusion criterion of the systematic review was a 
requirement of a 95% confidence interval to estimate overall prevalence, the number of 
papers identified was limited to only 16. Two studies were found by a hand search out 
with MEDLINE and EMBASE.  
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5.6.2 Methodological quality assessment 
This paper applied and adopted the quality assessment lists from previous systematic 
reviews of prevalence (Bishop et al., 2010, Prins et al., 2002), which are based on 
theoretical considerations as well as common sense, and can also be used for a 
systematic review of other conditions in the general population. These lists cover all the 
methodology required to construct the prevalence study. The distinction made between 
valid and invalid in the assessment is based on overall scores, and the use of cut-off 
points is arbitrary. It should be recognized; however, that some of the selection studies 
have a high number of negative scores (No), with a score equal to zero, as shown in 
Table 5.3. Additionally, the overall qualities of the studies were mixed, with more than half 
of the studies scoring > 50 %. One of the quality assessment lists had separate validity 
criteria in addition to the overall quality assessment, such as the representativeness of the 
study population (item d); 5 studies reported response rates lower than 70% and 
insufficient data were available on the representativeness of the population. However, 
quality seemed to be unrelated to reported prevalence. The method of study might not 
relate to prevalence rates.  
5.6.3 Comparison of prevalence rates 
This review shows that reports of prevalence for GDM vary considerably, as seen in the 
other systematic reviews outlined below, and that there are major population and 
screening test differences between the studies. It is unclear, however, whether this 
variance in prevalence reflects a true difference between populations, screening test 
procedure and screening test guideline. The differences of those characteristic precluded 
the comparison of prevalence rates in most of the studies. Previously, in 1998, King 
reported that the prevalence of women with GDM was between 1% and 16%, depending 
on diagnostic criteria and population studies. King’s study used standardised population-
based information of diabetes in adult communities worldwide produced by WHO (King, 
1998). Another multi-stage cross-sectional prevalence study reported a range of 1% to 
14% for GDM in women whose ages were between 15 and 49 years, in the USA in 1988 
(Engelgau et al., 1995). Many factors have caused these two papers to produce different 
results for prevalence, such as screening test use and population group. Another problem 
regarding reports of prevalence of GDM is that epidemiology data is obtained from 
different test techniques. Numerous screening test guidelines for GDM have been 
developed and published within the last decade. Most countries have their own diabetes 
associations, each publishing their own guidelines for GDM, which may differ slightly. 
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However, the screening test strategies for GDM are still debated, and no consensus has 
been established yet. (Metzger and Coustan, 1998) 
    Differences in the prevalence of GDM may be related to variations in ethnicity. 
Hispanic, Native American, South or East Asian, Middle Eastern, South Asian and Black 
Caribbean women are in ethnic groups with relatively high rates of carbohydrate 
intolerance during pregnancy and of diabetes later in life (Metzger and Coustan, 1998) 
(Hoffman, 1998) (Bardenheier et al., 2013) and so there ethnic groups are also classified 
as high risk groups for GDM. Ethnic origin was the dominant influence on the prevalence 
of GDM in this review. A Canadian study undertaken among Cree women in the eastern 
James Bay region of northern Quebec, reported the highest prevalence in the reviewed 
papers of 12.8%, using the third international workshop conference on GDM criteria 
(Rodrigues et al., 1999). The authors also mention that this prevalence was at least twice 
as high as that reported in the general North American population. Another study in this 
review conducted on the same population, also reported a slightly high prevalence, about 
8.5% (Godwin et al., 1999). Two additional studies also stated that the Cree ethnic group 
are the second highest prevalence of GDM reported in an aboriginal group worldwide 
(Sermer et al., 1995) (Magee et al., 1993). Similarly, In the United Arab Emirates a study 
of high risk populations reported a prevalence rate of about 19.3% (Agarwal et al., 2006).   
Prevalence of GDM also varies between racial and ethnic groups within the same 
country. Two studies in Iran included in this review presented slightly different 
prevalence’s, 6.3% and 4.3% (Hadaegh et al., 2005) (Hossein-Nezhad et al., 2007). The 
lower prevalence, reported in the study of rural populations, assumed a significantly 
different lifestyle (Hossein-Nezhad et al., 2007). Moreover, prevalence significantly differs 
for size and diversity of the population available for study in terms of geographic diversity 
(states, regions, and countries) and the definition used to identify women with GDM. Two 
studies in Australia reported a slightly high prevalence of 6.7% and 9.6% (Yue et al., 
1996) (Moses et al., 2011). In the 2011 study, carried out in New South Wales City, it was 
not possible to record the women’s country of birth at the time of collection. However the 
authors refer to the Australian Institute of Health and Welfare which reports that 83.5% of 
women giving birth in 2009 were born in Australia or were from countries with a 
predominately Caucasian background (Moses et al., 2011). 
  The systematic review of prevalence of GDM showed no association with 
screening strategy. Six popular screening strategies were used world-wide, including, in 
order of year proposed, O’Sullivan and Mahan (O'Sullivan and Mahan, 1964), NDDG 
(National Diabetes Data Group, 1979), C&C (Carpenter and Coustan, 1982), WHO (WHO, 
1999b), the third international workshop conference on GDM (Metzger, 1991) and the 
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fourth international workshop conference on GDM (Metzger and Coustan, 1998). 
Screening and diagnostic test criteria have various associated screening test guidelines, 
which have been developed and published for GDM. Most countries have their own 
diabetes associations, these societies often publish guidelines for GDM, which may differ 
slightly. Therefore, the screening test strategies for GDM are still debated (Metzger and 
Coustan, 1998). Three studies that estimate the prevalence of GDM using the C&C 
criteria reported comparisons with the NDDG criteria. These three studies reported a 
similar trend, whereby prevalence derived from the C&C criteria were reported to be 
higher than the prevalence from NDDG (Ferrara et al., 2002) (Karcaaltincaba et al., 2009) 
(Hadaegh et al., 2005). The average increase in the prevalence of GDM, reported in two 
of the three studies, was 50% (Ferrara et al., 2002) (Ricart et al., 2005). NDDG suggested 
a two step screening procedure in 1979; Women are screened by 50g GCT with “hour 1” 
oral glucose tolerance test and undergo a diagnostic test “hour 3”, 100g OGTT, after 
abnormal screening tests. On the other hand, In 1982, The C&C proposed two step 
screening; “hour 1”, 50 g GCT with cutoff point ≥7.8, and then diagnoses by “hour 3”, 100g 
OGTT; fasting, ≥5.3 mmol/l; “hour 1”, ≥10.0 mmol/l; “hour 2”, ≥8.6 mmol/l; “hour 3”, ≥7.8 
mmol/l. In both sets of criteria, GDM was diagnosed by at least two plasma glucose 
measurements exceeding the reported cut off point during the diagnostic tests. In addition, 
both NDDG and C&C strategies revised the O’Sullivan and Mahan criteria, converting 
whole blood values to plasma values. The diagnostic criteria from NDDG have been used 
most often, but some maternal care clinics apply C&C criteria, which set the threshold for 
normal at a lower value (Turok et al., 2003) (National Diabetes Data Group, 1979). 
Prevalence of GDM was therefore higher when using C&C criteria compared with NDDG 
criteria. 
    The distribution of classical risk factors in the general population of pregnant 
women is an important consideration in determining the optimal screening protocol. 
Selective screening screens all pregnant women with more than one risk factor, showing 
higher prevalence than universal screening. In this review, it was shown that papers 
conducted on high risk groups presented significantly higher prevalence rates (Godwin et 
al., 1999) (Rodrigues et al., 1999) (Chanprapaph and Sutjarit, 2004) (Pedersen et al., 
2010). The results of selective screening tests including all mothers with high risk factors 
(as confirmed by diagnostic tests) demonstrated higher prevalence rates than universal 
screening tests. This is evidenced in the selective screening tests performed on high risk 
ethnic groups in two Canadian studies (Godwin et al., 1999) (Rodrigues et al., 1999). 
Consequently, the higher prevalence rates from selective screening seen in this review 
may have been driven by ethnicity.  
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Additionally, three retrieved studies reported subject ages (Schmidt et al., 2000) 
(Ferrara et al., 2002) (Karcaaltincaba et al., 2011). There was little evidence to conclude 
that GDM prevalence estimates are dependent on the age of pregnant women studied in 
those three studies. However, pregnant mothers over 35 years old are classified as a 
high-risk group for GDM. One of those presented the lowest prevalence as 1.3%, which 
was found in teenage pregnancies in Ankara, Turkey, for women who were aged less than 
19 years. Similarly, a study in Northern California reported a lower prevalence in 
pregnancy age < 25, of about 1% with NDDG criteria and about 1.7% based on the C&C 
criteria (Ferrara et al., 2002). The prevalence of GDM increases with the increased age of 
pregnant women (Getahun et al., 2008). Thus, age difference of screened mothers was 
shown to result in various prevalence estimates of GDM.  
   Variation in the prevalence of GDM can be explained by screening tests and 
population characteristics. Reports of prevalence among different ethnic groups in the 
Scottish population are not available in any known studies. In the UK, NICE reports the 
estimated incidence of gestational diabetes as 3.5% based on assuming age-
standardised prevalence of 3.5% with type 2 DM and on a population of 39,57,157 aged 
18 years or older (NICE, 2008a). Dornhorst and colleagues reported that women from 
ethnic groups other than white had a higher frequency of gestational diabetes than white 
women (2.9% vs 0.4%, p < 0.001) in the UK. Compared to white women, the relative risk 
of gestational diabetes in the other ethnic groups in the UK, was: Black 3.1 %, South East 
Asian 7.6 %, Indian 11.3 %, and miscellaneous 5.9 % (Dornhorst et al., 1992). This study 
confirms that different ethnic groups in the UK have dissimilar susceptibility with regard to 
the development of GDM. This result clearly shows that women in ethnic minority groups 
have an increased risk of GDM in UK. The largest ethnic population group in Scotland, at 
around 80% of the population, is white, and is similar to England & Wales (The Scottish 
Government, 2011) (Office for National Statistics, 2012).Therefore, prevalence of GDM in 
Scotland is taken to be approximately 3.5%.  
5.6.4 Limitation and recommendation for future research 
  Publication bias was not investigated in this review, as funnel plots were not 
considered appropriate due to the variation across studies. It is unlikely that the set of 
published papers are biased with respect to the prevalence reported. However, it is 
possible that some studies were not identified in the searches if they were not published in 
mainstream journals. However, studies brought together in a systematic review will differ 
(Glasziou and Sanders, 2002). In this systematic review it was not possible to pool 
prevalence estimates of GDM because of the considerable heterogeneity across 
individual studies. There are many factors which impact the heterogeneity of GDM. Those 
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factors may include socio-demographic features of the population such as: age, the ethnic 
group and screening test procedure. Another factor that may have had an impact is the 
number of papers identified, which was limited to only 16. This was because one of the 
inclusion criteria of the systematic review was the requirement of a 95% confidence 
interval to estimate overall prevalence, and many papers are poor at reporting prevalence 
within a 95% confidence interval.   
   Variability in ethnicity of those screened for GDM resulted in wide differences in 
prevalence. Even more concerning is that the diversity in screening test criteria for GDM 
usually results in varying prevalence. Moreover, unclear risk factors for GDM in each 
study such as family history of diabetes mellitus before pregnancy, history of macrosomia 
in previous pregnancy, history of preeclampsia during gestation and weight gain during 
pregnancy may have resulted in heterogeneity in this study. A move towards the 
application of similar strategies for screening tests for similar populations may reduce the 
heterogeneity of prevalence for GDM.  
5.7 Conclusion 
  This review has shown some of the influences on variation of prevalence for GDM. 
The present review indentified several studies. These studies were heterogeneous in 
methodological quality and results.  Variation in over half of the studies can be explained 
by ethnicity and screening test strategies. Other important factors were whether universal 
or selective screening protocols for GDM were adopted and whether 75g or 100g OGTT 
were used. The impact of these identified factors on prevalence estimates should be 
further investigated as they may be acting as proxies for other influences on prevalence. 
For example, although the literature on prevalence and the incidence of GDM is varied, 
there should be a general consensus for GDM screening strategies with regard to 
population. Accurate prevalence for GDM is as important as health-care planning and 
epidemiological research, as they provide essential knowledge to assess the burden of a 
condition within a population. Documentation of GDM‘s impact on quality of life and costs 
help to inform public health planning. Moreover, it is essential to begin base line 
prevalence rates, so that researchers can monitor trends.  
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Table 5.5 Description of the characteristics of the study  
Author Year Country Study design Source of 
population 
Ethnicity  Age Total (N) Duration of 
Follow-up 
Time of 
screening 
(weeks) 
Strategy Screening  Prevalence 
 (95% CI) 
 (Yue et al., 1996) 1996 Australia Retrospective 
study 
GDM in Obstetrics 
clinics 
Mix NR 5243 2 years 24-28 ADIPS Universal  6.7 (6.0-7.4) 
 (Godwin et al., 
1999) 
1999 Canada  Retrospective  Medical chart who 
give birth at 
hospital 
Cree women NR 1401(1298) 8 years 24 -28 3
rd
 
 
Selective  8.5 (6.0-9.9) 
 (Rodrigues et al., 
1999) 
1999 Canada Cross-
sectional study 
Patient charts on 
pregnancies  
Cree women NR 704(654) 1 year 22 and 
above 
NDDG Selective  12.8 (10.1-15.5) 
(Seyoum et al., 
1999) 
1999 Ethiopia  Community 
base study 
Mother who 
register a health 
institution 
Ethiopia NR (930)890 NR 24 and 
above 
WHO Universal  3.7 (2.5 – 4.9) 
(Schmidt et al., 
2000) 
2000 Brazil Cohort study Prenatal care 
clinics of National 
Health Service 
Brazilian ≥ 20 5564(5004) 5 years 20 - 28 WHO Universal  7.6 (6.9 – 8.4) 
 (Ferrara et al., 
2002) 
2002 USA Cross-
sectional study 
Computerized 
hospitalization 
record  
Mix 14-49 28330(26,481) 1 year 24-28 NDDG Universal  3.2 (3.0-3.4) 
 (Jimenez-Moleon 
et al., 2002) 
2002 Spain Retrospective 
cohort study 
The birth register 
of all the 
pregnancy  
Spanish NR 2780(2574) 1 years 24-28 4
th
 Universal  2.53 (1.9 – 3.2) 
(Chanprapaph and 
Sutjarit, 2004) 
2004 Thailand Retrospective 
study 
Medical record of 
pregnant women 
at the antenatal 
care  
Thai NR 1000 15 Months 24 -28 ECDC Selective  7.05 (4.8 – 9.9) 
 (Hadaegh et al., 
2005) 
2005 Iran Prospective 
study 
GDM in Obstetrics 
clinics 
Iran NR 800(700) 2 years 24 -28 NDDG Universal  6.3 (4.7 – 8.4) 
NR = not reported, Organisation (C&C) Indicated Carpenter and Constant, (NDDG) National Diabetes Data Group, (WHO) World Health Organisation, (ADIPS) The Australasian Diabetes in Pregnancy 
Society, ( 3
rd
)Third International work shop Conference on GDM, (4
th
) Forth International Workshop Conference on GDM, (ECDC) The Expert Committee on the Diagnosis and Classification of DM in USA 
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Table 5.5 (Continue)  
Author Year Country Study design Source of 
population 
Ethnicity  Age Total (N) Duration of 
Follow-up 
Time of 
screening 
(weeks) 
Strategy Screening  Prevalence 
 (95% CI) 
(Janghorbani et al., 
2006) 
2006 UK  Prospective 
study 
A clinical based in 
Plymouth UK 
English NR 4,942 2 years 26-28  WHO Universal  1.8 (1.4 – 2.2) 
 (Hossein-Nezhad 
et al., 2007) 
2007 Iran Cross-
sectional study 
All women referred 
to antenatal clinics 
Iran NR 2416 18 months 24 -28 C&C Universal  4.7 (3.9 – 5.6) 
 (Karcaaltincaba et 
al., 2009) 
2009 Turkey Retrospective 
study 
Hospital 
information system 
recorded  
Turkish NR 21531 2 years 24-28 NDDG Universal  3.1 (3.0 – 3.2) 
(Pedersen et al., 
2010) 
2010 Greenland Retrospective 
study 
Birth-log and 
medical recorded 
Greenlander NR 268(233) 1 year NR WHO Selective  4.3 (0 – 10 ) 
 (Karcaaltincaba et 
al., 2011) 
2011 Turkey Retrospective 
study 
Data women 
pregnancy ≤ 19 
years 
Turkish ≤ 19  1659 2 years 24-28 C&C Universal  1.35 (0.7 – 1.8) 
(Moses et al., 
2011) 
2011 Australia Prospective 
study 
GDM in Obstetrics 
clinics 
Mix NR 1,422(1,275) 1 year 24 -28 ADIPS Universal 9.6(8.1-11.4) 
(Anzaku and Musa, 
2013) 
2013 Nigeria Cross-
sectional study 
GDM in Obstetrics 
clinics 
Nigerian NR 265 4 months 24 -28 WHO Universal 8.3(5.2-12.4) 
NR = not reported, Organisation (C&C) Indicated Carpenter and Constant, (NDDG) National Diabetes Data Group, (WHO) World Health Organisation, (ADIPS) The Australasian Diabetes in Pregnancy 
Society, ( 3
rd
)Third International work shop Conference on GDM, (4
th
) Forth International Workshop Conference on GDM, (ECDC) The Expert Committee on the Diagnosis and Classification of DM in USA 
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Chapter 6 Literature review of economic 
evaluation in GDM  
6.1 Introduction 
Screening tests for gestational diabetes mellitus (GDM) are widely reported to be a cost 
effective intervention. This implies that any additional benefits achieved by preventing 
adverse complications in both mother and offspring and its consequences are worth the 
additional cost to a health service implementing screening and treatment for GDM. In 
order to provide valid information to inform policy makers, the economic evaluation of 
screening tests for GDM must be based on an appropriate model of the disease process 
and appropriate estimates of the incidence of the disease and its consequences. Over the 
past decade, decision making in healthcare has increasingly been based on 
considerations of cost effectiveness. This trend is reflected in most national guidelines 
concerning GDM screening. Several cost and cost-effectiveness studies of screening 
tests for GDM have been published in recent years. In the absence of comprehensive 
reviews of costs and economic evaluations of screening tests for GDM, the aim therefore 
of this chapter is to present a review of published papers about the cost and cost-
effectiveness of screening tests for GDM.  
   The review is split into two sections with the first section focusing on cost analysis. 
Cost analysis is a partial form of economic appraisal; it looks only at the costs of the 
programmes and does not provide information on the health outcomes of interest.  
However the attention that the cost analysis studies have received to date from analysis is 
relatively low. Therefore, cost analysis was separated from the economic evaluations 
(CEA, CUA) because cost analysis is not a full economic evaluation. However, the cost 
analyses do give important information on the key costs associated with screening tests 
for GDM. This section discusses the key concepts of the economic evaluations identified 
in chapter 2, including perspectives, patient groups, comparators, outcome measures, the 
results of the evaluations and the handling of uncertainty, all of which were used to assess 
the studies.  
   In the second section, economic evaluations of screening tests for GDM are 
reviewed. The fundamental task of any economic evaluation is to compare the costs and 
consequences of the alternatives being considered. However although economic 
evaluations consider costs in a similar way, their handling of benefits tend to differ. 
Therefore, in this review, the economic evaluations that have developed an economic 
model in terms of cost-effectiveness analysis (CEA) and cost-utility analysis (CUA) are 
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examined. CEA is one form of full economic evaluation where both costs and 
consequences in terms of natural effects or physical units of health intervention are 
examined. However, the outcomes of CEA may be insufficient. For this reason, CUA is 
now becoming more popular, because it is recognized that most health interventions 
impact upon both the length and quality of life. In addition to the key concepts outlined 
above, a description of the model’s structure, design and sources of input data and the 
assumptions used within each model are discussed. 
6.2 Methodology  
6.2.1 Search Strategy 
A structured search strategy that incorporated relevant keywords to identify relevant 
articles in economic evaluations was based on the NHS Economic Evaluation Database 
(NHS EED) (NHS EED, 2007).  The search keywords of screening tests for GDM were 
combined with the NHS EED search filter in order to find cost and cost-effectiveness 
analysis papers of screening tests for GDM, as detailed in Appendix 1.  A systematic 
literature search was carried out for literature published between January 1996 and 
December 2013 using MEDLINE, EMBASED, NHS Economic Evaluation Database (NHS 
EED), The Health Technology Assessment Database and the Cochrane Database of 
Systematic Reviews. In addition, the reference lists from key papers were hand-searched 
as well as searches for studies and papers. All retrieved studies were screened based on 
their titles and abstracts. Exclusion/ inclusion criteria were then applied and only the 
papers satisfying these criteria were selected. Predefined criteria were used to choose the 
final list of papers to be included in the systematic review.   
6.2.2 Eligibility criteria 
 The inclusion criteria are presented as five P.I.C.O.S. components as mentioned in 
the previous chapter (Liberati et al., 2009). The inclusion criteria applied to the papers are 
shown in Table 6.1. Articles fulfilling these criteria were included in the systematic review, 
while exclusion criteria included papers that were not written in English and those that 
only consisted of abstracts. 
 
Table 6.1Inclusion criteria in PICOS components 
PICOS components Inclusion criteria 
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Populations(P) All pregnant women  
Intervention(I) Any form of screening test intervening for GDM, including both universal 
and selective screening   
Comparative (C) No testing or alternative testing strategies (in economic modelling), 
Outcome (O) Information about cost and effectiveness were reported. The relevant costs 
of GDM have to be reported, as well as their method of calculation. 
Whether or not the effectiveness of the study is properly described. Studies 
reporting the results of economic models should be included such as; 
incremental costs per case detection, incremental costs per case 
prevention, incremental costs per life year gained and incremental coats 
per QALY/ DALY gained / adverted 
Study design chosen (S) Economic evaluation incorporating cost-effectiveness analysis and cost-
utility analysis, primary study of the costs   
 
6.2.3 Data collection process 
All information about the methodology and results from each study were extracted using a 
data extraction/collection form. Details relating to the characteristics and results of 
included articles were extracted, such as the study’s location and population, P.I.C.O.S, 
details of intervention and comparators, study design, sources of resource use, unit costs 
and consequences data, time horizon for cost and consequence and results of sensitivity 
analysis undertaken. Each article was summarised according to the above lists.    
6.2.4 Methodological quality assessment 
Despite the growing use of decision analytic modeling in CEA, Sculpher and colleagues 
developed lists for assessing quality in decision models (Sculpher et al., 2000). In brief, 
the tool consists of 35 items, which are broken down by structure (disease states, options, 
time horizon, and cycle length), data (identification, incorporation, handling uncertainty) 
and consistency (internal and external). Philips and colleagues proposed guidelines for 
quality assessment in decision-analysis models that are based on Sculpher’s checklist 
(Philips et al., 2004). The Philips checklist contains 23 items. This review used these 
reporting guidelines as the basis for quality assessment. In addition, the Philips checklist 
provides a structure for any critical appraisal of an economic model and is used to 
complement the Drummond checklist (Drummond and Jefferson, 1996). Though this 
review includes cost analysis which is a partial form of economic appraisal it only looks at 
the costs of the programs and does not provide information on the health outcomes of 
interest. Currently there is no accepted criterion for the quality assessment of cost 
analysis studies available. Therefore, this systematic review will ignore the critical 
appraisal of cost analysis papers. 
   In order to summarise and assess the findings of the quality assessment, a formal 
grading of the evidence was developed for this systematic review and presented as “++”, 
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“+” or “-“ based on the system developed for the National Institute for Clinical Excellence 
(NICE) Public Health Guidance (NICE, 2012). There were three possible answers to each 
of the 23 questions in the Philips checklist. These were “yes”, “no” and “not applicable”. A 
scoring system for the checklist has been devised for this review, and each study has an 
individual denominator: firstly, a score of one was given to the “yes” response to each of 
the 23 questions in the Philips checklist. Secondly, all questions resulting in a “not 
applicable” answer were removed from the denominator. For example, a study that 
resulted in “yes” responses to all the questions on the Philip checklist would get a score of 
100% (23/23). Whereas a study that resulted in one “non applicable” response, one “no” 
response and “yes” responses to the rest of the checklist questions, the total score would 
be 95.38% (21/22) This means the total score gives the proportion of “yes” responses for 
each study assessment. Studies with a score of equal or greater than 80% (≥ 80) were 
presented as “++”; studies with a score of equal or greater than 50% (≥ 50%) and lower 
than (< 80%) were presented as “+” and studies with a score of lower than 50% (< 50%) 
were presented as “-“.  
6.2.5 Statistical analysis methods 
Descriptive statistics were used to summarise the quality of papers and the characteristics 
of the studies in accordance with the guidelines in the PRISMA statement, as detailed in 
Appendix IV (Liberati et al., 2009). In the first instance, the quality of the economic 
evaluations of the studies was assessed. Papers that present as “++” and “+” were 
reviewed in full and marked with a pass. In the second stage the characteristics of the 
studies were recorded. This systematic review divided the articles for analysis into two 
sets; those with cost analysis studies and those with cost-effectiveness studies.   
6.3 Study selection 
A detailed diagram of the review process is presented in Figure 6.1.The electronic 
searches yielded 696 journal article references. Removing duplicates and English 
language limitations, a total of 651 papers remained. After a title and abstract review, 606 
studies were excluded. From the remaining articles, 45 were accepted for future reading. 
28 articles were omitted for the following reasons: outcomes did not perform a cost and 
cost-effectiveness analysis (n=24), no full text available (n=2) and study design (n=2). 
Finally, 17 articles were reviewed in decision analysis modeling. 
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Figure 6.1 Flowchart of article selection 
 
Table 6.2 below provides a concise summary of the features of each of the 17 economic 
evaluations, including the type of study (cost analysis, cost effectiveness analysis and 
cost utility analysis) the structure of the study (observational, RCT and model) and the 
main outcome measures used (case detection, accuracy of tests, case prevention and 
adverse complications, quality adjusted life year and disability adjusted life year). There 
has been a rapid increase in the number of cost analyses and economic evaluations 
published about GDM in recent years. Cost analysis was the most popular technique in 
the early years of GDM; approximately half of the evaluations were conducted using cost 
analysis (9/17). Of the later studies, most of the papers focus on modeling and the use of 
the QALY as an outcome measurement. Five papers were conducted using cost utility 
analysis (5/17). Seven used data from observational studies and eight used economic 
modeling. Case detection was the most frequently used outcome measurement, although 
others were also identified, including case prevention and adverse complications, QALY 
and DALY. As mentioned in the inclusion criteria, two types of economic evaluations 
which include cost-minimisation analysis and cost-benefit analysis are omitted from this 
systematic review. Therefore, two papers with these two types of economic evaluation 
were not taken into account (Kitzmiller et al., 1998) (Meltzer et al., 2010).  
Records identified through 
database searching 
(n= 696) 
 Duplicates 
(n=45) 
Abstracts accepted 
(n= 45) 
Studies included 
(n= 17) 
Studies excluded after 
screening title and 
abstract (n = 606) 
References screened 
(n= 651) 
Studies excluded (n = 28) 
Reason: 
Outcome (n =  24) 
Study design (n=2) 
Not full text available (n= 2) 
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Table 6.2 Summary of GDM economic evaluations  
 
6.4 Methodological quality assessment 
For the economic evaluation studies, eight papers were assessed in total for their overall 
quality. Generally the studies performed well, with one study being graded “+”, seven 
studies graded as “++” and no studies were graded “-“. The results for each of the studies 
are presented in the summary table of evidence (Table 6.3).  The last column in Table 6.6 
displays the grading of the quality assessment.  
 
 
Author Year
CA CEA CUA Obs RTC Sys Model CD CP QALY DALY
Moses et al 1997
Lemen et al 1998
Poncent et al 2002
DI Cianni et al 2002
Scott et al 2002
Larijani et al 2003
Nicholson et al 2005
Moss et al 2007
NICE 2008
Round et al 2011
Lohse et al 2011
Gillespie et al 2011
Werner et al 2012
Mission et al 2012
Gillespie et al 2012
Agarwal 2012
Marseille 2013
CA = Cost analysis, CEA = Cost effectiveness analysis, CUA = Cost utility analysis,
Obs = Observational, RCT = Randomize control trial, Sys = Systematic review, CD = Case detection, 
CP = Case prevention and adverse complicaiton,  QALY = Quality adjusted life year, DALY = Diability adjusted life year
Type Structure Outcome
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Table 6.3 Author and quality assessment of selection studies 
# Dimension of quality (Poncet et al., 
2002) 
(Nicholson et al., 
2005) 
(NICE, 
2008b) 
(Round et al., 
2011) 
 (Werner et al., 
2012)  
(Lohse et al., 
2011) 
(Mission et al., 
2012) 
(Marseille et al., 
2013) 
 Structure              
1 Statement of decision problem √ √ √ √ √ √ √ √ 
2 Statement of perspective  √ √ N/A √ √ N/A √ N/A 
3 Rational for structure √ √ √ √ √ √ √ √ 
4 Structure assumptions √ √ √ √ √ √ √ √ 
5 Strategies/comparators √ √ √ √ √ N/A √ N/A 
6 Model type √ √ √ √ √ √ √ √ 
7 Time Horizon N/A N/A N/A √ √ N/A N/A N/A 
8 Disease states √ √ √ √ √ √ √ √ 
9 Cycle length N/A N/A √ √ √ N/A √ N/A 
 Data               
10 Data identification √ √ √ √ √ √ √ √ 
11 Data modeling √ N/A √ √ √ √ √ √ 
12 Baseline data √ N/A √ √ √ √ √ √ 
13 Treatment effects √ √ √ √ √ √ √ √ 
14 Costs √ X √ √ X √ √ √ 
15 Quality of life weights X √ √ √ √ N/A √ √ 
16 Data incorporation √ X √ √ √ N/A √ N/A 
17 Assessment of uncertainty √ √ √ √ √ √ √ √ 
18 Methodological for uncertainty √ √ √ √ √ √ √ √ 
19 Structural uncertainty √ √ √ N/A N/A √ √ √ 
20 Heterogeneity X X √ X X X X X 
21 Parameter √ √ √ √ √ N/A √ √ 
 Consistency         
22 Internal consistency N/A N/A N/A N/A N/A N/A N/A N/A 
23 External consistency N/A √ √ √ √ √ √ √ 
 Total (17/19) (14/18) (20/20) (20/21) (19/21) (14/15) (20/21) (16/17) 
√= “ Yes”, X = “No”, N/A=”Not applicable”
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6.5  Review of the costs analysis studies  
The studies were published between 1997 and 2012. Nine of the papers used non-
modeling analysis, which is not a full economic evaluation and is discussed in this section. 
Seven papers conducted the cost analysis and one paper conducted the cost 
effectiveness analysis (Di Cianni et al., 2002). One study conducted a systematic review 
and an economic evaluation of GDM (Scott et al., 2002). A summary of each of the nine 
studies is discussed within this section, as shown in Table 6.4.   
Screening test strategies 
Various screening test methods were used in cost analyses to identify mothers with GDM,  
such as the 50g glucose challenge test (GCT), fasting plasma glucose (FPG), 2h 75g oral 
glucose tolerance test (OGTT) and 3h 100g OGTT. The most common standard test in all 
of the studies is 75g OGTT and 100g OGTT.  
 Methods 
Population numbers in each of the studies varied substantially from 907 to 2416. The 
populations were not different across the nine studies. The common populations were 
women with singleton pregnancy that were without diabetes before pregnancy. Of these, 
the main risk factors included women with a family history of diabetes, family origin with a 
high prevalence of diabetes, previous gestational diabetes, previous children with 
macrosomia, glycosuria, maternal age of 35 years or older and obesity which was based 
on criteria. 
   No references to perspectives were made in the eight papers. Only one paper 
reported the perspective of the study which was the health care provider (Moss et al., 
2007). However, of those papers, the type of costs and resources that were mainly used 
in the papers were either only direct costs or direct and indirect costs of medical care, 
such as drug costs, laboratory costs, staff administration costs and even allocated hospital 
overhead costs.  
   Of those papers, four papers contain evaluations in which two or more 
interventions are compared, but in which the costs and outcomes of each alternative are 
not examined simultaneously (Di Cianni et al., 2002) (Larijani et al., 2003) (Moss et al., 
2007) (Agarwal et al., 2012). There are four papers that are conducted without 
comparators. All pregnant women are usually offered universal screening based on 
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specific criteria (Moses et al., 1997) (Lemen et al., 1998) (Kitzmiller et al., 1998) (Gillespie 
et al., 2011). In order to compare screening programmes for GDM in cost analyses, 
screening tests were classified into two or three groups according to the objective of the 
study. Selective screening was the most popular comparator used in the three studies. 
However, one study of cost and consequence compared pregnant women in two groups; 
intervention and routine (Moss et al., 2007). 
   Two outcome measures were used within the studies. The most frequently used 
was case detection seen in nine non-modeling studies. In addition to this, others included 
cost per additional serious perinatal complication prevented and per perinatal death 
prevented (Moses, 2010). Six studies used data from observational studies, two used data 
from randomised clinical trials and one used literature review.  
   One-way sensitivity analysis was used in two studies (Larijani et al., 2003) 
(Gillespie et al., 2011). This analysis showed that an increasing prevalence of GDM led to 
increases in total cost estimates. Two additional factors which can change cost estimates 
are the sensitivity and specificity of screening tests and screening uptake rates (Gillespie 
et al., 2011).  
Results 
The costs incurred per GDM diagnosis varies by country, and is based on the unit cost of 
the test technique, the screening strategy and GDM prevalence in the population. The 
cost per case of GDM detected is calculated as AUS $10 using ADIPS criteria (Moses et 
al., 1997). With high and low risk factor screening based on criteria established by the 
ADA, in Iran the cost of screening for GDM was reported to decrease from US$3.80 to 
US$3.21, and the cost per detected case of GDM declined from US$80.56 to US$77.44 
(Larijani et al., 2003). In Italy in 2002, a cost per case of GDM detected of €6.23 was 
generated using 50g GCT with 100g OGTT. In the same study, the costs per case 
management were €366.40 (Di Cianni et al., 2002). In the USA the total cost per case 
diagnosed by universal screening was reported to be US$2,292 (Lemen et al., 1998). 
Gillespie and colleagues estimated the total health care cost in Ireland to be €12,433,320 
and the average cost per case detected was €1,621 (Gillespie et al., 2011). Moreover, in 
the same study a new estimate of the cost of universal screening for GDM recommended 
by the International Association of Diabetes and Pregnancy Study Group in Ireland was 
€46,311,301. The average cost per case detected and the average total cost per case 
detected and treated were €351 and €9,325, respectively. 
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 Many reports of cost analysis for GDM have determined the costs of screening 
and diagnostic strategies, but have not incorporated data on the costs of management 
during pregnancy or clinical adverse outcomes. A cost-consequence analysis on hospital 
treatment with insulin among 100 women with GDM revealed that the incremental cost of 
perinatal deaths prevented was $60,506 and life year gained was $2,988 (Moss et al., 
2007). However, actual management care costs will depend on the specific composition of 
the strategies employed in each study. 
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Table 6.4 Summary of cost analysis studies 
Author Country / 
(Cost /years) 
Interventions type Cost data sources Outcomes Results  Result (SA) 
(Moses et 
al., 1997) 
US (AUS dollar 
/1995) 
Universal screening by ADIPS criteria CA Cost estimated Case detections Per case detection around $10.00 NR 
(Lemen et 
al., 1998) 
USA ( US 
dollar/NR) 
Universal screening by ADA criteria CA Cost estimated 
(direct cost) 
Case detections Per case diagnosed $2,292 NR 
(Di Cianni et 
al., 2002) 
Italy(Euro/2002) S1: 50 g GCT + 100 g OGTT 
S2: Selective screening 
CEA the reimbursement 
tariffs of the Italian 
public health 
Case screened Per case screened was € 6.26. Per management case of GDM 
was € 366.04. 
NR 
(Scott et al., 
2002) 
UK/(Pound/NR) Systematic review SYS Cost 
estimated(direct 
cost) 
Screening test Total cost of screening (50-g GCT)£8.40, (FPG)£4.10, (75g 
OGTT)£19.80. 
NR 
(Larijani et 
al., 2003) 
Iran (US 
dollar/2002) 
S1: High risk by ADS Criteria 
S2: Intermediate risk 
S3: Low risk 
CA NR Case detections Per case detection S1: (130mg/dL) $ 80.56, (140mg/dL) 
$77.44. 
S2: (130mg/dL) $66.88, (140 mg/dL) $ 65.63 
OSA: Sen / Spe 
of tests  
 
(Moss et al., 
2007) 
AUS(AUS 
dollor/NR) 
S1: Intervention groups 
S2: Routine groups 
CCA Hospital costs (direct 
out and in patient) 
Out-patient service  Cost of outpatient service in S1: $674 , S2 $496. 
IC: perinatal death prevent $60,506 
IC: life year saved $2,988 
NR 
(Gillespie et 
al., 2011) 
Ireland 
(Euro/2008) 
Universal screening CA Cost estimated Health care cost of 
GDM 
Total health care costs of GDM was estimated at €12,433,320 OSA: 
prevalence, Sen 
and Spe of tests 
(Agarwal et 
al., 2012) 
United Arab 
Emirates (US 
dollar/NR) 
S1:50g GCT+ 100g OGTT 
S2:75g OGTT 
S3. FPG + 100g OGTT 
CA The laboratory 
workload units 
(WLU) 
One year cost of 
GDM 
One year cost for (S1) $31,985, (S2) $55,250, (S3) $35,875. 
WLU for (S1) $28975, (S2) $18,662, (S3) $12,215. 
NR 
(Gillespie et 
al., 2012) 
Ireland 
(Euro/2010) 
Universal screening CA Cost estimated Case detections Total health care costs of GDM was estimated at €46,311,301 
Total cost per case detected €9,325 
NR 
NR= Not report, ICER= Incremental cost- effectiveness ration, SA= Sensitivity analysis, OSA= One way sensitivity analysis, CA= Cost analysis, CBA= Cost benefit analysis, CMA= Cost minimisation analysis,  
SYS= Systematic review. QALY= Quality adjusted life years, DALY = Disability adjusted life years, IC= Incremental cost. 
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6.6 Review of the cost-effectiveness study 
Over the past decade, eight economic evaluation models of screening tests for GDM have 
been published. Cost-effective analysis and cost-utility analysis studies are methods 
which form part of a complete economic-evaluation, with the aim of comparing the costs 
and outcomes of various measures, and are discussed in this section. The summary of all 
studies is shown in Table 6.6.  
Screening test strategy  
The studies in this review employ a range of different screening test strategies; two use 
IADPSG (Werner et al., 2012) (Mission et al., 2012), another two studies use both WHO 
and O’ Sullivan strategies (Poncet et al., 2002) (Marseille et al., 2013), one study uses 
ADA (NICE, 2008b). The rest of the studies use screening test strategies other than those 
listed above (Nicholson et al., 2005) (Round et al., 2011) (Lohse et al., 2011). These 
guidelines recommend the same period of time to screen pregnant women, between 24 
and 28 weeks of gestation, for the diagnosis of GDM but recommend different test 
techniques and test approaches.  
Methods 
All studies used the decision tree to graphically model the consequences of screening test 
results and outcomes, and adequately reflect the time dependence of events (Poncet et 
al., 2002) (Nicholson et al., 2005) (NICE, 2008b) (Round et al., 2011) (Werner et al., 
2012) (Lohse et al., 2011) (Mission et al., 2012) (Marseille et al., 2013). The basic design 
of all 8 models in the review displayed the possible consequences of screening for and 
treating GDM in decision trees based on different screening strategies, as shown in Table 
6.5. The structure of decision trees, for short term complications, common to all the 
studies in this review, start with a decision node for test strategies followed by chance 
nodes for true disease state, post-test classification, antenatal and perinatal intervention, 
perinatal and offspring adverse outcomes (Poncet et al., 2002) (Nicholson et al., 2005) 
(NICE, 2008b) (Mission et al., 2012). The structure of the decision trees for long term 
complications were based on the structure used for short term complications and in two 
studies was followed by intervention to prevent type 2 DM (Lohse et al., 2011) (Round et 
al., 2011), while in one other study this structure was followed by a postpartum screening 
test and intervention to prevent type 2 DM (Werner et al., 2012).  
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   Round et al was the only study that presented the perspective in terms of third 
party payer (Round et al., 2011). Two articles were investigated from the societal 
perspective (Poncet et al., 2002) (Nicholson et al., 2005).      
   Four studies of the economic evaluation of GDM employed “no screening” as the 
reference case. This is the most widely used comparator for diagnostic test evaluation 
(DRUMMOND, 1987 ) (Nuijten et al., 1998) (Husereau et al., 2013). Of the eight studies, 
one study that developed a model to asses CEA for GDM did not mention a comparator in 
the model (Lohse et al., 2011).     
   Cost data mostly comprised of direct costs, including the cost of screening and 
diagnostic tests, antenatal care for mothers with GDM (diet and exercise counseling, 
glucose control medications, and treatment for complications, were derived from 
published studies or national cost report (Nicholson et al., 2005) (NICE, 2008b) (Round et 
al., 2011) (Werner et al., 2012) (Mission et al., 2012). In a study in France, the cost 
components were calculated by using a prospective study of 120 pregnancies, which 
included costs of the screening tests, costs of the obstetrical follow-up, costs of the 
management of GDM, and costs of delivery care (Poncet et al., 2002). Two studies used 
data on costs that were collected from available data in each setting, and the literature 
(Lohse et al., 2011) (Marseille et al., 2013). The entire clinical data presented in the 
papers were obtained from literature reviews based on similar population or databases of 
each country. Additional input data were also obtained through expert opinion. Clinical 
model parameters included: the probability of adverse outcomes in both mothers and 
offspring, probability of GDM treatment, health related quality of life mother and offspring, 
and test sensitivity and specificity. Various choices of clinical health outcomes in both 
mothers and offspring have been used in the economic evaluation of GDM, which are 
detailed in Table 6.5. The outcomes of the relevant parameters relate to maternal adverse 
complications, neonatal adverse complications, post-partum intervention and long term 
complications of type 2DM.  
   Measures of changes in health related quality of life that contributes to QALY or 
other preference-based measures have been used in the studies in this review. Only five 
of the eight CEA used QALY as outcome measures for the economic evaluations of 
screening tests for mothers with GDM (Nicholson et al., 2005) (NICE, 2008b) (Round et 
al., 2011) (Werner et al., 2012) (Mission et al., 2012). One study used per-case prevention 
rates as natural units (Poncet et al., 2002), and the last two used averted disability 
adjusted life-years (DALY) (Lohse et al., 2011) (Marseille et al., 2013).  One of the studies 
did not state the discount rate for both costs and utilities in the study (Poncet et al., 2002). 
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Two papers in the USA performed a 3% discount rate (Nicholson et al., 2005) (Werner et 
al., 2012). A 3.5% discount rate was used in the UK (Lohse et al., 2011) .  
   Five studies considered uncertainty within their analyses, with one-way sensitivity 
analysis being used in five of the eight papers (Poncet et al., 2002) (Nicholson et al., 
2005) (Werner et al., 2012) (Mission et al., 2012) (Marseille et al., 2013) . Additionally 
three of the eight papers used probabilistic sensitivity analysis (Round et al., 2011) (Lohse 
et al., 2011) (Werner et al., 2012).  
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Table 6.5 Details of the decision tree models for GDM 
Cost and clinical 
parameters 
 (Poncet et al., 2002) (Nicholson et al., 
2005) 
(NICE, 2008b) (Round et al., 
2011) 
(Lohse et al., 2011)  (Werner et al., 2012)  (Mission et al., 2012) (Marseille et al., 2013) 
Screening test - Risk factors 
- Screening test 
- Diagnostic test 
- Risk factors 
- Screening test 
- Diagnostic test 
- Risk factors 
- Screening test 
- Diagnostic test 
- Risk factors 
- Screening test 
- Diagnostic test 
- Screening test 
- Diagnostic test 
- Screening test 
- Diagnostic test 
- Screening test 
- Diagnostic test 
- Screening test 
- Diagnostic test 
Antenatal 
Treatment 
intervention 
- Endocrinology 
consultations 
- Diet 
- Biological test 
- Drugs 
NR -Diet 
-Pharmacotherapy 
(Glibenclamide, 
metformin) 
- Insulin therapy 
- Blood monitoring 
- Insulin therapy 
Treatment and 
other interventions 
- Nutritional 
counseling 
 - Blood glucose 
monitoring  
- Insulin therapy 
NR Treatment and other 
interventions 
Maternal Adverse 
complications 
- Prinatal morality 
- Hypertensive 
disorders 
- Hypertensive 
disorders 
- Polyhydramnios 
- Cesarean section 
and vaginal delivery 
with complications 
- Caesarean 
section 
-Induction of 
labour 
- Caesarean 
section 
Perinatal adverse 
outcome death 
mother 
- Preeclampsia 
- Cesarean section 
- Preterm birth 
- Preeclampsia 
- Cesarean section 
- Maternal death 
Perinatal adverse 
outcome death mother 
Neonatal  
Adverse 
complications 
- Macrosomia 
- Prematurity 
- Macrosomia 
- Mild hypoglycemia 
- Respiratory 
distress syndrome 
- Shoulder dystocia 
- mild, moderate, 
severe in morbidity 
- Neonatal death 
- Bone fracture 
- NICU 
- Shoulder 
dystocia 
-Jaundice 
- Hypoglycemia 
- Neonatal death 
- Shoulder 
dystocia 
- Nerve palsy 
- Phototherapy 
- NICU 
Perinatal adverse 
outcome death 
baby 
- Shoulder dystocia 
- NICU 
- Still birth 
 
- Macrosomia 
- Shoulder dystocia 
- NICU 
- Still birth 
- Respiratory distress 
syndrome 
- Shoulder dystocia 
-Hyperbilirubinemia 
Perinatal adverse 
outcome death baby 
Post partum 
intervention 
NR NR NR NR - Life style 
intervention 
- Screening 
- Intensive exercise 
- Nutritional 
counseling 
NR - Life style intervention 
Long term 
complication(T2DM) 
NR NR NR NR Mother and child Mother NR Mother and child 
C
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1
3
8
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Results 
Evaluating the cost-effectiveness of universal screening and selective screening versus 
no screening of the population, a French study reported that the screening of all pregnant 
women by the WHO strategy with 75g OGTT was the most efficient strategy and selective 
screening of pregnant women with high risk factors with 50g OGTT had the most 
favorable ICER (Poncet et al., 2002). Similar conclusions were drawn from studies that 
evaluated various screening tests against “doing nothing”. In the UK, evaluating the 
universal screening of all pregnant women and selective screening compared with no 
screening, from the analysis it would seem that offering a diagnostic test to women from a 
high-risk ethnic background would be cost-effective compared to not offering screening, 
with an ICER of  £3,677(NICE, 2008b).  
  Nicholson and colleagues showed that the combination of 50g GCT and 100g 
OGTT (S1) was the most cost-effective strategy when ICER of < $50,000/QALY were 
considered highly favorable toward a particular screening strategy (Nicholson et al., 
2005). Similar conclusions were drawn from other cost-effectiveness analyses which 
stated that the combination of a screening test with a diagnostic test or a two-step 
approach was cost-effective. For example, in the USA a study showed that the IADPGS 
approach for GDM screening tests (fasting plasma glucose) combined with a diagnostic 
test ( 75g OGTT) was cost-effective. That is to say, compared to the no-screening 
strategy or the current screening strategy, providing the GDM diagnosis gives an 
opportunity for early and intensive intervention and the prevention of future overt DM 
(Werner et al., 2012).   However, if a one-step approach to screen pregnant women, with 
ceiling ratios ranging from 50,000 – 100,000/QALY was used, screening with the OGTT 
(diagnostic test)  was more expensive and cost effective at $61,503/QALY, than the 50g 
GCT screening test (Mission et al., 2012). 
   However, only one study, in England, that evaluated the cost-effectiveness at 
different prevalence’s in the population reported that the most preferred option was the 
most effective strategy within the maximum willingness-to-pay threshold (£20,000 per 
QALY in this case). However, if the GDM risk was < 1% then the no screening/ treatment 
strategy is cost-effective. Where risk was between 1.0% - 4.2%, combinations of fasting 
plasma glucose (FPG) and 75g OGTT are the most cost-effective, and where risk was 
>4.2 screening all women with OGTT was cost-effective. This study concluded that 
screening strategies were most likely to be cost-effective, based on the range of GDM risk 
factors (Round et al., 2011). 
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Results of the study undertaken by Lohse and colleagues stated that net savings per 
woman for universal screening followed by postpartum lifestyle management in India was 
$78 and in Israel it was $1945. Cost-effectiveness DALYs averted in India were $256 and 
in Israel $2584. Nevertheless, the current findings of cost-savings or favourable cost-
effectiveness are robust to a wide range of plausible input values (Lohse et al., 2011). 
Similar economic evaluations of screening tests for GDM were conducted in the same 
setting within the real data. In terms of estimated costs and effectiveness of screening and 
treating mothers with GDM, considering PAEs and type 2 DM, ICER per DALY averted in 
India and Israel were $1,626 and $1,830, respectively. In both settings, cost-effectiveness 
was sensitive to the incidence of type 2 DM and to the costs and effectiveness of 
postpartum intervention (Marseille et al., 2013). 
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Table 6.6 Summary of eight cost-effectiveness studies 
Author Perspective Country / 
(Cost /years) 
Interventions Discount rate Outcome Results (ICER) Results (SA) Grading 
Poncet et al 
(Poncet et al., 
2002) 
 
Societal France 
 (Euro/  
 2001) 
S1: high risk + 50g OGTT 
S2: 50g OGTT 
S3: 75g OGTT  
S4: No screening 
NR ICER:  
per-case prevention rates 
(macrosomia, prematurity, 
perinatal mortality, and 
hypertensive disorder) 
- S2and S1: additional 
effectiveness 1.10-1.11  
- S3and S1 time 
additional effectiveness 3.27- 3.75 
time  
OSA: 
Results most sensitive 
to  
(i) Cost  
 
++ 
Nicholson et al 
(Nicholson et 
al., 2005) 
Societal USA/ 
( US dollar 
/ 2003) 
S1:50g GCT + 100g OGTT  
S2:100g OGTT  
S3:75g OGTT 
S4: No screening  
3% in both 
cost and 
benefit 
ICER : life of year saved 
QALY for maternal  
Reference 
$ 32,374 
Dominated 
Dominated 
OSA: NR 
 
+ 
   S1:50g GCT + 100g OGTT  
S2:100g OGTT  
S3:75g OGTT 
S4: No screening 
3% in both 
cost and 
benefit 
ICER : life of year saved 
QALY for neonatal  
Reference 
$ 8,252 
Dominated 
Dominated 
  
NICE 
(NICE, 2008b)  
NR England and 
Wales / 
(Pound 
sterling  / 
2008) 
S1: OGTT 
S2-S5: FPG,RBG,GCT,FPG 
          +75g OGTT 
S6: OGTT ADA criteria 
S7:GCT ADA criteria 
S8-S10: FPG,RBG,GCT  
S11-S12: FPG,GCT 
          + 75g OGTT 
S14-S18: age≥ 25 and30 
FPG,GCT + 75g OGTT 
NR ICER : QALY gained -S21(high risk ethnicity + OGTT) 
and no screening: ICER £3,677 
- S6 and S21: ICER £ 
21,738(higher than the £20,000 
per QALY threshold suggested by 
NICE) 
PSA:  
prevalence, treatment 
options, and the efficacy 
of using risk factors to 
define high and low risk 
population 
++ 
   S19-S21:high-risk ethnicity 
FPG,GCT +75g OGTT 
     
NR= Not report, ICER= Incremental cost- effectiveness ration, SA= Sensitivity analysis, OSA= One way sensitivity analysis PSA= Probabilistic sensitivity analysis, QALY= Quality adjusted life years, DALY = 
Disability adjusted life years.  
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Table 6.4 (Continued)  
Author Perspective Country / 
(Cost /years) 
Interventions Discount rate Outcome Results (ICER) Results (SA) Grading 
Round et al 
(Round et al., 
2011) 
third-party 
payer (NHS) 
England and 
Wales / 
(Pound sterling  
/ 2009) 
S1: 75 g OGTT 
S2:FPG 
S3:RBG 
S4: 50g GCT 
S5: PBG + 75g OGTT 
S6: FPG + 75g OGTT 
S7: 50g GCT + 75g OGTT 
S8: No screening 
3.5% in only 
benefit 
 
ICER : life of year gained 
QALY over life time  
 
No QALY present in the 
paper. 
 
PSA:  
Present which treatment more 
likely to be cost-effective by a 
range of GDM risk 
++ 
Lohse et al 
(Lohse et al., 
2011) 
NR India and Israel / 
(US dollar 
/ 2011) 
S1:Universal screening 5% in costs, 
3% for all 
future costs 
ICER : adverted disability-
adjusted life-years (DALY) 
DALYs adverted: India: 
$256, Israel: $ 2584 
PSA: robust to a wide range of 
plausible in put value, including 
highly unfavourable values. 
++ 
Werner et al 
(Werner et al., 
2012) 
 
Health care 
provider 
USA / 
(US dollar 
/ 2011) 
 
S1: no screening  
S2: 50gGCT +100g OGTT 
S3: FPG + 75g OGTT  
3% in both 
cost and 
benefit 
ICER : life of year gained 
QALY over life time  
 
Reference 
$ 16,689  
$ 20,336  
 
OSA: 
long-term behavioural 
intervention in GDM  
PSA: S3 CE with Probability 
96.4 % 
++ 
Mission et al 
(Mission et al., 
2012) 
Societal USA / 
(US dollar 
/ 2012) 
S1:50gGCT 
S2:75g OGTT 
3% in only 
benefit 
ICER : QALY gained Dominated 
$61,503 
OSA: Percentage of additional 
GDM diagnosed with 2h OGTT, 
cost of 2 h OGTT, Cost to treat 
GDM, and Efficacy of treatment 
++ 
Marseille et al 
(Marseille et al., 
2013) 
NR India and Israel / 
(US dollar 
/ 2011) 
India 
S1: no screening 
S2: 75g OGTT 
3% in costs ICER : adverted DALYs and 
net cost per DALY 
 
Reference 
$1,626 
OSA: the estimate incident of 
Type 2 DM in mother, cost per 
partum care. 
++ 
   India 
S1: no screening 
S2: 75g OGTT 
3% in costs ICER : adverted DALYs and 
net cost per DALY 
 
Reference 
$1,830 
  
NR= Not report, ICER= Incremental cost- effectiveness ration, SA= Sensitivity analysis, OSA= One way sensitivity analysis PSA= Probabilistic sensitivity analysis, QALY= Quality adjusted life years, DALY = 
Disability adjusted life years.  
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6.7 Discussion 
This is a systematic review of the literature focusing on the costs and cost-effectiveness 
analysis of GDM. Previous to this review, available data in this field of research had 
been summarised unsystematically. Cost analysis was separated from the economic 
evaluations (CEA, CUA) because cost analysis is not a full economic evaluation 
(Drummond, 1987). However, the cost analyses do give important information on the 
key costs associated with screening tests for GDM. In this review, 9 studies in cost 
analysis and 8 studies in cost-effectiveness analysis were identified. 
6.7.1 Quality assessment  
All economic evaluation studies that were included in this systematic review were good 
in terms of their overall quality; Seven were graded as “++”, indicating very good quality 
with only one study being graded as “+”, indicating moderate quality. Overall, the studies 
performed well in terms of study design. The studies met the criteria of stating the 
research question and describing the alternative screening test that they used to 
compare their evaluations. These eight studies also clearly detailed costs and price 
adjustments.  Most of the studies met the criteria of stating their source material for the 
estimation of treatment effectiveness, reporting the results to the answers of each of the 
research questions. Almost all of the studies accounted for the costs and benefits and 
then discounted them from their results. Two short term studies did not apply discount 
rates for their costs and benefits.   
   Some limitations could be found for the following criteria; more than half of the 
studies reviewed did not report the difference in cost and outcomes, or cost-
effectiveness that can be explained by variations between subgroups of patients with 
different baseline characteristics. However, this is perceived to be a minor limitation 
only, which would not affect the overall quality of this study. 
6.7.2 Cost analysis studies  
Costs associated with the screening and management of GDM vary widely by country 
and are dependent on tests used (FPG, 50g GCT, 75g OGTT and 100g OGTT), 
screening approach (universal and selective), screening steps (one-step and two-step), 
diagnostic criteria and prevalence of GDM in the population.  
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   In the early part of the study period for the review of cost analyses of GDM, 
studies reported cost per case detection at similar levels. Many of the reports have 
determined outcomes expressed in natural units, but few studies incorporated data on 
the cost of management during pregnancy or clinical adverse outcomes. In this early 
part of the study period, authors only pay attention to the cost of screening tests. 
However, results of cost analysis do not give much information in order to compare the 
screening test strategy, therefore, nowadays, decision-analytic models that represent a 
technique to synthesise evidence that is currently available on the costs and 
consequences of alternative health care interventions have become more important. 
Both screening test and treatment data from developing countries are not present in the 
published literature. 
 Given those findings, two studies that compared screening strategies stated that 
universal screening is less expensive than selective screening (Di Cianni et al., 2002) 
(Larijani et al., 2003). These studies suggest that selective screening may be an option 
in a situation where healthcare is very limited. Moreover, a selective approach tends to 
be performed in populations with a low prevalence of GDM; hence, there would be a 
small number of cases missed by selective screening. There is only one study that 
presents incremental costs (Moss et al., 2007). The treatment of mothers with GDM 
showed the reductions in incremental costs per perinatal death prevented and serious 
perinatal complication prevented, which was compared with routine service care. 
Moreover, the incremental cost per extra life year gained is highly favorable. 
     The costs of screening test techniques in this review show that screening tests, 
(FPG and 50g GCT), are less expensive than diagnostic tests (75g OGTT and 100g 
OGTT) (Scott et al., 2002). No previous studies have been conducted for costs in the 
UK. However, Scott and his colleagues conducted a systematic review and an economic 
evaluation of GDM in 2002 (Scott et al., 2002). In The Scott study, ten published articles 
on the costs of screening tests for GDM were reviewed between 1983 and 1998. Two of 
Scott’s studies were included in this systematic review. For example, Scott and 
colleagues estimated the costs of screening tests in the UK, including the costs of 
material used in the various screening and diagnosis tests, staff time for performing the 
tests, and biochemical analysis. They concluded that the total cost of FPG, 50g GCT 
and 75g OGTT were £4.10, £8.40 and £19.80, respectively (Scott et al., 2002). 
However, in the absence of any published studies or locally available data for UK 
costings, Scott‘s study calculated screening costs using data generated by the Scottish 
Health Purchasing Information Centre’s (SHPIC) costing unit. No economic evaluation 
modeling was reported in Scott’s study.  
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6.7.3 Cost-effectiveness analysis studies 
Decision-analytic models represent a technique to synthesise evidence that is currently 
available on the cost and consequence of alternative health care interventions (Philips et 
al., 2004). The use of decision-analytic modeling for health technology assessments has 
seen significant use in recent years. New diagnostic technologies have the potential for 
incurring substantial additional expenditure, creating the need for comparative economic 
and clinical analysis. Therefore, economic assessments of diagnostic tests are 
necessary for health technology assessment (HTA).  
   This systematic review identified 8 CEA. Over the past decade, decision making 
in healthcare has increasingly been based on cost-effectiveness considerations. This 
trend is reflected in most national guidelines concerning GDM screening. Many national 
guidelines have recommended screening test strategies for GDM, such as O’Sullivan 
and Mahan (O'Sullivan and Mahan, 1964), The National Diabetes Data Group (NDDG) 
(National Diabetes Data Group, 1979), The American Diabetic Association (ADA) 
(American Diabetes Association, 1998), The World Health Organization (WHO) (WHO, 
1999a), The National Institute for Health and Clinical Excellence (NICE) (NICE, 2008d), 
and The International Association of Diabetes and Pregnancy Study Group (IADPSG) 
(Metzger et al., 2010b). All studies in this review screen pregnant women during the 
same gestational time period, between 24 and 28 weeks. The studies in this review 
used different screening test techniques, such as RPG, FPG, and 50g GCT, and 
different screening test approaches, either universal and selective screening or one–
step or two-step approaches. However, all studies used 75g OGTT and 100g OGTT as 
standard tests and the assumed sensitivity and specificity of those tests is 100%.  It is 
crucial to select the appropriate comparators for the analysis of CEA (NICE, 2013).  “No 
screening” or “doing nothing” is suitable as a comparator for screening tests for GDM as 
it informs decision makers of the full impact of the alternative screening tests. 
 This systematic review has shown that the most common decision model used to 
evaluate cost-effectiveness analyses of different screening test strategies for GDM is the 
decision tree. The simple decision tree is usually appropriate for situations where the 
time frame is short or when the intervention does not change the underlying disease 
process, as with screening tests that can only detect the presence of a disease (Barton 
et al., 2004). While a Markov model is not inappropriate, it may be unnecessary where 
this is true. Decision trees for screening tests are unlike those for chronic disease which 
can become very bushy in modeling, making them unwieldy and complex to programme 
and analyse (Drummond, 1987) (Drummond and McGuire, 2007). It is therefore 
appropriate to use the decision tree to structure a decision model for screening tests for 
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GDM in both short and long term complications. Decision tree models are also suitable 
for the decision problem of screening for GDM as they can give a detailed description of 
the disease process (Philips et al., 2004). Decision trees for screening tests estimate the 
proportion of people tested and diagnosed and the testing costs for each screening 
strategy. These estimates applied to a population cohort, allow the model to estimate 
expected costs and expected outcomes. Any limitations of the decision tree models can 
be resolved using Markov models, which deal with patterns of recurring–remitting GDM 
after postpartum (GDM in subsequent pregnancy) and long term adverse complications 
with type 2 DM over a period of time.  
   Information on populations for which the cost-effectiveness of screening tests for 
GDM that are to be assessed is determined by the respective countries where the 
studies are performed. It is assumed that countries have their own national estimates on 
prevalence for specific disease areas and for population sub-groups. Costs and clinical 
parameters for short and long term complications were taken from published studies. All 
studies in this review stated the decision-making perspective of the study clearly and 
included all relevant costs for each study. The results of economic evaluations are likely 
to be dependent on the perspective employed and should be stated and defined 
(Roberts et al., 2012a).  
   The earlier studies of economic evaluations for GDM assessed cost and 
effectiveness in short term complications in mothers or offspring whereas three of the 
four later studies built models that included postpartum intervention to prevent DM in 
mothers (Werner et al., 2012), as well as in both mothers and offspring (Lohse et al., 
2011) (Marseille et al., 2013). Variability was observed in terms of what costs and 
outcomes were modeled in each of the studies. The economic evaluations of screening 
tests for GDM should consider both short and long term complications. Case 
identifications and short term complications are not the endpoint outcomes for GDM 
screening tests. The effect of screening and the treatment of GDM, that includes blood 
glucose monitoring, oral medication and regulating insulin, is a reduction in the likelihood 
of developing short term complications and type 2 DM in both mothers and offspring. 
Long term consequences are appropriate outcomes for the CEA of screening tests for 
GDM. A major reason for introducing screening programmes in the population is that it is 
important to initiate the appropriate treatment after positive cases have been identified. 
When patients have positive screening test result, this may reduce their quality of life. 
This can only be compensated for by providing treatment that improves health and 
prolongs life. Therefore, using screening tests for GDM over multiple time horizons, such 
as one year and over a lifetime, might be appropriate for the analysis of data with 
respect to short and long term complications.  
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   One study used per-case prevention rates as natural units and did not apply a 
discount rate (Poncet et al., 2002). This was because the model measures outcomes in 
terms of short term adverse complications, and due to the short time frame, costs and 
outcomes do not need to be discounted. In the UK, NICE suggests a discount rate of 
3.5% for both costs and outcomes (NICE, 2013). Models, for which the costs and 
outcomes of screening are not realised for several years however, need to be 
discounted. Discount rates tend to vary depending on location, setting, time horizon and 
perspective of the analysis (Husereau et al., 2013). 
   Two outcome measures were used, including QALYs and DALY, in the 
economic evaluation of screening tests for GDM.  Health related quality of life measures 
(QALYs) are recommend for use as a measurement of health outcomes to ensure that 
cost-effectiveness results are comparable to some extent between countries.  Round 
and colleagues used QALY during pregnancy and three months after deliver for short 
term adverse complications for randomised clinical trials, which used short form – 36 
(SF-36) (Crowther et al., 2005). SF- 36 is not an appropriate measure of health 
outcomes in CEA because it is not a preference-based measure of health-related quality 
of life (HRQoL). The generic preference based instrument with EuroQul- 5D (EQ-5D) is 
a popular method usually used for measuring changes in health-related quality of life in 
CEA studies (Richardson and Manca, 2004) (Husereau et al., 2013). The preferred 
outcome measure in economic evaluations is QALY, which combines length of life and 
HRQoL in a single metric (Husereau et al., 2013), and is considered a particularly useful 
outcome measure for economic evaluations of screening tests for GDM. QALY can also 
be compared both within and across disease areas. As methodologies used in cost-
effectiveness studies have evolved differently, it would be beneficial to use similar 
outcome measures such as QALY to increase the comparability of studies. The use of a 
range of different outcome measures can cause problems for decision makers, who 
have to make judgements based on disparate results.  
   Two studies in this review measured health outcomes in terms of DALY, for both 
short and long term complications. The DALY for short term complications were 
estimated based on health status utility. Whereas, for long term complications they were 
estimated based on lifetime utility of type 2 DM in mothers with a history of GDM, while 
for offspring they were obtained by comparing disability adjusted life expectancy with 
and without type 2 DM at the estimated age of onset of type 2 DM (Lohse et al., 2011) 
(Marseille et al., 2013). Both QALY and DALY are based on preferences of health and 
are appropriate to measure health outcomes in CEA (Marseille et al., 2013).    
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  In offspring, various health outcomes and techniques were used to estimate 
health utility. Two studies retrieved data from the literature and measured outcomes in 
terms of categories of health states such as normal health (utility 1), preterm birth (utility 
0.96), permanent brachial plexus injury (utility 0.87) and death (utility 0) (Nicholson et 
al., 2005) (Werner et al., 2012). Other papers in this review estimated (by weighting 
average) QALY for serious perinatal complications, calculated based on the relative 
frequency of each individual component. Outcomes used in economic evaluations for 
offspring are more difficult to estimate than for adults. The choice of outcomes affects 
the findings of an economic evaluation, and so it is important that the reasons for 
choosing one measure of outcome over any other should be outlined (Husereau et al., 
2013). Because the studies used different costs, outcome measures and made different 
assumptions about the parameters used, it was not possible to draw comparisons 
between the results of the studies. Also different strategies in modeling and different 
outcomes used were not allowed for comparison. 
  The differences in effectiveness, and hence cost-effectiveness, among the 
models is related to the different assumptions each model makes about the 
effectiveness of screening tests for GDM. Therefore this review cannot definitively state 
the single most-effective or cost-effective strategy for screening tests for GDM. Four of 
the studies compared various screening test strategies with risk factor screening 
(selective screening) in the study (Poncet et al., 2002) (Nicholson et al., 2005) (NICE, 
2008b) (Round et al., 2011). Two of those studies stated that the most favourable ICER 
was the  screening of high-risk pregnancy with a screening test technique such as 50g 
OGTT (Poncet et al., 2002) and 100g OGTT (Nicholson et al., 2005). Two studies in the 
UK suggested the optimal strategy varies according to the women’s risk factors (Round 
et al., 2011) (NICE, 2008b). This review can say that in the low risk factor group, the 
most effective strategy is to do nothing. Screening that is based on individual risk factors 
is possibly more sophisticated and cost-effective in comparison to methods based on 
multiple risks that are commonly considered in the literature. As only a few of the studies 
in this review combine screening test techniques and risk factor screening it was not  
possible to specify what the most appropriate screening test strategy should be.  
     Furthermore, none of the models address the potential QALY gains of screening 
in terms of subsequent pregnancies or delayed progression or developing type 2 
diabetes. One potentially essential outcome for the detection of GDM is the identification 
of women who are at high risk of developing type 2 DM or at high risk of GDM in 
subsequent pregnancies. The model for economic evaluation for GDM should account 
for the effectiveness of postpartum screening for type 2 DM.  In addition, there were no 
studies that presented the results of value of information (VOI) for screening tests for 
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GDM. VOI is used to make meaningful recommendations to decision makers, who can 
then make informed decisions as to whether a new intervention should be adopted or 
reject based on current evidence, or whether further information is required to help make 
the decision.  
   A willingness to pay threshold exists in some countries, but not for all studies.  
An interpretation of whether a certain screening test is cost-effective or not can only be 
made if there is a monetary value that is deemed appropriate to achieve one additional 
QALY. However, if willingness to pay is not available, the conclusion after modeling 
different strategies can only be in relation to how much it would cost to gain one QALY 
and not whether it would be cost-effective to implement a particular strategy compared 
to another.  
The interpretation of any cost-effectiveness result will depend on the level of uncertainty 
that surrounds the input parameters. A series of one-way and multi-way sensitivity 
analyses depicted what would happen when the value of one or more of the parameters 
were changed, including prevalence, treatment options, and the efficacy of using risk 
factors to define high and low risk populations. An assessment of uncertainty should be 
included within an economic evaluation to reflect costs and health outcome results, 
which were obtained from the study. Prevalence, costs and the efficiency of using risk 
factors to define high and low risk population parameters are the greatest influence on a 
model’s results. 
6.7.4 Limitation and recommendation for future research 
This systematic review ignores the critical appraisal of cost analysis papers. The study 
of cost analysis, which is a partial form of economic appraisal, only looks at the costs of 
the programs and does not provide information on the health outcomes of interest. 
Presently there is no accepted criterion for the quality assessment of cost analysis 
studies available. It is difficult to assess the quality of cost analysis studies.  
6.8 Conclusion 
This chapter has presented a review of published papers about the economic evaluation 
for GDM and has critically appraised the economic evaluation of screening tests for 
GDM. A systematic review of all publications has been conducted that has addressed 
the health economic evaluations of screening tests for GDM, as well as their structural 
and methodological aspects.  
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The review of the CEA study has significant implications for future research and policy 
making. The available information on cost effectiveness provide strong evidence in 
support of the use of risk factor screening tests for GDM in high-risk groups, such as 
family origin with a high prevalence of diabetes, previous gestational diabetes and 
obesity. The difference within the reviewed studies in terms of: study design, 
comparators, interventions, outcome measures and the analysis of uncertainty makes 
meaningful comparison between the studies very difficult. A decision must be made as 
to the most suitable screening test based upon and supported by all available 
knowledge. 
  Based on these findings, the following two chapters detail and construct an 
economic evaluation for GDM, which may estimate the benefit of diagnostic tests as a 
function of their expense and the prevalence of disease. The decision tree for case 
identification will be developed in the next chapter based on its findings.  
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Chapter 7 Decision analysis for screening tests 
for GDM: Case identification 
  
7.1 Introduction 
The aim of this chapter is to use decision analytic modeling in order to compare the 
relative costs and outcomes (effects) of five strategies of screening programmes for 
GDM. Health economists use economic models to represent real systems where 
information on the natural history of disease is combined with measures that quantify the 
major drivers of cost and effect. Decision makers can make reimbursement decisions 
based on all the available information relating to the disease and the effectiveness of its 
treatment. In addition, real systems are highly complex and economic modelling 
provides a way in which one can combine information on the natural history of disease 
and the effect of treatment in a potentially useful and meaningful way.   Once these 
elements are clearly understood, then an appropriate modelling structure can be 
selected which allows for these relevant elements to be included within the model. With 
structural decisions made, the model can be developed using available and relevant 
data sources.  
   This chapter begins by identifying the decision problems of screening tests for 
GDM in Scotland. The subsequent section then illustrates the structure of a decision 
tree that involves five different strategies for screening tests in Scotland. There then 
follows a discussion on how to apply the decision tree analysis to the evaluation of 
diagnostic tests for GDM. Within the decision tree, different test methods are applied, 
dependant on the strategies employed. In the section following this all costs and 
outcome parameters are presented and discussed and then the final section of this 
chapter cost per case identifications are calculated and presented in terms of both 
deterministic and probabilistic analysis dependant on the screening strategy. 
7.2 A new economic model for GDM screening tests 
The majority of previous full economic evaluation models have used the decision tree to 
structure economic modelling for GDM screening tests. The decision tree is probably the 
most common structure that describes a clinical decision and its possible outcomes 
(Drummond, 2005a) (Briggs et al., 2008). The basic principle of the decision tree in 
economic evaluations is detailed in Chapter 2 section 2.7.5.  The decision analysis 
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method has been proposed to evaluate screening and diagnostic tests in terms of 
possible clinical consequences; occurrence or no-occurrence of an event. The statistics 
of the diagnostic outcome basically consist of the outcome of the test (T) and the 
presence of disease (D). The decision analysis measures the association between the 
tests (T), with positive (T+) and negative (T-) results and the presence of disease (D): 
with disease (D+) and without disease (D-) (Andrew, 2008).  
   In previous decision modelling of GDM simplified decision tree models were 
based on the screening strategy, disease status and screening test accuracy, and 
dependant on the strategies and studies discussed in Chapter 6. In this model, decision 
trees screening tests for GDM start with screening strategies, similar to the decision 
trees in other economic evaluations of GDM. Following the screening strategies, chance 
nodes that present true disease status (prevalence) are then followed by screening and 
diagnostic test classifications such as true positive (TP), false negative (FN), false 
positive (FP), and true negative (TN). At this point, the decision trees can indentify 
mothers with and without GDM.   
   The decision trees in other economic evaluations of GDM, as reviewed in 
chapter 6, were built based on the screening tests used in each strategy, antenatal 
treatments, short term complications in mothers or offspring, and long term 
complications in mothers and offspring. In this model, following the screening test 
strategy (case identification) section, the decision tree is broken down into three 
separate decision trees; a decision tree for antenatal treatment, decision trees for both 
short and long term adverse complications. These three individual decision trees are 
attached to the screening test decision tree as mentioned above and are outlined in the 
following chapter.   
In conclusion, within this chapter a new economic model for GDM screening test 
case identification in Scotland is developed and detailed. The model is constructed 
similar to decision trees in previous studies while avoiding the limitations of economic 
evaluations in previous studies as mentioned in the preceding chapter.  
7.3 Decision making in screening tests for GDM  
Economic evaluations have been applied in different areas of medical and public health 
programmes, such as primary prevention (risk factor reduction), secondary prevention, 
screening and diagnostic test programmes. In diagnostic procedures, clinical decision 
analysis requires a model to link the diagnostic accuracy data and the long-term 
effectiveness of available treatment. The expected value of diagnostic tests depends 
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strongly on prevalence of disease, risk association with the test, diagnostic accuracy, 
and the relationship between the net benefit of treating truly diseased patients and the 
net harm of unnecessarily treating non-diseased patients. In an economic analysis, 
savings from advanced disease prevention must be included in the model along with the 
diagnostic tests and treatment costs. Specifically, the challenge in diagnostic studies is 
the definition of the optimal cut-off point, which differentiates between positive and 
negative test results. There is no study, however, on the economic evaluation of 
screening and diagnostic tests for GDM in Scotland. This study populated a probabilistic 
model of decision analysis in order to estimate the incremental cost-effectiveness ratios 
(ICER) of four alternative strategies versus the strategy “no screening”. 
7.3.1 Perspective  
In economic modelling it is important to decide at the outset what the end use of the 
model will be. NICE also recommends that all economic evaluations should be based on 
UK population preference and this was adopted within this chapter (NICE, 2008c). This 
study preformed a decision analysis from a health care provider’s perspective to inform 
policy makers on this important issue by establishing the optimal cost-effective 
screening and diagnostic tests of GDM.  The cost of implementing each screening test 
and related treatment is derived from the study perspective which includes hospital 
costs and professional fees for the initial screening tests for risk factors. Health sector 
perspectives concern the health-related cost and impact on the government and on the 
private sector. Moreover, the next component that is an important perspective is 
valuation.  An economic evaluation of GDM defines the currency reference that will be 
used to present the resource expenditure associated with a given cost in “pound 
sterling”.   
7.3.2 Interventions and comparators 
The model was developed to compare the expected costs and health outcomes of five 
possible screening strategies of GDM in all pregnant women without a prior diagnosis of 
diabetes in Scotland, during 24-28 weeks. This study described GDM as carbohydrate 
intolerance of varying degrees of severity, with onset or first recognition during 
pregnancy. 
   This economic evaluation of screening tests for GDM selected screening 
strategies based on the screening strategy recommendations in the UK list in Table 4.8, 
and a combination of the test results from section 3.4. Four screening guidelines were 
selected included SIGN 2001, NICE 2008, Consensus 2010 and SIGN 2010 for the 
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reasons outlined below and based on an experts suggestion (Robert Lindsay). Table 7.1 
shows a summary of the types and methods of screening tests which were used in each 
strategy. The two guidelines proposed in SIGN 2001 and SIGN 2010 were selected 
because they were proposed by The Scottish Intercollegiate Guidelines Network (SIGN, 
2001) (SIGN, 2010). Although, those two guidelines were published by the same 
organisation, they recommend different screening test methods and procedures. 
Although SIGN 2010 is the most recent up-date to this report, it remains unclear as to 
which of the guidelines is the most effective, as there is no cost-effectiveness study in 
either the SIGN 2001 or the SIGN 2010. The inclusion of both guidelines in this study 
therefore allows for a comparison of their relative cost effectiveness. Both of these 
guidelines have also been compared to the other guidelines referred to in this study.   
   The third screening test used was the NICE 2008. NICE 2008 published 
Diabetes in Pregnancy Clinical Guideline 63 which is used throughout England & Wales 
(NICE, 2008d). NICE 2008 was selected because it is used all over England & Wales 
and has similar population characteristics to Scotland (Office for National Statistics, 
2012) (The Scottish Government, 2011). Lastly, the fourth method selected was the 
New Consensus Criteria for GDM (Moses, 2010), and was chosen for this study as it is 
the result of an international consensus, based on the HAPO study as outlined in 
Diabetes Care  (Metzger et al., 2010a). According to the combination of test approaches 
mentioned in section 3.4, all guidelines that recommend screening tests for GDM 
employ a negative dominant strategy (NDS).  
   Moreover, the four screening tests in this model (other than ‘no screening’) 
include either a one step approach where a diagnostic test is performed without prior 
screening or a two step approach where a diagnostic test is performed to confirm a 
positive screening test. In addition, the screening tests use either universal or selective 
screening procedures. For example, both the NICE 2008 and SIGN 2010 guidelines 
recommend selective screening using exactly the same risk factors for GDM screening, 
but different test methods. Universal screening is the screening of all pregnant women 
during 24 -28 weeks with various tests depending on the strategies recommended in 
SIGN 2001 and the 2010 Consensus Criteria. Additionally, the various screening test 
procedures and test methods used in the four different strategies can be matched to the 
various combinations of test results discussed in section 3.4. Discounting was not 
applied, as the time horizon was shorter than a year.  
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Table 7.1 Screening and diagnostic strategies used in cost effectiveness analysis 
Strategies S1:SIGN 2001 S2: NICE 2008 S3:2010 consensus  S4: SIGN 2010 
Reference  (SIGN, 2001) (NICE, 2008d) (Moses, 2010) (SIGN, 2010) 
Screening type Universal screening Selective screening Universal screening Selective screening 
 2 step approach 2 step approach 1 step approach 2 step approach 
Screening 
threshold 
random glucose  ≥ 
5.5mmol/l 
Fasting≥7.0mmol/l Fasting≥5.1 mmol/l  
Diagnosis  
threshold 
Fasting≥5.5mmol/l 
OR 
2 hour >9.0mmol/l 
Fasting≥7.0mmol/l OR 
2 hour ≥7.8mmol/l 
Fasting≥5.1mmol/l OR 
1 hour≥ 10 mmol/l 
2 hour≥8.5mmol/l 
Fasting≥5.1mmol/l OR 
1 hour≥ 10 mmol/l 
2 hour ≥8.5mmol/l 
Clinical risk 
factors 
 - body mass index above 
30 kg/m2 
- previous macrosomic 
baby weight 4.5 kg or 
above  
- previous gestational 
diabetes 
- family history of diabetes 
(first degree relative with 
diabetes) 
- family origin with a high 
prevalence of diabetes: 
South Asian, Black 
Caribbean and Middle 
Eastern  
 - body mass index above 
30 kg/m2 
- previous macrosomic 
baby weight 4.5 kg or 
above  
- previous gestational 
diabetes 
- family history of 
diabetes (first degree 
relative with diabetes) 
- family origin with a high 
prevalence of diabetes: 
South Asian, Black 
Caribbean and Middle 
Eastern  
 
  The five different strategies (including ‘no screening’) used in this model are 
described in detail in this section in terms of both screening steps and screening 
methods. Screening test strategy is denoted by “S”.   
   S1: SIGN 2001, the screening of all pregnant women with random plasma 
glucose. The threshold for positive screening is a random glucose value greater than or 
equal to 5.5mmol/l. Patients with positive random glucose subsequently underwent a 
fasting plasma glucose test and/or 2 hour 75g OGTT, which was used as the actual 
diagnosis test for gestational diabetes mellitus. The positive threshold was greater than 
or equal to 5.5mmol/l or 75g OGTT 2-hour greater than or equal to 9.0mmol/l 
respectively. This test is recommended by SIGN 2001. 
 
   S2. NICE 2008, selected pregnant women with one or more specific high risk 
factors underwent the fasting plasma glucose test, as shown in Table 7.2. A fasting 
plasma glucose test value greater than or equal to 5.5mmol/l meets the threshold for the 
diagnosis of gestational diabetes. The patient needs a further diagnosis test. The 
positive screening test must be confirmed by fasting glucose and 2 hour 75g OGTT for 
diagnostic test. The threshold for a positive diagnosis is a fasting glucose value greater 
Chapter 7   156 
than or equal to 7mmol/l and/or a 2 hour 75g OGTT value greater than or equal to 7.8 
mmol/l. This test is recommended by NICE 2008.   
 
    S3. 2010 Consensus, all pregnant women underwent fasting plasma glucose or 
1 and 2h 75g OGTT screening tests.  Gestational diabetes mellitus was diagnosed if the 
fasting plasma glucose value was greater than or equal to 5.1mmol/l and/or 1 hour 
greater than or equal to 10mmol/l, 2 hour greater than or equal to 8.5mmol/l 
respectively. Both screening tests and diagnosis tests used the same threshold. These 
criteria were proposed by the 2010 consensus. 
  
 S4. SIGN 2010, all pregnant women with one or more high risk factors were 
requested to undertake fasting plasma glucose and 1 and 2h 75g OGTT screening tests, 
as shown in table 3. The threshold for positive diagnosis is fasting plasma glucose 
greater than or equal to 5.1 mmol/l and/or 1-hour greater than or equal to 10mmol/l, 2-
hour greater than or equal to 8.5mmol/l respectively. This strategy was conducted by 
SIGN 2010. 
 
   S5. No screening test, All pregnant women “do nothing” or in other words no 
pregnant women receive screening or diagnostic tests for GDM, as a comparator 
intervention.  The conditions of “do nothing” represent the standard of care. 
   Universal screening is the screening of all pregnant women during 24 – 28 
weeks with various tests depending on the strategy (S1: SIGN 2001 and S3: 2010 
consensus). On the other hand, selective screening is performed during the first 
interview or visit to a clinic by screening all pregnant women for risk factors. Women 
who have positive risk factors undergo further screening tests depending on the strategy 
(S2: NICE 2008 and S4: SIGN 2010).  It is assumed that all pregnant women that 
perform risk factor screening at first visit and undergo screening tests are either positive 
or negative for risk factors, at 24-28 weeks. The various risk factors are introduced in 
each of the guidelines, as mentioned in section 4.6.2.1. The most common risk factors 
referred to in this model are summarised and listed in Table 7.2.  
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Table 7.2  Clinical risk factors for gestational diabetes mellitus  
 Clinical Risk Factors for Gestational diabetes mellitus 
• Body mass index (BMI) above 30 kg/m
2 
 
• Previous macrosomia baby weighing 4.5 kg or above  
• Age over 30 years 
• Previous gestational diabetes  
• Family history of diabetes (first-degree relative with diabetes)  
• Family origin with a high prevalence of diabetes:  
– South Asian (specifically women whose country of origin is India, Pakistan or 
Bangladesh) 
– Middle Eastern (specifically women whose country or family origin is Saudi 
Arabia, United Arab Emirates, Iraq, Jordan, Syria, Oman, Qatar, Kuwait, 
Lebanon or Egypt). 
– Other, South-east Asian, Aborigine, Hispanic, African, Black Caribbean,  
Pacific Islander and Indigenous Australian ancestry 
 
7.4 Decision tree structure of GDM screening tests: case 
identification  
In all screening test strategies, when the screening test result is positive, the standard 
procedure is to confirm the result by further diagnostic tests, as mentioned in section 
4.7. In other words, only patients whose tests return positive will undergo further testing. 
In the four screening test strategies used in this study (not including ‘no screening test’) 
there also exists the need for further testing when test results are found to be over the 
accepted threshold, known as the negative dominant strategy (NDS). All guidelines that 
recommend screening tests for GDM employ the NDS. 
   In this economic evaluation, decision trees are designed to assess the five 
strategies of GDM. Decision trees for case identification were built based on the 
combinations of test approaches that include the negative dominant strategy (NDS) and 
the positive dominant strategy (PDS) as mentioned in section 3.4. This economic 
evaluation of GDM screening tests was applied to both of these approaches in order to 
build decision trees. However, decision tree maps in previous economic evaluations for 
GDM were applied only to NDS, which offers a second diagnostic test to people who 
initially test positive in their screening tests. 
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  This model introduces a new approach by applying PDS to the economic 
evaluation of GDM. This section illustrates and discusses the differences between the 
decision trees in both NDS and PDS strategies. 
   As mentioned, the four different screening test strategies in this model (not 
including ‘no screening’) have different approaches that include a one step approach, a 
two step approach, universal screening and selective screening. However in the 
construction of decision trees for the selective screening approach in previous economic 
evaluation studies the true disease stage branch precedes the risk factor branch.  With 
such a construction, risk factor screening cannot function as a screening tool. Therefore 
to improve on previous studies and present risk factors as a screening tool, the decision 
trees in this economic model begin with risk factor screening for the selective screening 
approach. Risk factor screening can function as a screening tool and is able to benefit 
the selective screening approach. The details of the decision tree structure are outlined 
below.    
 Decision node: The tree begins with a decision node which indicates the five 
strategies of the screening test and represents the decision being addressed in the 
model.  
   Chance node: In universal screening tests, there are two possible chance 
nodes: with disease (D+) or without disease (D-). Branches of chance nodes present 
possible outcomes of probability for the prevalence of gestational diabetes. For selective 
screening, the initial chance nodes are for risk factor status, considered as risk factor 
positive (R+) and negative (R-). Following the risk factor chance nodes is the true 
disease stage with and without risk factors. Subsequently chance nodes indicate the 
screening and diagnostic stages. Branches of chance nodes illustrate the possible 
positive (T+) or negative (T-) test results. The series of chance nodes show the following 
points of uncertainty.  The basic statistics for the clinical diagnosis tests are indicated in 
each branch of possible outcomes of a screening and diagnostic test. Sensitivity is the 
probability of a positive test result if disease is present, and specificity the probability of 
negative screening if gestational diabetes is absent.  
   Terminal node: Each pathway ends in a terminal node, which represents the 
possible outcome of each pathway. The decision trees terminate at case identifications 
of GDM with 4 possible outcomes; True Positive (TP), False Negative (FN), False 
Positive (FP) and True Negative (TN) as shown in Table 7.3. Mothers with TP and FP 
receive treatment during gestation. 
Chapter 7   159 
Table 7.3 The details and signs of terminal nodes of screening tests for GDM 
Results at terminal nodes Details 
True positive GDM with treatment 
False negative GDM without treatment 
False positive No GDM with treatment 
True negative No GDM without treatment 
 
7.4.1 Case identification: decision tree structure for GDM 
screening tests in the negative dominant strategy (NDS)  
   Figure 7.1 illustrates the NDS decision tree for the various screening test 
strategies.  NDS is defined as a test strategy in which positive test results are dominated 
by negative test results, and in which patients with negative screening results receive no 
further tests.  In other words this means that all pregnant women are asked to undertake 
a follow up diagnostic test after screening positive. For example, SIGN 2001 proposed a 
two-step universal screening NDS approach. In this approach there is only one TP result 
following positive results in both test 1 (screening test) and test 2 (diagnostic test) in the 
disease branch. The probabilities along each of the TP pathways represent the 
probabilities of cases detected for each strategy.  
   In another example, SIGN 2010 proposed the use of selective screening, 
whereby the decision tree commences with the true risk factors stage. This model 
considers risk factor screening to be a selective screening tool. Therefore, if a patient is 
negative for risk factors the decision pathway subsequently terminates; those with 
disease being classified as FN and those without as TN. 
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Figure 7.1 Decision tree model for screening tests for GDM (negative dominant strategy) 
 
Positive (T2+|D+) Negative dominant strategy
TP
Positive (T1+|D+)
Negative (T2-|D+)
GDM P(D+) FN
S1: SIGN 2001 Negative (T1-|D+)
Universal Screening FN
Positive (T2+|D-)
FP
Positive (T1+|D-)
Negative (T2-|D-)
No GDM P(D-) TN
Negative (T1-|D-)
TN
Positive (T2+|D+)
TP
Positive (T1+|D+)
Negative (T2+|D+)
GDM P (D+|R+) FN
Negative (T1-|D+)
Risk factors P(R+) FN
Positive (T2+|D+)
FP
Positive (T1+|D-)
Negative (T2+|D+)
S2: NICE 2008 No GDM P (D-|R+) TN
Selective screening (Risk factors)
Negative (T1-|D-)
TN
GDM P (D+|R-)
FN
Risk factors P(R-)
No GDM P (D-|R-)
TN
#
Positive (T1+|D+)
TP
GDM P(D+)
S3: 2010 consensus Negative (T1-|D+)
Universal Screening FN
Positive (T1+|D-)
FP
No GDM P(D-)
Negative (T1-|D-)
TN
Positive (T1+|D+)
TP
GDM P (D+|R+)
Negative (T1-|D+)
Risk factors P(R+) FN
Positive (T1+|D-)
FP
S4: SIGN 2010 No GDM P (D-|R+)
Selective screening (Risk factors)
Negative (T1-|D-)
TN
GDM P (D+)
FN
Risk factors P(R-)
No GDM P (D-)
TN
GDM P (D+)
FN
S5: No screening
No GDM P (D-)
TN
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7.4.2 Case identification: decision tree structure for GDM 
screening tests in the positive dominant strategy (PDS)  
   Another test combination approach which needs to be considered for screening 
tests is the PDS.  PDS is defined as a test strategy in which negative test results are 
dominated by positive test results. In this strategy patients with positive screening 
results do not receive additional tests, and all patients that have negative screening 
tests undertake follow up diagnostic tests. Figure 7.2 illustrates the PDS decision tree 
for the five different strategies. For example adapting SIGN 2001 to a PDS approach, it 
can be seen that there are two TP results, one following a positive screening test in the 
disease branch and the second resulting from a negative screening test and positive 
diagnostic test, in the same disease branch. Therefore, to calculate the probability of 
cases detected for this strategy, the probabilities for both TP pathways were added 
together.  
     Similarly, considering selective screening in terms of PDS, in which risk factors 
are considered to be a screening test tool, patients that test positive for risk factors 
receive no further tests and the decision pathway is terminated. In the arm for positive 
risk factors, patients with disease are classified as TP while mothers without disease are 
FP. 
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Figure 7.2 Decision tree model for screening for GDM (positive dominant strategy)  
 
Positive (T1+|D+) Positive dominant strategy
TP
GDM P(D+)
Positive (T2+|D+)
TP
Negative (T1-|D+)
SIGN 2001
Universal screening Negative (T2-|D+)
FN
Positive (T1+|D-)
FP
No GDM P(D-)
Positive (T2+|D-)
FP
Negative (T1-|D-)
Negative (T2-|D-)
TN
GDM P (D+|R+)
TP
Risk factors P(R+)
No GDM P (D-|R+)
FP
NICE 2008 Positive (T1+|D+)
Selective screening (Risk factors) TP
GDM P (D+|R-)
Positive (T2+|D+)
TP
Negative (T1-|D+)
Risk factors P(R-) Negative (T2-|D+)
FN
Positive (T1+|D-)
FP
No GDM P (D-|R-)
Positive (T2+|D-)
FP
Negative (T1-|D-)
Negative (T2-|D-)
TN
# Positive (T1+|D+)
TP
GDM P(D+)
2010 consensus Negative (T1-|D+)
Universal screening FN
Positive (T1+|D-)
FP
No GDM P(D-)
Negative (T1-|D-)
TN
GDM P (D+|R+)
TP
Risk factors P(R+)
No GDM P (D-|R+)
SIGN 2010 FP
Selective screening (Risk factors)
Positive (T1+|D+)
TP
GDM P (D+|R-)
Negative (T1-|D+)
Risk factors P(R-) FN
Positive (T1+|D-)
FP
No GDM P (D-|R-)
Negative (T1-|D-)
TN
GDM P(D+)
FN
No screening
No GDM P(D-)
TN
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7.5 Parameters in economic evaluation modelling for 
gestational diabetes mellitus: case identification 
Having stated and determined the perspective of the model, the appropriate structure of 
the model was established. Following this it is necessary to identify available data to 
populate the model, as described in chapter 2, section 2.7.3. The process of populating 
screening test models involves bringing together all the relevant evidence and 
synthesizing it appropriately in terms of input parameters within the model. The search 
terms that were searched from MEDLINE and EMBASE include prevalence of GDM, 
prevalence of GDM with present or absent risk factors, screening test accuracy and 
screening costs. The base-case estimates were obtained from various data sources in 
the published literature.  Importantly, parameter estimates were obtained through 
systematic review and meta-analysis, where not available however, randomised 
controlled trials and prospective cohorts were used. Expert opinions or internal data 
from the author’s institution were used when no other sources of information were 
available. 
7.5.1 Baseline probabilities in case identification  
The essential clinical parameters used to populate the screening test model for GDM 
include base-case prevalence and screening test accuracy for GDM, both of which were 
directly converted into probabilities. If multiple data is available, data can be pooled from 
trials to calculate the baseline risk parameter, as is explained in section 8.3.3.  The 
principles for choosing the most relevant evidence for case identification are discussed 
in this section. 
Prevalence  
The construction of the decision tree for the economic evaluation model for GDM 
screening tests begins with true disease status in the universal screening approach. The 
primary branch probabilities indicate the probability of outcomes for the patient within a 
specific population, in terms of presence and absence of disease in universal screening. 
Prevalence studies of GDM have been published in the past couple of decades  (NICE, 
2008d) (Jimenez-Moleon et al., 2002). However, in this model, prevalence rates are 
considered from articles that studied GDM from the perspective of establishing 
prevalence. Papers that presented results for prevalence but where studied from the 
perspective of establishing the accuracy of screening were omitted.   
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   The NICE study reports the estimated incidence of gestational diabetes as 3.5% 
(NICE, 2008d) whilst in the classical prevalence study it ranged from 1 – 16 % (King, 
1998). In the systematic review of population-based studies from chapter 5, prevalence 
was presented as between 1.35% and 12.80%, as shown in Table 7.4. In summary, due 
to the absence of prevalence estimation in Scotland and following expert advice (Robert 
Lindsay), the prevalence for GDM of 3.5% reported by NICE is used to represent the 
baseline parameter for P (D+) in this model. The NICE report was chosen because its 
data is based on that from England & Wales, which has a similar population 
demographic to Scotland (The Scottish Government, 2011) (Office for National 
Statistics, 2012). 
Table 7.4 List of baselines and range of relevance parameters with references (disease 
status) 
Variables Base 
case 
Range Details Data source 
Prevalence      
GDM in pregnancy (D+) 3.5 NA Report by NICE (NICE, 2008d) 
 3.3 2.57-4.21 Cross-sectional in Spain  (Jimenez-Moleon et al., 2002) 
 3.1 1.35-7.60 Systematic review Chapter 5 
Positive risk factor given that  38.0 NA Study in Philippines (Lim-Uy et al., 2010) 
GDM  positive (R+ D+)  68.2 NA Retrospective in Turkey (Karcaaltincaba et al., 2011) 
Positive risk factor given that  39.2 NA Observational in Australia (Moses et al., 1995) 
GDM negative  (R+ D-)  37.3 NA Cross-sectional in Thailand (Sumeksri et al., 2006) 
Positive GDM given that risk  50.0 NA Systematic review (Scott et al., 2002) 
factor positive  (D+ R+)  44.0 NA Report by NICE (NICE, 2008d) 
 
   For the selective screening protocol, the decision tree begins with risk factors, for 
which prevalence values are required; denoted by P(R+) and P(R-) in the decision tree 
model. The branch following risk factors is for true disease status denoted by P
(D+ R+) , P (D- R+) , P (D+ R-)  and P (D- R-) . For example, P (D+ R+)  represents 
the probability of being positive for GDM given that risk factors are present. This study 
used Bayes’ Rule for calculating conditional probabilities for all of the base line 
prevalence’s (Lesaffre et al., 2007). Conditional probability is a very helpful technique 
and is outlined in section 3.3. To calculate conditional probabilities for all four of those 
conditions three values are required; the base line prevalence of GDM P(D+), the 
probability of having risk factors given that a mother has GDM P (R+ D+)  and the 
likelihood of having risk factors given that a mother does not have GDM  P (R+ D-) . The 
previous section produced a base line prevalence of GDM P (D+) of 3.5%. However, two 
studies have reported the baseline of P (R+ D+)  and pooling the values in the articles 
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produces a figure of 47.2%  with a range of 38.0% to 68.2% (Lim-Uy et al., 2010) 
(Karcaaltincaba et al., 2011). Similarly, two articles have reported the baseline of P
(R+ D-)  and by pooling these data, an average of 37.8% is calculated with a range of 
36.2% to 50.0%  (Moses et al., 1995) (Sumeksri et al., 2006). From the above figures, 
the conditional probability can be calculated, as shown below.  
The above information provides the following values and as shown in Figure 7.3. 
    P (D+)   =  0.035 
    P (R+ D+)     = 0.472 
    P (R+ D-)     = 0.378 
 
 
Figure 7.3 Decision tree for risk factors screening  
 
 
   Given this information, we can compute the posterior probability of having GDM 
given that a mother presents with risk factors.   
    P (D+ R+)   = 
 
   
P( R+ D+)P D+
P( R+ D+)P D+ +P( R+ D-)P D-
 
    
         = 
 
   965.0*378.0035.0*472.0
035.0*472.0

   
       = 0.043 
   We can also compute the posterior probability of not having GDM given the 
absence of risk factors.  
 
Risk factor P(R+│D+) 0.472 (T+│ D+)
Disease P (D+) 0.035
Risk factor  P(R-│D+) 0.528 (T-│ D+)
Disease
Risk factor P(R+│D-) 0.378 (T+│ D-)
No Disease P (D-) 0.965
Risk factor  Pr(R-│D-) 0.622 (T-│ D-)
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     P (D- R-)   =  
 
   
P(R- D-)P D-
P(R- D-)P D- +P(R- D+)P D+
 
 
         =
 
   035.0*528.0965.0*622..0
965.0*622.0

 
        = 0.970 
 
There is therefore a high probability of 97% for GDM when there is an absence of risk 
factors. However for the estimated probability of GDM in the presence of positive risk 
factors, the result is only 4.3%. The lower number of (D+ R+)  was a direct result of the 
prevalence figure of 3.5% that was used to calculate the conditional probability of risk 
factors based on the prevalence of GDM in a low risk factor population. 
   These results can be applied to the decision tree to calculate the probability of 
P(R+) and P(R-) for GDM, as show in Figure 7.4. Using the same information, the 
baseline with and without risk factors of GDM can be calculated.   
     P (R+)  = P(D+)P(R+ D+)+P(D-)P(R+ D-)  
        = (0.035*0.472) + (0.965*0.378) 
         = 0.381 
     P (R-)     =  P(D+)P(R+ D+)+P(D-)P(R- D-)  
          = (0.035*0.528) + (0.965*0.622) 
        = 0.619 
 
 
Figure 7.4 Decision tree for calculating the posterior probability 
Disease  P(D+│R+) 0.043 (T+│ D+)
Risk factor P(R+) 0.381
No Disease  P(D-│R+) 0.957 (T+│ D-)
Risk factor
Disease  P(D+│R-) 0.030 (T-│ D+)
Risk factor P(R-) 0.619
No Disease  P(D-│R-) 0.970 (T-│ D-)
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Applying the Bayes’ Rule, the baseline risk factor probability P(R+) of GDM was 
calculated as 38.1%, whereas without risk factors P(R-) it was found to be 61.9%.These 
numbers were then used in the GDM decision tree for selective screening. In 
comparison, NICE reported a 44% prevalence for risk factors, which included BMI >30, 
a high risk ethnic group, previous gestational diabetes and a family history of diabetes 
(NICE, 2008d), as shown in Table 7.4.  Likewise, a systematic study indicated that about 
50% of women had historical and clinical risk factors for GDM (Scott et al., 2002). The 
maximum and minimum values for prevalence observed in these articles ranged from 
38.1% to 68.2%.  
   For the probabilistic analysis, Beta distribution is appropriate for the prevalence 
data. Parameter estimates were derived from a systematic review of the prevalence of 
GDM. A summary of the disease status and probabilistic distribution are shown in Table 
7.5. 
Table 7.5 Summary of clinical parameters in the model (disease status) 
Variables Parameter 
estimated  
Distribution Parameters of 
distribution 
Data source 
   Alpha Beta  
GDM P(D+) 0.035 Beta 44 1,219 (NICE, 2008d) (Jimenez-
Moleon et al., 2002) 
Women with risk factor P(R+) 0.381 Beta 481 782 (Moses et al., 1995) 
(Sumeksri et al., 2006) 
Positive for GDM given that 
risk factors positive P
(D+ R+)  
0.043 Beta 20 462 Baye’s Theorem 
Negative for GDM given that 
risk factors negative P (D- R-)  
0.970 Beta 24 757 Baye’s Theorem 
 
Screening and diagnostic test accuracy for GDM 
The decision tree begins with disease status, and subsequent branching represents 
possible test outcomes. These pathways indicate the accuracy of the test results as 
mentioned in chapter 3 section 3.3.3. The pathways that represent test outcomes have 
sensitivity and specificity values outlined. The most important point of a screening and 
diagnostic test is to use it to make a diagnosis. This study includes five different 
screening strategies and uses various screening test techniques such as RPG, FPG, 
and 75g OGTT. Numerous published articles reported sensitivity and specificity in 
various screening test techniques. A systematic review in accuracy of RPG reported 
sensitivity and specificity within a 95% confidence interval (CI) (van Leeuwen et al., 
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2010). This model uses those two published papers as the baseline case of RPG. For 
RPG, sensitivity was reported as 64.00 (95% CI 25.00-75.00), with a corresponding 
specificity of 80.00 (95% CI 37.00-97.00).  
   Three studies of the accuracy of screening with FPG reported various values of 
sensitivity and specificity with a 95% CI (Reichelt et al., 1998) (Senanayake et al., 2006) 
(Riskin-Mashiah et al., 2010). From these three papers the mean baseline of sensitivity 
was calculated to be 78.1 with a range of 12.00 and 97.30, and likewise the mean 
baseline of specificity was found to be 69.57 with a range of 28.90 to 99.50.  
   In all studies, the accuracy of screening tests for various screening test 
techniques use 75g OGTT and 100g OGTT as a gold standard to diagnose GDM. 
However as all four strategies adopted by this model use the 75g OGTT as a diagnostic 
test, this study assumes 75g OGTT as a gold standard with a sensitivity and specificity 
of 100%. In addition, there is no trade-off between sensitivity and specificity, and are 
treated independently. The list of test accuracies is shown in Table 7.6.  
Table 7.6 List of baselines and range of relevance parameters with references (test 
accuracy) 
Variables Base 
case 
Range Details Data source 
RPG sensitivity 64.00 25.00-75.00 Systematic review (van Leeuwen et al., 2010) 
RPG specificity 80.00 37.00-97.00 Systematic review (van Leeuwen et al., 2010) 
FPG sensitivity 90.00 88.00-94.00 Various  threshold ranges (Reichelt et al., 1998) 
 61.50 15.60-80.00  Various  threshold ranges (Riskin-Mashiah et al., 2010) 
 82.70 12.00-97.30 Various  threshold ranges (Senanayake et al., 2006) 
FPG specificity  66.00 51.00-78.00 Various  threshold ranges (Reichelt et al., 1998) 
 75.70 46.90-95.90 Various  threshold ranges (Riskin-Mashiah et al., 2010) 
 67.00 28.90-99.50 Various  threshold ranges (Senanayake et al., 2006) 
75g OGTT sensitivity 100.00  Reference test  
75g OGTT specificity 100.00  Reference test   
RPG=Random plasma glucose, FPG=Fasting plasma glucose, 75g OGTT= 75g Oral glucose tolerance test 
  
  The test accuracy and distribution used in the probabilistic analysis are reported 
in Table 7.7. Sensitivity and specificity are both probability parameters and the data is 
binomial. Beta distributions have therefore been used in the probabilistic analysis.  All 
the above papers on test accuracy reported mean values with associated confidence 
intervals (CI) for both sensitivity and specificity. Consequently, to fit with a beta 
distribution the Method of Moments was employed by using the sensitivity and specificity 
estimates and the respective standard errors calculated using the upper and lower 
confidence limits as mentioned in 2.15.3 (Briggs et al., 2006). There is no uncertainty for 
Chapter 7   169 
75g OGTT, everyone diagnosed with GDM will undergo this test, and therefore this was 
held constant in the probabilistic analysis.  
Table 7.7 Screening and diagnostic test accuracy parameter estimates 
Test Accuracy Parameters 
estimate 
Distribution Parameters of 
distribution 
Data source 
   Alpha Beta  
RPG sensitivity 0.640 Beta 8.423 4.748 (van Leeuwen et al., 2010) 
RPG specificity 0.800 Beta 4.664 1.166 (van Leeuwen et al., 2010) 
FPG sensitivity 0.781 Beta 2.042 0.574 (Reichelt et al., 1998) 
(Senanayake et al., 2006) 
 (Riskin-Mashiah et al., 2010) 
FPG specificity 0.696 Beta 3.845 1.682 (Reichelt et al., 1998) 
(Senanayake et al., 2006)  
(Riskin-Mashiah et al., 2010) 
75g OGTT sensitivity 1.000 Deterministic  Reference test 
75g OGTT specificity 1.000 Deterministic  Reference test 
 
7.5.2 Cost estimates for case identification 
All relevant costs and consequences of outcomes should be related to the decision 
making perspective. The health economic analysis performed in this model is performed 
from the health care provider perspective, where all relevant screening test costs tend to 
focus on direct costs only. However, the productivity costs of screening tests include 
inventory carrying costs; the time taken to compound or dispense drugs in pharmacies; 
the time nurses take to administer drugs and even the allocation of hospital overhead 
costs. Likewise productivity costs include the costs of screening for GDM, such as the 
costs of materials used in various screening and diagnostic tests as well as staff time in 
performing the tests and biochemical analysis. The costs of various screening tests, 
derived from published literature, are presented in this section. In order to represent the 
costs in pounds sterling (£) and at 2011 prices, all relevant costs in different currencies 
were converted into pounds sterling at the same rate for each year. Next, the Hospital 
and Community Health Services (HCHS) pay and inflation report was used to adjust 
costs in other years to those in 2011 (PSSRU, 2010). Prices presented in the report 
were multiplied by annual percentage increases to calculate expected prices in 2011.  
   In this model, screening costs include the cost of initial screening test 
programmes (risk factor screening, RPG and FPG), and the cost of diagnostic tests 
performed to confirm the results for pregnant women who screen positive with 75g 
OGTT. The costs of screening tests were retrieved from various published literature. For 
example, a costing report for antenatal care incorporating diabetes in pregnancy was 
produced by NICE to provide an implementation tool to estimate the financial impact on 
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the National Health Service (NHS) (NICE, 2008a). All costs and activity assessments in 
the report were estimated based on a number of assumptions. The costs of nursing and 
midwifery assistant time and the costs of biochemical tests were included. Other costs 
were retrieved from a systematic review of economic evaluations of screening tests for 
GDM (Scott et al., 2002). This review includes the costs of materials used in the various 
screening and diagnostic tests, staff time in taking the tests, and biochemical analysis. 
Another published paper, in Italy, presented intensive metabolic management of GDM, 
which was obtained by reimbursements for hospitalisation based on disease related 
groups (DRG) (Di Cianni et al., 2002). In addition, with risk factor screening tests, it is 
assumed that all pregnant women who receive selective screening (risk factors) do so 
during their initial visit to the clinic. The unit cost of risk factor screening in the NICE 
report is calculated using nursing costs based on an average time of five minutes spent 
at a clinic, as shown in Table 7.8. 
Table 7.8 The list of the resources’ cost of screening test 
Variables Base 
case 
Range Details Data source 
RPG/FPG 4.84 NA Price yr 2002* (Scott et al., 2002) 
 3.60 NA Price yr 2008** (NICE, 2008a) 
 11.60 NA Price yr 2002*** (Di Cianni et al., 2002) 
75 g OGTT 23.36 NA Price yr 2002* (Scott et al., 2002) 
 18.76 NA Price yr 2008** (NICE, 2008a) 
Selective screening  4.95 NA Price yr 2002* (Scott et al., 2002) 
 9.50 NA Price yr 2008** (NICE, 2008a) 
* Cost data generated by Scottish Health Purchasing Information centre (SHPIC)/Systematic review for screening test 
and economic evaluation 
** Costing report based on a national tariff  
*** Reimbursements for hospitalisation are based on DRG  
 
The cost estimates and distributions used in case identifications are reported in Table 
7.9. In probabilistic analysis, normal distributions are considered suitable to represent 
the cost parameters, however, the characteristic costs of screening and diagnostic tests 
are the charge price and fixed cost. Therefore, this model presents screening and 
diagnostic test costs as deterministic values, as NICE have established the price of its 
tests. In risk factor screening, the unit cost is not the charge price, therefore this model 
assumes the unit cost of risk factor screening to have a normal distribution. 
Unfortunately, there was no information available on the variance of mean for unit costs, 
so the coefficient of variation was used in order to relate the variance to the mean value. 
Although 0.4 is an arbitrary value, it was chosen to give a large variance (Briggs, 2007). 
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Table 7.9 Costs for Screening test parameter model 
Variables Parameter 
estimate 
Distribution Parameters of 
distribution 
Data source 
RPG / FPG 3.60 Deterministic - (Scott et al., 2002) 
 (NICE, 2008a) 
75g OGTT 18.76 Deterministic - (Scott et al., 2002) 
 (NICE, 2008a) 
Risk factor screening 9.50 Normal SE = 0.4 (NICE, 2008a) 
 
7.6 Populating the screening test decision tree for GDM 
In the beginning of this chapter, the decision tree was outlined and shown to be 
constructed of decision and chance nodes pertaining to various screening and 
diagnostic methods based on various test strategies. Moreover, all the relevant evidence 
presented in previous sections was used to populate the decision tree for case 
identification.  The relevant parameters were converted into probabilities and expressed 
as a number between zero and one. Probability can be calculated by dividing the 
desired outcome by a hundred or by the total number of outcomes. All probabilities can 
then be applied to the branches of the decision tree to represent the possible events 
patients may experience at any point in the tree.  For example, disease status, the first 
chance node relates to whether or not a mother experiences disease. The probability of 
GDM prevalence is applied to the disease positive branch (D+), whereas, 1 minus the 
probability of GDM prevalence is applied to the disease negative branch (D-). Moving 
from left to right, all subsequent branches show the probability of sensitivity and 
specificity for all screening and diagnostic tests. This section presents pathway 
probabilities and the costs of case identification for GDM, with each strategy being 
summarised as four possible outcomes of case identification.       
7.6.1 Expected case identifications 
In the decision tree for GDM, the statistics of disease status and diagnostic outcomes 
indicate the probability along each of the pathways for prevalence of disease (D+) or 
without disease (D-), prevalence of risk factors (R+) or without risk factors (R-), test 
positive (T+) and test negative (T-). The combination of branches in the tree that 
represent screening for GDM outline a series of pathways along which the mother can 
pass through. The probabilities show the likelihood of a particular event occurring at 
branches throughout the GDM decision tree. The screening test strategies employed 
define pathways in the decision tree, for instance S1: 6 pathways, S2: 8 pathways, S3: 4 
pathways, S4: 6 pathways and S5: 2 pathways. The expected outcomes are then 
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calculated by multiplying the pathway probabilities, which are joint probabilities. The 
probabilities for each strategy must total 1. For example, in strategy 2 (S2), there are 
four relevant probabilities, namely the probability of having a positive risk factor (R+), the 
probability of having GDM given the presence of risk factors P (D+ R+) , the probability 
of being test 1 positive given a positive disease state 1(T + D+)  and the probability of 
being test 2 positive given a positive disease state 2(T + D+) , all of which have the 
values 0.381, 0.016, 0.781 and 1.000, respectively.  The pathway probabilities are then 
multiplied along the pathway giving a result of 0.005.    
Expected case identifications for NDS  
In the negative dominant strategy, a true positive result (cases detected) is taken into 
account for women who have positive results for both screening tests and diagnosis. 
Consequently, probabilities in the decision tree pathways for each strategy only present 
one TP result each, as shown in Table 7.10. More than one FN and TN are likely to be 
found in an NDS. As a result, the probabilities for FN and TN each have to be presented 
as one probability by adding the individual values. For example, S1 (NDS) has two FN 
results, namely 0.000 and 0.013. By adding these FN results together the probability of 
FN in S1 (NDS) is 0.013. Similarly, two results for TN are found in S1 (NDS) giving a 
result of 0.965 when added together (0.193 + 0.772).  
   Combining the test results, assuming diagnostic tests have 100% sensitivity and 
specificity (gold standard), the probabilities for TN and FN are the same in each 
strategy, whereas, the probabilities of TP and FN outcomes vary depending on the 
sensitivity of the test employed. In NDS, S3 (NDS) presents higher case identifications 
than the other strategies. S3 (NDS) is a one-step approach, which involves screening all 
pregnancies by a diagnostic test with 100% sensitivity and specificity. Therefore, 
diagnostic tests with 100% accuracy detect GDM from pregnancy close to the actual 
prevalence in the population (3.5%).  
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Table 7.10 Expected case identifications for NDS 
 
Expected case identifications for PDS 
Table 7.11 presents the results for expected case identifications in the PDS. There is 
more than one TP result in each strategy. Therefore, to calculate case detection of each 
strategy, the probabilities of the TP results in each parthway were added up. For 
example, two results for PT are found in S1 (PDS) giving a result of 0.035 when added 
together (0.022+0.013). Patients that have an absence of disease but FP are more likely 
to be found in the PDS. For example, S1 (NDS) has two FP results, namely 0.193 and 
0.000. By adding these FN results together the probability of FP in S1 (NDS) is 0.193. 
Hence, the case identification rates in all PDS strategies are close to the prevalence in 
the population (3.5%).  
Probabiltiy from decision tree pathways Probability for strategy
Disease state Probability Disease state Probability
S1 (NDS) TP 0.022 S1 (NDS) TP 0.022
FN 0.000 FN 0.013
FN 0.013 FP 0.000
FP 0.000 TN 0.965
TN 0.193
TN 0.772
1.000 1.000
S2 (NDS) TP 0.012 S2 (NDS) TP 0.012
FN 0.000 FN 0.022
FN 0.003 FP 0.000
FP 0.000 TN 0.965
TN 0.111
TN 0.254
FN 0.019
TN 0.600
1.000 1.000
S3 (NDS) TP 0.035 S3 (NDS) TP 0.035
FN 0.000 FN 0.000
FP 0.000 FP 0.000
TN 0.965 TN 0.965
1.000 1.000
S4 (NDS) TP 0.016 S4 (NDS) TP 0.016
FN 0.000 FN 0.019
FP 0.000 FP 0.000
TN 0.365 TN 0.965
FN 0.019
TN 0.600
1.000 1.000
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    In combination of the test results, assuming diagnostic tests have 100% 
sensitivity and specificity (gold standard), the probability of TP outcomes in PDS is equal 
to the prevalence in the population. However, in PDS, the probabilities for TP and FN 
are the same in each strategy, whereas, the probabilities of FP and TN outcomes vary 
depending on the specificity of the test employed. 
Table 7.11 Expected case identifications for PDS 
 
7.6.2 Expected costs 
Each pathway in the GDM tree has associated costs, including risk factor screening, 
screening and diagnostic tests, depending on the strategy. For example, in the first 
pathway of S2 (NDS), the significant costs are risk factor screening £9.50, screening 
tests £3.60 and diagnostic tests £18.76, totalling £31.86. The same principle is used for 
other pathways in the tree and it can be seen that for some pathways the total sum of 
the costs remain the same. The expected costs for each strategy can be calculated by 
Probabiltiy from decision tree pathways Probability for strategy
Disease state Probability Disease state Probability
S1 (PDS) TP 0.022 S1 (PDS) TP 0.035
TP 0.013 FN 0.000
FN 0.000 FP 0.193
FP 0.193 TN 0.772
FP 0.000
TN 0.772
1.000 1.000
S2 (PDS) TP 0.016 S2 (PDS) TP 0.035
FP 0.365 FN 0.000
TP 0.015 FP 0.548
TP 0.004 TN 0.417
FN 0.000
FP 0.183
FP 0.000
TN 0.417
1.000 1.000
S3 (PDS) TP 0.035 S3 (PDS) TP 0.035
FN 0.000 FN 0.000
FP 0.000 FP 0.000
TN 0.965 TN 0.965
1.000 1.000
S4 (PDS) TP 0.016 S4 (PDS) TP 0.035
FP 0.365 FN 0.000
TP 0.019 FP 0.365
FN 0.000 TN 0.600
FP 0.000
TN 0.600
1.000 1.000
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summing the values for the pathway costs weighted by the pathway probabilities. The 
total costs of risk factor screening, screening and diagnostic tests are shown as the 
expected value of each pathway. The pathway probabilities represent the sum of the 
different probabilities for each branch in the pathway. Of those, S2 (NDS) for example, 
has a pathway probability 0.012 and a pathway value of £31.86, a weighted value can 
be calculated to give the expected costs of this pathway, equaling 0.39, as shown in 
Table 7.12. The same principle is used for the other pathways in the tree to calculate 
expected costs. Adding up the expected costs along the pathways for each strategy can 
generate expected costs for the strategies. With the same example S2 (NDS), the 
expected cost is £13.19. Another way of working out the expected costs and 
consequences for a given option in a decision tree is by rolling back the tree. By doing 
so, the expected outcomes will be exactly the same as summing across all the 
pathways.  
7.7 Cost per case identification 
If a screening test is adopted as standard, other tests cannot then be employed. 
Considering this problem, a decision has to be made based on the cost and 
effectiveness of all relevant screening tests. This section discusses incremental cost-
effectiveness ratios (ICER). There are four different screening test strategies being 
considered along with an alternative of ‘doing nothing’.  The outcomes were measured 
for cases detected, and defined by the probability of the true positive result in each 
strategy. Costs were measured in pounds sterling, and were calculated by the 
summation of all the costs within each strategy. 
7.7.1 Cost per case identification in the NDS 
For the negative dominant strategy, S1 (NDS) shows a lower expected cost of about 
£7.64, as shown in Table 7.12. On the other hand, S3 (NDS) is seen to be more 
effective in detecting cases of GDM with a TP of 0.035. S3 (NDS) is a universal 
screening test, which involves screening all pregnancies by a diagnostic test with 100% 
sensitivity and specificity. Diagnostic tests with 100% accuracy detect GDM from 
pregnancy close to the actual prevalence in the population (3.5%), with expected cost of 
£18.76. S2 (NDS) has the highest screening cost £31.86, because it includes three 
different screening methods, namely risk factor screening, screening tests and 
diagnostic tests. 
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Table 7.12 Expected costs of case identification in the negative dominant strategy. 
 
 
 
 
 
 
 
 
 
 
Detection status Probability Screening cost Expected cost
S1 (NDS) TP 0.022 22.36 0.50
FN 0.013 25.96 0.05
FP 0.000 22.36 0.00
TN 0.965 25.96 7.09
1.000 7.64
S2 (NDS) TP 0.012 31.86 0.39
FN 0.022 54.46 0.23
FP 0.000 31.86 0.00
TN 0.965 54.46 12.57
1.000 13.19
S3 (NDS) TP 0.035 18.76 0.65
FN 0.000 18.76 0.00
FP 0.000 18.76 0.00
TN 0.965 18.76 18.11
1.000 18.76
S4 (NDS) TP 0.016 28.26 0.45
FN 0.019 37.76 0.18
FP 0.000 28.26 0.00
TN 0.965 37.76 16.02
1.000 16.65
S5 TP
FN
FP
TN
0 0.00
Chapter 7   177 
7.7.2 Cost per case identification in the PDS 
In the positive dominant strategy, the expected costs of screening in S4 (PDS) are high, 
about £21.12 per strategy, because it includes two different screening methods, namely 
risk factor screening and diagnostic tests. S1 (PDS), on the other hand, shows a lower 
expected cost of about £18.32, as shown in Table 7.13. The expected costs of 
screening in S3 (PDS) are £18.76, which is a similar value to the expected cost of 
screening in S3 (NDS).   
Table 7.13 Expected costs of case identification in positive dominant strategy.  
 
 
 
 
 
Detection status Probability Screening cost Expected cost
S1 (PDS) TP 0.035 25.96 0.36
FN 0.000 22.36 0.00
FP 0.193 25.96 0.69
TN 0.772 22 17.27
1.000 18.32
S2 (PDS) TP 0.035 54.46 0.48
FN 0.000 31.86 0.00
FP 0.548 54.46 5.86
TN 0.417 31.86 13.30
1.000 19.64
S3 (PDS) TP 0.035 18.76 0.65
FN 0.000 18.76 0.00
FP 0.000 18.76 0.00
TN 0.965 18.76 18.11
1.000 18.76
S4 (PDS) TP 0.035 37.76 0.69
FN 0.000 28.26 0.00
FP 0.365 37.76 3.47
TN 0.600 28.26 16.96
1.000 21.12
S5 TP
FN
FP
TN
0 0.00
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7.7.3 Incremental cost-effectiveness ratios for case 
identification in GDM screening 
The costs per case identification in the above section can be used in a cost-
effectiveness analysis where the costs and cases of GDM detected (outcomes) are 
compared for both NDS and PDS. The 10 strategies (5 NDS and 5 PDS) were used to 
calculate the incremental cost effectiveness ratio (ICER). Of those, both the NDS and 
PDS results for Strategy 5 (S5) “do nothing” were grouped and presented as a single 
strategy comparator. Likewise, the NDS and PDS results for Strategy 3 were grouped as 
a single strategy because they presented with identical results for both costs and cases 
detected. So, there were a total number of 8 strategies.  
   Table 7.14 shows the expected costs and case identification of 8 screening test 
strategies.  The screening test strategies were ranked according to costs.  S2 (NDS) 
and S4 (NDS) are seen to be more costly and with less cases detected than S1 (NDS). 
Similarly, S3, S2 (PDS) and S4 (PDS) were more costly and had less case detections 
compared with S1 (PDS).  
Table 7.14 Cost and effectiveness in difference screening test strategy 
 
The CE plane of cases detected was plotted on a graph for each strategy, with an x-axis 
of probability of cases detected and y-axis of screening costs, as seen in Figure 7.5. For 
example, for S1 (PDS), cases detected and screening costs were 0.032 and £18.32, 
respectively. The ICER is the sloping line between screening strategies in Figure 7.5.  
For example, the sloping blue line between S1 (NDS) and S1 (PDS) has a value of 
851.86, as discussed below.  
 
Screening strategies Costs (£) Case identification
 [C] [E] 
S5 0.00 0.00000
S1(NDS) 7.64 0.02230
S2(NDS) 13.19 0.01234
S4(NDS) 16.65 0.01580
S1(PDS) 18.32 0.03484
S3 18.76 0.03484
S2(PDS) 19.64 0.03483
S4(PDS) 21.12 0.03483
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Figure 7.5 the cost-effectiveness plane for cases detected for GDM screening tests 
 
However, it is not possible to draw any definitive conclusions regarding the cost-
effectiveness of different screening tests based on the average cost effectiveness ratios 
(ACER) as shown in the third column of Table 7.14. Because of this, the ICER has to be 
calculated to summarise the cost per case detected for GDM. To estimate the ICER’s, 
the alternative screening test strategies were ranked according to costs. Each ICER 
[C/E] was then calculated by dividing the incremental cost [C] by the incremental 
effect [E] for each screening test.  From these results, S2 (NDS) and S4 (NDS) are 
seen to be more costly and with less cases detected than S1 (NDS). So, S1 (NDS) is 
dominant to S2 (NDS) and S4 (NDS). The dominated screening test strategies are then 
excluded and the ICER recalculated. Similarly, S3, S2 (PDS) and S4 (PDS) were more 
costly and had less case detections compared with S1 (PDS). Therefore, S3, S2 (PDS) 
and S4 (PDS) are dominated by S1 (PDS). Having excluded S2 (NDS), S4 (NDS), S2 
(PDS) and S4 (PDS), the ICER was recalculated for S5, S1 (NDS) and S1 (PDS), as 
shown in Table 7.15. 
Table 7.15 Incremental cost-effectiveness ratios along the efficacy frontier when exclusion 
of more costly and less effective alternatives 
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Screening strategies Costs (£) Case identification Incremental costs Incremental effect ICER 
 [C] [E] [C]  [E] [C/E]
S5 0.00 0.00000 0.00 0.000 0.00
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7.7.4 Probabilistic result 
Probabilistic sensitivity analyses explore uncertainty in cost-effectiveness outcomes. 
The economic models of screening tests for GDM are analysed probabilistically using 
Monte Carlo simulation (1000 iterations) in order to determine expected costs, outcomes 
and cost-effectiveness. The costs relate to screening test costs in each strategy while 
outcomes relate to case identifications. The results of the 1000 replications from the 
model are presented on the cost-effectiveness plane, as shown in Figure 7.6. S3 is 
shown as a line because the screening test costs in this model are fixed cost and it is a 
one step approach strategy, with no uncertainty in the costs.    
 
Figure 7.6 Results of 1000 Monte Carlo simulation evaluations for screening tests for GDM 
on the cost-effectiveness plane 
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The aim of calculating a CEAC is to summarise and illustrate graphically the probability 
that a particular intervention or screening test is the optimal choice over a wide range of 
values for the ceiling ratio (λ). The CEAC in terms of screening tests for GDM shows the 
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CEAC presents the results in cost per quality-adjusted life years (QALYs) which is 
suitable for the decision maker because it is the acceptable threshold used by decision 
making institutions (Roberts et al., 2012b). To interpret the results in the absence of 
QALYs, this thesis presents the outcomes of case identifications of GDM in terms of 
natural units. In the UK, the willingness to pay threshold recommended by the NICE is 
£20,000 - £30,000 per QALYs (NICE, 2008c). This means that if the ICER for a specific 
intervention is below the cost effectiveness threshold then society will be willing to fund 
it, while on the other hand if the ICER is greater than the threshold society will not be 
willing to fund it. Thus, it is inappropriate to interpret the results using natural units in 
terms of the arbitrary willingness to pay threshold. However, CEAC illustrates graphically 
the probability that a particular screening test is the optimal choice over a wide range of 
values for the ceiling ratio. Therefore, for case identification, a willingness to pay range 
of £0 - £3,000 is used to present the decision uncertainty surrounding the cost-
effectiveness of each screening test strategy. From Figure 7.7, at the willingness to pay 
of £0 - £3,000, the CEAC illustrates that the probability that S2 (PDS) would be cost-
effective is approximately 39%.  
 
Figure 7.7 Cost-effectiveness acceptability curves of case identifications for GDM 
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7.8 Discussion  
The probabilistic sensitivity analysis suggested that at willingness to pay of £0 to £5,000 
the probability of S2 (PDS) being cost-effective is 39%. S2 is a screening test strategy 
that was published by NICE in 2008 (NICE, 2008b). The NICE guidelines recommend 
NDS with selective screening that screens all mothers with risk factors at first visit 
followed by FPG and 75g OGTT. According to the results, S2 using a PDS approach 
with selective screening followed by a two-step approach using FPG and 75g OGTT 
yielded the highest rate of case identification and the lowest costs for screening tests for 
GDM. 
   No studies carried out a model-based economic evaluation to assess the cost-
effectiveness of screening tests for GDM using an outcome of cost per case 
identifications.  In this study, the cost per case identifications ranges from £7.64 - £21.12 
depending on the screening test used.  However, to interpret the results in the absence 
of QALY, cost per case identifications of GDM were compared with those in a cost per 
case screening study in Canada that involved three different screening strategies for 
GDM, and in which the costs ranged from CA$89.03 – $108.38  (Meltzer et al., 2010). 
The key difference in cost identification in each of the studies was due the evaluation of 
direct and productivity costs. The Canadian study included technician time and 
laboratory analysis as direct costs of the screening tests. While, the productivity costs, 
which included one-way transportation from home to hospital, the cost of time women 
spent in one-way transit to the blood test centre and to complete the glucose testing 
were also accounted for.  In contrast, the costs presented in this thesis take into account 
only the direct costs of the test methods, and are therefore likely to be underestimated. 
However, the objective of introducing a screening programme is to offer treatment and 
to prevent short and long term complications of GDM, for this reason case detection is 
perhaps not an appropriate outcome to use for CEA. The CEA of case identification 
measures health outcomes in terms of natural units, which do not take into account the 
impact of FP and FN. Therefore, it is important to analyse the longer term impact of 
diagnostic tests, and similarly the impact that FP and FN results have on patients. 
Health related quality of life for short and long term complications may be the 
appropriate outcome to capture the health outcome impact of FP and FN results. 
Moreover, it is difficult to interpret the results in the absence of QALYs in CEAC, as 
mentioned in the previous section. 
   The combinations of tests in NDS and PDS represent alternative approaches in 
evaluating the economic assessment of diagnostic tests. Screening test strategies for 
GDM and screening tests for other diseases usually recommend NDS to screen and 
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detect disease in individuals in the general population. In NDS, only patients that test 
positive in the first test (screening test) undergo a second test (diagnostic test), however 
only a few people test positive in the second test and so only a small proportion of the 
population with the disease are detected (TP). TN and FN results are therefore the main 
outcomes of NDS. Therefore there is a high probability that patients without the disease 
have a negative result in NDS. In NDS, clinicians should be concerned about tests with 
high sensitivity, as tests that can identify patients with the disease who have positive test 
results reduce the numbers of FN patients. In PDS, it is patients that are negative in the 
first test (screening test) that undergo an additional second test (diagnostic test). TP and 
FP results are the main outcomes of PDS where screening and diagnostic tests involve 
positive results. In PDS, clinicians should be concerned about tests with high specificity, 
as tests that can identify patients without the disease who have negative results reduce 
the numbers of FP patients.  
    The NDS and PDS approaches allow the clinician to consider test results in 
terms of the differences in FN and FP test results. The trade-off between sensitivity and 
specificity or detection and unnecessary testing is at the heart of screening and 
diagnostic tests and the accuracy of the tests in terms of sensitivity and specificity is an 
important consideration for clinicians. Even if clinicians are able to keep both specificity 
and sensitivity high in tests, FP and FN outcomes will still persist.  
7.9 Conclusion  
An economic model for screening for GDM was been developed and presented as a 
decision tree model which starts with a decision for the screening strategy followed by 
true disease status (prevalence), screening and diagnostic test classification (TP, FN, 
FP, TN) and case detection. The perspective of the model was stated and determined 
initially, allowing the appropriate structure of the model to be established. Then the 
necessary available data to populate the model was identified, including the costs for 
screening tests, prevalence of disease and accuracy of tests.  
   With regard to the costs per case of GDM identifications, PDS was found to be 
more costly than NPS. As the population has a low prevalence of GDM (3.5%), the 
number of cases detected was low and is reflected in the TP result. This chapter 
evaluated CEA by expressing consequences in terms of natural units, determined here 
as cases of GDM detected, and the use of which maximises the number of cases 
identified. However, case detection may not be an appropriate outcome to use for CEA 
in this study as the objective to introduce a screening programme is to offer treatment 
and prevent short term and long term complications of GDM.  The next chapter will 
Chapter 7   184 
recalculate CEA by using long and short term complications instead of case 
identification.   
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Chapter 8 The decision analysis in gestational 
diabetes mellitus: treatment and short term and 
long term complications 
  
8.1 Introduction 
This chapter presents the development and results of a decision analysis model of 
screening tests for GDM including treatment during gestation as well as short term and 
long term complications. The structure of decision models are based on the nature of 
the disease and its treatment. The decision analysis for GDM for treatment is discussed 
at the beginning of this chapter and in the first section the model for treatment during 
gestation is structured as a decision tree. Following this the parameters and costs 
relevant to treatment are discussed and selected.  
   If mothers with GDM are not diagnosed and are treated inappropriately, this can 
lead to adverse complications in both mother and child. The next section deals with how 
to construct a decision tree with regard to adverse short term complications. The 
appropriate parameters and costs relevant to adverse complications are evaluated and 
discussed. The techniques used to estimate the baseline parameters are also shown. 
Before calculating the utility for mothers, the duration of pregnancy is required to identify 
when adverse complications would occur during gestational and postpartum periods. 
The following section after this briefly discusses the formal methods used to translate a 
person’s perception of quality of life in various health states into Health Related Quality 
of Life (HRQoL) scores for GDM. Quality adjusted life years (QALY) for short term 
complications in both mothers and offspring are also evaluated and discussed.  
   Lastly with respect to long term complications, type 2 diabetes mellitus (DM) can 
develop after a diagnosis of gestational diabetes in both mothers and offspring. 
Therefore, life tables and life expectancies are generated and used to calculate lifetime 
QALY for long term complications in both mothers and offspring with DM. This section 
also details all relevant information that is used to calculate lifetime QALY. HRQol for 
type 2 DM in the general population and different age groups are also discussed.   
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8.2 Decision analysis of screening tests for GDM: 
treatment 
Pregnant women diagnosed with GDM have to be treated to reduce the risks of 
complications to themselves and their offspring.  Two randomised controlled trial (RCT) 
studies state that the treatment of GDM with nutritional counselling, dietary control and 
insulin reduced serious adverse complications in both mothers and offspring (Crowther 
et al., 2005) (Landon et al., 2009). In addition, the Scottish Intercollegiate Guidelines 
Network for the management of diabetes (SIGN) and the National Institute for Health 
and Clinical Excellent (NICE) guidelines for antenatal care of diabetes in pregnancy are 
recommended for the treatment of mothers with GDM with dietary control with glucose 
monitoring, oral medication and insulin therapy. Management of GDM in these 
guidelines are the same and similar to the two RCT above, including dietary therapy and 
blood glucose monitoring on the one hand, and pharmacotherapy (Glibenclamide and 
Metformin) or insulin therapy (Regular insulin, Insulin aspart and Insulin lispro) on the 
other. Therefore, treatment of GDM in this study includes dietary control with glucose 
monitoring, oral medication and insulin therapy based on the SIGN and NICE guidelines 
for antenatal care of diabetes in pregnancy (SIGN, 2010) (NICE, 2008d). This study 
assumes that all women identified as having GDM received treatment, that they 
received this treatment without fail and that all treatment was completed.  
8.2.1 Treatment: decision tree structure  
The decision trees for the treatment branches are attached after the case identification 
tree, as shown in Figure 8.1. The four possible outcomes for the identification of GDM 
include true positive (TP), false negative (FN), false positive (FP), and true negative 
(TN) results for GDM. Of those outcomes, there are only two possible pathways that 
take into account mothers that receive treatment. These include a TP outcome, cases 
where both the disease and the test show positive; and FP outcomes, namely cases 
without disease but where the test result shows the presence of disease. For the other 
two case identification results, treatment is not considered and the decision tree 
terminated at these points. These include FN which are cases where there is disease 
but the test indicates that there is not; and TP which are cases without disease where 
the test confirms its absence. This model assumes that pregnant women that have FN 
and TN results do not receive any treatment until delivery, and are screened once per 
person. 
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Figure 8.1 Decision tree model for treatment 
 
8.2.2 Treatment: baseline probabilities  
Based on treatment guideline form NICE and SIGN, the probability of mother being 
treated with three different treatment is needed to populated the treatment model. NICE 
also reported the percentage of treatment for GDM as 65.0%, 20.0%, and 15.0% for diet 
and lifestyle, oral medication and insulin or insulin analogues, respectively (NICE, 
2008a). The list of clinical parameters for treatment and references are shown on Table 
8.1.  
Table 8.1 List of clinical parameters in treatment. 
Variables Base case Range Details Reference 
Diet and life style  65.0 NA Report by NICE (NICE, 2008a) 
Oral medication 20.0 NA Report by NICE (NICE, 2008a) 
Insulin or insulin analogues 15.0 NA Report by NICE (NICE, 2008a) 
 
This model adopted the NICE figures to calculate and adjust the relevant treatment 
costs for GDM. This model assumes that all women identified as having GDM receive 
care management without fail and that their treatment is completed. It is assumed that 
women with TP and FP outcomes would start treatment at a gestational age of 27 
weeks and that this would continue for 90 days. There is no uncertainty in treatment 
during the gestation period, all treatment during gestation was held constant in this 
probabilistic analysis, as shown in Table 8.2.    
 
 
Diet and lifestyle control
TP Oral medication
Insulin or insulin analogues
FN
Diet and lifestyle control
#
FP Oral medication
Insulin or insulin analogues
TN
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Table 8.2 Clinical parameter of treatment in the model 
Variables Probability Distribution Parameters of 
distribution 
Reference 
Diet and life style (Blood 
glucose monitoring) 
0.650 Deterministic - (NICE, 2008a) 
Oral medication 0.200 Deterministic - (NICE, 2008a) 
Insulin or insulin analogues 0.150 Deterministic - (NICE, 2008a) 
 
8.2.3 Treatment: cost estimates  
Costs data for treatment were derived from published literature. The cost of 
implementing each treatment is derived from a health care provider’s perspective.  All 
relevant costs derived from different currencies were converted and recalculated using 
the same technique that was used for the screening tests, as mentioned in section 7.5.2.  
The main treatment costs are derived from the National Institute for Health and Clinical 
Excellence  report, Antenatal Care, Diabetes in Pregnancy Costing Report, which 
consists of the cost of oral medication, insulin/ insulin analogues, and blood monitoring 
(NICE, 2008d). These costs assumed 90 days medication and 12 week monitoring (to 
allow time for diet and exercise to be tried) during pregnancy. The list of relevant costs 
and references are shown on Table 8.3. 
Table 8.3 List of costs in treatment. 
Variable Base case (£) Range Details Reference 
Diet and life style  122.56 NA Price yr 2008* (NICE, 2008d) 
(Blood glucose monitoring) 146.44 NA Price yr 2002*** (Moss et al., 2007) 
 132.70 NA Price yr 2002** (Di Cianni et al., 2002) 
     
Oral medication 3.30 NA Price yr 2008* (NICE, 2008d) 
     
Insulin or insulin analogues 63.58 NA Price yr 2008* (NICE, 2008d) 
 224.90 NA Price yr 2002*** (Moss et al., 2007) 
 120.22 NA Price yr 2002** (Di Cianni et al., 2002) 
*Costing report based on a national tariff 
**Reimbursements for hospitalization are based on DRG 
***Hospital cost 
  
 
All costs used in the decision tree model are summarised in Table 8.4. The treatment 
costs are taken from the above NHS reports and as they are fixed costs or charge price 
they are held constant in the probabilistic analysis. 
Table 8.4 Costs for Screening test parameter in model 
Variable Point estimate Distribution Parameters of 
distribution 
Reference 
Diet and life style 
(Blood glucose 
monitoring) 
122.56 Deterministic - (NICE, 2008d) 
Oral medication 3.30 Deterministic - (NICE, 2008d) 
Insulin or insulin 
analogues 
63.58 Deterministic - (NICE, 2008d) 
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8.2.4 Expected treatment costs for GDM 
The costs for each type of treatment presented in Table 8.5 are weighted for probability 
and costs. These weightings can be aggregated to give the total expected treatment 
costs for GDM, £89.86 per person.  
Table 8.5 Treatment costs for GDM 
Variable Probability Cost (£) Expected cost (£) 
Diet and life style (Blood glucose monitoring) 0.650 122.56 79.66 
Oral medication 0.200 3.30 0.66 
Insulin or insulin analogues 0.150 63.58 9.54 
Total   89.86 
 
As mentioned in section 8.2.1, there are only two possible case identification outcomes 
which result in treatment being received, namely TP and FP results. The expected cost 
of treatment for GDM of £89.86 is shown in the treatment arms where women test 
positive for GDM (TP) and where women test positive in the absence of disease (FP), as 
shown in Table 8.6. On the other hand, in the non treatment arms, treatment costs per 
person during pregnancy are invisible. Previous economic evaluations included delivery 
care costs with treatment during gestational period. This may lead to a double count in 
adverse complication costs for mothers who require caesarean section. Therefore, this 
model was designed to calculate normal delivery care costs together with short term 
complications, as discussed in the next section.  
Table 8.6 Treatment costs based on case identification  
Variable Expected cost (£) 
True positive (TP) 89.86 
False negative (FN)  
False positive (FP) 89.86 
True negative (TN)  
 
8.3 Decision analysis of GDM: short term complications 
Diabetes in pregnancy involves a risk of adverse complications to the mother and the 
developing foetus. Many clinical guidelines recommend the management of diabetes 
and its complications for women who wish to conceive and those who are already 
pregnant (NICE, 2008d) (SIGN, 2010). Effective management of GDM, including blood 
glucose monitoring, oral medication and regulating insulin, reduce adverse effects for 
both mother and child. GDM is associated with substantial maternal and prenatal 
complications, as mentioned in section 4.3. Risks for Short term complications (SC) 
such as preeclampsia, hypertensive disorder, caesarean sections, macrosomia, 
shoulder dystocia and metabolic problems as mentioned in section 4.4 were selected 
based on the adverse complications that were commonly used in previous studies of 
economic evaluation of screening tests for GDM, as outlined in chapter 6. Some studies 
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included perinatal adverse outcomes, namely maternal and neonatal death or stillbirth in 
economic evaluations of screening tests for GDM (Lohse et al., 2011). It is reported in 
randomised clinical trials that such cases of adverse outcomes are very rare (Crowther 
et al., 2005) (Landon et al., 2009). Thus, this model decided to exclude maternal and 
neonatal death as well as stillbirth from short term adverse complications. This study 
assumes that all mothers and offspring have the possibility of developing all of the 
adverse complications included in the study. 
   This model estimates the cost-effectiveness of screening for and treating GDM, 
considering short term complications in both mothers and offspring for four alternative 
strategies versus a strategy of “no screening”. In the UK, the average age at first 
pregnancy is 26 years old (Office for National Statistics, 2013). This model therefore 
assumes all pregnant women experience their first pregnancy at age 26. The model for 
the utility for mothers over a 1 year period after delivery was considered from age 27. 
Therefore, the calculations for utility over a 1 year period after delivery were performed 
for mothers up until age 28. Costs and outcomes are considered for both mothers 
(pregnancy period plus 3 months after delivery) and offspring (neonatal period plus 11 
months of infancy) over a period of one year. However, a discount rate was not applied 
to this analysis, as is the case with economic evaluations with short time horizons (1 
year).     
8.3.1 Short term complications in mothers: decision tree 
structure  
The SC decision trees for both mothers and offspring are attached to the decision tree 
for GDM screening tests. They are attached after the treatment tree for mothers who get 
treatment during gestation, both TP and FP. Whereas, another point where SC decision 
trees attach is after case detection in mothers who are TN, and FN, and who are also 
able to present with adverse complication. The following section illustrates two different 
tree maps for both mothers and offspring. 
   In the economic evaluations performed in previous GDM studies, the SC 
decision trees were constructed in either the gestation or post partum periods after 
pregnancy. To construct the decision tree in only one period of gestation might not 
represent the actual period within which SC occurs. Therefore, the decision tree for SC 
in this model reflects both periods after pregnancy, i.e. the gestation and postpartum 
periods. Preeclampsia and hypertension occur during the gestation period. Caesareans 
section and normal delivery is a technique for childbirth which may affect the mother 
Chapter 8  191 
during the postpartum period. Therefore, the decision tree for SC in mothers starts with 
the chance node of three main outcomes including, preeclampsia hypertension, and no 
AC which represent the gestation period. Each of those outcomes is then followed by 
chance nodes for whether or not a mother experiences caesarean section or normal 
delivery.  From these branches, the probability of the event is represented. Moreover, 
normal delivery is assumed as natural childbirth without the use of any medical 
interventions and without any complication during postpartum. Figure 8.2 illustrates the 
decision tree of SC in mothers.  
 
Figure 8.2 Decision tree model for SC in mother 
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8.3.2 Short term complications in offspring: decision tree 
structure  
Figure 8.3 shows the decision tree of SC in offspring where the chance nodes have four 
main outcomes including macrosomia, shoulder dystocia, metabolic problems, and no 
AC. All these SC are taken into account from after delivery until age at one year. This 
model assumes that SC in offspring are conditionally independent of SC in mothers and 
therefore no link is drawn between complications in mothers and offspring. Applied to 
these branches are statistics for the likelihood of the risk of adverse outcomes and the 
relative risks of adverse outcomes with and without glucose control similar to the SC in 
mothers.  
 
Figure 8.3 Decision tree model for SC in offspring 
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8.3.3 Short term complications: baseline probabilities   
Base-case estimates were obtained from data available in published literature.  A search 
was performed on MEDLINE and EMBASE that included the following terms;  
gestational diabetes, pregnancy complications, preeclampsia, hypertension, caesarean 
section, macrosomia, shoulder distocia, metabolic problems, screening test for 
gestational diabetes, costs, and utility, as addressed in chapter 4. Parameter estimates 
were determined from systematic reviews, meta-analysis, randomised controlled trials, 
and perspective cohort studies where available. Retrospective cohort studies, expert 
opinions or internal data from our institution were used when no other sources of 
information were available. In addition, a brief presented of short and long term 
complications has only been made in chapter 4, however this was not clear enough to 
populate the economic model for GDM. As a result, all baseline probabilities were 
clearly tabulated in this section including references and probability distributions.  
   All outcomes from the various studies can be integrated into a single number, 
and it is assumed that the parameters are drawn from some common prior distribution 
whose parameters are unknown. If there are multiple trials analysing the same 
populations then we can pool information from the trials. α is used to denote the number 
of mothers who have events per study, and n the number of patients per study, while  
denotes the estimated results obtained from pooling the data together.  For example, 
Caesarean delivery is reported in two RCTs (Crowther et al., 2005) (Landon et al., 2009) 
from control groups. The sum of the values for α divided by the sum of the n values can 
be pooled to estimate . The baseline parameter of caesarean delivery is therefore 
estimated to be 32.95 (318/965), as shown in Table 8.7. This figure is the baseline risk 
from control group.  
Table 8.7 Pooling the parameter numbers 
Variable Reference α β n  
Caesarean delivery (Landon et al., 2009) 154 301 455 33.85 
Caesarean delivery (Crowther et al., 2005) 164 346 510 32.16 
  318 647 965 32.95 
 
The RCTs were undertaken to evaluate the clinical effectiveness of treatment for GDM. 
Baseline risks used in the model were taken from the control groups in the trials, as in 
Table 8.7 (32.95). Additionally, to estimate the probability of adverse complication rates 
with and without treatment, odds ratios were used. Systematic review and meta-analysis 
of the effects of treatment in women with GDM which present odds ratios are used to 
calculate probability in the treatment arms. For example, the effect of treatment in 
women with GDM from meta-analysis reported odds ratios at 0.86 (95% CI 0.72-
1.02)(Horvath et al., 2010). This study applied odds ratios to baseline probabilities in 
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order to estimate the corresponding probability in the treatment arms. This is done by 
first converting baseline probabilities into odds, multiplying by the odds ratio and 
converting the resulting odds back into a probability, equalling 0.297 as in the example, 
and representing probability in the treatment arm. The severity of glucose intolerance in 
women with GDM is not taken into account for complications. All essential and relevant 
evidence for the GDM model are addressed in this section. A list of the baseline cases 
and references are shown in Table 8.8. For mothers without GDM or in healthy 
pregnancy, risks were obtained from articles that studied a similar type of population as 
used in this study and converted into probabilities for this group. However, there was a 
lack of studies that presented the risk of SC for healthy pregnancy with treatment for 
GDM that involved low side-effects as mentioned in chapter 4.  This model therefore 
assumes that healthy pregnancy carries the same risk of developing SC as healthy 
pregnancy with treatment for GDM.     
   Previously, different outcome measures have been used in the economic 
evaluations of screening tests for GDM in both mothers and offspring, as mentioned in 
section 6.5.3. In presenting the outcomes for both mothers and offspring, most of the 
economic evaluation models combined the outcomes (for mothers and offspring) and 
presented them as one single outcome. Such combined outcomes were observed in the 
cost-effectiveness studies of screening tests for GDM itself and also in the cost-
effectiveness analyses of other interventions (Round et al., 2011) (Werner et al., 2012). 
Consequently, these QALYs were summed as in other maternal and fetal cost-
effectiveness studies (Werner et al., 2011). This section illustrates how to calculate the 
outcome parameters for SC in both mothers. The outcomes are summed and the results 
outlined in the following chapter.  
Preeclampsia 
In mothers, preeclampsia is a common complication that occurs during pregnancy 
(Hosseing-Nezhad et al., 2007) (HAPO, 2009).This model uses Hyperglycemia and 
Adverse Pregnancy Outcome (HAPO) data which considers the risk of adverse 
outcomes associated with various degrees of maternal glucose intolerance in 9 
countries. The prevalence of preeclampsia in a healthy pregnancy is 4.80% with a range 
of 1.4% – 11.4%. This model applies this prevalence regardless of whether the mothers 
that receive treatment in healthy pregnancy result from TN or FP tests. In mothers with 
GDM, this model also estimates the probability of preeclampsia for individuals with and 
without treatment from two RCT’s (Crowther et al., 2005) (Landon et al., 2009). The 
baseline case for preeclampsia in GDM without treatment is calculated by pooling the 
data from those studies together. 12.34 represents the baseline probability in the non 
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treatment arm and ranges from 5.5 – 18.0.  The odds ratio from the systematic review 
and meta-analysis of the effect of treatment in GDM was 0.27 and this is used to 
calculate the risk of preeclampsia for the treatment arm from the baseline risk (Horvath 
et al., 2010).  This gives a risk of 3.63 in the treatment arm with a range between 2.5 -
12.0.  
Hypertension 
The prevalence of hypertension estimates for normal pregnancy were reported as 5.9 % 
ranging from 0.7% to 17.7% (HAPO, 2009).This model applies this prevalence 
regardless of whether the mothers that receive treatment in healthy pregnancy result 
from TN or FP tests. Pregnancies diagnosed with GDM are at a higher risk of 
hypertension.  Two RCTs were used to estimate the probability of hypertension for 
individuals with and without treatment (Crowther et al., 2005) (Landon et al., 2009). 
13.6% (13.5% -13.7%) represents the baseline in the non treatment arm by pooling the 
data from those studies together. With a lack of any odds ratio for the effect of treatment 
in GDM for hypertension, this study assumes the odds ratio of preeclampsia to 
represent the risk of hypertension for the treatment arm from the baseline risk. The 
probability of hypertension in the treatment arm is estimated as 4.08% (4.0% - 8.60%).  
Caesarean sections 
Healthy pregnancy’s carry a risk of caesarean section (Xiong et al., 2001) (HAPO, 2009) 
(Hosseing-Nezhad et al., 2007). In the HAPO study 16%, with a range of between 8.6% 
and 23.5%, is assumed to be the probability of healthy pregnancy with caesarean 
section, regardless of whether treatment is received or not, resulting from TN and FP 
tests. Macrosomia is an indirect adverse outcome, which appears to lead to an increase 
in caesarean deliveries and instrumental deliveries (forceps and ventouse deliveries). 
GDM patients who are untreated are more prone to giving birth to infants with a weight 
of over 4000g and required to have caesarean delivery. Different studies on effective 
treatment of GDM present similar baseline risk factors in control groups (Crowther et al., 
2005) (Landon et al., 2009). The findings of these papers are summarised to indicate 
the probability in the non treatment arm; approximately 32.9% and ranging from 32.0% 
to 58.13%. 0.86 is the odds ratio from a systematic review and meta-analysis of the 
effect of treatment in GDM and this is used to calculate the baseline in this arm (Horvath 
et al., 2010). By applying the odds ratio to the baseline risk of caesarean sections, 
29.7% (26.9% - 31.0%) is calculated to be the probability for the treatment arm.  
Macrosomia 
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In offspring, the risk of macrosomia in healthy pregnancy in three different papers show 
similar rates (Xiong et al., 2001) (Brody et al., 2003) (Chauhan et al., 2005). Chauhan’s 
review of the prevalence of macrosomia in international papers reported risk in the 
United Kingdom averaging 9%, ranging from 2% to 10%. This is selected to represent 
the risk of macrosomia in women without GDM (Chauhan et al., 2005). Macrosomia is 
one of the most common complications related to GDM. Untreated GDM is more likely to 
lead to infants being born over weight. 14% - 21% of offspring with macrosomia are born 
form a mother with GDM (Crowther et al., 2005) (Landon et al., 2009). The pooling of 
baseline figures from RCTs papers gives 17.89 % with a range of 9.09% - 25.5% and 
were used to indicate the non treatment arm. In the same meta-analysis study it was 
reported that the odds ratio of the effect of treatment in GDM with macrosomia was 0.38 
(Horvath et al., 2010). Baseline risk in the treatment arm which was calculated based on 
applying the odds ratio to the baseline risk presented as 7.65% with range from 5.9% - 
10.0 5%.  
Shoulder dystocia 
The prevalence of shoulder dystocia in normal pregnancy is 2.10% (0.3 % - 6.4%), and 
was used to indicate the baseline for mothers without GDM (HAPO, 2009). A high 
prevalence of macrosomia can cause birth trauma in the offspring of a mother with 
GDM, and this can make delivery difficult because one of the offspring’s shoulders can 
get stuck behind the pelvic bone. The studies in effectiveness of treatment in GDM were 
used to estimate the baseline case in the non treatment arm. The pooling of the baseline 
figures gives a result of 3.47%, ranging between 3.0% from 4.0% (Crowther et al., 2005) 
(Landon et al., 2009). 0.4 is the odds ratio from meta-analysis of the benefits and harm 
of treatment for women with GDM (Horvath et al., 2010). In the treatment arm, the risk of 
shoulder dystocia is estimated as 1.42% (1.0% - 1.5%), based on applying the odds 
ratio to the baseline risk.   
Metabolic problems 
There is a low prevalence of infants with metabolic problems in healthy pregnancy 
(HAPO, 2009) (Hosseing-Nezhad et al., 2007). The prevalence of metabolic problems 
seen in the HAPO study was 2.10% (0.3% - 6.4%), and has been selected to indicate 
the baseline for metabolic problems. The children of mothers with GDM may present 
with metabolic problems. 5.92% with a range of 5.6% - 20.1%, is used to represent the 
effectiveness of treatment in control groups after pooling the number of events and total 
level at risk from the two trial studies presented (Crowther et al., 2005) (Landon et al., 
2009). The odds ratio from the systematic review and meta-analysis is reported to be 
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about 0.4.  After applying the odds ratio to the baseline risk, the estimate comes out as 
2.46% ranging between 2.0% - 5.30% in the treatment arm.  
Table 8.8 The list of the resource’s of adverse complications. 
Variables Base case Range Details Data source 
Mother complication: Preeclampsia   
No GDM  4.80 1.4-11.4  HAPO study in 9 countries (HAPO, 2009) 
 2.01 1.4-2.8 Cross-sectional study (Hunking et al., 2001) 
GDM without treated 5.50 NA RTC (Landon et al., 2009) 
 18.00 NA RTC (Crowther et al., 2005) 
 4.38 1.4-9.9 Cross-sectional study (Hosseing-Nezhad et al., 2007) 
GDM with treated 2.50 NA RTC (Landon et al., 2009) 
 12.00 NA RTC (Crowther et al., 2005) 
 4.50 NA Cross-sectional study (Bryson et al., 2003) 
Mother complication: Hypertension   
No GDM 5.90 0.7-17.7 HAPO study in 9 countries (HAPO, 2009) 
 11.40 NA Retrospective cohort study (Xiong et al., 2001) 
GDM without treated 13.60 NA RTC (Landon et al., 2009) 
GDM with treated 8.60 NA RTC (Landon et al., 2009) 
 4.40 NA Case control study (Bryson et al., 2003) 
Mother complication: Cesarean section   
No GDM 16.00 8.6-23.5 HAPO study in 9 countries (HAPO, 2009) 
 28.10 26.71-29.52 Cross-sectional study (Hosseing-Nezhad et al., 2007) 
 16.20  Retrospective cohort study (Xiong et al., 2001) 
GDM without treated 33.80 NA RTC (Landon et al., 2009) 
 32.00 NA RTC (Crowther et al., 2005) 
 47.13 32.00-58.13 Cross-sectional study (Hosseing-Nezhad et al., 2007) 
GDM with treated 26.90 NA RTC (Landon et al., 2009) 
 31.00 NA RTC (Crowther et al., 2005) 
Offspring complication: Macrosomia   
No GDM 9.00 2.0-10.0 Review prevalence (Chauhan et al., 2005) 
 10.00 NA Review prevalence  (Brody et al., 2003) 
 9.00 NA Retrospective cohort study (Xiong et al., 2001) 
GDM without treated 14.30 NA RTC (Landon et al., 2009) 
 21.00 NA RTC (Crowther et al., 2005) 
 15.80 9.09-25.5 Cross-sectional study (Hosseing-Nezhad et al., 2007) 
GDM with treated 5.90 NA RTC (Landon et al., 2009) 
 10.00 NA RTC (Crowther et al., 2005) 
Offspring complication: Shoulder dystocia   
No GDM 2.10 0.3-6.4 HAPO study in 9 countries (HAPO, 2009) 
GDM without treated 4.00 NA RTC (Landon et al., 2009) 
 3.00 NA RTC (Crowther et al., 2005) 
GDM with treated 1.50 NA RTC (Landon et al., 2009) 
 1.43 NA RTC (Crowther et al., 2005) 
Offspring complication: Metabolic problems   
If no GDM 2.10 0.3-6.4 HAPO study in 9 countries (HAPO, 2009) 
 3.90 3.32-4.55 Cross-sectional study (Hosseing-Nezhad et al., 2007) 
GDM without treated 6.80 NA RTC (Landon et al., 2009) 
 11.49 5.6-20.1 Cross-sectional study (Hosseing-Nezhad et al., 2007) 
GDM with treated 5.30 NA RTC (Landon et al., 2009) 
 
The baseline clinical parameters used in the decision tree model are summarised in 
Table 8.9. The data are binomial, in the form of a baseline probability, and therefore it 
was decided that Beta distribution was appropriate to represent uncertainty in the 
probabilistic analysis for TN, FP and FN. On the other hand, in the TP arm, this model 
uses the odds ratio from the literature review to incorporate the effect of treatment into 
the model. The appropriate distribution for this is lognormal (Briggs et al., 2006). 
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Table 8.9 Summary short term complication parameters in the model 
Variables Parameter Probability  Parameters of distribution Data source 
 estimated distribution Alpha Beta  
Mother complication: Preeclampsia    
No GDM without treated 0.046 Beta 1,116 24,389 (HAPO, 2009) 
No GDM with treated 0.046 Beta 1,116 24,389 (HAPO, 2009) 
GDM without treated 0.122 Beta 118 847 (Crowther et al., 2005) 
(Landon et al., 2009) 
GDM with treated 0.700 Log normal SE = 0.159 (Horvath et al., 2010) 
Mother complication: Hypertension     
No GDM without treated 0.057 Beta 1,370 24,135 (HAPO, 2009) 
No GDM with treated 0.057 Beta 1,370 24,135 (HAPO, 2009) 
GDM without treated 0.136 Beta 62 393 (Crowther et al., 2005) 
(Landon et al., 2009) 
GDM with treated 0.700 Log normal SE = 0.159 (Horvath et al., 2010) 
Mother complication: Cesarean section    
No GDM without treated 0.171 Beta 3,731 21,774 (HAPO, 2009) 
No GDM with treated 0.171 Beta 3,731 21,774 (HAPO, 2009) 
GDM without treated 0.333 Beta 318 674 (Crowther et al., 2005) 
(Landon et al., 2009) 
GDM with treated 0.860 Log normal SE = 0.089 (Horvath et al., 2010) 
Offspring complication: Macrosomia     
No GDM without treated 0.097 Beta 763 7,854 (Chauhan et al., 2005) 
No GDM with treated 0.097 Beta 763 7,854 (Chauhan et al., 2005) 
GDM without treated 0.179 Beta 175 803 (Crowther et al., 2005) 
(Landon et al., 2009) 
GDM with treated 0.380 Log normal SE = 0.125  (Horvath et al., 2010) 
Offspring complication: Shoulder dystocia    
No GDM without treated 0.014 Beta 311 23,005 (HAPO, 2009) 
No GDM with treated 0.014 Beta 311 23,005 (HAPO, 2009) 
GDM without treated 0.035 Beta 34 945 (Crowther et al., 2005) 
(Landon et al., 2009) 
GDM with treated 0.400 Log normal SE = 0.325 (Horvath et al., 2010) 
Offspring complication: Metabolic problems    
No GDM without treated 0.042 Beta 950 22,366 (HAPO, 2009) 
No GDM with treated 0.042 Beta 950 22,366 (HAPO, 2009) 
GDM without treated 0.777 Beta 75 904 (Crowther et al., 2005) 
(Landon et al., 2009) 
GDM with treated 0.760 Log normal SE = 0.241 (Horvath et al., 2010) 
 
8.3.4 Short term complications: cost estimates  
All important costs calculated in foreign currencies were converted into pound sterling 
(£) for use in calculations in the model as mentioned in section 7.5.2. The model also 
includes the costs of additional outcomes from systematic reviews, meta-analysis and 
randomised controlled trials on the effect of treatment of GDM on pregnancy. Care costs 
for maternal and infant complications have been sourced from published literature and 
cost reports (Barton et al., 2006), as shown in table 8.10. A report of hospital costs, 
namely the Admitted Patient Care Mandatory Tariff produced by the Health Resource 
Group (HRG) has been used in this study (NHS TARIFF 06/07, 2007) (NHS TARIFF 
10/11, 2011). The cost of a normal delivery is £971.00 (lower percentile at 721 and 
upper percentile at 1174).  In this study, delivery costs without complications are 
calculated and included in the costs for the care of adverse complications. Regarding 
caesarean section costs within the report, only caesarean section without complications 
is considered. Hypertension costs during gestation were not reported. Thus, 
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hypertension costs are assumed to be the same as preeclampsia costs. All costs that 
have been used in the decision tree model are summarised in Table 8.10.  
Table 8.10 The list of the resource’s cost of adverse complications. 
Variable Base case (£) Range Details Reference 
Healthy mother     
Normal delivery 
without complications 
971.00 NA Price yr 2011* (NHS TARIFF 10/11, 
2011) 
     
Mother adverse compilations    
Preeclampsia 261.87 NA Price yr 2008* (NHS TARIFF 06/07, 
2007) 
 1,335.77 1,012-13,184.14 Price yr 2006* (Barton et al., 2006) 
Hypertension 261.87 NA Price yr 2008* Assumed as the same 
price as preeclampsia 
Caesarean without 
complications 
1,544.00 NA Price yr 2011* (NHS TARIFF 10/11, 
2011) 
 5,274.45 NA Price yr 2002** (Di Cianni et al., 2002) 
     
Offspring adverse compilations    
Macrosomia 623.71  Price yr 2008* (NHS TARIFF 06/07, 
2007) 
Shoulder dystocia 683.48  Price yr 2008* (NHS TARIFF 06/07, 
2007) 
Metabolic problems 896.45  Price yr 2008* (NHS TARIFF 06/07, 
2007) 
 1,318.41 533.70-3,994.87 Price yr 2003* (Gilbert et al., 2003) 
** Hospital cost, ** Reimbursements for hospitalization are base on DRG  
 
The gamma distribution is frequently used to model costs (Briggs et al., 2006). The 
reason some papers prefer it over the normal is that the normal assumes a symmetric 
distribution while the gamma allows for a right skewed distribution, which is usually 
apparent in raw cost data. However, although costs on the raw scale are likely to be 
right skewed our interest for modelling lies in the distribution of mean costs, and if the 
sample from which costs are estimated is large enough the distribution of mean costs 
may be approximately normally distributed even if the underlying distribution is not 
(Briggs et al., 2006). This is why costs are often modelled using a normal distribution.  
     As mentioned above, normal delivery costs were found to be £971.00 (lower 
percentile (15) at 721 and upper percentile (75) at 1174). NHS reference costs however 
only provide 15th & 75th percentiles of the cost distribution.  To fit cost data with the 
normal distribution, an estimate of the standard error (SE) is needed. Normally the SE 
can be calculated using the confidence interval, namely (upper-lower) / (2*1.96). The 
95% CI covers 95% of the normal distribution and equates to 2 standard deviations (SD) 
from the mean value.  The 15th and 75th percentiles can be used to calculate a 95% CI, 
and as the difference between the lower (15) and upper (75) percentiles equals 3.2 SD 
from the mean value, the value for 1SD can then be calculated.  
   Recalling the cost of a normal delivery, 1SD is calculated as (1174 – 721)/3.2 = 
141.60. The cost has a mean of 971.00. The 95% confident interval is therefore 
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computed by subtracting 2 (SD) from the mean to find the lower value and adding 2 
(SD) to give the upper value of the 95% CI, which equal 687.88 and 1254.13, 
respectively. In cases where no SE is available from data sources, an alternative 
approach is to use data that present a 95% CI and mean value to make the necessary 
calculations. Unfortunately, if the cost values do not report both SE and 95% CI, it is 
common to assume some measure of uncertainty. In this respect, one of the most 
common approaches in the literature is to assume what is called a coefficient of 
variation. So for example, a coefficient of variation of 20% would mean that the SE is 
20% of the mean. The choice of 20%, 30% or 100% is completely arbitrary. This model 
assumes the SE is the same value as the mean (Briggs et al., 2006).  The unit cost, SE 
and distribution used in the probabilistic analysis are report in Table 8.11. 
Table 8.11 Cost parameters in the model 
Cost Parameter 
estimate 
Probability 
distribution 
SE Data source 
Healthy mother     
Normal delivery 
without complications 
971.00 Normal 144.45 (NHS TARIFF 10/11, 2011) 
Mother adverse 
compilations 
    
Preeclampsia 261.87 Normal 127.55 (NHS TARIFF 06/07, 2007) 
Hypertension 261.87 Normal 261.87 (NHS TARIFF 06/07, 2007) 
Caesarean 1544.00 Normal 346.94 (NHS TARIFF 06/07, 2007) 
Offspring adverse 
compilations 
    
Macrosomia 623.71 Normal 623.71 (NHS TARIFF 06/07, 2007) 
Shoulder dystocia 683.48 Normal 683.48 (NHS TARIFF 06/07, 2007) 
Metabolic problems 896.45 Normal 896.45 (NHS TARIFF 06/07, 2007) 
 
8.3.5 Short term complications: QALY over one year in mothers 
The term “quality of life” and more specifically health related quality of life (HRQoL) refer 
to the physical, psychological, and social domains of health, which cover all WHO 
aspects, as mentioned in section 2.5.1 (Marcia and Donald, 1996). To estimate the 
quality adjusted life year, it is necessary to quality-adjust the period for which the 
average patient is alive within the model using an appropriate utility or preference score. 
As mentioned in the above section, GDM have various SC events in both mother and 
offspring. The GDM SC in mothers required for this economic model includes healthy 
pregnancy, preeclampsia, hypertension, and caesarean section.  
    In order to determine utility for individual GDM events, estimates of utility were 
obtained from various data in the published literature. Currently, there are many 
instruments available to measure HRQoL. The most common technique for measuring 
the HRQoL in pregnant women is 36-Item Short Form (SF-36), which is a widely used 
generic health related quality of life instrument which assesses eight aspects of health 
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status including physical functioning, role physical, bodily pain, general health, vitality, 
social functioning, role emotional and mental health (Symon, 2003) (Brazier et al., 
2002). However, SF-36 cannot be used in cost effectiveness analysis using cost per 
QALY because it is not preference based.  Instead, preference-based measures such as 
the EQ-5D are generally used (Rowen et al., 2009) (NICE, 2013). In addition, EQ-5D is 
a standardised instrument which is applicable to a wide range of health conditions and 
treatments, and used as a measure of health outcomes. This instrument provides a 
simple descriptive profile and a single index value for health status that can be used in 
the economic evaluation of health care. Moreover, EQ-5D had specially been designed 
to complement other quality of life measures such as the SF-36, NHP and disease-
specific measures (SIGN., 2002). Mapping from health status measures onto generic 
preference-base measures, which was studied by Rowen and colleagues, is being 
utilised when health state utility values are not available for economic evaluation (Rowen 
et al., 2009). SF-36 dimension scores are mapped on to the EQ-5D index using a 
published algorithm (Rowen et al., 2009). In this model, both mother and offspring, 
calculated their utility over one year (52 weeks).  The calculation of the utility over one 
year period is discussed in this section.  
   Before introducing the utility in the mother, it is important to consider the duration 
of pregnancy, as shown in Figure 8.4. The duration of pregnancy in humans is about 9 
months (266 days / 38 weeks) from the time of fertilization until birth. In obstetrics, it is 
considered to begin on the first day of women’s last normal menstrual period prior to 
fertilization, thus beginning approximately 280 days (40 weeks) before birth. Those 40 
weeks, counting from the first day of a woman’s last normal period, are grouped into 
three trimesters. Normally, childbirth occurs about 38 – 40 weeks after conception or the 
last normal menstrual period. The first trimester starts from week 1 to week 12, the 
change in maternal hormones affects almost every organ system in the mothers body. 
Consequently, week 13 to week 28 is the second trimester for gestation, in which the 
maternal abdomen will expand as the baby continues to grow and in which the mother 
feels their baby beginning to move. Lastly, the third trimester starts from week 29 to 
week 40, all of the discomfort from the second trimester continue in addition to many 
more symptoms. This is due to the baby getting bigger and consequently putting more 
pressure on the mother’s organs. Furthermore, pregnancy is considered “at term” when 
gestation has lasted 37 complete weeks, but is less than 42 weeks gestational age. 
Likewise, “full term delivery” refers to gestation having lasted 40 weeks from the first day 
of the mother’s last menstrual period. Events before completion of 37 weeks (259 days) 
are considered preterm.  Delivery after week 42 (294 days) is considered postterm of 
pregnancy. The expected utility of life for the mother in this model is calculated within 1 
year (52 weeks). This model assumed all healthy pregnancies give birth at 40 weeks 
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“full term”. The duration of one year breaks down into two periods of time, which 
includes 40 weeks during gestation and 12 weeks after delivery. Utility calculation is 
shown in the following section. 
 
Figure 8.4 Overlay of trimester, gestational week, and term of pregnancy 
 
Utility of healthy mothers 
   The baseline utility of life refers to healthy mothers with vaginal delivery, 
calculated over 1 year. During the progress of pregnancy hormonal and organ specific 
changes impact physical as well as the mental wellbeing of the mother. A study in 
Switzerland, in 2005, has evaluated the impact of pregnancy on health related quality of 
life (Forger et al., 2005). HRQoL of healthy pregnant women at 29 years old was 
measured by SF-36 and carried out at the following times: one at the first trimester 
(between weeks 9 and 11), one at the second trimester (between 20 and 22), one at the 
third trimester (between weeks 30 and 34), and once each at 6 and 12 weeks 
postpartum.  All eight aspects of SF-36 in the Swiss study were mapped onto EQ-5D to 
present the EQ-5D tariff in healthy pregnancy for each trimester and at 6 and 12 weeks 
postpartum. Then, multiplying the duration of time spent in a “health state” with the EQ-
5D tariff, during gestation, within 40 weeks, the utility of healthy mothers was presented 
for each trimester as 0.97, 0.96, and 0.88, respectively. At 12 weeks postpartum, the 
utility of life for a vaginal delivery based on the first six weeks is a utility of 0.85. The 
remainder of the 6 weeks of normal delivery for recovery is a utility of 0.98. The following 
section will demonstrate how to calculate QALY over one year from the above figure. 
   There were two steps to calculate QALY over one year of health pregnancy. 
Firstly, the utility over the gestational period of healthy pregnancy is calculated simply by 
multiplying the duration of time spent in a health state (40 weeks) by the HRQoL weight 
(utility score), as shown in Table 8.12.  For example, in the 1st trimester, utility was 0.97. 
The utility of the gestational period is calculated by multiplying the utility for each 
trimester (0.97) by the proportion of weeks within the 40 week period, namely 13.3. The 
1st trimester utility was calculated to be 0.323 and the mean utility for the gestational 
period was 0.934, calculated by summing the utilities for each of the three trimesters. 
Secondly, in the postpartum period of 12 weeks, the utility for the first 6 weeks was 0.85. 
As before, the utility for this first period (0.85) was multiplied by its proportion (6 weeks) 
Last menstruation
Fertilisation
First trimester Second trimester Third trimester 
Prenatal development
Embryogenesis Fetal development
Week 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40
Month         
Classification Preterm Term
Childbirth on average
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within the postpartum period of 12 weeks. This is calculated as 0.85*(6/12), equalling 
0.425. The mean utility is then calculated by summing the utilities for the 6 and 12 week 
periods, resulting in 0.915.  
Table 8.12 Utility calculation over gestational and postpartum periods  
 
   The utility over one year (52 weeks) of healthy pregnancy is calculated in this 
section. The gestation utility was calculated to be 0.719 by multiplying the utility 
calculated in the previous section (0.934) by the proportion of the year (52 weeks) that 
the gestation period covers (40 weeks). Likewise, the utility of the post postpartum 
period (0.915) was calculated to be 0.211, calculated by multiplying the utility by the 
proportion of time within the one year period. The mean utility for a healthy mother with 
vaginal delivery is 0.930 over 1 year that includes both gestation and postpartum 
periods, as shown in Table 8.13. 
Table 8.13 Utility calculation over 1 year 
 
 
   Figure 8.5 illustrates the utility of life in healthy pregnancy over 1 year. This 
figure shows the utility (y-axis) for different periods of time (x-axis) covering both 
gestational and postpartum periods in terms of weeks. The EQ-5D tariff in healthy 
pregnancy for each trimester and at 6 and 12 weeks postpartum are plotted. The red 
line is represents the utility over a 1 year period which breaks down into three trimesters 
during gestation and every 6 weeks during postpartum. The purple line represents the 
mean utility of healthy pregnancy over 1 year at 0.93.   
Duration Calculation Utiliy Duration Calculation Utiliy
(1-13 weeks)1st 0.97*(13.3/40) 0.323 6 weeks 0.85*(6/12) 0.425
(13 - 28 weeks) 2nd 0.96*(13.3/40) 0.319 12 weeks 0.98*(6/12) 0.490
(29 - 40 weeks) 3rd 0.88*(13.3/40) 0.293
Mean utility 0.934  Mean utility 0.915
Gestational period  (40 weeks) Postpartum period (12 weeks)
Duration Calculation Utiliy
Gestation (40 weeks) 0.934*(40/52) 0.719
Postpartum (12 weeks) 0.915*(12/52) 0.211
 Mean utility 0.930
Utility over 1 year
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Figure 8.5 Overlay of healthy pregnancy over 1 year 
 
Utility with preeclampsia  
Preeclampsia usually develops sometime after the 20th week of gestation and gets 
better within 6 or 12 months after postpartum (Wagner, 2004). Preeclampsia symptoms 
include severe headache, problems with vision, vomiting and sudden swelling of the 
face, hands or feet and severe pain just below the ribs. Treatment with oral medication 
as first-line can improve maternal quality of life (NICE, 2011). The severity of 
preeclampsia can cause complications for both mother and offspring. There are few 
studies investigating quality of life in mothers with preeclampsia. However, of the studies 
that have been done, most use SF-36. In the Netherlands, Hoedjes studied the HRQoL 
in pregnancy for ages over 18 years who had complications by preeclampsia. The 
HRQoL of Hoedjes’s study stated that women who experienced severe preeclampsia 
had a lower postpartum HRQoL than those pregnancies that had mild preeclampsia.  All 
participants completed the SF-36 at 6 weeks and 12 weeks postpartum after mild and 
severe preeclampsia (Hoedjes, 2011). This model, then maps the SF-36 in Hoedjes 
study to the EQ-5D as described above. In particular for women that have experienced 
severe preeclampsia the EQ-5D tariff at 6 and 12 weeks postpartum were estimated to 
be 0.765 and 0.874, respectively. In this model, all women diagnosed with preeclampsia 
in the 20th week of gestation are assumed to have severe preeclampsia without failure 
in treatment. The benefits of the treatment of preeclampsia were also ignored.  
As no utility for the gestation period was available, to calculate the utility of severe 
preeclampsia, the utility of life is separated into three periods; two 20 weeks periods 
followed by the 12 week postpartum period, as shown in figure 7.6, and a calculation is 
performed for the postpartum period using the EQ-5D tariff from Hoedjes study. The 
utility of life for postpartum with severe preeclampsia was based on the first 6 weeks 
with a utility of 0.765 and the remaining 6 weeks of recovery at a utility of 0.874, as 
illustrated by the red line in Figure 8.6. Therefore, the mean utility of postpartum 
following severe preeclampsia was 0.82, as presented by the broken blue line in the 
postpartum period.  
Utility 
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Figure 8.6 Overlay of utility pregnancy with preeclampsia over 1 year 
 
The mean utility between 0 and 20 weeks gestational was then calculated, with the 
assumption that all women remain in healthy pregnancy before being diagnosed with 
preeclampsia and have a utility of 0.93, as represented by the purple line in the figure. 
This gives a result of 0.465 (0.93*0.5) for the mean utility over the first 20 week period.  
   The utility of the second 20 week period of gestation with preeclampsia was then 
calculated. A purple line was drawn on the figure to represent healthy pregnancy over 
the 52 week period, and at week 20 utility was considered to be 0.93 falling to a utility of 
0.82 at week 40, as shown by the green line in the figure. The average utility during this 
gap period is given by adding the highest and lowest utilities and dividing by 2, i.e. (0.93 
+ 0.82)/2 = 0.874. The utility for this section is therefore 0.874 multiplied by 0.5 which 
equals 0.437. Therefore, the mean utility over the 40 week period for women with severe 
preeclampsia was 0.902.  Utility at 40 weeks (0.902) and at 12 weeks (0.82) are 
multiplied by the proportions of time for both the gestational and postpartum periods in 
the year. This gives a mean utility of 0.88 over 1 year for women with severe 
preeclampsia. 
Utility with hypertension  
Hypertension is a common complication in pregnancy, and is defined as mothers 
diagnosed with a blood pressure of 140/90 or above. On the other hand, preeclampsia is 
a syndrome which includes hypertension and loss of protein in the urine (Xiong et al., 
2002). There is a slight difference in blood pressure between hypertension in pregnancy 
and preeclampsia (Hermida et al., 2000). However, as no data for the utility of life in 
pregnant women who have hypertension was available, this model uses the HRQoL for 
mild preeclampsia in Hoedjes’s study to represent the utility of life for hypertension 
(Hoedjes, 2011).  
As in the previous section SF-36 was mapped into EQ-5D and the HRQol of women with 
mild preeclampsia at 6 weeks and 12 weeks postpartum were estimated to be 0.893 and 
Utility 
1
0.9
0.8
0.7
0.6
0.5
0.4
0.3
0.2
0.1
0 weeks
4 8 12 16 20 24 28 32 36 40 4 8 12
Gestational period Postpartum period
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0.941, respectively. The mean utility at 12 weeks of hypertension was 0.88. To calculate 
the utility of hypertension over 1 year it is best to separate the utility of life into three 
periods as for preeclampsia. Figure 8.7 illustrates those three periods. The same 
technique that was used to calculate utility in preeclampsia was again used to estimate 
utility in hypertension over the gestation (40 weeks) and postpartum (12 weeks) periods. 
During the first 20 weeks, all pregnancy is assumed to be healthy. 0.93 is used to 
represent the health of mothers during this period. After 20 weeks gestation (utility at 
0.93) the utility starts to fall until 40 weeks (utility 0.88) as shown by the green line. The 
average utility is then given by the sum of the highest value and the lowest value divided 
by 2; (0.93+0.88)/2, calculated as 0.905. The utility of the first 20 weeks (0.93) and the 
following 20 weeks (0.905) are multiplied by the proportion of time within the 40 week 
period, equalling 0.464 and 0.453, respectively. Therefore, the mean utility of 
hypertension in pregnancy at 40 weeks was 0.917. The mean utility over 1 year for 
women with hypertension was 0.910, calculated by multiplying the utility for both the 40 
weeks of gestation (0.917) and the 12 weeks postpartum (0.88) with their relative 
proportions of the 52 week period.   
 
Figure 8.7 Overlay of the utility of pregnancy with hypertension over 1 year 
 
A comparison of the utility of hypertension in general with/ without hypertension and 
pregnancy with/ without hypertension is discussed in this section. The systematic review 
of HRQoL in hypertension stated that the quality of life of individuals with hypertension is 
slightly worse than that seen in healthy people. The meta-analysis showed lower quality 
of life in both the MCS score (-1.68: 95% confidence interval -2.14 to -1.23) and the PCS 
score (-2.43: 95% confidence interval -4.77 to 0.88) (Trevisol et al., 2011).  This study 
calculates the figure for HRQoL from a population based study in Sweden by using the 
SF-36 from the study to represent the baseline utility in the general population and also 
compares the HRQoL of people with and without hypertension by age and sex. The 
results obtained for HRQoL in women are used to present the quality of women in the 
general population with and without hypertension. After mapping the SF-36 into EQ-5D, 
the HRQol of women with and without hypertension were 0.73 and 0.86, respectively. 
The difference in HRQoL in both groups is 0.13 per utility. Similarly, the utility difference 
Utility 
1
0.9
0.8
0.7
0.6
0.5
0.4
0.3
0.2
0.1
0 weeks
4 8 12 16 20 24 28 32 36 40 4 8 12
Gestational period Postpartum period
Chapter 8  207 
in hypertension in pregnancy with and without hypertension in this calculation was 0.2 
(0.93 – 0.91). 
Utility with caesarean delivery 
Caesarean delivery might increase the risk of surgical intervention and problems 
resulting from hospitalisation. Consequently, this affects the quality of life for women 
following delivery. This model assumes all pregnant mothers experience caesarean 
delivery without complications at week 40 of gestation. There are only a few studies that 
review quality of life following caesarean section, all of them present the HRQoL using 
SF-36.  Postnatal quality of life in women after caesarean section was studied by Torkan 
and his colleagues in Iran (Torkan et al., 2009). Quality of life of the women in the study 
was measured using SF-36 for two periods of time (time 1: 6 to 8 weeks after delivery; 
time 2: 12 to 14 weeks after delivery). Postpartum quality of life was improved from 
period 1 to period 2. After mapping, the EQ-5D tariff for women with experience of 
caesarean section at 6 and 12 weeks was 0.77 and 0.82, respectively (Torkan et al., 
2009). The postpartum quality of life was calculated from Token’s study. The expected 
quality of life for a caesarean delivery without complications was based on the first 6 
weeks with a utility of 0.77, followed by a utility of 0.82 for the following 6 week, as 
shown in Figure 8.8.  Therefore, the mean utility in the postpartum period (12 weeks) of 
caesarean section was 0.80.  
   To calculate the utility of caesarean sections at 40 weeks of gestation, this model 
assumed that all pregnant women during the gestational period are healthy. The utility of 
healthy pregnancy was calculated as 0.93. Therefore, the utility over 1 year was 
calculated by multiplying the utility estimated for each period by the proportion of each 
period in 52 weeks. The utility for caesarean delivery over one year was found to be 
0.903.     
 
Figure 8.8 Overlay the utility of pregnancy with caesarean section over 1 year 
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8.3.6 Short term complications: QALY over one year in offspring 
The GDM SC for offspring required for this economic model included macrosomia, 
shoulder distocia and metabolic problems. Before calculating the utility of AC in 
offspring, it is necessary to introduce the short and long term complications after having 
macrosomia, shoulder dystocia, metabolic problems and NICU. The beginning of this 
section discusses these short and long term complications in offspring and the details 
are summarised in Table 8.14. 
    Macrosomia has long been associated with an increased risk for mother and 
baby, both during pregnancy and after childbirth, as mentioned in section 4.5. Possible 
maternal complications of foetal macrosomia might include labor problems, genital tract 
LCerations, bleeding after delivery, and uterine rupture. Possible complications of foetal 
macrosomia for babies might include higher than normal blood sugar levels, childhood 
obesity, metabolic syndrome and shoulder dystocia. Macrosomia impacts on the 
offspring in the long term more than short term in terms of complications. It is assumed 
that all mothers who give birth to babies weighing over 4500g, receive caesarean 
sections. This study therefore ignores possible maternal complications after delivery. 
   Shoulder dystocia occurs when a baby’s shoulder is trapped during delivery and 
requires prompt medical attention by delivery room staff or NICU. 20% of babies suffer 
some sort of injury either temporary or permanent following shoulder dystocia delivery.  
Usually, both mother and baby do well and have no permanent complications. In most 
cases injury to nerves in the shoulder, arms and hand, problems go away in 6 – 12 
months.  Regarding serious complications for the newborn, shoulder dystocia can cause 
brain damage, cerebral palsy, permanent brachial plexus injury and bone fracture 
(namely of the clavicle and/or the humerus), contusions and LCerations. These 
conditions can be mild, disappearing in a short period of time, or severe conditions that 
affect a child for the whole of his or her life. They can be significant and debilitation and 
can have a serious impact on the child’s quality of life along with that of his or her 
parents. Babies that have arm paralysis due to shoulder dystocia are often told that 
within a matter of months or a year the arm’s function will return to normal. Paralysis 
does not go away in more severe cases, however a full recovery can be expected in 
cases where nerve injury has been less severe. The injury requires physical therapy and 
rehabilitation and there is loss of quality of life.  
   Neonatal metabolic problems result in increased admissions to Neonatal 
Intensive Care Units (NICU). Jensen et al. showed in their study that about 46.2% of 
offspring with GDM mothers were admitted to a neonatal unit compared to 11.9% of 
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mothers without GDM (Jensen et al., 2000). Neonates require intensive care treatment 
much more than an adult. Approximately 70% of neonates stay 20 days or more in the 
NICU. This prolonged hospitalization suggests that an infant’s intensive care experience 
could inform strategies to minimize the burdens associated with NICU interventions to 
improve HRQoL of the child. On the other hand, long term complications for offspring 
with GDM mother include type 2 diabetes mellitus (DM).  
Table 8.14 Short and long term complications in offspring AC events 
Offspring AC events Short term complications Long term complications 
Macrosomia -Shoulder dystocia 
-Genital tract LCerations  
-Bleeding after delivery  
-Uterine rupture 
-3 days in NICU 
 -type 2 DM 
Shoulder distocia -Nerves of  the shoulder, arms 
and hand 
 (the problem go away in 6 – 12 
months) 
- 1 month in NICU 
- Brain damage 
- Cerebral palsy 
 - Permanent brachial plexus 
injury 
- Bone fracture 
-Type 2 DM 
Metabolic problems 1 week in NICU -Type 2 DM 
 
   For cases that involve an adverse outcome following birth, this model calculated 
the utility for offspring over 1 year (52 weeks) after delivery, including the neonatal 
period (birth to 1 month) and infancy (1 month to 1 year). It is assumed that all offspring 
are delivered at 40 weeks of gestation.  The utility of life for offspring during the 12 
weeks after delivery is calculated based on the consideration of short term complications 
only and for the remaining 40 weeks it is assumed that all offspring return to prefect 
health. Neonatal quality of life cannot readily be studied. The utility in offspring during 
this 12 week period has not been determined in previous studies. Therefore the mean 
utility of macrosomia, shoulder dystocia and metabolic problems in this model has been 
assumed based on the study by Tan and colleagues of the cost-effectiveness of external 
cephalic version for term breech presentation and expert opinions (Tan et al., 2010). 
The study by Tan and his colleagues, assumed the mean utility in NICU’s to be 0.20 
with a utility of 0.66 for the subsequent 2 weeks. For the rest of the period, the utility was 
0.77. This model has adapted the above figures proved by experts in the field as follows.  
Utility with Healthy offspring 
As mentioned above, there are no studies that review quality of life during the neonatal 
period. Perfectly healthy offspring are assumed to be children born by vaginal delivery 
without complications.  The mean utility for healthy neonatal offspring and infants over 
the 40 week period is equal to 1. 
Chapter 8  210 
Utility with macrosomia   
Macrosomia with short term complications are used to estimate utility in offspring in the 
12 weeks after birth. The utility of macrosomia was based on 3 days in NICU at utility of 
0.2.  The following 2 weeks post-delivery utility was 0.66, with a utility of 0.77 for the 
following 8 weeks until there was a return to perfect health. The mean utility of offspring 
with macrosomia at 12 weeks was 0.746,  calculated from the utilities at the three 
different stages (0.2,0.66 and 0.77)  multiplied by their relative proportion of the 12 week 
period, 0.5, 2.5 and 9 weeks respectively. The model assumes all offspring with 
macrosomia subsequently return to perfect health at utility of 1. Therefore, the utility of 
macrosomia over 1 year was 0.94,  calculated by taking the utility for the 12 week period 
(0.746) multiplied by its proportion of 52 weeks and adding it to the utility at 40 weeks (1) 
multiplied by its proportion of the 52 week period. Utility over a 1 year period for 
offspring with macrosomia is displayed in Figure 8.9. 
 
Figure 8.9 Overlay the utility of offspring with macrosomia over 1 year 
 
Utility with shoulder dystocia 
Based on the study by Tan et al. and other expert opinion it was assumed that offspring 
with shoulder dystocia and short term complications require a 4 week stay in NICU with 
a utility of 0.20 and that the following 8 weeks have a utility of 0.77 (Tan et al., 2010), as 
shown in figure 8.10. The mean utility over 12 weeks for shoulder dystocia was 0.58. 
After 12 weeks delivery, all offspring return to perfect health at utility 1. Therefore, utility 
over 1 year with shoulder dystocia was 0.90, calculated from the utility at 12 weeks and 
at 40 weeks multiplied by their proportion of the 52 week period, 12 and 40 weeks, as 
shown in Figure 8.10 
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Figure 8.10 Overlay the utility of offspring with shoulder dystocia over 1 year 
 
Utility with metabolic problems  
The expected quality of life for offspring with metabolic problems and no complications 
was based on the first weeks at NICU with a utility of 0.2 and the remaining 11 weeks 
recovery period with a utility of 0.77. (Tan et al., 2010). The mean utility when there are 
metabolic problems was 0.72 within 12 weeks post-delivery. After 12 weeks, offspring 
return to perfect health at a utility 1. The mean utility over 1 year for offspring with 
metabolic problems and no complications was 0.94 at 52 weeks, as shown in Figure 
8.11.   
 
Figure 8.11 Overlay the utility of offspring with metabolic problems over 1 year 
 
Gamma distributions were set on disutility (disutility = 1 – utility) so that the distribution 
was constrained within the interval zero to infinity, allowing very low and even negative 
utility values. The mean utility value and corresponding SE were reported form the 
literature, and therefore, the method of moment for gamma was used to calculate the α 
and β parameter to fit the Gamma distribution, as shown in Table 8.15.   
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Table 8.15 Short term adverse complication utility parameters in model 
Utility Point estimate Probability  Parameters of distribution Data source 
  distribution Alpha Beta  
Healthy pregnancy      
1
st
 trimester 0.97 Gamma 34.65 1.07 (Forger et al., 2005) 
2
nd
 trimester 0.96 Gamma 50.37 2.10 (Forger et al., 2005) 
3
rd
 trimester 0.88 Gamma 76.24 10.40 (Forger et al., 2005) 
6 weeks postpartum 0.85 Gamma 117.69 20.77 (Forger et al., 2005) 
12 weeks 
postpartum 
0.98 Gamma 52.80 1.08 (Forger et al., 2005) 
Preeclampsia      
6 weeks postpartum 0.76 Gamma 276.69 85.00 (Hoedjes, 2011) 
12 weeks 
postpartum 
0.87 Gamma 225.45 32.50 (Hoedjes, 2011) 
Hypertension      
6 weeks postpartum 0.82 Gamma 136.31 29.32 (Hoedjes, 2011) 
12 weeks 
postpartum 
0.93 Gamma 38.45 32.096 (Hoedjes, 2011) 
Caesarean section      
6 weeks postpartum 0.77 Gamma 153.33 44.01 (Torkan et al., 2009) 
12 weeks 
postpartum 
0.82 Gamma 147.02 32.06 (Torkan et al., 2009) 
Offspring      
Macrosomia 0.93 Gamma 1568.78 79.58 (Tan et al., 2010) 
Shoulder dystocia 0.88 Gamma 157.48 16.90 (Tan et al., 2010) 
Metabolic problems 0.92 Gamma 163.22 11.17 (Tan et al., 2010) 
 
8.3.7 Impact of GDM events (events decrements) 
The HRQol score is a heath utility score which uses weight life years to generate quality 
adjusted life years (QALY). Individuals are rarely in perfect health, with perfect health 
equating to 1 on the scale. A reduction in utility from perfect health is called a utility                
decrement. Various events and complications have the potential to reduce HRQoL. This 
model calculated the utility for seven GDM events and assumed that there is a 
possibility for all pregnant women to experience these events.  In the previous section, 
perfect health has a utility of 0.93 for mothers and 1 for offspring. For these results, the 
utility of AC events were subtracted from the utility for perfect health in both mothers and 
offspring. This event decrement was presented over one year. The GDM event 
decrements rank health from 0.02 (hypertension) to 0.10 (shoulder dystocia), as shown 
in Table 8.16. The greatest reductions in HRQoL were found with shoulder dystocia in 
offspring and preeclampsia in mothers.  
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Table 8.16 GDM event decrements  
 
In previous cost-effectiveness studies of GDM screen tests, different outcome measures 
have been used in the economic evaluation of GDM. The utility decrement for events 
was not presented in any of these studies. This model provides comprehensive and 
nationally representative estimates of the impact of a wide range of GDM events on 
preference weighted HRQoL. These estimates can be used in burden of disease studies 
to estimate the quality of life for mothers and offspring with GDM. The HRQoL 
reductions serve as utility decrements that can be used in economic evaluations to 
quantify the impact of interventions designed to prevent or lessen the quality of life 
impact of GDM.  
8.3.8 Expected costs and QALY for short term complications over 
1 year for mother  
This model assigns a probability value to each outcome branch. The sum of the 
probabilities for all outcome branches of a single chance node must equal one, as 
shown in column probability in Table 8.17. Once, the substituted actual numerical 
variables in each branch apply then the possible decisions by a process called folding 
back (multiplying associated probability by the monetary and QALY values at each 
terminal node) can be used. The sum of those processes is called the expected value. 
This model uses the folding back process in the SC decision tree to present costs and 
QALY in TP, FN, FP and TN.  
   Consequence care costs for GDM are calculated by weighting the costs of SC 
care (costs column) and the baseline parameters of SC (probability column), as shown 
in Table 8.17. The SC care costs for mothers who have preeclampsia with caesarean 
section is the highest cost (£1,750.53). The total cost in each arm of TP, FN, FP, and TN 
were £1,174.11, £ 1,209.29 and £1,086.55, and £1,086.55, respectively.  
Variables QALY over 1 year Utility drecrement at 1 year
Mother
Healty pregnancy 0.930
Preeclampsia 0.883 0.05
Hypertension 0.907 0.02
Caesarean 0.903 0.03
Offspring
Health offspring 1.000
Macrosomia 0.941 0.06
Shoulder dystocia 0.903 0.10
Metabolic problems 0.936 0.06
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   Expected outcomes of QALY are based on the summation of the pathway values 
weighted by the probability in each pathway. Utility decrement was weighted by the 
probability for each AC event. For example, to calculate expected outcomes for 
preeclampsia in the treatment group, the baseline case in the previous section was 
used.  In the disease arm utility decrement at 0.90 (0.94 – 0.04) was multiplied by the 
probability of women with GDM in the treatment group that have experienced 
preeclampsia. Similar calculations were made or the hypertension arm. On the other 
arm, the utility of healthy mothers (0.94) were multiplied by 1 minus the probability of 
women with GDM in the treatment group that have experienced preeclampsia and 
hypertension.    
   However, healthy pregnancy with treatment for GDM involves low side-effects as 
mentioned in chapter 4. Various treatments for type 2 DM may differ in ways that have 
an impact on patient preference and HRQoL. Louis and colleagues studied the utility or 
disutility of diabetes medication-related attributes (weight change, gastrointestinal side 
effect and fear of hypoglycaemia in patient with type 2 DM age between 30 and 75 years 
old in England and Scotland by using the EQ-5D (Matza et al., 2007).  In their study, the 
mean utility of diabetes without complications was 0.89 and the mean utility for patients 
with oral medication only was 0.87. The different between those utilities is 0.002. This 
model therefore assumes this number as the disutility of treatment for GDM in healthy 
pregnancy. The disutility of 0.002 is subtracted from the utility in the FP arm, as shown 
in Table 8.17. 
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Table 8.17 Expected costs and QALY over one year in mother   
 
 
8.3.9 Expected costs and QALY for short term complications over 
1 year for offspring 
Expected SC care costs and QALY over 1 year for offspring are calculated by folding 
back the decision tree, similar to that for SC in mothers. The total costs in each arm of 
TP, FP, FN, and TN were £110.57, £204.02, £107.91 and £107.91, respectively.  
Expected QALY over one year in offspring are shown in Table 8.18. The results for the 
expected utility values show a slight difference from each other.       
 
 
Short term adverse complications Probability Costs(£) Expected cost(£) Utility Expected Utility
True positive (TP)
Preeclampsia+Cesarean 0.026 1,750.53              46.21 0.884 0.0233
Preeclampsia+Normal delivery 0.062 1,232.87              77.00 0.891 0.0557
Hypertension+Cesarean 0.030 1,750.53              51.72 0.908 0.0268
Hypertension+Normal delivery 0.070 1,232.87              86.18 0.914 0.0639
NoAC+Cesarean 0.241 1,488.66              359.00 0.923 0.2226
NoAC+Normal delivery 0.571 971.00                  553.99 0.930 0.5305
1.000 1174.11 0.9229
False negative (FN)
Preeclampsia+Cesarean 0.040 1,750.53              70.54 0.884 0.0356
Preeclampsia+Normal delivery 0.082 1,232.87              101.08 0.891 0.0731
Hypertension+Cesarean 0.045 1,750.53              78.60 0.908 0.0408
Hypertension+Normal delivery 0.091 1,232.87              112.64 0.914 0.0835
NoAC+Cesarean 0.244 1,488.66              363.73 0.923 0.2255
NoAC+Normal delivery 0.497 971.00                  482.71 0.930 0.4623
1.000 1209.29 0.9208
False positive (FP)
Preeclampsia+Cesarean 0.008 1,750.53              13.73 0.884 0.0068
Preeclampsia+Normal delivery 0.038 1,232.87              46.75 0.891 0.0330
Hypertension+Cesarean 0.010 1,750.53              17.03 0.908 0.0086
Hypertension+Normal delivery 0.047 1,232.87              57.99 0.914 0.0421
NoAC+Cesarean 0.154 1,488.66              228.93 0.923 0.1419
NoAC+Normal delivery 0.744 971.00                  722.13 0.930 0.6915
1.000 1086.55 0.9240
True negative (TN)
Preeclampsia+Cesarean 0.008 1,750.53              13.73 0.884 0.0069
Preeclampsia+Normal delivery 0.038 1,232.87              46.75 0.891 0.0338
Hypertension+Cesarean 0.010 1,750.53              17.03 0.908 0.0088
Hypertension+Normal delivery 0.047 1,232.87              57.99 0.914 0.0430
NoAC+Cesarean 0.154 1,488.66              228.93 0.923 0.1419
NoAC+Normal delivery 0.744 971.00                  722.13 0.930 0.6915
1.000 1086.55 0.9260
Chapter 8  216 
Table 8.18 Expected costs and QALY over one year in offspring  
 
8.3.10 Conclusion  
For SC in mothers, Preeclampsia is the most serious complication for GDM and has the 
highest utility decrement in pregnancy. Moreover, preeclampsia remains a leading 
cause of direct maternal deaths in the UK (Milne et al., 2005). Mothers that have had 
preeclampsia are associated with increased long term risks in later life such as acute 
renal failure (1-5%), eclampsia (<1%), liver failure or haemorrhage (<1%), and in rare 
cases stroke and death (NICE, 2011) (Sibai et al., 2005). Therefore, long term 
complications of preeclampsia would not contribute to the overall QALY loss from death 
and stroke. In addition, it was conservatively assumed that most infants born with 
complicaitons do not suffer significant long-term morbidity. However a minority of babies 
will experience much longer term impairment. For example, shoulder dystocia may 
result in permanent brachial plexus dysfunction. 4 -16% of shoulder dystocia cases lead 
to brachial plexus injuries and less than 10% lead to permanent dysfunction (Gherman 
et al., 1998) (Clements, 2001). It would contribute relatively little to the overall QALY 
loss from shoulder dystocia. Therefore, long term complications of shoulder dystocia 
were assumed to not reduce life expectancy of offspring.   
   Preeclampsia and shoulder dystocia or short term complications in general may 
not be adequate to present the effectiveness of screening programmes for GDM. With 
Short term adverse complications Probability Costs(£) Expected cost (£) Utility Expected Utitliy 
True positive (TP)
Macrosomia 0.076 623.71 47.70 0.941 0.0720
Shoulder dystocia 0.014 683.48 9.70 0.903 0.0128
Metabolic problems 0.059 896.45 53.17 0.936 0.0555
NoAC 0.850 0.00 1.000 0.8500
1.000 110.57 0.9903
False negative (FN)
Macrosomia 0.179 623.71 111.61 0.941 0.1685
Shoulder dystocia 0.035 683.48 23.74 0.903 0.0314
Metabolic problems 0.077 896.45 68.68 0.936 0.0717
NoAC 0.710 0.00 1.000 0.7097
1.000 204.02 0.9812
False positive (FP)
Macrosomia 0.097 623.71 60.59 0.941 0.0915
Shoulder dystocia 0.014 683.48 9.24 0.903 0.0122
Metabolic problems 0.042 896.45 38.08 0.936 0.0398
NoAC 0.847 0.00 1.000 0.8469
1.000 107.91 0.9903
True negative (TN)
Macrosomia 0.097 623.71 60.59 0.941 0.0915
Shoulder dystocia 0.014 683.48 9.24 0.903 0.0122
Metabolic problems 0.042 896.45 38.08 0.936 0.0398
NoAC 0.847 0.00 1.000 0.8469
1.000 107.91 0.9903
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the low affect of QALY over one year in mothers and offspring, this model will try to 
examine long term complications in those groups. Long term complications are 
discussed in the next section. 
8.4 Decision analysis of GDM: long term complications 
In long term complications (LC), both mothers and offspring remain at high risk of 
developing type 2 DM in future life (Kim et al., 2002). Three systematic reviews state 
that women who have had GDM have, at least, about a seven-fold increased risk of 
developing type 2 DM in the future compared with those without GDM, as mentioned in 
section 4.5 (Kim et al., 2002) (Kitzmiller et al., 2007) (Bellamy et al., 2009). Moreover, 
Clausen and colleagues studied glucose tolerance in adult offspring born of women with 
and without GDM in Denmark. More than 20% of offspring born to mothers with diet-
treated GDM presented type 2 DM at the age of 22 years. The aim of screening test for 
GDM not only reduced risk of short term complications but also reduced risk of 
developing type 2 DM. Case detection and SC are not the endpoint outcomes for GDM 
screening tests. Therefore, this section constructed a decision analysis and cost-
effectiveness analysis for GDM screening tests to consider both SC (QALY over one 
year) and LC (lifetime QALY of type 2 DM) together in both mothers and offspring. This 
model therefore assumes all pregnant women experience their first pregnancy at age 
26. In LC, costs and outcomes are taken into account at age 28 till 78 years for mothers 
and at age 1 till 78 years for offspring. According to this model, costs and utilities were 
discounted at a baseline rate of 3.5% based on average inflation. 
   This model assumes that long term consequences are conditionally independent 
of SC and therefore no link is drawn between SC and LC. This model assumes that all 
mothers and offspring have a chance to develop type 2 DM in the future. With the 
effective management of GDM, that includes blood glucose monitoring, oral medication 
and regulating insulin, it is assumed that there will be a reduced likelihood of developing 
type 2 DM in both mother and child in LC. Therefore, treatment during gestation is linked 
to the risk of developing type 2 DM in the TP group. Whereas, for mothers without GDM 
that receive treatment (FP) and offspring who are born to such mothers, treatment 
during gestation is not linked to the risk of developing type 2 DM. This section will 
discuss long term complications in both mothers and offspring. .  
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8.4.1 Long term complications in mother: decision tree structure  
Many guidelines suggest postpartum follow up glucose tolerance tests for mothers with 
GDM (WHO, 1999a) (ACOG, 2000) (NICE, 2008d) (American Diabetes, 2004) (Hoffman 
et al., 1998).  This model perform long term complication based on the American 
diabetes Association (ADA) and the Australasian Diabetes in Pregnancy Society 
(ADIPS), guidelines mentioned in section 4.8, women with a history of GDM should test 
their blood glucose by FPG or 2h 75g OGTT within 1-3 days post-delivery. If the test is 
negative, the next test should be delayed until 6-12 weeks after delivery, for women with 
GDM who do not have DM immediately postpartum. Then, mothers should receive a 
confirmation test again around their early postpartum visit using 75g OGTT. If glucose 
levels are normal on all previous follow ups, reassessment of glycaemia should be 
undertaken at a minimum of 3 year intervals (American Diabetes, 2004) (Hoffman et al., 
1998). The construction of the decision tree for LC in mothers in this model is based on 
the above guidelines. Patients with DM are denoted as DM+. Patients without DM are 
denoted as DM-. The decision tree which is based on 4 follow-up type 2 DM postpartum 
screening tests for mothers with a history of GDM begins with two chance nodes for 
mothers with and without GDM, both in receipt of and not in receipt of treatment. Each 
chance node within both of the arms present with two possible pathways, DM+ and DM-, 
as shown in Figure 8.12. For example, during screening in year 1, if the results of the 
tests are found to be normal, mothers should be re-evaluated 3 further times at 3 yearly 
intervals. The decision tree terminates when mothers are diagnosed with DM. The 2 h 
75 g OGTT method assumed to use in all 4 follow-up type 2 DM in mothers with a 
history of GDM.  
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Figure 8.12 Decision tree model for LC in mother 
 
8.4.2 Long term complications in offspring: decision tree 
structure  
There are no guidelines for the screening and treatment of offspring born to mothers 
with a history of GDM. Therefore, the construction of the decision tree map for offspring 
is based on the decision tree for mothers. Each chance node within both arms presents 
with two possible pathways, DM+ and DM-, as shown in Figure 8.13.  
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Figure 8.13 Decision tree model for LC in mother 
 
8.4.3 Long term complications: Baseline probabilities   
Mothers 
In the UK, the average age at first pregnancy is 26 years old (Office for National 
Statistics, 2013). This model therefore assumes all pregnant women experience their 
first pregnancy at age 26. The model for the utility for mothers over a 1 year period after 
delivery was considered from age 27. Therefore, the calculations for utility over a 1 year 
period after delivery were performed for mothers up until age 28. It is reported that in 
England and Wales life expectancy at birth for a newborn baby boy is 78.7 years and for 
a new born baby girl is 82.6, if mortality rates remain the same as they were in 2009-
2011 (Office for National Statistics, 2013). In addition, the average Scottish man and 
women will live to the age of 75.9 and 80.4, respectively (General register office for 
Scotland., 2011). Therefore, this model assumes life expectancy to be 78 years for all 
mothers and all surviving offspring, which is the same life expectancy used in the study 
of cost-effectiveness for GDM and The Office for National Statistic (Werner et al., 2012) 
(Office for National Statistics, 2013). Therefore, the LC in mothers is calculated from age 
28 until age 37. Based on the LC decision tree, mothers are assumed to receive 4 
postpartum screening tests at 1, 3, 6 and 9 year postpartum which should be at age 28, 
31, 34 and 37, respectively.  
    In the TP arm, those women who are diagnosed with GDM will have follow up 
blood glucose tests for the first time at age 28, according to guidelines. Mothers with 
onset DM at age 28 or with abnormal blood glucose levels at age 28 should start 
Decision status Offspring long term outcome
DM+
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DM-
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DM+
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treatment as a normal DM patient. For mothers with GDM who do not present with DM 
at 1 year postpartum, reassessment for glycaemia is performed at a minimum of 3 
yearly intervals at age 31, 34 and 37 respectively. Therefore the rate of development of 
Type 2 DM among mothers with and without GDM is required. Assuming no 
intervention, women with GDM have a 12.6% (95% CI 12.1 -13.9) likelihood of 
progressing to overt DM (Bellamy et al., 2009). Feig and colleagues used a population-
based database to determine the incidence of DM after diagnosis of GDM in Canada.  
21,823 women with GDM in the database showed the incidence of DM rising over the 9 
year study period. The probability of developing DM was 3.7% at 9 months, 4.9% at 15 
months and 13.1 at 5.2 years. By the end of follow up, the incidence was 18.9% at 9 
years. In contrast, the incidence of type 2 DM in women without GDM (n= 637,341) was 
1.95 at 9 years (Feig et al., 2008) .This model used the figures from the study by Feig 
and colleagues to present the rate of development of type 2 DM in mothers with GDM. 
Mothers that have abnormal blood glucose levels in the interval tests are assumed to 
receive treatment as normal DM patients. Mothers that receive treatment for type 2 DM 
are assumed to have a lower chance of developing type 2 DM with complications. This 
model assumes that mothers continue to receive treatment until they die. Mothers with 
normal blood glucose in each interval test remain in perfect health until diagnose with 
type 2 DM.  
   In the other arm, mothers that have a false negative result for GDM  do not 
receive any postpartum screening tests for type 2 DM, do not receive treatment, and 
may have chance to develop type 2 DM. The same rate of development of type 2 DM, 
as mentioned in the above paragraph, was used in the decision tree arms for the false 
negative result for GDM. Moreover, if the mother’s blood glucose levels remain higher 
than normal without treatment over a long period of time, their blood vessels can 
gradually become damaged; high glucose levels can damage nerves, organs and lead 
to serious illness. This may lead to a range of complications (often years after first 
developing diabetes). It is assumed in this model that such mothers may develop type 2 
DM with complications; by the time these mothers are diagnosed, those with Type 2 
diabetes will show signs of complications. The associated serious complications include 
heart disease, stroke, blindness, kidney disease, nerve damage and amputations 
leading to disability and premature mortality.  
 In the disease status of FP and TN, this model assumed mothers present with 
type 2 DM without complications. The Scottish diabetes survey 2001 by NHS Scotland 
reported 247,278 people were diagnosed with diabetes in Scotland, with a prevalence of 
4.7% for both type 1 and type 2 DM. The survey reported the incidence rate (per 
100,000 populations per year) of type 2 diabetes by age group from 2008 – 2011(NHS 
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Scotland, 2012).  This model applies the incident rate in the report for 2011 to baseline 
probabilities of type 2 DM in the general population. This is done by converting the 
incident rate per 100,000 into probabilities. 
Offspring  
The children of type 2 DM or GDM mothers may be prone to developing type 2 DM in 
future life, as mentioned in section 4.3.4 (Weintrob et al., 1996). The prevalence of type 
2 diabetes in the 20 – 24 year age group was found to vary in different subjects; 1.4% in 
non-diabetes and 8.6% in offspring of pre-diabetic mothers. In another study, the 
prevalence of type 2 DM in the adult offspring of women with GDM in the 18 – 27 year 
age group was 11.7% (Clausen et al., 2008). All mothers with GDM in the Clausen study 
received diet and lifestyle treatment. This model assumes the age of offspring that 
develop type 2 DM are between the ages of 20 – 29 years. Additionally the figures in the 
Clausen study are taken to be representative of probability for the offspring of mothers 
with GDM.  
   There are no articles that review the effect of treatment in women with GDM on 
adult offspring with DM. However, in South Australia a multi-centre randomised control 
trial looked at the effect of the treatment of mild GDM compared to no treatment on the 
body mass index (BMI) of 4-5 year olds. The difference between the treatment groups 
was 1.19 (95% CI 0.78 – 1.82), representing very little change in the BMI for the 4-5 
year age group (Gillman et al., 2010). Therefore, this model assumes the relative risk of 
developing type 2 DM in offspring with GDM that is untreated to be 1.19. In mothers 
without GDM (FP and TN) the risk of developing DM in the offspring of women without 
GDM at age 20 – 29 years is used in this arm. This model also applies the Scottish 
diabetes incident rate in this decision tree (NHS Scotland, 2012).  
Considering how the distribution of probability parameters are determined in LC 
for mothers and offspring, Table 8.19 details the prevalence parameters and distribution 
used in the probabilistic analysis. Uncertainty in the prevalence of developing type 2 DM 
in both mothers and offspring were accounted for by fitting a Beta distribution, fitted by 
using the method of moment to find α and β, given the reported mean value and SE 
(Briggs et al., 2006).  
 One of the most common types of parameter used to integrate treatment effects 
into a model are relative risk parameters. Using the relative risk of developing type 2 DM 
in adult offspring of 1.19, results in a negative probability. Relative risk values greater 
than 1 cannot be used and the odds ratio can be employed as an alternative. This is 
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only a possible consequence of relative risk; it is not found with the odds ratio. The 
appropriate distribution for the odds ratio is lognormal.  
Table 8.19 Long term prevalence parameters in model 
Prevalence parameters Point estimate 
 
SE Probability 
distribution 
Data source 
Mothers with GDM     
1 year postpartum  
(onset DM at 28y)  
0.036 0.001 Beta (Feig et al., 2008) 
3 year postpartum  
(onset DM at 31y) 
0.116 0.002 Beta (Feig et al., 2008) 
 6 year postpartum  
(onset DM at 34y) 
0.116 0.001 Beta (Feig et al., 2008) 
9 year postpartum  
(onset DM at 37y) 
0.159 0.002 Beta (Feig et al., 2008) 
Mothers without GDM     
9 year postpartum  
(onset DM at 37y) 
0.020 0.001 Beta (Feig et al., 2008) 
Offspring in Mother with GDM    
Onset DM at 20-29 y 0.214 0.032 Beta (Clausen et al., 2008) 
OR of developing DM 
with untreated GDM 
1.290 0.424 Log normal (Gillman et al., 2010) 
Offspring in mother without GDM    
Age 10-19 years 0.000 0.000 Beta (NHS Scotland, 2012) 
Age 20-29 years 0.002 0.000 Beta (NHS Scotland, 2012) 
Age 30-39 years 0.224 0.001 Beta (NHS Scotland, 2012) 
Age 40-49 years 0.289 0.003 Beta (NHS Scotland, 2012) 
Age 50-59 years 0.144 0.006 Beta (NHS Scotland, 2012) 
Age 60-69 years 0.347 0.008 Beta (NHS Scotland, 2012) 
Age > 70 years 0.726 0.007 Beta (NHS Scotland, 2012) 
 
8.5 Long term complications: life time cost estimates  
Patients with diabetes, over the long term, experience a decrease in quality of life and 
an increase in the use of health care services (Loukine et al., 2012). The costs for long 
term complications include postpartum screening for diabetes and treatment costs for 
type 2 DM with and without complications. For postpartum screening tests, mothers with 
TP and FP receive postpartum screening for diabetes after 6 weeks, then at an interval 
of at least once every 1-2 years for women with normal glucose tolerance. The 
postpartum follow up for type 2 DM is screened for by using a 2 hour 75g OGTT and 
costs £18.76 a time (NICE, 2008a).  
   Treatment costs for type 2 DM were obtained from UKPDS 65. The UKPDS 65 
estimated costs based on patient-level data from a randomised clinical controlled trial 
involving 5,102 UKPDS patients, mean age 52.4 years at diagnosis (Clarke et al., 2003). 
This study was conducted in 23 hospital-based clinics in England, Scotland and 
Northern Ireland as part of the UK Prospective Diabetes Study (UKPDS). This study 
presents estimated annual hospital in-patient costs, conditional on some in-patient cost 
being incurred and the expected mean in-patient costs of complication were found to be 
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£2,543 (95% CI 2,406-2,697) and £157 (95% CI 145-170), respectively. For out-
patients, the estimated costs, conditional on cost being incurred, and the expected mean 
annualised non-in-patient costs were £70 (95% CI 66-76) and £159 (95% CI 149-173), 
respectively.  This model uses those figures to present annual costs for type 2 DM with 
and without complications.   
   The cost parameters and distributions used in the probabilistic analysis are 
detailed in Table 8.20. The relevant costs were calculated by adjusting the costs in other 
years to be equivalent to those in 2011, as mentioned in section 7.5.2. As they are fixed 
costs it is appropriate to hold the costs of screening tests for post partum follow up 
constant in the probabilistic analysis. A normal distribution is suitable to represent the 
unit cost parameters in both in-patients and out-patients, and the SE value was 
calculated from a 95% CI range.  
Table 8.20 Long term cost parameters in the model 
Cost (annual hospital) Point estimate 
(£) 
SE Probability 
distribution 
Data source 
Screening test     
postpartum follow up 18.76  Deterministic (NICE, 2008a) 
No complications      
In-patient costs 2,973.00 86.79 Normal (Clarke et al., 2003) 
Out-patient costs 82.57 2.98 Normal (Clarke et al., 2003) 
With complications     
In-patient costs  183.55 7.46 Normal (Clarke et al., 2003) 
Out-patient costs  187.75 4.18 Normal (Clarke et al., 2003) 
 
   Life time costs for mother and offspring with diabetes are shown in Table 8.21. 
Life time costs of type 2 DM without complications are about 1.1 times lower than life 
time costs for type 2 DM with complications. Life time cost of type 2 DM with an onset at 
age 20 – 29 presented with the highest value at £ 170,518.85.  
Table 8.21 Life time costs for mothers and offspring by disease status  
 
Age at diagnosis Disease status Cost (£)
Mother 
1 year postpatum(onset at 28y) DM + 147,397.65        
DM + with C 165,523.56        
3 year postpatum(onset at 31y) DM + 138,727.20        
DM + with C 155,786.88        
6 year postpatum(onset at 34y) DM + 130,056.75        
DM + with C 146,050.20        
9 year postpatum(onset at 37y) DM + 121,386.30        
DM + with C 136,313.52        
Offspring
On set at 20-29 DM + 170,518.85        
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8.6 Life table and life expectancy  
This model estimates the life time health outcomes for mothers and offspring with and 
without type 2 DM and calculates outcomes in terms of mean life expectancy (LE), 
defined as the average number of years a person life expectancy is.  Moreover, they can 
also be used to estimate future health care costs for patients with type 2 DM and quality-
adjusted life expectancy, which will be mentioned in the next section. This calculation 
starts with life tables for both mothers and offspring at different ages. Complete life 
tables are a convenient way to analyse age specific death rates and are a standard 
demographic tool which are used to outline life expectations for a range of ages 
(Wesley, 1998). This model created life tables for mothers and offspring based on 
mortality rate data from the Office for National Statistic in order to estimate life 
expectancy (Office for National Statistics, 2013). Life tables for mothers and offspring 
with perfect health start at age 27 and age 1, respectively.  
   Life table analysis was applied to calculate the life expectancy impact of DM. To 
calculate the life expectancy for Patients with type 2 DM (DM+), mortality rates from the 
Office for National Statistics are multiplied by relative differences in death rates to 
diabetes sourced from population-based cohorts of 4,842 people with diabetes living in 
South Tees in the UK (Roper et al., 2002). This study reported the death rate per 1,000 
person-years of type 2 DM at ages 40-59, 60-79 and 80+ as 22.14, 57.12 and 155.56, 
respectively, and relative risk (RR) to the all-cause mortality rate of type 2 DM at ages 
40-59, 60-79 and 80+ were 3.30 (95% CI 2.15-3.95), 1.41  (95% CI 1.28-1.56) and 1.09 
(95% CI 0.92-1.29), respectively. The death rate reported in this study was not used 
because death rates per 1000 are particular to the population studied and are likely to 
differ from this particular population. Relative rates are generally thought to be more 
generalisable and give a better estimate of the underlying/baseline rate from UK life 
tables. 
One of the most common types of parameter used to integrate life tables into a 
model are relative risk parameters. The appropriate distribution for the RR is lognormal. 
The various RR used in probabilistic analysis are detailed in Table 8.22.  
Table 8.22 DM parameters in model 
Prevalence parameters Point estimate 
 
SE Probability 
distribution 
Data source 
Death with DM     
Age 30-49 years 3.15 0.116 Log normal (Roper et al., 2002) 
Age 50-64 years 1.41 0.344 Log normal (Roper et al., 2002) 
Age 65-74 years 1.09 0.086 Log normal (Roper et al., 2002) 
 
Chapter 8  226 
8.7 Long term complications: quality-adjusted life 
expectancy  
UK Population Norms for EQ-5D were used to calculate quality-adjusted life expectancy 
in healthy mothers and offspring. The EQ-5D result is nationally representative of 3,395 
men and women aged 18 or over living in the UK interviewed for the survey (Paul et al., 
1999). The mean weighted health state index by age and standard region (Scotland) are 
used to calculate the quality-adjusted life expectancy in healthy offspring.  Moreover, the 
mean weighted health state index by age and standard region (Scotland) for females is 
used to calculate the quality-adjusted life expectancy in healthy mothers. Life 
expectancy for each age in the life tables were multiplied by the mean utility in each age 
group of EQ-5D to present quality-adjusted life expectancy in healthy mothers and 
offspring. Mothers with GDM may be concerned about how their babies will be affected 
in the future, and this could have an additional impact on the utility of the mothers. 
However, in this model, the utility of mothers with GDM is calculated from the health 
related quality of life for short and long term complications. Consequently, the disutility of 
mothers with relation to their offspring was ignored. 
   The utilities from UK population Norms for EQ-5D are suited to a Beta 
distribution, by using the method of moment to fit Beta distribution to the utility data. 
Table 8.23 details the utility and distributions used in probabilistic analysis in terms of 
calculating quality-adjusted life expectancy in a normal population.   
Table 8.23 UK population Norms for EQ-5D in all sexes and females in Scotland  
Utility Point estimate 
 
SE Probability 
distribution 
Data source 
UK Population Norms for EQ-5D (all sexes)   
Under 25 year 0.950 0.015 Beta (Paul et al., 1999) 
Age 25 – 34 years 0.910 0.021 Beta (Paul et al., 1999) 
Age 35 – 44 years 0.920 0.019 Beta (Paul et al., 1999) 
Age 45 – 54 years 0.880 0.035 Beta (Paul et al., 1999) 
Age 55 – 64 years 0.820 0.027 Beta (Paul et al., 1999) 
Age 65 – 74 years 0.730 0.043 Beta (Paul et al., 1999) 
Over 75 years 0.7840 0.045 Beta (Paul et al., 1999) 
UK Population Norms for EQ-5D (female)   
Under 25 year 0.950 0.024 Beta (Paul et al., 1999) 
Age 25 – 34 years 0.890 0.031 Beta (Paul et al., 1999) 
Age 35 – 44 years 0.900 0.029 Beta (Paul et al., 1999) 
Age 45 – 54 years 0.910 0.025 Beta (Paul et al., 1999) 
Age 55 – 64 years 0.810 0.041 Beta (Paul et al., 1999) 
Age 65 – 74 years 0.680 0.064 Beta (Paul et al., 1999) 
Over 75 years 0.750 0.059 Beta (Paul et al., 1999) 
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8.7.1 Quality-adjusted life expectancy with DM 
DM occurs as a result of GDM, therefore, quality of life associated with diabetes mellitus 
was assumed to represent the QALY in LC for GDM. In fact, individuals with diabetes 
have reduced HRQol compared with those without diabetes in the same age group with 
diabetes-related complications (Solli et al., 2010). The effect of DM on Quality of life has 
been addressed by a number of authors (Diabetes Control and Complications Trial 
Research Group, 1996) (Testa et al., 1998) (Hanninen et al., 1998) (Wu et al., 1998) . 
Various tools that have been employed to estimate quality of life in diabetes including 
SF-36 (Ware and Sherbourne, 1992) (Wu et al., 1998), SF-20 (Hanninen et al., 1998), 
EQ-5D (Solli et al., 2010) and others (Testa et al., 1998) (Brown et al., 2000). In Norway, 
the study in HRQol in diabetes mellitus was conducted on 1,000 individuals with type 1 
and type 2 diabetes using EQ-5D (Solli et al., 2010). All patients with DM completed EQ-
5D questionnaires by using a time trade-off method. For DM without complications, the 
EQ-5D index for type 2 DM was 0.85 (95%CI 0.82-0.87). There was another study in the 
Netherlands which aimed to estimate the HRQoL and treatment satisfaction for patients 
with type 2 DM (Redekop et al., 2002). Of the 1,348 Dutch type 2 DM patients surveyed, 
the EQ-5D utility scores reported by age groups <50 years, 50-59 years, 60-69 years 
and equal and over 70 years were 0.79 (SD 0.26), 0.75 (SD 0.26), 0.78 (SD 0.25) and 
0.70 (SD 0.28), respectively. To calculate the quality adjusted life expectancy with DM, 
this model used all utility figures from the Netherlands study and multiplied them by the 
life expectancy in each age group. In order to determine QALY after type 2 DM 
develops, this model assumes all patients who received screening and treatment do not 
suffer from any complications of DM until the end of their life at age 78.  
   The HRQol in type 2 DM is appropriate for a Beta distribution, by using the 
method of moment to fit Beta distribution to the utility data. Table 8.24 outlines the utility 
and distributions used in probabilistic analysis with respect to the calculation of quality-
adjusted life expectancy in patients with type 2 DM.   
Table 8.24 HRQol in type 2 DM 
Utility Point estimate 
 
SE Probability 
distribution 
Data source 
HRQoL in type 2 DM    
Under 50 year 0.790 0.008 Beta (Redekop et al., 2002) 
Age 50 - 59 years 0.750 0.008 Beta (Redekop et al., 2002) 
Age 60 – 69 years 0.780 0.007 Beta (Redekop et al., 2002) 
Over 75 years 0.700 0.008 Beta (Redekop et al., 2002) 
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8.7.2 Quality-adjusted life expectancy with DM with 
complications  
Diabetes without treatment results in high glucose levels in the blood, which can 
damage nerves, organs and lead to serious illness. Diabetes with complications leads to 
poor health, premature mortality, and to a reduction of life expectancy and quality-
adjusted life expectancy (Loukine et al., 2012). 
  In the Solli and colleagues study, the EQ-5D dimensions were able to capture 
diabetes related complications with the strongest determinants of reduced HRQoL as 
being ischemic heart disease, stroke and neuropathy. For type 2 DM with complications 
the EQ-5D index was 0.73 (95% CI 0.69-0.78) and for more than 2 complications it was 
0.64 (95%CI 0.56-0.71) (Solli et al., 2010).  
The two figures of EQ-5D in diabetes with complications in this study are used to 
calculate life time QALY of DM with complications. This model assumes that patients 
develop type 2 DM and that when they receive a diagnosis, those with Type 2 DM will 
present with a single complication. Moreover, this model assumes that twenty years 
after diagnoses patients will present with more than 2 complications.  
   The HRQol in type 2 DM with complications suits a Beta distribution, by using 
the method of moment to fit Beta distribution to the utility data. Table 8.25 details the 
utilities and distributions used in probabilistic analysis in terms of calculating quality-
adjusted life expectancy in patients presenting with type 2 DM with complications. 
Table 8.25 HRQol in type 2 DM with complication 
Utility  Point estimate 
 
SE Probability 
distribution 
Data source 
HRQoL in type 2 DM with 
complication 
   
Type 2 DM with any 
complication 
0.730 0.082 Beta (Solli et al., 2010) 
Type 2 DM with >2 
complications 
0.640 0.038 Beta (Solli et al., 2010) 
 
 Table 8.26 presents the results of life expectancy for mothers with DM- and 
DM+. The total life years of mothers at age 27 with perfect health and for those suffering 
from DM with no complications were 74 (27+47.79) and 72 (27+45.85), respectively.  
The life expectancies for DM in this model were slightly high. The low mortality rate of 
diabetes identified in the paper by Roper and colleagues (2002) may influence the high 
life expectancy in mothers with DM. 
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Table 8.26 Estimates of life expectancy and Quality-adjusted life expectancy in mothers by 
age at diagnosis of type 2 DM  
 
However, life expectancy based on these calculations gives a similar result as the 
United Kingdom Prospective Diabetes Study (UKPDS) outcome model (UKPDS no.68). 
The UKPDS developed a simulation model for type 2 DM that can be used to estimate 
the likely occurrence of major diabetes-related complications over a lifetime, in order to 
calculate life expectancy and quality adjusted life year (Clarke et al., 2004). Table 8.27 
shows a comparison of the estimate of life expectancy and quality-adjusted life 
expectancy with DM by age at diagnosis of type 2 DM, and as can be seen, the results 
for estimated life expectancy in mothers show similar results to the UKPDS study 
(Clarke et al., 2004).  
Table 8.27  Estimations of life expectancy with DM+ by age at diagnosis of type 2 DM  
 
The same method is used to calculate life expectancy in offspring; life 
expectancies of offspring with and without DM in the 20-29 age groups were 74 (20+ 
54.82) and 72 (20+52.41) years, respectively, as show in Table 8.28. This estimate is 
slightly similar to the UKPDS study. For the 50-54 age groups, the UKPDS outcome 
model reported life expectancy and quality-adjusted life expectancy with DM to be 23.58 
and 17.62, respectively. Again this estimate is similar to the results for the 50-59 age 
groups. Life expectancy and quality-adjusted life expectancy with DM are 25.94 and 
25.26, respectively. 
Mother Life time  Life year lost QALY QALY lost 
1 year postpatum(onset at 28y) DM- 47.79 39.84
DM + 45.85 1.94 35.17 4.67
DM + with C 31.95 7.89
3 year postpatum(onset at 31y) DM- 44.84 37.21
DM + 43.00 1.84 32.92 4.29
DM + with C 29.86 7.35
6 year postpatum(onset at 34y) DM- 41.90 34.59
DM + 40.18 1.72 30.69 3.90
DM + with C 27.80 6.79
9 year postpatum(onset at 37y) DM- 38.97 31.96
DM + 37.41 1.56 28.49 3.47
DM + with C 25.76 6.20
Age Life expectancy Qauality-adjusted life expectancy 
DM+ DM+ (UKPDS) DM+ DM+ (UKPDS)
45-49 30.27 26.80* 22.82 20.26*
50-54 25.95 23.58* 19.38 17.62*
55-59 22.32 20.16* 14.64 15.10*
60-64 17.02 17.65* 12.68 13.15*
*Based on Table 5 in study UKPDS no.68
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Table 8.28  Estimate of life expectancy and Quality-adjusted life expectancy with DM in 
offspring by age at diagnosis of type 2 DM  
 
  
8.7.3 Expected costs and QALY for long term complications in 
mothers  
The probabilities in section 8.4.3 were assigned to each of the outcomes in the decision 
tree branches. Then, the expected costs and quality-adjusted life expectancy of LC in 
offspring were calculated by multiplying the substituted actual numerical variables in 
each branch with the monetary cost and QALYs. This model uses the folding back 
technique to calculate costs and QALYs in TP, FN, FP, and TN, as shown in Table 8.29. 
The highest expected life time costs for LC were £57,073.81 in FN. The lowest expected 
quality-adjusted life expectancy was 30.57 in FN. However, the results of expected 
QALYs should be ordered from the worst outcomes to the best, namely FN, TP, FP and 
TN, respectively. For the expected QALYs for long term complications, the FP (31.96) 
arm appears to be associated with greater expected QALYs than TP (31.64). As 
mentioned at the end of section 8.4, long term consequences are conditionally 
independent of SC and therefore no link is drawn between SC and LC. For mothers in 
the FP groups, disutility is taken into account for SC. Therefore, the FP group appears to 
be lower than TP for SC. With the low side effects of treatment during gestation, the 
effects will disappear after delivery. Mothers with FP tests have a chance to receive 
postpartum screening which will allow the early detection of type 2 DM. Moreover, 
mothers with FP from SC have an opportunity to receive post partum screening to 
prevent type 2 DM with complications. Mothers with FP from SC therefore receive 
additional benefit from this screening with respect to LC. Therefore, the FP arm presents 
with greater expected QALYs than the TP arm in LC.  
Offspring Life time  Life year lost QALY QALY lost 
Onset at 10-19 y DM- 64.70 56.53
DM + 62.29 2.41 48.23 8.31
Onset at 20-29 y) DM- 54.82 47.14
DM + 52.41 2.41 40.42 6.72
Onset at 30-39 y DM- 45.04 37.99
DM + 42.67 2.37 32.72 5.27
Onset at 40-49 y DM- 35.38 29.12
DM + 33.67 1.70 25.58 3.53
Onset at 50-59 y DM- 25.94 20.57
DM + 25.26 0.68 18.88 1.69
Onset at 60-69 y DM- 16.88 12.80
DM + 16.56 0.32 12.35 0.45
Onset at >70 y DM- 8.18 6.01
DM + 8.11 0.07 5.68 0.33
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Table 8.29 Expected lifetime costs and QALY in mothers 
 
8.7.4 Expected costs and QALY for long term complications in 
offspring 
Based on the probabilities in section 7.4.3, this model assigns a probability value to 
each outcome branch. The sum of the probabilities of all outcome branches from a 
single chance node must equal one. The substituted actual numerical variables in each 
branch were multiplied by the monetary costs and QALYs. The sum of those processes 
is called the expected value of the node. This model folded back the LC decision tree to 
present costs and QALYs in TP, FN, FP, and TN, as shown in table 7.22. Table 8.30 
shows the expected life time cost and quality-adjusted life expectancy in offspring.  The 
expected cost in FN was the highest costs at £26,366. Whereas, offspring born with 
GDM mothers without treatment showed the lowest life time QALY at 46.16. Expected 
QALYs for FP is 47.14, a value that is greater than the expected QALYs for TP (46.35). 
This is also the case for TP and FP outcomes for expected QALYs in mothers in the 
previous section.  Children with GDM mothers may be more prone to developing type 2 
DM in future life than children born to mothers without GDM, for the same reason that 
offspring born to FP mothers have a lower risk of developing type 2 DM than offspring 
Age onset DM after postpartum Probabiltiy Life time cost (£) Expected costs(£) life time QALY Expected QALY
True positive (TP)
Screening at 1 year (onset at 28y) DM+ 0.0357 155,834.07             5,557.14                 35.17 1.25
Screening at 3 year (onset at 31y) DM+ 0.1117 146,686.12             16,380.17              32.92 3.68
Screening at 6 year(onset at 34y) DM+ 0.0987 137,538.18             13,580.14              30.69 3.03
Screening at 9 year (onset at 37y) DM+ 0.1198 128,390.23             15,384.98              28.49 3.41
Screening at 9 year (onset at 37y) DM- 0.6341 75.06                       47.60                      31.96 20.27
1.0000 568,523.67             50,950.02              31.64
False negative (FN)
NoScreening at 1 year (onset at 28y) DM+ 0.0357 174,770.37             6,232.42                 31.95 1.14
NoScreening at 3 year (onset at 31y) DM+ 0.1117 164,489.76             18,368.27              29.86 3.33
NoScreening at 6 year (onset at 34y) DM+ 0.0987 154,209.15             15,226.19              27.80 2.74
NoScreening at 9 year(onset at 37y) DM+ 0.1198 143,928.54             17,246.93              25.76 3.09
NoScreening at 9 year(onset at 37y) DM- 0.6341 0.0000 0.00 31.96 20.27
1.0000 637,397.82             57,073.81              30.57
False positive (FP)
Screening at 1 year (onset at 28y) DM+ 0.0002 155,834.07             35.84 35.17 0.01
Screening at 3 year (onset at 31y) DM+ 0.0011 146,667.36             165.60                    32.92 0.04
Screening at 6 year(onset at 34y) DM+ 0.0011 137,500.65             155.08                    30.69 0.03
Screening at 9 year (onset at 37y) DM+ 0.0011 128,333.94             144.58                    28.49 0.03
Screening at 9 year (onset at 37y) DM- 0.9964 75.06                       47.60                      31.96 31.85
1.0000 568,411.08             548.69                    31.96
True positive (TN)
NoScreening at 1 year (onset at 28y) DM+ 0.0002 155,834.07             35.84                      35.17 0.01
NoScreening at 3 year (onset at 31y) DM+ 0.0011 146,667.36             165.60                    32.92 0.04
NoScreening at 6 year (onset at 34y) DM+ 0.0011 137,500.65             155.08                    30.69 0.03
NoScreening at 9 year(onset at 37y) DM+ 0.0011 128,333.94             144.58                    28.49 0.03
NoScreening at 9 year(onset at 37y) DM- 0.9964 0.00 0.00 31.96 31.85
1.0000 568,336.02             501.09                    31.96
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born to TP mothers. Therefore, offspring born to FP mothers appear to be associated 
with greater expected QALYs than those born to TP mothers.  
Table 8.30 Expected life time costs and QALY in offspring 
 
8.8 Conclusion 
The process of populating the outcomes of screening tests for GDM models involves 
bringing together all the relevant evidence and synthesizing it appropriately in terms of 
input parameters within the model. This study defines SC mothers as hypertensive, and 
as having preeclampsia and caesarean sections and the SC for offspring include 
macrosomia, metabolic problems and shoulder dystocia. The SC show very low impact 
on QALYs in mothers with GDM.  Therefore, this economic evaluation of screening tests 
for GDM takes into account the LC in both mothers and offspring to show the large 
impact of screening programs. This cost-effectiveness study of screening tests for GDM 
also presented the results in four different outcomes. Mothers with FN showed 
significant high treatment costs and low QALYs when compared to other outcomes. 
Therefore, in the negative dominated strategy there is a probability of false negative 
case identification and the likelihood of higher costs and expenditure for the treatment of 
SC and LC.  On the other hand, the PDS showed a probability of FN, while the cost of 
treating false negatives FP was not high and QALY was similar to that of healthy 
pregnancy. However, the results from chapter 7 were based on a deterministic model. 
The next chapter will present the results of cost-effectiveness analysis based on a 
probabilistic model, which might give different results.  
Long term complications Probability Costs(£) Expected cost (£) Utility Expected Utitliy 
True positive (TP)
DM+ 0.1173 180278.63 21,140.17             40.42 4.74
DM- 0.8827 47.14 41.61
1.0000 21,140.17             46.35
False negative (FN)
DM+ 0.1463 180278.63 26,366.00             40.42 5.91
DM- 0.8537 47.14 40.24
1.0000 26,366.00             46.16
False positive (FP)
DM+ 0.0002 180278.63 41.46 40.42 0.0093
DM- 0.9998 47.14 47.13
1.0000 47.14
True negative (TP)
DM+ 0.0002 180278.63 41.46 40.42 0.0093
DM- 0.9998 47.14 47.13
1.0000 47.14
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Chapter 9 A decision analysis for the cost-
effectiveness analysis of screening tests for 
gestational diabetes mellitus  
  
9.1 Introduction 
In the previous chapter, having detailed the development of the models for screening 
tests for GDM and how they were parameterised for both mothers and offspring, this 
chapter presents the deterministic and probabilistic results. In the models, the 
effectiveness of screening tests for GDM were measured in quality adjusted life years 
(QALY) with regard to short and long term complications. The beginning of this chapter 
details the deterministic results for each model reporting the incremental cost per QALY 
gain in short term complications and life time QALY in long term complications. In the 
subsequent section, an exploration of uncertainty through probabilistic sensitivity 
analysis and value of information analysis is reported.  
9.2 Deterministic results 
The models of screening tests for GDM were developed in order to estimate costs and 
outcomes in both mothers and offspring of four alternative strategies versus a strategy 
of “no screening”. In this economic evaluation, decision trees are designed to assess the 
five strategies of GDM and were built based on the combinations of test approaches that 
include the negative dominant strategy (NDS) and the positive dominant strategy (PDS).  
Eight strategies were employed for a comparison of cost-effectiveness analysis, as 
mentioned in section 7.7.2. The evaluations were undertaken from a health care 
provider’s perspective (NHS) to inform policy makers on this important issue by 
establishing the optimal cost-effective screening and diagnostic tests of GDM. This 
section presents the deterministic results in both short and long term complications.  
9.2.1 Short term complications  
The costs and consequences in terms of QALY of short term complications from both 
mothers and offspring are added up to present the cost-effectiveness of GDM screening 
tests for short term complications. In the mother, the expected costs include screening 
test costs, treatment care costs during gestation period, and treatment care costs for 
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adverse complications during gestation delivery. In offspring, the only expected costs 
taken into account are treatment care costs for adverse complications.    
   The total cost and QALYs generated for each strategy under the baseline 
assumptions are presented in Table 9.1. In the mother, costs and QALY in short term 
complications are presented as C1 and Q1. Similarly, C2 and Q2 are costs and QALY of 
short term complications in offspring. Costs in both short (C1) and long (C2) term 
complications are added up to present the total cost of screening for GDM in each 
strategy. Similarly, QALY gained for screening tests of GDM include both mothers (Q1) 
and offspring (Q2) term.  S5 has the lowest cost (£1,202), whereas the highest QALY 
gain is for S3 (1.9162) for screening tests of GDM in short term complications.     
Table 9.1 Summaries of short term complications in mothers and offspring  
 
Table 9.2 presents the analysis of the incremental cost-effectiveness ratios (ICER) for 
the analysis of screening tests for GDM in short term complications. The ICER examines 
the additional costs that one strategy incurs over another and compares this with the 
additional benefits. The alternative screening test strategies are ranked according to 
their costs. S5 has the lowest cost but not the highest QALY gain when compared with 
the other strategies. Next, S2 (NDS) and S4 (NDS) are seen to be more costly and have 
less QALY gained than S1 (NDS). Therefore, S2 (NDS) and S4 (NDS) are dominated by 
S1 (NDS). S3, which is less expensive and highly effective, dominates over S1 (PDS), 
S4 (PDS) and S2 (PDS). The screening test strategies that are the most expensive and 
less effective are then excluded and the ICER recalculated again.  
Strategy
Costs(C1) QALY(Q1) Costs(C2) QALY(Q2) Costs (C1+C2) QALY (Q1+Q2)
S1 (NDS) 1,108                 0.9259 109                            0.9902 1,217                      1.9161
S2 (NDS) 1,106                 0.9259 111                            0.9900 1,216                      1.9159
S3 (NDS) 1,112                 0.9259 108                            0.9903 1,220                      1.9162
S4 (NDS) 1,109                 0.9259 110                            0.9901 1,219                      1.9160
S5 (NDS) 1,091                 0.9259 111                            0.9900 1,202                      1.9158
S1 (PDS) 1,158                 0.9247 108                            0.9903 1,266                      1.9150
S2 (PDS) 1,165                 0.9247 108                            0.9903 1,273                      1.9150
S3 (PDS) 1,112                 0.9259 108                            0.9903 1,220                      1.9162
S4 (PDS) 1,147                 0.9252 108                            0.9903 1,255                      1.9155
S5 (PDS) 1,091                 0.9259 111                            0.9900 1,202                      1.9158
Mothers Total
Short term adverse complications
Offspring
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Table 9.2 Cost per QALY gain in screening tests for GDM in short term complications in 
mother and offspring 
 
The ICER was recalculated for S5, S1 (NDS) and S3 after excluding the dominated 
screening strategies, S2 (NDS), S4 (NDS), S1 (PDS), S4 (PDS) and S2 (PDS), as 
shown in Table 9.3.  
Table 9.3 Exclusion of more costly and less effective alternatives 
 
S5 is the “Do Nothing” strategy and represents the comparator in this model. S5 is less 
costly than the other screening strategies as there are no screening costs associated 
with the strategy. Additionally as S5 involves no screening the only possible results for 
both mothers and offspring are false negative (FN) and true negative (TN).  
   The next most effective strategies are S1 (NDS) and S3 when costs and 
effectiveness are compared with S5. S1 (NDS) and S3 are universal screening 
strategies developed by SIGN 2001 and Consensus 2010, respectively (SIGN, 2010) 
(Moses, 2010).  S1 (NDS) is therefore the second most cost-effective screening strategy 
for short term complications in mothers and offspring, as it was for case identification, as 
mentioned in sections 7.7.2.    
    Figure 9.1 presents the CE plane for short term complications, with an x-axis of 
QALY over one year and y-axis of costs in pounds sterling. The total costs and total 
effectiveness for each strategy are plotted on the CE plane. On this plane, the screening 
test strategies are plotted against S5, shown as the origin of the graph. As can be seen 
from the graph, for S5 the costs and QALY gained per year were £1,202 and 1.9158 
respectively. Extended dominance is also illustrated in the figure; S4 (NDS) is 
Strategy
Costs (£) Effects Incremental costs Incremental effect ICER 
 [C]  [E] [C]  [E] [C/E]
S5 1,202                 1.9158 0.00 0.0000 0
S1 (NDS) 1,217                 1.9161 14.47 0.0003 46760
S2 (NDS) 1,216 1.9159 -0.56 -0.0002 2515 Dominate
S4 (NDS) 1,219 1.9160 2.56 0.0001 27250 Dominate
S3 1,220                 1.9162 0.92 0.0002 4282
S1 (PDS) 1,266 1.9150 46.36 -0.0012 0 Dominate
S4 (PDS) 1,255 1.9155 -11.37 0.0005 0 Dominate
S2 (PDS) 1,273 1.9150 18.75 -0.0005 -38914 Dominate
Strategy
Costs (£) Effects Incremental costs Incremental effect ICER 
 [C]  [E] [C]  [E] [C/E]
S5 1,202                 1.9158 0 0.0000 0
S1 (NDS) 1,217                 1.9161 14 0.0003 46760
S3 1,220                 1.9162 3 0.0001 33969
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dominated by S2 (NDS) and S1 (NDS). If S4 (NDS) is used to screen all patients in the 
population, this will cost £1,219 and the total effectiveness will be 1.9160. However, 
1.9160 effectiveness units can be achieved at a low cost by using a combination of S2 
(NDS) and S1 (NDS).   
 
Figure 9.1 the cost-effectiveness plane for short term complications 
 
9.2.2 Long term complications in mothers and offspring 
In the previous section, the cost-effectiveness analysis is presented as short term 
clinical outcomes for both mothers and offspring in terms of costs and QALY over 1 
year. An economic evaluation requires the analytical timeframe to cover a period of time 
that takes into consideration the final outcome relevant to the decision being made. In 
this section, the costs and QALY for short term and long term complications in mothers 
and offspring are added up to represent long term complications in GDM. The total costs 
included the cost of treatment during gestation, short term complication treatment costs 
and lifetime treatment costs for type 2 DM, while the utility included QALY over one yere 
and health-related quality of life for type 2 DM in mothers and offspring.  
   With the same GDM prevalence of 3.5% as before, the long term costs and 
consequences in both mothers and offspring are presented in Table 9.4 in terms of cost 
and effectiveness. Costs in both mothers and offspring are presented as C1, C2, C3 and 
C4. Similarly, QALY of both mothers and offspring are present as Q1, Q2, Q3 and Q4.  
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All costs and QALY are added up to present the total cost of long term complications for 
GDM in each strategy. For short term complications, NDS is less expensive and more 
effective than PDS, as mentioned in the previous section. However for long term 
complications, PDS is less expensive and more effective than NDS. After adding up the 
total costs and QALY for both short and long term complications, PDS becomes the 
dominant screening test strategy. For long term complications, the strategy with the 
lowest costs and highest effectiveness was S4 (PDS) at £4,088 and 80.9736, while the 
strategy with the highest costs and lowest effectiveness was S5 at £4,620 and 80.9287, 
respectively.  
Table 9.4  Summaries of long term compilations in mothers and offspring 
 
The analysis of the incremental cost-effectiveness ratios (ICER) of the different 
screening tests for long term complications of GDM are shown in Table 9.5. The 
different screening test strategies are ordered based on costs. S4 (PDS) has higher 
QALY (80.9736) and is less expensive (£4,088) than the other strategies. S4 dominates 
the other screening test strategies for long term complications.  
Table 9.5 Costs per life time QALY gained in screening tests for GDM 
 
Strategy
Cost QALY
Cost(C1) QALY(Q1) Cost(C2) QALY(Q2) Cost(C3) QALY(Q3) Cost(C4) QALY(Q4) (C1+C2+C3+C4) (Q1+Q2+Q3+Q4)
S1 (NDS) 1,086            0.9261 109 0.9903 2,335            31.9338 842 47.1069 4,372                   80.9571
S2 (NDS) 1,091            0.9261 110 0.9902 2,396            31.9232 894 47.1050 4,491                   80.9445
S3 (NDS) 1,097            0.9262 108 0.9904 2,259            31.9472 776 47.1094 4,240                   80.9731
S4 (NDS) 1,095            0.9261 110 0.9902 2,375            31.9269 876 47.1057 4,455                   80.9489
S5 (NDS) 1,078            0.9261 111 0.9901 2,472            31.9100 959 47.1026 4,620                   80.9287
S1 (PDS) 1,110            0.9257 108 0.9904 2,273            31.9472 776 47.1094 4,268                   80.9727
S2 (PDS) 1,136            0.9249 108 0.9903 2,315            31.9472 776 47.1094 4,335                   80.9718
S3 (PDS) 1,097            0.9262 108 0.9904 2,259            31.9472 776 47.1094 4,240                   80.9731
S4 (PDS) 1,124            0.9253 108 0.9903 2,079            31.9485 776 47.1094 4,088                   80.9736
S5 (PDS) 1,078            0.9261 111 0.9901 2,472            31.9100 959 47.1026 4,620                   80.9287
Total
Offspring
Short term complications Long term complications
Mother Offspring Mother
Strategy
Costs (£) Effects Incremental costs Incremental effect ICER 
 [C]  [E] [C]  [E] [C/E]
S4 (PDS)             4,088 80.9736
S3 4,240 80.9731 152.63 -0.0004 -345,648 Dominated 
S1 (PDS) 4,268 80.9727 27.31 -0.0005 -59,343 Dominated 
S2 (PDS) 4,335 80.9718 67.40 -0.0008 -80,602 Dominated 
S1 (NDS) 4,372 80.9571 37.43 -0.0147 -2,547 Dominated 
S4 (NDS) 4,455 80.9489 82.47 -0.0083 -9,986 Dominated 
S2 (NDS) 4,491 80.9445 36.13 -0.0044 -8,176 Dominated 
S5 (PDS) 4,620 80.9287 128.44 -0.0157 -8,156 Dominated 
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The CE plane for long term complications, with an x-axis of lifetime QALY for type 2 DM 
and a y-axis of costs in pounds sterling is presented in Figure 9.2. On the CE plane, the 
screening test strategies are plotted against S5, shown as the origin of the graph. As 
can be seen from the graph, for S4 the costs and QALY gained per year were £4,088 
and 80.9736 respectively.  
 
Figure 9.2 the cost-effectiveness plane for long term complications 
 
S4 is a negative dominant selective screening strategy developed by SIGN 2010 (SIGN, 
2010), whereby all pregnant women with one or more high risk factors are requested to 
undertake 1h and 2h 75g oral glucose tolerance test (OGTT) diagnostic tests. On the 
other hand, S4 (PDS) involves the screening of all pregnant women with one or more 
risk factors and if the mothers test positive for risk factors they then receive treatment. 
However, mothers that do not present with risk factors undergo a diagnostic test with 
75g OGTT. If the diagnostic test results are over a specified cut-off point, mothers 
receive treatment. This selective screening strategy shows more cost effectiveness than 
all of the other screening strategies for long term complications. Regarding the 
comparison of the test approach combinations, PDS is dominant to NDS in long term 
complications, with PDS being able to prevent both mothers and offspring developing 
type 2 DM with complications, as shown in Table 9.5.  
   S3, however, is a one step approach using 75g OGTT as a gold standard with 
100% sensitivity and 100% specificity, with the probability of true positive (TP) and true 
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negative (TN) results being equal to one. Therefore, S4 (PDS) and S3 give the same 
probability of TP at 3.5%. The reason that the results of the total costs of S4 (PDS) are 
lower than S3 for long term complications is due to the cost of the screening tests 
themselves; risk factor screening tests (£9.50) are less expensive than diagnostic tests 
(£18.57). 
9.3 Probabilistic results 
The probabilistic analysis explores uncertainty in cost-effectiveness outcomes. The two 
economic models of screening tests for GDM in both mothers and offspring are 
analysed probabilistically using Monte Carlo simulation (1000 iterations) in order to 
determine expected costs, outcomes and cost-effectiveness. The costs relate to lifetime 
costs of screening tests in each strategy while outcomes relate to QALY gained. 
Incremental costs and QALY are reported to demonstrate the impact of parameter 
uncertainty on the costs and QALY outcomes for each analysis. Incremental costs and 
incremental effectiveness can be represented visually using a cost-effectiveness plane 
(CE plane) , which is used to present the probability of cases detected (Fenwick et al., 
2001) (Fenwick and Byford, 2005) (Fenwick et al., 2006). The joint distribution of the 
costs and effectiveness from the Monte Carlo simulations (1000 iterations) are plotted 
on a cost-effectiveness plane in order to show the impact of uncertainty in the model 
parameters on the model outcomes in both expected incremental costs and effects. 
Uncertainty in the incremental outcomes is demonstrated when the results cross over 
the y-axis, representing both QALY gains (in the eastern quadrants) and QALY losses 
(in the western quadrants). Similarly, a spread through the origin passing through the x-
axis represents uncertainty in the incremental costs of the intervention.  The size of the 
spread also shows the extent of uncertainty in the costs.    
   Considering the deterministic model in the previous section, costs and 
effectiveness in both short and long term complications are seen to be slightly different 
in each strategy.  When those results are plotted on the CE plane the distributions for 
each strategy overlap each other to such an extent that they cannot be distinguished 
clearly. Therefore, instead of presenting a distribution of cost and effectiveness on the 
CE plane, this model presents confidence intervals for each strategy, calculated using 
the percentile method (2.5 and 97.5 percentiles).  
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9.3.1 Short term complications in mothers and offspring 
The costs and outcomes for each strategy, including their means and 95% CI’s are 
presented in Table 9.6. The means of costs and outcomes from the Monte Carlo 
Simulation (1,000 iterations) for each strategy give slightly different results from the 
deterministic model. For example, S5 costs in the deterministic model are £1,202 and in 
the probabilistic model they are £1,180 (95% CI £918 – £1,463). Similarly, the means of 
the outcomes for S5 in the deterministic and probabilistic models are 1.9158 and 1.9158 
(95% CI 1.8858 – 1.9404), respectively.  
Table 9.6 The confident intervals for costs and QALY in short term complications 
 
9.3.2 Long term complications in mothers and offspring 
Table 9.7 shows probabilistic results for costs and outcomes in terms of their means and 
95% CI’s for long term complications. The mean costs for each strategy in the table 
show similarity to the deterministic model.  For example, the costs of S4 (PDS) range 
from £3,064 to £5,424 with a mean cost of £4,053. Likewise, there is uncertainty in the 
costs for long term complications when compared to the deterministic model (£4,088). 
On the other hand, the outcomes in both the deterministic and probabilistic models are 
slightly similar; 80.9736 and 80.9084 (95% CI 78.8925 – 82.7718), respectively.   
Strategy
Mean Lower 95% CI Upper 95% CI Mean Lower 95% CI Upper 95% CI
S5 1,180                918                      1,463                   1.9158            1.8858                1.9404                
S1 (NDS) 1,186                923                      1,469                   1.9161            1.8861                1.9406                
S2 (NDS) 1,193                931                      1,477                   1.9160            1.8859                1.9405                
S4 (NDS) 1,196                933                      1,480                   1.9160            1.8860                1.9405                
S3 1,197                935                      1,479                   1.9162            1.8862                1.9407                
S1 (PDS) 1,207                941                      1,487                   1.9159            1.8860                1.9404                
S4 (PDS) 1,219                957                      1,502                   1.9155            1.8854                1.9401                
S2 (PDS) 1,228                969                      1,509                   1.9152            1.8850                1.9396                
Costs (£) Effectiveness 
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Table 9.7 The confident intervals for costs and QALY in long term complications 
 
9.4 Decision uncertainty 
The aim of calculating a Cost Effectiveness Acceptability Curve (CEAC) is to summarise 
and illustrate graphically the probability that a particular intervention or screening test is 
the optimal choice over a wide range of values for the ceiling ratio (λ). The CEAC is an 
appropriate way to present uncertainty in a cost-effectiveness analysis because it 
directly addresses uncertainty of the outcomes and costs of health care intervention 
(Fenwick et al., 2001). In multiple intervention decision, the CEAC for each screening 
test strategy can be established by calculating the proportion of iterations (from a Monte 
Carlo simulation) where the screening is optimal for a variety of willingness to pay 
values. The multi curve in CEAC of screening tests for GDM shows the decision 
uncertainty surrounding the cost-effectiveness of each strategy as discussed below.  
9.4.1 Short term complications in mothers and offspring 
For short term complications, the CEAC show the decision uncertainty surrounding the 
cost-effectiveness of each strategy by plotting the probability of screening test strategies 
being cost effective against a range of ceiling ratios. For example, in Figure 9.3, at the 
ceiling ratio of £30,000/QALY the probability that S1 (NDS) is cost effective is 64%. 
Following this, for the remaining strategies S5, S2 (NDS), S4 (NDS), S3 , S1 (PDS), S4 
(PDS) and S2 (PDS) the probabilities for their cost effectiveness are shown to be 31.3%, 
3.9%, 0.3%, 0.5%, 0%, 0% and 0.01%, respectively. At the ceiling ratio of £30,000 per 
QALY, S1 (NDS) has the highest expected net benefit, but the error probability is about 
36% (0.36 chances will be wrong decision).  If the decision maker’s ceiling ratio is below 
£20,000/QALY then S5 would be the screening test of choice since it is the cheapest. 
However, at the willingness to pay from £20,000/ QALY to £80,000, S1 (NDS) is cost-
effective.      
Strategy
Mean Lower 95% CI Upper 95% CI Mean Lower 95% CI Upper 95% CI
S4 (PDS) 4,053               3,064                  5,424                  80.9084          78.8925              82.7718              
S3 4,213               3,300                  5,682                  80.9077          78.8954              82.7653              
S1 (PDS) 4,236               3,341                  5,692                  80.9075          78.8952              82.7651              
S2 (PDS) 4,308               3,351                  5,692                  80.9068          78.8913              82.7659              
S1 (NDS) 4,358               3,416                  5,877                  80.8910          78.8806              82.7488              
S4 (NDS) 4,457               3,459                  5,868                  80.8829          78.8748              82.7447              
S2 (NDS) 4,497               3,489                  5,915                  80.8783          78.8731              82.7266              
S5 4,622               3,528                  6,388                  80.8620          78.8511              82.7262              
Costs (£) Effectiveness 
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Figure 9.3 Cost-effectiveness acceptability curves for short term complications 
 
9.4.2 Long term complications in mothers and offspring 
The uncertainty in cost-effectiveness estimated for long term complications is illustrated 
in a CEAC in Figure 9.4. At a threshold of £30,000/QALY, the CEA illustrates that the 
probability that S4 (PDS) will be cost-effective is approximately 55.8%. At the same 
threshold, the probability that S3, S1 (NDS), S5, S2 (NDS), S4 (NDS), S2 (PDS), S1 
(PDS) will be cost-effective are approximately 37.6%, 0.3%, 1.4%, 0.6%, 0.1%, 0.4% 
and 0.0%, respectively.  However, the probability that S4 (PDS) will be cost-effective in 
the CEAC remains at approximately 55.8%.   
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Figure 9.4 Cost-effectiveness acceptability curves for long term complications 
 
9.5 Value in further research: EVPI and EVPPI 
The probabilistic sensitivity analysis results have been presented in previous sections 
and the decision uncertainties for each of the analyses have also been explored, 
however to demonstrate the probability that each intervention is cost-effective at 
different thresholds it is necessary to consider two issues, namely, knowing the decision 
uncertainty and current evidence, should the screening test be adopted or not and is 
additional research essential in order to support the decision (Briggs et al., 2006). If 
such questions are left unanswered, it may be the case that decision makers attempt to 
interpret the cost effectiveness results in terms of how to make the decision to adopt or 
reject the screening tests given the uncertainty. The outcomes from the probabilistic 
sensitivity analysis in the previous section can help inform funders and decision makers 
to answer those questions about how to interpret the results for each screening test and 
the appropriate next steps to take. 
   The potential value of undertaking further research is estimated using a 
Bayesian Value of Information Analysis (VOI) and is discussed in this section.  Firstly, 
the expected value of perfect information (EVPI) is estimated, the value of eliminating all 
the uncertainties within the model, providing a maximum value for the return on further 
research. The EVPI was calculated using the probability of cost-effectiveness for each 
strategy, and were generated in the CEAC calculation within a range of values at 
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intervals of £500 from zero to £100,000/QALY. It is important to represent what this 
EVPI per patient is in terms of the relevant patient populations who would benefit for the 
additional information. Representing the EVPI per decision in terms of the patient 
population, the population value for EVPI, gives an idea of the upper limit for 
expenditure on future research into the decision question. It is calculated by multiplying 
the patient population (both present and future) that is able to benefit from the 
information, by the difference between a decisions expected value (the greatest net 
benefit expected) with current information and with perfect information (Briggs et al., 
2006).  
   In order to reduce uncertainty in the cost effectiveness decision, it is necessary 
to consider what parameters are driving uncertainties in the model. In this respect, the 
expected value of perfect parameter information (EVPPI) is used to distinguish 
parameters for which it would be valuable to have more accurate estimates. Parameter 
uncertainty for one or a group of parameters can be eliminated instead of the EVPI for 
all parameters being estimated at once. The EVPPI is calculated from the difference 
between the maximum net benefit calculated from current estimates that involve some 
uncertainty and the expected net benefit that is calculated from partial perfect 
information. This provides the proportion of general uncertainty furnished by any single 
or group of parameters and gives a guide to where research should be focused for 
greatest efficiency.  
9.5.1 EVPI in short term complications  
The EVPI results showed that at a willingness to pay threshold of £30,000/QALY, the 
value of perfect information for short term complications is £1.06. This EVPI is very low; 
however an explanation for this may be due to a lack of decision uncertainty as seen in 
Figure 9.3 in the previous section. At a threshold of £30,000 per QALY, the probability 
that S1 (NDS) would be cost-effective was only 64%. The EVPI equates to the 
opportunity loss form choosing the optimal strategy in a situation where the optimal 
strategy would have been wrong had perfect information been provided. This therefore 
means that there is approximately a 36% probability that S1 (NDS) is the wrong 
decision. Thus it can be inferred that the opportunity loss of choosing the screening 
strategy is high at a willingness threshold of £30,000/QALY. 
   Having estimated EVPI per patient, the population EVPI for one year is 
calculated using population estimates. In order to determine the population value for 
EVPI, the patient population over the lifetime of the technology must be taken into 
account in terms of the relevant patient population who would benefit from the screening 
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tests. The annual pregnancy population is estimated to be 60,000 mothers (NHS, 2013). 
With regard to screening tests for GDM, this study assumes an effective technology life 
of 10 years with new patients eligible for treatment each year. Therefore, a timeframe of 
ten years was applied and discounted at 3.5% (NICE, 2008c). The EVPI for the 
population has the same relationship to the CEAC calculation (Figure 9.3). Figure 9.5 
details the results from the expected value of perfect information analysis (EVPI) at a 
population level for short term complications. At a willingness to pay threshold of 
£30,000/QALY the expected value of perfect information for the populations is 
approximately £494,990. If a monetary threshold of £100,000 per QALY were applied, 
then the population value of further research would be £658,717. At the willingness to 
pay £20,000/ QALY, the line of population EVPI starts to drop and then rises again at a 
willingness to pay of £80,000. This drop relates to the CEAC for short term 
complications in Figure 9.3, in which the S1 (NDS) strategy shows the highest 
probability of cost-effectiveness between the willingness to pay values stated above. For 
example, at a willingness to pay of £20,000/QALY, the probability that S1 (NDS) is cost 
effective is 64% and the probability that the other strategies are cost effective is 36%. 
Therefore, at a willingness to pay of £20,000/QALY a peak in population EVPI can be 
seen in the graph in Figure 9.5 it shown uncertainty at this willingness to pay. However, 
there is still considerable uncertainty surrounding this decision, and at a willingness to 
pay value of £30,000/QALY the probability that S1 (NDS) is cost-effective is 
approximately 64%. 
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Figure 9.5 EVPI for short term complications – population level 
 
At a willingness to pay threshold of £30,000/QALY, the population EVPI was 
approximately £500,000. Therefore it is potentially worthwhile undertaking further 
research to explore screening tests for GDM if further research costs less than £50,000. 
If it costs more than £50,000, further research is not worthwhile. 
9.5.2 EVPI in long term complications 
The EVPI results indicated that at a threshold of £30,000/QALY, the expected value of 
perfect information per patient is £229.14. This value can be explained by taking into 
consideration the decision uncertainty shown by the CEAC in Figure 9.4. The CEAC for 
long term complications showed that at a threshold of £30,000/QALY, the S4 (NDS) 
would be approximately 55% cost-effective, with a 45% probability that a wrong decision 
would be made.   
   In order to determine the overall population value of EVPI, the analysis for long 
term complications was performed based on the same technology time frame and 
population of pregnant women in Scotland (60,000) (NHS, 2013). Figure 9.6 illustrates 
the results from the expected values of perfect information at the population level for 
long term complications. When scaled up to reflected this value to the population, the 
EVPI results showed that at a monetary threshold of £30,000/QALY the expected value 
of perfect information per populations for GDM screening tests in mothers is 
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approximately £107 million. This means that further research is worth £107 million as 
shown in Figure 9.6. The EVPI for the population has the same relationship to the CEAC 
calculation in Figure 9.4. In the CEAC, the probability that S4 (PDS) will be cost-effective 
remains at approximately 55% from willingness to pay threshold of £0/QALY to 
£100,000/QALY. Therefore, the line of population EVPI starts to rises up as a straight 
line at a willingness to pay threshold of £0/QALY to £100,000/QALY. 
 
Figure 9.6 EVPI for long term complications – population level 
 
The EVPI results show that it is worthwhile collecting more information about the use of 
S4 (PDS), as a selective screening test strategy for GDM. At a willingness to pay 
threshold of £30,000/QALY the population EVPPI was £107 million. Even at a 
willingness to pay of zero, the population EVPPI is still extremely high at £75 million.  
With such a high population EVPI, it can be concluded there is potential in undertaking 
future research to reduce the uncertainty that surrounds the question of screening tests 
for GDM using S4 (selective screening). 
9.5.3 EVPPI in short and long term complications  
The EVPI per patient of £1.06 translated to population level EVPI £494,990, at a 
willingness to pay threshold of £30,000/QALY in short term complications. Whereas, in 
long term complications, the EVPI per patient of £229.14 translated to population level 
EVPI £107 million, at a willingness to pay threshold of £30,000. Considering the EVPI at 
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the population level, there would be value in investigating further information on 
screening tests for GDM. In terms of which parameters would add the most value in this 
additional information and how it should be collected, the expected value of perfect 
parameter information (EVPPI) is used; understanding what drives the uncertainty is 
necessary to establish the type and perhaps the scale of future research. The EVPPI 
analysis reports results in terms of the value per patient and these are presented in 
terms of the pertinent patient population that may benefit from this supplementary 
information. The parameters are arranged in two main groups based on short and long 
term complications, as summarised in Table 9.8. Each group consists of sub-groups that 
contain individual parameters specific to screening tests for GDM. For short term 
complications, the five sub-groups indentified were prevalence, diagnostic test accuracy, 
costs of treatment, clinical effectiveness and utility. Whereas, the sub-groups for long 
term complications include prevalence, cost for treatment, life table, and utility. Individual 
parameters and groups of parameters were selected in order to find out which 
parameters may be causing the high EVPI.  
Table 9.8 EVPPI parameters 
Parameter Groups Parameters 
Short term complications 
Prevalence  GDM 
 GDM with and without risk factors 
  
Diagnostic test accuracy  Random plasma glucose: sensitivity & specificity 
 Fasting plasma glucose: sensitivity & specificity 
  
Cost of treatment  Normal delivery 
 Short term complications in mothers 
 Short term complications in offspring 
  
Clinical effectiveness  GDM with treatment (TP) 
 GDM without treatment (FN) 
 No GDM with treatment (FP) 
 No GDM without treatment (TN) 
  
Utility  Normal delivery 
 Short term complications in mothers 
 Short term complications in offspring 
Long term complications 
Prevalence  Development of type 2 DM in mother with and without GDM 
 Development of type 2 DM in offspring  with mother with and without GDM 
  
Cost of treatment  Type 2 DM with no complications : in and out patient costs 
 Type 2 DM with no complications : in and out patient costs 
  
Life table   Death rates 
 Death rates with DM 
  
Utility UK Population Norms for EQ-5D 
 HRQoL in type 2 DM 
 HRQoL in type 2 DM with complication 
 
The population EVPPI was estimated based on the population of pregnant women, 
60,000 (NHS, 2013). The EVPPI analyses, in terms of the values per decision, are 
presented based on the relevant patient population that benefits from the additional 
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information. The EVPPI was run using 100 X 100 iterations for each of the individual 
parameters and groups of parameters, at a willingness to pay threshold of 
£30,000/QALY. For the individual parameters and sub-group parameters for both short 
and long term complications, the EVPPI analyses show that there is zero value in 
undertaking further research. It is clear that these parameters may have some 
uncertainty surrounding them, but not enough to warrant any further information. It is 
completely reasonable for EVPPI for all individual parameters to be zero, but as a group 
they may be sizeable (Briggs et al., 2006). The sum of individual parameter groups does 
not necessarily equal the EVPPI of all groups together. The reason for this is that when 
the individual parameter groups are considered separately they may not resolve in a 
way that has enough impact on the difference in net-benefit for the decision to be 
changed. Parameters for both short and long term complications have zero individual 
EVPPI, but when combined they may have the effect of reducing uncertainty. With 
EVPPI of zero for individual parameters, it is not worthwhile to collect information on 
individual parameters. However, for example, if the prevalence of the GDM group had 
an EVPPI per patient of £5, then this translates to population values of approximately 
£50,000. Consequently, it may be possible to undertake research on this parameter at a 
cost lower than £50,000. However, all individual parameters have zero results and so it 
is clear that the parameters may have some uncertainty surrounding them, although the 
uncertainty is extremely low and not enough to warrant any further information.  
    The EVPPI was recalculated based on the two groups of parameters; short and 
long term complications. For those two groups of parameters, the EVPPI analysis 
reported a value of zero for short term complications and for long term complications, 
the value of EVPPI was worth £1.67 per patient. Short term complications reported a 
value of zero because the low EVPI for short time complications was £494,990, with 
willingness to pay a threshold of £30,000/QALY. The EVPI for population level in short 
term complications was not a high value when compared with the EVPI for population 
level in long term complications (£107 million). Another reason for a zero value is that 
the individual parameter groups are different for short and long term complications. The 
EVPPI groups for both short and long term complications result in different values and 
the uncertainty in the individual parameters. For example, the individual parameter 
groups for short term complications included diagnostic test accuracy and clinical 
effectiveness; whereas the individual parameter groups for long term complications did 
not include these groups. Therefore, EVPPI for all groups in both short and long term 
are not directly comparable as they are composed from different components. If this is 
scaled up to the population level it gives a population EVPPI of £784,042 for long term 
complications, as shown in Figure 9.7. These results shows that there is greater 
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uncertainty with respect to long term complications and that collecting information on 
long term complications is likely to be worthwhile.   
   Clearly it is the parameters for long term complications that are driving 
uncertainty in the model, and leading to uncertainty in the cost-effectiveness decision. 
Moreover, it can be seen that it would be best for EVPPI analysis to first be conducted 
on individual parameters or small groups of parameters, with the grouping of parameters 
being of particular importance if they are correlated. Also even though it may be quite 
possible for EVPPI to equal zero on all the individual parameters, as groups they may 
have substantial value.  
 
Figure 9.7 EVPPI for short and long term complications – population level (£30,000) 
 
This model is the first economic evaluation of screening tests for GDM that has applied 
VOI analysis in order to decide whether or not to adopt screening tests and whether or 
not to carry out further research. There is uncertainty about the probability of the 
parameters used in long term complications, such as costs, prevalence of developing 
type 2 DM, and QALY. This means that the decision is uncertain and that there is a 
probability of decision error. The EVPPI showed that, at the willingness to pay threshold 
of £30,000/QALY, it is worthwhile reducing uncertainty in all parameters for long term 
complications. Given the result of the EVPPI, the type of further research that would be 
required is likely to be a trial to evaluate the development of type 2 DM in mothers with 
GDM and in offspring born to mothers with GDM. A randomised controlled trial (RCT) 
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would provide strong evidence as to whether long term complications in mothers with 
and without GDM develop type 2 DM. However, any such further research on long term 
complications would require a lengthy study period and incur high costs.   
9.6 Discussion 
Results for decision models for which probabilistic sensitivity analysis has been applied 
can be estimated by VOI analysis. This chapter explored uncertainty in the results of 
screening tests of GDM and demonstrated the use of the VOI method. The results can 
be examined in terms of decision uncertainty to give meaningful recommendations for 
further research. The results for each of the analyses are discussed and summarised. 
9.6.1 Short term complications  
The cost-effectiveness planes for short term complications showed that there was a lot 
of uncertainty surrounding all strategies. Of all the screening tests for GDM, S1 (NDS) is 
the most cost-effective, and at a willingness to pay of £30,000/QALY was 64% cost-
effective, representing a large uncertainty surrounding the decision. In considering the 
value of further research, the EVPI value was very small, reflecting the low decision 
uncertainty. In addition, individual and sub-group parameters for short term 
complications had zero values in the EVPPI analysis. Therefore, given current evidence 
it is certain that the use of S1 (NDS) as recommended by SIGN 2001 is cost-effective, 
and that there is no value associated with the collection of further information. It is 
surprising that short term complications in screening tests for GDM are not driving 
uncertainty in the model. Individual parameters such as prevalence rate and diagnostic 
test accuracy should drive uncertainty in short term complications.  However, the EVPI 
shows that perfect information would not change the cost-effectiveness decision, and 
therefore there is no value in conduction further research. 
   In short term complications, S1 (NDS) is a universal screening strategy with a 
two step approach that screens by random plasma glucose (RPG) followed by a 75g 
oral glucose tolerance test (OGTT) when the screening test is positive (SIGN, 2001). For 
populations with low prevalence of GDM at 3.5%, this model found that universal 
screening is a cost-effective strategy for short term complications.  S1 (NDS) shows the 
lowest screening costs at £7 with an expected case identification rate of 2.2%. In 
contrast all of the PDS strategies were able to classify 3.5% of mothers as having GDM, 
which is close to the prevalence rate used by this model. Therefore, the screening with 
the highest case identification rate is not necessarily the most cost-effective in short 
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term complications. There may be some desirable trade-off between detection, 
unnecessary testing and treatment for GDM. 
   In short term complications, when comparing PDS and NDS, NDS is more cost-
effective than PDS as illustrated in Figure 9.1. In the cost-effectiveness plane for short 
term complication, all NDS screening test strategies were presented at the bottom of the 
graph. The NDS results are due to an error in FN tests, in which all patients with disease 
are undiagnosed and do not receive any treatment to prevent short term complications. 
On the other hand, the PDS strategies presented with a zero probability for FN. In FN, 
mothers with GDM do not receive any treatment, however the treatment of GDM 
reduces serious adverse complications in both mothers and offspring (Crowther et al., 
2005), and so mothers who show FN results cost more money due a greater need to 
treat for both short and long term complications, in comparison to the other results; TP, 
TN and FP. Therefore screening test strategies with low screening test costs and a low 
number of FN results are cost-effective.  
The cost-effectiveness estimates in this model are similar to the estimates in a 
number of economic evaluations previously mentioned concerning the screening of 
GDM and short term complications. The results in the present model conclude that the 
sequential screening test or two step approach in which patients that test positive in the 
first test (screening test) undergo a second test (diagnostic test), was the most cost-
effective strategy. Several economic evaluations of screening tests for GDM reported 
sequential screening tests as being cost-effective (Poncet et al., 2002) (NICE, 2008b) 
(Round et al., 2011). A study in cost-utility for different screening tests in England and 
Wales reported that a sequential strategy of FPG followed by OGTT is the optimal 
strategy for short term complications, with 100% sensitivity and specificity (Round et al., 
2011).       
   The RPG test has reasonable sensitivity with low levels of prevalence in the 
population. This means that the additional number of GDM cases that would be missed 
is small. It also represents a lower cost strategy than testing all women with 75g OGTT. 
Nevertheless, confirming an RPG positive with 75g OGTT is still cost-effective as the 
cost of the test is offset completely by the savings made from not treating FP cases. If it 
is assumed that 75g OGTT diagnostic test acceptance is not 100%, the number of 
cases missed will be established by combining test sensitivity and acceptability. From 
this, it is clear that when the assumption of 100% sensitivity and specificity is relaxed, 
OGTT itself is not therefore used as a cost-effective screening test. Regarding 
diagnostic test accuracy in this study, fasting plasma glucose (FPG) can classify more 
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GDM cases than RPG, however when there is low risk of GDM in the population, the 
probability of case identification by FPG and the cheaper RPG is small.  
This clarifies why RPG followed by 75g OGTT is cost-effective. With 100% 
sensitivity and specificity, as part of a combined testing strategy where the woman has 
already had one positive result with RPG, it is cost-effective to use 75g OGTT to confirm 
a positive RPG or GCT before treatment. This is because the use of the diagnostic test 
results in savings made from not treating FP.  The probability of FP cases in NDS is 
zero; however the probability of FP in PDS for each of the strategies does exist. 
Therefore, Universal screening with RPG and 75g OGTT for mothers and offspring 
represents the best screening test strategy when considering costs and outcomes over 
one year. In short term complications, the time horizon may not reflect the clinical 
outcome in both mothers and offspring with GDM.    
9.6.2 Long term complications  
For long term adverse complications, the CEAC indicated that at a willingness to pay 
threshold of £30,000/QALY the probability of S4 (PDS) being cost-effective is 55%. The 
probability that S4 (PDS) is cost-effective in the CEAC remains the same at willingness 
to pay thresholds of between £30,000/QALY and £100,000/QALY. There is a lot of 
uncertainty surrounding all of the strategies. At a population level the EVPI is £107 
million for long term complications and £494,990 for short term complications, and 
therefore there is potential worth in collecting further information to inform the decision 
regarding whether to use S4 (PDS) in the future. The population EVPI analysis of long 
term complications demonstrates that further research is worthwhile. As a research 
recommendation, outcomes of the EVPI are useful in terms of being able to set upper 
limits on future research costs, such that research has to have a lower cost than the 
EVPI for it to be deemed of potential worth.  
    The EVPPI outcomes for various individual parameters and sub-groups of 
parameters equal zero with the exception of the group of long term complications which 
was £1.67 per patient, and £784,042 at the population level. To help make decisions as 
to what type and scale of research is most suitable, EVPPI analysis can be employed. It 
takes into consideration which parameters drive uncertainty in a cost-effectiveness 
decision, such that by determining the relevant parameters, the most suitable type of 
research can be identified. Long term complications are driving the uncertainty in this 
model. Further research should focus on whether long term complications in mothers 
and offspring with and without GDM develop type 2 DM. However, such further research 
would require a lengthy study period and may incur high costs. However, large scale 
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RCT would not necessarily be required; indeed the type of research would be 
dependent on which parameters required additional information. Performing EVPI and 
EVPPI with the use of VOI analysis, there is potential worth in making most use of 
outcomes and in making informed recommendations to those providing funds as well as 
decision makers.  
   For short term complications, universal screening with NDS is a cost-effective 
strategy, whereas for short and long term complications, PDS with selective screening 
tests is cost-effective. For short term complications, a diagnostic test reduces the costs 
involved in treating FP, as there is a zero probability of FP in NDS. As there are no costs 
incurred in the treatment of FP, NDS is the dominant strategy for short term 
complications. Moreover, the high cost and low utility come from the probability of FN in 
NDS itself. FN is considered to be worse than FP, as mothers with GDM will not get any 
treatment and because the treatment of GDM reduces serious adverse complications in 
both mothers and offspring (Crowther et al., 2005). Mothers who show FP results will 
cost more money due to unnecessary treatment of short term complications. 
   When comparing PDS and NDS, PDS is more cost-effective than NDS. An 
explanation follows as to why PDS replaces NDS and selective screening replaces 
universal screening as the most cost effective strategy when considering long term 
complications as opposed to short term complications. To understand the diagnosis 
outcomes more clearly from both NDS and PDS, it is advisable to look at the 
probabilities of each test’s accuracy in section 7.6.1. The main reason that PDS is 
dominant for GDM screening tests is because it is able to detect all mothers with a true 
disease state due to the high sensitivity and specificity of the tests used in the model 
(equal to prevalence of the disease in populations, 3.5%), and so the probability of FN 
results for PDS equals zero. Moreover, the PDS strategies involve FP test result errors 
whereby all patients receive unnecessary treatment during gestation to prevent short 
term complications. It is therefore recommended that mothers in the FP group (over-
diagnose) for short term complications receive postpartum screening for type 2DM, in 
the same way that TP patients do. In other words, all patients in the TP and FP groups 
are screened for type 2 DM which allows for the early detection of the disease and its 
treatment, preventing the onset of complications.  
   When both short and long term complications were included in the same model 
to analyse the cost-effectiveness of screening tests for GDM, costs and outcomes were 
presented in terms of lifetime QALY in type 2 DM. According to this model, S4 (PDS) 
that involved screening for GDM with risk factors at initial visit followed by 75g OGTT 
was found to be the most effective. For long term complications, mothers with GDM are 
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at an increased risk of developing type 2 DM (Bellamy et al., 2009). This model 
assumes all mothers with GDM receive postpartum screening for type 2 DM at three 
intervals over 10 years. With this assumption, all postpartum mothers with GDM are 
screened for type 2 DM. Therefore, mothers with GDM receive a chance to be screened 
for type 2 DM. When the results of screening tests are positive those mothers receive 
the appropriate treatment to prevent type 2 DM complications. Diabetes without 
treatment results in high glucose levels in the blood, which can damage nerves, organs 
and lead to serious illness. Diabetes with complications leads to poor health, premature 
mortality, and to a reduction of life expectancy and quality adjusted life expectancy. 
Therefore, screening tests for GDM that can capture all true disease in a population may 
reduce the costs of treatment of type 2 DM complications and improve QALY in mothers 
with GDM who develop type 2 DM. Thus, a screening strategy with PDS that can detect 
all patients in the population and does not show any FN results is cost-effective. 
Screening with the highest case identification rate is the most cost-effective strategy for 
long term complications. Therefore, with a GDM prevalence of 3.5%, it is cost effective 
for all pregnant women that screen positive for risk factors at first visit to receive 
treatment care for GDM, and for women with negative risk factors to undergo diagnostic 
tests with 75g OGTT.  
   The cost-effectiveness estimates in this model are similar to the estimates in a 
number of economic evaluations previously mentioned concerning the screening of 
GDM and long term complications. This model demonstrates that the selective 
screening approach to GDM screening and diagnosis is cost-effective compared to a no-
screening strategy as long as GDM diagnosis provides an opportunity for early intensive 
intervention and prevention of overt DM (Poncet et al., 2002) (Nicholson et al., 2005). 
Selective screening with risk factors followed by 75g OGTT was cost-effective for long 
term complications. As discussed previously for short term complications, it is cost-
effective to use 75g OGTT to confirm positive results for either risk factors, FPG or RPG 
rather than using 75g OGTT alone. Similarly, two studies of the cost-effectiveness of 
screening tests for GDM stated that the most favourable ICER was the screening of 
high-risk pregnancies with test techniques such as 50g OGTT (Poncet et al., 2002) and 
100g OGTT (Nicholson et al., 2005). Moreover, a further two studies in the UK 
suggested that the optimal strategy varied according to the women’s risk factors (Round 
et al., 2011) (NICE, 2008b). However, in the low risk factors group (GDM risk is < 1%), 
the most effective strategy is to do nothing (Round et al., 2011). Therefore, screening 
based on individual risk is potentially more sophisticated and cost-effective to that based 
on an approach to risk factor screening that is widely discussed in the literature. In 
addition, this model was designed to include a no-screening strategy specifically so that 
it could be determined under what circumstances screening is cost-effective.  The 
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results of the present model concluded that sequential screening tests or the two step 
approach, in which patients that test positive in the first test (screening test) undergo a 
second test (diagnostic test), also was the most cost-effective strategy as discussed in 
Section 9.6.1.   
   To this knowledge, this model assesses the costs and effects associated with 
GDM over the course of a lifetime, which is similar to other economic evaluations of 
screening tests for GDM (Lohse et al., 2011) (Werner et al., 2012) (Marseille et al., 
2013). Several other studies have examined the cost-effectiveness of GDM treatment, 
but only in short term complications (Poncet et al., 2002) (Nicholson et al., 2005) (NICE, 
2008b) (Round et al., 2011) (Mission et al., 2012). This model however, confirms and 
high-lights the need for long term intervention for postpartum screening, to curb 
progression to diabetes if any GDM screening program is to be cost-effective. In 
addition, the strength of this model is that it includes the quality of life of the infants after 
deliver in relations to short term complications and their life expectancy as they develop 
type 2 DM through childhood and young adulthood. This economic evaluation model 
included screening tests for GDM, management during pregnancy and postpartum 
screening in order to assess the cost-effectiveness of screening tests for GDM.   
9.7 Conclusion  
This chapter has presented a decision analytical model to estimate the cost-
effectiveness of screening tests for GDM. To calculate the cost-effectiveness of 
diagnostic testing, modelling procedures are required for which intermediate measures 
associated with assessments of diagnostic tests are translated into short and long term 
outcomes and costs. This model used a decision tree to model the short term 
complications over a 1 year period and long term complications over a life cycle. The 
model was populated by using a combination of data from published literature and 
expert opinion to yield parameter uncertainty. Therefore, applying a decision analytic 
model and a VOI technique allows decision makers to make informed decisions as to 
whether a new intervention should be adopted or rejected based on current evidence.   
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Chapter 10 Main findings, Policy implications, 
limitations and future research 
  
10.1 Introduction 
The overall aim of this thesis is to study the cost-effectiveness of screening and 
diagnostic tests for GDM in Scotland. The narrative and systematic review, based on 
economic evaluations, diagnostic test evaluations and screening tests of GDM, are 
addressed at the beginning of this thesis. The systematic review of economic 
evaluations was performed to undertake a structural review and critical appraisal of the 
methods used in the cost-effectiveness analysis of screening tests for GDM and to 
inform the development of the model. Based on the critical assessment of the literature 
in the first six chapters, the empirical analyses undertaken in chapter 7, chapter 8 and 
chapter 9 presented issues in the research field that have not been dealt with previously 
in the literature, using a combination of test results for both the negative dominant 
strategy (NDS) and the positive dominant strategy (PDS). This thesis has, for the first 
time, evaluated the economic evaluation of NDS, PDS and the value of information 
(VOI) for screening tests for GDM.      
   Section 10.2 of this final chapter summarises the main findings of this thesis. 
Subsequently, in section 10.3, potential policy implications are outlined, followed by a 
discussion of possible limitations of the analyses in the thesis and generalisability in 
Section 10.4. Lastly, section 10.5 provides a presentation of how this work could be 
taken forward in the future.  
10.2  Main findings 
Models of screening tests for GDM were developed in order to estimate costs and 
outcomes in both mothers and offspring for four alternative strategies versus a strategy 
of “no screening”. In this economic evaluation, decision trees were designed to assess 
the five strategies of screening for GDM were constructed based on the combinations of 
test approaches for NDS and PDS. Moreover, the analyses were performed from a 
health care provider’s perspective (NHS). 
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10.2.1 The combination of test results 
The thesis has shown that the most appropriate model makes use of a combination of 
tests as either “negative dominant strategy” (NDS) in which patients who tested positive 
after an initial screening test are brought back for a second test to further reduce false 
positives, or “positive dominant strategy” (PDS) whereby patients that test negative in 
the initial test are tested a second time to identify any missed true positives. As such the 
NDS and PDS approaches allow the clinician to consider test results in terms of the 
differences in false negative (FN) and false positive (FP) test results. Combining the 
tests in terms of NDS and PDS involves a trade-off between sensitivity and specificity. 
With a two-step approach, PDS benefits from sensitivity, and results in an overall larger 
number of positive outcomes, both true positive (TP) and FP, and a reduction in 
negative outcomes. This is at the expense of indentifying fewer TN and also gives a 
greater proportion of FP (trading-off specificity for improved sensitivity). The net effect of 
testing the negatives from the first test is finding more TP (net sensitivity will be higher 
than sensitivity from individual test).  In terms of treatment for patients, the proportion of 
FP must be considered, as they can lead to over treatment.  Whereas the NDS 
approach favours specificity and results in a larger proportion of true negative (TN) and 
FN.  Therefore, NDS benefits from the specificity of both tests, at the expense of lower 
overall sensitivity (trading-off sensitivity for improved specificity). The net effect of testing 
the positive from the first test is finding more TN (net specificity will be higher than 
specificity from individual test). Again in terms of treatment for patients, the proportion of 
FN must be considered, as this is likely to lead to missed treatment. The trade-off 
between sensitivity and specificity is at the heart of screening and diagnostic tests and 
the accuracy of the tests, in terms of sensitivity and specificity, is an important 
consideration for clinicians. 
10.2.2 The prevalence of GDM: Systematic review 
Prevalence of GDM is one of the most important parameters in cost-effectiveness 
analyses. However, there remains considerable uncertainty regarding its estimate. The 
prevalence estimates for GDM in the systematic review reported that the pregnancies of 
76,312 women ranged from 1.35% to 12.80%. However, considerable heterogeneity in 
the prevalence of GDM was identified and so pooled estimates were not calculated. 
Variation in GDM prevalence is likely explained by ethnicity and diagnostic screening 
strategies. This is because mothers that belong to a high risk ethnic group are more 
likely to test positive which in turn leads to higher prevalence rates compared to other 
populations.  Indeed, screening ethnic groups that have a high risk of developing GDM 
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can result in high prevalence estimates, ranging from 8.5% - 12.8%. Other important 
factors are whether universal or selective screening protocols for GDM are adopted and 
whether 75g or 100g OGTT are used. The impact of these factors on prevalence 
estimates should be further investigated as they may be acting as proxies for other 
influences on prevalence. Furthermore, accurate decision models require accurate 
estimates of prevalence and decision model outputs are highly sensitive to the 
prevalence. Additionally, in economic evaluations of screening tests prevalence is 
required as a probability in the construction of decision trees. 
10.2.3 Costs and cost-effectiveness analysis of screening 
tests for GDM: Systematic review 
Costs associated with the screening and management of GDM vary widely by country, 
ranging approximately from £2.42 to £50.9 per case detection, and are dependent on 
the tests used, the screening approach, how the costs are calculated and the 
prevalence of GDM in the population. The difference within the reviewed studies in 
terms of comparators, interventions, outcome measures and the analysis of uncertainty, 
make meaningful comparison between the studies very difficult. The available 
information on cost effectiveness provides strong evidence in support of the use of risk 
factor screening tests for GDM in high-risk groups, such as family origin with a high 
prevalence of diabetes, previous gestational diabetes and obesity. However, the review 
of the CEA study has significant implications for future research and policy making. Two 
key findings followed from the review. The first was that CEA of screening tests for GDM 
should use multiple time horizons, such as one year and over a lifetime and as such 
case identifications and short term complications (one year time horizons) are not the 
endpoint outcomes for GDM screening tests.  A major reason for introducing screening 
programmes in the population is that it is important to initiate the appropriate treatment 
after positive cases have been identified with respect to short term time horizons. 
However, the effect of screening and the treatment of GDM, that includes blood glucose 
monitoring, oral medication and regulating insulin, is a reduction in the likelihood of 
developing short term complications and also long term complications, namely type 2 
DM in both mothers and offspring. Indeed, a potentially essential outcome for the 
detection of GDM is the identification of women who are at high risk of developing type 2 
DM or at high risk of GDM in subsequent pregnancies. Long term consequences are 
therefore appropriate outcomes for the CEA of screening tests for GDM and the model 
for economic evaluation for GDM should account for the effectiveness of postpartum 
screening for type 2 DM over the long term. The second finding was that no studies in 
the review presented the results of value of information (VOI) for screening tests for 
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GDM. VOI can be used to make meaningful recommendations to decision makers, who 
can then make informed decisions as to whether a new intervention should be adopted 
or reject based on current evidence, or whether further information is required to help 
make the decision. Its use is important as a decision on the most suitable screening test 
must be based upon and supported by all available knowledge.  
10.2.4 Case identification 
The decision analytic model studied cost effectiveness by expressing consequences in 
terms of natural units as cases of GDM detected. Decision trees for case identification 
were constructed based on the combinations of test approaches that include NDS and 
PDS. This model was developed from the relationship between the prevalence and the 
positive and negative predictive values of the risk factors to estimate the case 
identification rate and the proportion of mothers indentified for subsequent testing. In the 
CEA of case detection, the strategy that can detect all patients in a population with low 
screening costs is the most cost-effective. The costs per case identifications range from 
£7.64 - £21.12 depending on the screening test used.  According to the results, S2 using 
a PDS approach with selective screening followed by two-step approach using FPG and 
75g OGTT yielded the highest rate of case identification and the lowest costs for 
screening tests for GDM. S2 is a screening test strategy that was published by NICE in 
2008 (NICE, 2008b). The NICE guidelines recommend NDS with selective screening 
that screens all mothers with risk factors at first visit followed by FPG and 75g OGTT.  
   This model assumed a GDM prevalence of 3.5% in the population and that 
diagnostic tests have 100% sensitivity and specificity (gold standard). Combining the 
test results and assuming the diagnostic tests have 100% sensitivity and specificity (gold 
standard), the probability of TP outcomes in PDS is equal to the prevalence in the 
population. In PDS, the sensitivity for each strategy was 100% where the probability of 
case identification equaled the prevalence in the population (TP) and the probability of 
obtaining FN results equaled to zero. However, in PDS, the probabilities for TP and FN 
are the same for each strategy, whereas, the probabilities of FP and TN outcomes vary 
depending on the specificity of the test employed. On the other hand, using this gold 
standard for tests, the specificity for each strategy in the model in NDS was 100%, and 
allowed for all patients without disease who have a negative test result to be identified 
(TN), whereas the probability of obtaining FP results is equal to zero. In NDS, the 
probabilities for TN and FN are the same for each strategy, whereas, the probabilities of 
TP and FN outcomes vary depending on the sensitivity of the test employed. There are 
additional costs associated with the unnecessary testing of FP outcomes in PDS. Unlike 
PDS there is a high probability of FN outcomes in NDS. Consequently patients are miss-
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diagnosed. Using PDS for screening tests, all patients in the population can be detected. 
The case identification rate is a significant component of the model, as treatment costs 
and outcomes are predicated in it.   
 No CEA studies were identified in the review in Chapter 6 that presented 
outcomes in terms of case detection of GDM. One potentially essential outcome for the 
detection of GDM is the identification of women who are at high risk of developing type 2 
DM or at high risk of GDM in subsequent pregnancies. The model for economic 
evaluation for GDM should account for the effectiveness of postpartum screening for 
type 2 DM. However, case identification may not be an appropriate outcome measure to 
use for CEA, as the objective to introduce a screening programme is to offer treatment 
and prevent short term and long term complications of GDM. If, however the clinician 
wishes to consider outcomes in terms of case detection the screening strategy with the 
highest detection rate is the most cost-effective. However, in PDS, the screening test 
strategy that has the highest detection rate may produce a higher probability of FP 
outcomes and so patients without disease receive treatment. Clinicians should be aware 
of a high number of FP results as well, otherwise patients may receive unnecessary 
treatment which may be harmful to their health.   
10.2.5 Short term complications 
This model estimates the cost-effectiveness of screening for and treating GDM, 
considering short term complications in both mothers (pregnancy period plus 3 months 
after delivery) and offspring (neonatal period plus 11monthsof infancy) over a period of 
one year. The combinations of test approaches NDS and the PDS approach were used 
to construct the decision trees. The cost effectiveness acceptability curve (CEAC) 
demonstrated that a willingness to pay at a threshold value of £30,000/QALY, the 
probability that S1 (NDS) is cost-effective was 64%, and when compared with other 
screening test strategy this is the most effective strategy at this threshold. From this it is 
concluded that S1 (NDS) is a cost-effective screening test strategy to prevent short term 
complications in both mothers and offspring, in comparison with the other screening 
strategies. The combination of a screening test (random plasma glucose) followed by a 
diagnostic test (75g OGTT) and screening with the highest case identification rate is not 
necessarily the most cost-effective strategy with respect to the prevention of short term 
complications. It is potentially worthwhile undertaking further research to explore 
screening tests for GDM if further research costs less than £50,000. If it costs more than 
£50,000, further research is not worthwhile. 
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   In short term complications NDS was found to dominate PDS for screening tests. 
With the same GDM prevalence of 3.5% in the population and assuming diagnostic tests 
have 100% sensitivity and specificity (gold standard), the probability of TP outcomes in 
PDS is equal to prevalence in the population (3.5%). In PDS, the probabilities for TP and 
FN are the same in each strategy, whereas, the probabilities of FP and TN outcomes 
vary depending on the specificity of the test employed. A consequence of screening in 
PDS is the unnecessary inconvenience and worry associated with FP, such as side 
effects of treatment care during the gestational period. The detrimental effect of treating 
mothers without the disease changes utility outcomes in NDS and PDS to approximately 
the same extent. Treatment for GDM during gestation has a low impact on utility 
outcomes; therefore FP cases do not influence PDS results for short term complication.   
However, as there is a higher probability of FP outcomes in PDS, for diseases whose 
treatment results in serious side effects, PDS should not be considered as a screening 
test strategy. 
    On the other hand in NDS, the probabilities for TN and FN are the same in each 
strategy, whereas, the probabilities of TP and FN outcomes vary depending on the 
sensitivity of the test employed. Unlike PDS there is a high probability of FN outcomes in 
NDS. Consequently patients are miss diagnosed, and so patients with the disease do 
not receive treatment leading to high costs associated with the treatment of serious 
complications and low health-related quality of life in short term complications. 
Therefore, the probability of FN or misdiagnosis in NDS have driven the cost-effective 
outcomes in short term complications and the purpose of introducing screening tests is 
to prevent short term complications in both mothers and offspring. 
 The RPG test has reasonable sensitivity with low levels of prevalence in the 
population. This means that the additional number of GDM cases that would be missed 
is small. It is also represents a lower cost strategy than testing all women with 75g 
OGTT. Assuming 100% specificity and sensitivity, using 75g OGTT alone no longer 
appears to be a cost-effective strategy. Therefore, confirming an RPG positive with 75g 
OGTT is still cost-effective as the cost of the test is offset completely not only the 
savings made from not treating FP cases but also saving costs of treatment in short 
term complication in both mother and offspring.   
10.2.6 Long term complications  
Case detection and short term complications are not the endpoint outcomes for GDM 
screening tests. This economic evaluation of screening tests for GDM estimates cost-
effectiveness considering both short term complications (QALY over one year) and long 
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term complications together (lifetime QALY of type 2 DM). According to this model, at a 
willingness to pay threshold value of £30,000/QALY, the estimated probability that S4 
(PDS) is cost-effective is 42%, the highest compared with other screening strategies at 
this threshold. S4 (PDS) is a two step approach with selective screening that involves 
screening for GDM with risk factors at initial visit followed by 75g OGTT. With such a 
high population EVPI, it can be concluded there is potential in undertaking future 
research to reduce the uncertainty that surrounds the question of screening tests for 
GDM using S4 (selective screening). 
   Considering both short term and long term complications together in order to 
reduce risk of type 2 DM, PDS was found to dominate NDS for screening tests. Using 
the gold standard for tests, the sensitivity and specificity for diagnostic tests in the model 
were 100%, PDS has a higher proportion of patients in the population with positive 
screening test results (TP). In term of short term complications, patients with disease 
that have also been diagnosed with the disease receive treatment during gestation, 
which reduces costs associated with the treatment of complications in both mothers and 
offspring. There is a higher probability of FP outcomes in PDS, and so a high proportion 
of patients without disease subsequently undergo unnecessary treatment (FP) for short 
term complications, with the possibility of an associated high level of unnecessary costs. 
Treatment given to mothers without disease during gestation for GDM has a low impact 
on utility outcomes. In long term complications, in PDS, mothers who have a history of 
GDM in both the TP and FP outcome groups undergo postpartum screening tests for 
type 2 DM three times over a 10 year period. Patients with type 2 DM that are diagnosed 
early receive treatment to prevent type 2 DM with complications. The treatment will 
result in improved quality of life and cost savings, as the patients will not need to be 
treated for type 2 DM with complications. Therefore, the probability of FP or over 
diagnosis in PDS has driven the cost-effective outcomes in long term complications.  
   Test errors result in FN outcomes in NDS, whereas the probability of obtaining 
FP results is equal to zero in NDS. Mothers in the FN group have a high risk of 
developing type 2 DM, however, as mothers with symptoms of type 2 DM in the FN 
group will not be tested for type 2 DM, they will not be detected or treated. As disease in 
these patients is not detected or treated they have an increased risk of developing 
complications of type 2 DM. FN or miss diagnosis outcomes in NDS did not influence 
the results of long term complications.  Screening with the highest case identification 
rate is the most cost-effective strategy for long term adverse complications. The 
detection rate is an important component of screening tests when considering long term 
complications, as treatment costs and the effect of treatment are dependent on it.   
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   This model assumes that long term complications and short term complications 
are conditionally independent of screening tests for GDM. Adding costs and outcome 
results for both short term complications and long term complications together alters the 
ranking of screening test strategies according to their cost effectiveness, as shown in 
table 9.4 For example, for short term complications, S1 (NDS) is ranked second 
according to costs, whereas in long term complications S1 (NDS) is ranked fourth, 
however when both are added together S1 (NDS) is ranked sixth compared to other 
strategies. Therefore, the construction of a model for short and long term complications 
that are conditionally independent on screening tests, using PDS and NDS impacts the 
cost-effectiveness of the strategies.  
10.2.7 Impact of uncertainty  
The aim of probabilistic modeling is to reflect the uncertainty in the input parameters of 
the decision model and describe what this means for uncertainty over the output of 
interest:  the measure of cost, effect and cost-effectiveness. Considering the 
deterministic model, costs and effectiveness in both short and long term complications 
are seen to be slightly different for each strategy.  However, the mean costs and 
effectiveness of the probabilistic model show similarity to the deterministic model. The 
deterministic results showed that screening for GDM was cost-effective. However, this 
result was sensitive to the addition of uncertainty. At willingness to pay threshold of 
£30,000/QALY, the probabilistic model showed that the screening program was cost-
effective only 64% of the time in short term compilations and 42% of the time in long 
term complications. Thus it can be inferred that the opportunity loss of choosing the 
screening strategy is high at a willingness threshold of £30,000/QALY. In the 
populations EVPI at the same willingness to pay, results show that it is worthwhile 
collecting more information to explore screening tests for GDM in both short term 
complications (£494,990) and long term complications (£107 million). EVPPI in long 
term complications approximately £784,042, it can be concluded there is potential in 
undertaking future research to reduce the uncertainty that surrounds the question of 
screening tests for GDM. Clearly it is the parameters for long term complications that are 
driving uncertainty in the model, and leading to uncertainty in the cost-effectiveness 
decision. In addition, one-way sensitivity analysis was performed to further examine the 
outcomes that had an impact on the cost-effectiveness of screening for GDM. Varying 
the values of the prevalence parameters slightly changed the results of the incremental 
cost effectiveness ratio.    
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10.3 Policy implications 
Healthcare resources are limited and as a result their use must be as effective as 
possible, an issue that those working in the health care system have always been 
acutely aware of. Consequently decisions made by public health officials and clinicians, 
that relate to the use of resources, must not only take into consideration the 
effectiveness of procedures but also the costs that they incur. In this respect, cost-
effectiveness analysis provides a useful method to make such decisions more scientific 
in nature.  
   Economic assessments of diagnostic tests are inherently difficult as 
assessments of therapeutic intervention, mainly because of uncertainty about the 
relation between diagnosis and outcomes. The outcomes of screening tests are more 
usually measured by additional case detection which depends on the sensitivity and 
specificity of the tests. The trade-off between sensitivity and specificity or detection and 
unnecessary testing is a central issue for screening and diagnostic tests and the 
accuracy of the tests, in terms of sensitivity and specificity, is a consideration of great 
importance for clinicians. Even if clinicians are able to keep both specificity and 
sensitivity high in tests, FP and FN outcomes will still persist. However, on combining 
the tests, when the second test is performed to confirm the first test, there is a trade-off 
between the sensitivity and specificity of the tests. The two-step approach is considered 
to be better than using individual tests. If the first test has high specificity and low 
sensitivity, then by using PDS the second test can increase sensitivity. In contrast, if the 
first test has high sensitivity and low specificity, by using NDS the second test can 
increase specificity. 
    In PDS, it is patients that are negative in the first test (screening test) that 
undergo an additional second test (diagnostic test).There are a higher proportion of 
patients in the population with positive screening test results in this strategy (TP), 
whereas there is only one possible outcome for FN results in PDS. On the other hand, 
patients without disease that test positive in either the first or second test identify as FP. 
TP and FP results are the main outcomes of PDS where screening and diagnostic tests 
involve positive results. In PDS, clinicians should be concerned about tests with high 
specificity, as tests that can identify patients without the disease who have negative 
results reduce the numbers of FP patients.  
   In NDS, only patients that test positive in the first test (screening test) undergo a 
second test (diagnostic test), however only a few people test positive in the second test 
and so only a small proportion of the population with the disease are detected (TP). The 
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only possible TP outcome in NDS is for diseased patients that test positive in both 
screening and diagnostic tests. Additionally, in NDS diseased patients that have 
negative test results in either the screening or diagnostic tests identify as false negative 
(FN), whereas patients without disease that have positive results in both the screening 
and diagnostic tests identify as false positive (FP), the only possible FP outcome in 
NDS. TN and FN results are therefore the main outcomes of NDS where either 
screening or diagnostic tests involve negative results. Therefore there is a high 
probability that patients without the disease have a negative result in NDS. In NDS, 
clinicians should be concerned about tests with high sensitivity, as tests that can identify 
patients with the disease who have positive test results reduce the numbers of FN 
patients. 
    An earlier diagnosis can be the result of screening; however it has been shown 
that screening tests do not always result in benefits to the patients that are screened. 
Some possible adverse effects that can result from screening and diagnosis include 
misdiagnosis, over-diagnosis, and creating a false sense of security (Laking et al., 
2006). This economic evaluation of screening for GDM was applied to both NDS and 
PDS approaches in order to help inform the clinician and policy maker of possible 
alternative outcomes. This allows the clinician to consider the accuracy of the test 
results in terms of TP, FN, FP and TN. The possible adverse effects that can result from 
misdiagnosis (FN) are worse than the adverse effects that can result from over-
diagnosis (FP) cases.   Due to errors in the results (FN, FP), it can be understood why 
PDS replaces NDS as the most cost effective strategy when considering long term 
complications as opposed to short term complications. The unnecessary costs that 
result from FN screening tests and of treatment due to FP results are highlighted as an 
issue of error in the accuracy of the tests. However, all guidelines for GDM screening 
tests are performed as NDS with regard to both screening tests and postpartum 
screening. This study found that long term complications are the most important factor 
affecting the results of screening test strategies. Therefore, policy makers or clinicians 
should consider screening tests for GDM in order to prevent long term complications 
and perform screening tests as PDS.  
   Accordingly, the results of this study provide useful information for policymakers 
deciding whether to adopt screening for GDM with treatment followed by screening for 
type 2 DM during postpartum to delay or prevent onset of type 2 DM. This economic 
evaluation of screening for GDM was applied to both of these strategic approaches in 
order to help inform the clinician and policy maker of possible alternative outcomes. In 
terms of screening tests, numerous national guidelines recommend screening tests for 
GDM, however only a few guidelines recommend postpartum screening tests for type 2 
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DM among women with histories of GDM. If women have received previous diagnoses 
of GDM, this should trigger regular screening for type 2 DM so that it is discovered early 
on, before the onset of symptoms or the development of complications associated with 
type 2 DM. The early detection and prevention of type 2 DM should potentially result in 
cost savings and clinical benefits. For mothers with GDM that have been correctly 
diagnosed (TP) and mothers diagnosed with GDM that do not have disease (FP), 
postpartum screening tests for type 2 DM should be employed to allow early detected 
and delayed progression of type 2 DM with complications. Given the link between GDM 
and the highly elevated risk of future type 2 DM, and a rapidly increasing number of type 
2 DM, policy makers should consider GDM in relation to type 2 DM in both mothers and 
offspring. As a consequence of this study, policy makers should consider the 
implementation of screening tests for type 2 DM in the general population too, in order to 
prevent the development of type 2 DM with complications.   
   Although there is no universal standard of screening and care for GDM, most 
high-income countries have developed policies or guidelines for GDM in terms of 
screening tests and the treatment of GDM (Jiwani et al., 2012). National guidelines for 
screening tests and the treatment of GDM can inform the policy maker but need to be 
tailored to local prevalence as well as the structure and capabilities of the local health 
care system in order to deliver results in a way that is meaningful to local policy makers.  
   Moreover, VOI is a useful tool for decision makers to evaluate screening tests for 
GDM. Using this tool decision makers are able to make informed decisions with regard 
to the adoption or rejection of new interventions, based on current evidence, or indeed 
whether additional information should be obtained to help decision making.  
10.4 Limitations 
In any analytical model there are limitations that affect the interpretation of its findings, 
as is the case in this study.  
 The most cost-effective screening test strategy might vary according to local 
prevalence.  This model acknowledges that context specific prevalence data is important 
and this thesis conducted a systematic review to identify prevalence estimates. No 
estimate of the Scottish population was identified. In the absence of this specific 
parameter, this thesis used a broadly applicable estimate from NICE of 3.5%, based on 
an expert suggestion. The NICE estimate represents the best available evidence. This 
thesis acknowledges that this is a limitation of the model and decision makers should 
look to conduct a study to estimate GDM prevalence to reduce this uncertainty. 
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However, this thesis felt the uncertainty in this estimate was well represented as this 
model explored a range of values in the probabilistic model as well as different one-way 
scenario analyses. In terms of representing the Scottish context, this thesis, therefore 
takes into account some important parameters from the Scottish context to conducted 
an economic evaluation for screening tests for GDM, such as the EQ-5D mean weighted 
health state index by age and standard region (Scotland), the incident rate of type 2 DM 
reported by NHS Scotland, and the annual pregnancy population to determine the 
population value for EVPI. 
   Moreover, many screening test strategy models included GDM risk factors, either 
alone or in combination. The model does not capture the impact and interdependence of 
multiple risk factors. As the proportion of the population with risk factors various for 
mothers with GDM, there would be concomitant increase in the proportion with multiple 
risk factors, which would change the positive and negative value of test results. 
However, there is no reason why the proportion of the population with multiple risk 
factors would constant with respect to prevalence. 
    Decision analysis has its own specific limitations in representing outcomes in the 
real-world. During pregnancy, GDM women receive interventions including dietary 
control, home glucose monitoring, as well as insulin therapy when needed. The 
treatment care for GDM in this study included dietary control, home glucose monitoring 
and insulin therapy. This study assumes that all women identified as having GDM 
received different treatment, that they received this treatment without fail and that all 
treatment was completed. In a real word situation, if initial treatment of dietary control 
during gestation fails, patients would be offered alternative forms of treatment, such as 
insulin therapy. However, this model did not account for the effect of treatment during 
gestation and treatment to prevent type 2 DM. 
   Short term outcomes in both mothers and offspring are modeled as separate 
outcomes that cannot coexist; for example an offspring in this model cannot have both 
macrosomia and shoulder dystocia, although this would be possible in the real world. 
The coexistence of short term outcomes may result in higher costs and lower QALY 
than for individual adverse outcomes for both mothers and offspring.  
   Patients with GDM may suffer from the side effects of treatment or they may for 
example spend a significant amount of time searching for information about the 
condition of their health, despite this disutility in mothers associated with stress of a 
GDM diagnosis or treatment during the gestation period was not taken into account in 
the model.  However, one study on health-related quality of life related to the effect of 
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treatment of GDM on pregnancy outcomes found that QALY was not negatively 
impacted by a GDM diagnosis (Crowther et al., 2005).   
   In this model, screening test accuracy information uses the same test threshold 
to determine a positive result for fasting plasma glucose and random plasma glucose as 
other studies in the literature. This model assumed the second test to have 100% 
sensitivity and 100% specificity. The model treated sensitivity and specificity 
independently and there was no trade-off between sensitivity and specificity with respect 
to the accuracy of the tests. This is a limitation of the model. However, independent 
modeling of sensitivity and specificity has been shown to underestimate true test 
performance when studies use the same and different thresholds. In addition, if a 
probabilistic modeling approach is used, the approach will estimate the uncertainty 
incorrectly(Novielli et al., 2010). The probabilistic approach randomly sampled sensitivity 
and specificity independently; thus it was possible that a very high sensitivity and low 
specificity were simultaneously sampled. Consequently, the true cost-effectiveness of 
the test has not been ascertained however, as the optimal operating point could not be 
identified, as only one test threshold has been used (Sanghera et al., 2013).  
Sometimes a test result can be positive in patients who do not actually have the 
disease, which is called serendipity. Serendipity refers to the coincidental detection of 
disease following the review of a false-positive screening test result. As the test result is 
abnormal due to factors other than the presence of the target disease, disease detection 
is not attributed to the screening test (Vis et al., 2002). Serendipity in this model refers to 
identifying cases (TP) in the absence of a screening test. Even without a screening test 
for GDM, mothers might report to a clinic with a symptom of GDM. Although S5 includes 
no screening tests and therefore no case detection, it might therefore underestimate 
both the costs and outcomes of the tests. 
10.5 Generalisability  
To assess the relative generalisability of the decision model some limitations need to 
considered. Firstly, the data used in this analysis were derived from the best available 
data and the assumptions used in the model were designed before the analysis. The 
construction of the decision tree for the economic evaluation model for GDM screening 
tests begins with true disease status. The systematic review in chapter 5 stated that the 
variation in the prevalence of GDM can be explained by screening tests and population 
characteristics, therefore, in this model, the prevalence for GDM of 3.5% reported by 
NICE is used to represent the baseline parameter for true disease status. The NICE 
report of prevalence was chosen because its data is based on that from England & 
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Wales, which has a similar population demographic to Scotland. The prevalence of 
GDM at 3.5% represents the prevalence of GDM in countries where the majority of the 
population is white. This represents a potential limitation in the generalisability of the 
findings because the prevalence of GDM varies dependent on ethnicity, which is an 
important risk factor of GDM. Geographical characteristics can affect the incidence and 
prevalence of the disease and lead to generalization of cost-effectiveness results across 
geographic areas. Moreover, it is important to consider heterogeneity of the disease 
frequency in the population, as this may introduce bias. In addition, this model used 
multi-parameter evidence synthesis derived from systematic review and Meta-analysis. 
For example, clinical effectiveness data for short term complications in mothers and 
offspring were derived from meta-analysis, whereas clinical effectiveness data for long 
term complications were derived from systematic review.  
    Three independent decision trees were constructed, including screening tests 
for GDM, short term complications and long term complications, covering all outcomes 
of screening tests for GDM. Moreover, this model assumes that short term complications 
and long term complications are conditionally independent of screening tests for GDM, 
which allows policy makers to focus on each part of the model separately. Conditionally 
independent decision trees for screening tests for GDM form a more robust decision tree 
in terms of diagnostic test evaluation. The four screening tests in this model (other than 
‘no screening’) include either a one step approach (the diagnostic test is performed 
without prior screening) or a two step approach (diagnostic test is performed to confirm 
a positive screening test) and a universal or selective approach, which together cover all 
the fundamental approaches of performing screening tests, which allows for 
generalisability.  
   Lastly, this study performed a decision analysis from a health care provider’s 
perspective, not a societal perspective, in order to inform policy makers in Scotland. This 
model excluded productivity costs or out-of-pocket direct costs incurred by the patient. 
Therefore, the perspective of the study (payer or societal) can limit generalisability. 
10.6 Future research 
Evidence in this thesis and from previous research has shown that screening tests for 
GDM are cost-effective. This is the first cost-effectiveness study that used Scottish 
screening test guidelines based on the UK population prevalence. However, further 
important research questions remain, as outlined below.  
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10.6.1 Expected value of sample information (EVSI)  
The population EVPI at a threshold value of £30,000/QALY was £124 million, indicating 
that commissioning further research is of extremely high value for long term 
complications. Having determined this and having used EVPPI to specify the most likely 
type of information and type of study that is potentially required. Long term adverse 
complication parameters are clearly what are driving uncertainty in the model and are 
leading to uncertainty in the cost-effectiveness decision. According to the EVPPI results, 
for particular research designs, an expected value of sample information (EVSI) analysis 
can be performed to assess the additional benefit that can be expected from increased 
sample size before a decision is made. The additional information that can be acquired 
from the sample can allow for more informed and in turn better decisions. EVSI can 
estimate what this expected improvement may be before sample data is examined, and 
therefore allows an evaluation of the costs involved of the additional research.  
10.6.2 Developing an economic evaluation of screening tests 
for type 2 DM after diagnosis of GDM 
Further research on the cost-effectiveness of type 2 DM after postpartum in women with 
GDM should be considered. Also, this future research could examine the optimum 
number of times that screening should be performed and the corresponding time frame 
for type 2 DM. One potentially important outcome for the detection of GDM is 
identification of mothers who are at high risk of subsequent type 2 DM or at high risk of 
GDM in subsequent pregnancies. In mothers with GDM, shortly after delivery, glucose 
homoeostasis is restored to non-pregnancy levels, but affected women remain at high 
risk of developing type 2 DM in the future. Screening tests and treatment after 
postpartum intervention are highly effective in reducing the incidence of type 2 DM. It is 
recommended that women who have had GDM have their glucose tolerance assessed 6 
weeks after delivery.  
   There are many guidelines that suggest postpartum follow up glucose tolerance 
tests for mothers with GDM (WHO, 1999a) (ACOG, 2000) (American Diabetes, 2004) 
(NICE, 2008d). Those guidelines suggest screening all postpartum mothers with GDM 
over different periods of time and with different screening test techniques. Postpartum 
screening for type 2 DM is a controversial issue in terms of the appropriate time and 
methods for screening (Bentley-Lewis et al., 2008) 
Chapter 10 272 
10.6.3 Long term study to investigate the potential link 
between GDM and offspring outcome  
The population EVPI at a threshold value of £30,000/QALY was £142 million, and 
therefore research that costs less than this value is potentially worthwhile. However, the 
EVPI for the individual parameters and sub-group parameters for long-term adverse 
complications, the EVPPI analyses show that there is zero value in undertaking further 
research. However, the EVPPI result from the group of long-term adverse complications 
parameters was £832,423 at the population level and suggests that further research 
would be of worthwhile potential. It was difficult to identify which individual parameters 
were driving uncertainties in the cost-effectiveness decision; therefore, the type of 
further research that would be required is likely to be a randomised trial. Such a trail 
should be long-term trial in nature in order to study type 2 DM among women with 
histories of GDM and offspring born to women with GDM. According to the VOI analysis, 
the EVPI and EVPPI provided information about whether it was worthwhile to conduct 
further research. It is clear that the parameter for long term complications is driving 
uncertainty in the model.  Given the result of the EVPPI, the type of further research that 
would be required is likely to be a trial to evaluate the development of type 2 DM in 
mothers with GDM and in offspring born to mothers with GDM. However, there were no 
studies in the review that looked into the effect of treatment in women with GDM and 
offspring born to mothers with GDM. Most studies looked at the short term effects of 
treating GDM compared to no treatment, such as the body mass index or obesity in 
adults. The emerging field of developmental origins of human disease suggests that 
glucose intolerance during pregnancy is associated with long-term outcomes such as 
type 2 DM, hypertension and obesity. 
   The application of VOI analysis is useful as it helps decision makers to make 
informed decision as to whether a new intervention should be (used) or reject based on 
current evidence.  . If funding were made available for further research in this area, a 
randomised controlled trial (RCT) would provide strong evidence as to whether long 
term complications in mothers with and without GDM develop type 2 DM. Therefore, 
long term study to investigate the potential link between GDM adult outcomes for the 
offspring of mothers with GDM is needed. However, long-term trials cost more in terms 
of money and time. An alternative study design such as retrospective data base analysis 
would be better to estimate long term complications.  
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10.7 Conclusion  
This thesis discussed and demonstrated the application of decision analytic modelling in 
healthcare. Both NDS and PDS have been included in this economic evaluation of 
screening tests for GDM in order to inform the clinician and policy maker. The 
combinations of the tests in NDS and PDS are alternative approaches in evaluating the 
economic assessments of diagnostic tests. Screening test strategies for GDM and 
screening tests for other diseases usually recommend NDS to screen and detect 
disease in individuals in the general population. The NDS and PDS approaches allow 
the clinician to consider test results in terms of the differences in FN and FP test results. 
Due to these errors in the tests there is a higher probability of FN outcomes in NDS and 
so patients with a true disease state do not receive treatment. In contrast, there is a 
higher probability of FP outcomes in PDS and so patients without disease receive 
treatment.  
   Three independent decision trees were constructed, including screening tests for 
GDM, short term complications and long term complications, which allows policy makers 
to focus on each part of the model separately. Economic modeling in this study shows 
that selective screening tests with 75g OGTT are cost-effective when compared to other 
strategies.  Selective screening generated more QALYs at a lower cost than other 
screening test strategies. This study also found that the cost effectiveness of screening 
tests for GDM to prevent short term complications is dependent on the probability of 
GDM being left undiagnosed based on strategy employed. Additionally, treatments 
during gestation are important as they reduce additional cost that may be required to 
treat serious adverse complications.  
In long term complications, screening tests for GDM that can detect all patients 
in the population or result in over-diagnosis are cost-effective. If mothers have received 
previous diagnoses of GDM, regular screening should be performed for type 2 DM so 
that it is discovered early on, before the onset of symptoms or the development of 
complications associated with type 2 DM. Screening for GDM and its subsequent 
treatment presents an important opportunity to reduce type 2 DM. The outcome of 
screening tests is dependent on the test’s sensitivity and specificity.   NDS and PDS 
allow the clinician to understand error in screening test results (FN, FP).  
     Modelling procedures, in which intermediate measures that have a connection to 
the assessments of diagnostic tests are converted into costs and long-term health 
benefits, are usually needed in order to calculate the cost-effectiveness of diagnostic 
testing. The VOI method makes meaningful recommendations to decision makers, who 
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can then make informed decisions as to whether a new intervention should be adopted 
or rejected based on current evidence, or whether further information is required to help 
make the decision, as opposed to making decisions on subjective reasoning. 
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Appendix I: Literature search strategy 
 
All concept of gestational diabetes mellitus (Chapter 4) 
1. exp Pregnancy/ 
2. exp Diabetes Mellitus, Type 1/ or exp Diabetes Mellitus, Lipoatrophic/ or exp Diabetes     
Mellitus, Type 2/ or exp Diabetes Mellitus/ 
3. 1 and 2 
4. exp Diabetes, Gestational/ 
5. mass screening/ 
6. (screen* or test* or detect* or (case adj2 find*)).mp. [mp=ti, ab, ot, nm, hw, kf, px, rx, 
ui, sh, tn, dm, mf, dv, kw] 
7. 5 or 6 
8. (pregnan* adj12 diabetes*).mp. [mp=ti, ab, ot, nm, hw, kf, px, rx, ui, sh, tn, dm, mf, dv, 
kw] 
9. 3 or 4 or 8 
10. 7 and 9 
11. (guideline$ or guidance).tw. 
12. (management and treatment).tw. 
13. 11 or 12 
14. 10 and 13 
15. Pregnancy Complications/ 
16. ((adverse or negative) adj3 outcome$).mp. [mp=ti, ab, ot, nm, hw, kf, px, rx, ui, sh, 
tn, dm, mf, dv, kw] 
17. 15 or 16 
18. 10 and 17 
19. ("true positive" or "false positive" or "false negative" or "true negative" or "predictive 
value$" or ROC or likelihood or evaluat$ or accura$ or "receiver operating 
characteristic").mp. [mp=ti, ab, ot, nm, hw, kf, px, rx, ui, sh, tn, dm, mf, dv, kw] 
20. ((sensitivity and specificity) adj3 ("glucose challenge test" or "fasting plasma 
glucose" or "random plasma glucose" or "glucose tolerance test$" or GCT or FPG or 
RPG or OGTT or "glucose screening test$")).tw. 
21. ("glucose challenge test" or "fasting plasma glucose" or "random plasma glucose" or 
"glucose tolerance test$" or GCT or FPG or RPG or OGTT or "glucose screening 
test$").tw. 
22. 19 and 20 and 21 
23. 10 and 22 
24. Quality of life/ 
25. ("qualtiy adjusted life years" or "disabiltiy adjusted life years" or QALY or QALYs or 
DALY or DALYs).mp. 
26. 24 or 25 
27. 10 and 26 
28. 14 or 18 or 23 or 27 
29. remove duplicates from 28 
 
 
Prevalence (Chapter 5) 
1. exp Pregnancy/ 
2. exp Diabetes Mellitus, Type 1/ or exp Diabetes Mellitus, Lipoatrophic/ or exp Diabetes 
Mellitus, Type 2/ or exp Diabetes Mellitus/ 
3. 1 and 2 
4. exp Diabetes, Gestational/ 
5. mass screening/ 
6. (screen* or test* or detect* or (case adj2 find*)).mp. [mp=ti, ab, ot, nm, hw, kf, px, rx, 
ui, sh, tn, dm, mf, dv, kw] 
7. 5 or 6 
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8. (pregnan* adj12 diabetes*).mp. [mp=ti, ab, ot, nm, hw, kf, px, rx, ui, sh, tn, dm, mf, dv, 
kw] 
9. 3 or 4 or 8 
10. 7 and 9 
11. exp Epidemiology/ 
12. epidemiolog*.mp. [mp=ti, ab, ot, nm, hw, kf, px, rx, ui, sh, tn, dm, mf, dv, kw] 
13. exp Prevalence/ 
14. prevalen*.mp. [mp=ti, ab, ot, nm, hw, kf, px, rx, ui, sh, tn, dm, mf, dv, kw] 
15. 11 or 12 or 13 or 14 
16. 9 and 15 
 
 
Economic evaluations of screening test for GDM (Chapter 6) 
MEDLINE (Ovid) (monthly search) 
 
1. economics/ 
2. exp "costs and cost analysis"/ 
3. Economics, Dental/ 
4. exp "economics, hospital"/ 
5. Economics, Medical/ 
6. Economics/ or Economics, Nursing/ 
7. Economics, Pharmaceutical/ or Economics/ 
8. (economic$ or cost or costs or costly or costing or price or prices or pricing 
orpharmacoeconomic$).ti,ab. 
9. (expenditure$ not energy).ti,ab. 
10. value for money.ti,ab. 
11. budget$.ti,ab. 
12. or/1-11 
13. ((energy or oxygen) adj cost).ti,ab. 
14. (metabolic adj cost).ti,ab. 
15. ((energy or oxygen) adj expenditure).ti,ab. 
16. or/13-15 
17. 12 not 16 
18. letter.pt. 
19. editorial.pt. 
20. historical article.pt. 
21. or/18-20 
22. 17 not 21 
23. Animals/ 
24. Humans/ 
25. 23 not (23 and 24) 
26. 22 not 25 
27. exp Pregnancy/ 
28. exp Diabetes Mellitus, Type 1/ or exp Diabetes Mellitus, Lipoatrophic/ or exp 
Diabetes Mellitus, Type 2/ or exp Diabetes Mellitus/ 
29. 27 and 28 
30. exp Diabetes, Gestational/ 
31. mass screening/ 
32. (screen* or test* or detect* or (case adj2 find*)).mp. [mp=ti, ab, ot, nm, hw, kf, px, rx, 
ui, sh, tn, dm, mf, dv, kw] 
33. 31 or 32 
34. (pregnan* adj12 diabetes*).mp. [mp=ti, ab, ot, nm, hw, kf, px, rx, ui, sh, tn, dm, mf, 
dv, kw] 
35. 29 or 30 or 34 
36. 33 and 35 
37. 26 and 36 
38. remove duplicates from 37 
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EMBASE (Ovid) (weekly search) 
 
1. health-economics/ 
2. exp economic-evaluation/ 
3. exp health-care-cost/ 
4. exp phamacoeconomics 
5. 1 or 2 or 3 or 4 
6. (economic$ or cost or costs or costly or costing or price or prices or pricing or 
pharmacoeconomic$).ti,ab 
7. (expenditure$ not energy).ti,ab 
8. (value adj2 money).ti,ab) 
9. budget$.ti,ab 
10. 6 or 7 or 8 or 9 
11. 5 or 10 
12. letter.pt. 
13. editorial.pt. 
14. note.pt 
15. 12 or 13 or 14 
16. 11 not 15 
17. (metabolic adj cost).ti,ab. 
18. ((energy or oxygen) adj cost).ti,ab. 
19. ((energy or oxygen) near expenditure).ti,ab. 
20. 17 or 18 or 19 
21. 16 not 20 
22. exp animals/ 
23. exp animal-experiment/ 
24. nonhuman/ 
25. (rat or rats or mouse or mice or hamster or hamsters or animal or animals or dog or 
dogs or cat or cats or bovine or sheep).ti,ab,sh 
26. 22 or 23 or 24 or 25 
27. exp human/ 
28. exp animal-experiment/ 
29. 27 or 28 
30. 26 not (26 and 29) 
31. 21 not 30 
32. exp Pregnancy/ 
33. exp Diabetes Mellitus, Type 1/ or exp Diabetes Mellitus, Lipoatrophic/ or exp 
Diabetes Mellitus, Type 2/ or exp Diabetes Mellitus/ 
34. 27 and 28 
35. exp Diabetes, Gestational/ 
36. mass screening/ 
37. (screen* or test* or detect* or (case adj2 find*)).mp. [mp=ti, ab, ot, nm, hw, kf, px, rx, 
ui, sh, tn, dm, mf, dv, kw] 
38. 31 or 32 
39. (pregnan* adj12 diabetes*).mp. [mp=ti, ab, ot, nm, hw, kf, px, rx, ui, sh, tn, dm, mf, 
dv, kw] 
40. 29 or 30 or 34 
41. 33 and 35 
42. 26 and 36 
43. remove duplicates from 42 
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Appendix II: Guideline of screening test for GDM and 
reference 
Organisation Year Diagnostic 
method 
Threshold  values (mmol/l) Type of 
screening 
Remark 
   0h 1h 2h 3h   
O’Sullivan-
Mahan(Carpent
er and 
Coustan, 1982) 
(O'Sullivan and 
Mahan, 1964) 
1964 100g OGTT ≥5.2 ≥9.9 ≥8.5 ≥7.7 Universal  
NDDG 
(National 
Diabetes Data 
Group, 1979) 
(Turok et al., 
2003) 
1979 50g GCT  ≥7.8   N/A Two or more value must be 
met 
  100g OGTT ≥5.8 ≥10.5 ≥9.2 ≥8.1  or exceeded 
C&C(Coustan 
and Carpenter, 
1998) 
1982 50g GCT  ≥7.8   Selective  Age > 24 years 
  100g OGTT ≥5.3 ≥10.0 ≥8.6 ≥7.8   
EADS(Lind and 
Phillips, 1991) 
1991 FPG ≥4.8    Universal  
  50g GCT  ≥8.2     
  75g OGTT ≥6.0  ≥9.0    
Thirst  1991 50g GCT  ≥7.8   Selective   
international   75g OGTT ≥5.3 ≥10.0 ≥8.6    
Workshop 
(Metzger and 
Coustan, 1998) 
 100g OGTT ≥5.3 ≥10.0 ≥8.6 ≥7.8   
Fourth  1998 50g GCT  ≥7.8   Selective  Screening test : optional,  
international   75g OGTT ≥5.3 ≥10.0 ≥8.6    2 step 50 /100 g or 1  
Workshop 
(Metzger et al., 
2007) 
 100g OGTT ≥5.3 ≥10.0 ≥8.6 ≥7.8  step 75g GCT Diagnostic test : 
75 g or 100g  
Two or more abnormal values 
ADA(Jovanovic
, 1998) 
(American 
Diabetes 
Association, 
1998) 
1998 50g GCT  ≥7.2   Selective  Obesity, > 25 years of age, 
  75g OGTT ≥5.3 ≥10.0 ≥8.6   Family history of 1st relative 
DM, Race(Hispanic ,Asian, 
  100g OGTT ≥5.3 ≥10.0 ≥8.6 ≥7.8  African, Pacific Islander)  
Two or  more abnormal values 
and One or two step approach 
WHO(WHO, 
1999a) 
1998 50g GCT  ≥7.8   Universal One-step approach to 
screening 
  75g OGTT ≥7.0  ≥7.8   and diagnosis, one or more 
criteria must be met or 
exceeded  and one step 
approach 
CDA(Metzger 
and Coustan, 
1998) 
1998 50g GCT  ≥7.8   Selective Or C&C conversion and  
  75g OGTT ≥5.3 ≥10.6 ≥8.9   two step approach 
ADIPS(Hoffma
n et al., 1998) 
1998 50g GCT  ≥7.8   Universal Universal unless low GDM  
  75g OGTT ≥5.5  ≥8.0 
≥9.0 
(Aus) 
(NZ) 
 Incidence or resources limited 
ACOG(Serlin 
and Lash, 
2009) 
2001 50g GCT  ≥7.8   Universal /  Test every one or in  
  75g OGTT ≥7.2  ≥7.8  selective  case of risk factors, history of 
  100g OGTT ≥5.3 ≥10.0 ≥8.6 ≥7.8  previous GDM 
SIGN(SIGN, 
2001) 
2001 RPG ≥5.5    Universal Urine for screening for every  
  FPG ≥5.5     visit 
  75g OGTT ≥7.0  ≥9.0    
CREST(Clinical 
Resource 
Efficiency 
Support Team, 
2001) 
2001 RPG ≥5.5    Universal Urine for screening for every  
  75g OGTT ≥6.0  ≥9.0   visit and 28 weeks gestation 
SOGC(Berger 
et al., 2002) 
2002 50 g GCT  ≥7.8   Universal Routine screening with 50 g  
  75g OGTT ≥5.3 ≥10.0 ≥8.6   GCT except in mother who 
fulfill 
  100g OGTT ≥5.3 ≥10.0 ≥8.6 ≥7.8  The criteria for low risk 
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HTA UK(Scott 
et al., 2002) 
2002 50g GCT  ≥7.8   Selective Very selective screening 
based on age, obesity and 
ethnic origin 
NICE(NICE, 
2008d) 
2008 FPG ≥7.0    Selective Women with on of risk factor  
  75g OGTT ≥7.0  ≥7.8   should be offer screening test 
IADPSG(Metzg
er et al., 2010a) 
2010 FPG ≥5.1 ≥10.0 ≥8.5  Universal  
  75g OGTT ≥7.0  ≥7.8    
Consensus(Mo
ses, 2010) 
2010 75g OGTT ≥7.0  ≥7.8  Universal   
SIGN(SIGN, 
2010) 
2010 FPG ≥5.1    Selective one or more value must  
  75g OGTT ≥10.0  ≥8.5   be met or exceeded 
Organisation (C&C) Indicated Carpenter and Constant, (NDDG) National Diabetes Data Group, (WHO) World Health 
Organisation, (ADIPS) The Australasian Diabetes in Pregnancy Society,(ADA) American Diabetes Association, (CDA)Canadian 
Diabetes Association, (ACOG) American College of Obstetricians and Gynecologists ,(EASD) European Association for the Study 
of Diabetes. (CREST) linical Resource Efficiency Support Team, (SIGN) The Scottish Intercollegiate Guidelines Network, (SOGC) 
The Society of Obstetricians and Gynaecologists of Canada (NICE) The National Institute for Health and Clinical Excellence 
,(IADPSG) International Association of Diabetes and Pregnancy Study Groups Consensus Panel,(Aus) Australia, (NZ) New 
Zealand : Tests (OGTT) Oral Glucose tolerance Test, (GCT) Glucose challenge test, ( FPG) Fasting Plasma Glucose, (RPG) 
Random Plasma Glucose : Threshold Now, if you want to convert mg/dl of glucose to mmol/l, you can divide the result in mg/dl 
by 18 or multiply by 0.055 but, if you want to convert mmol/l of glucose to mg/dl, just multiply by 18. 
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Appendix III: the methodological quality assessment  
 
Criteria for prevalence studies 
 External validity 
Source population 
(a) Does the method to select and invite participants result in a study population that covers the complete 
population or random sample? 
Description of eligibility criteria 
(b) Is the age range specified? 
(c) Are inclusion and exclusion criteria specified? 
Participants and nonresponders 
(d) Is the response rate > 70%, or is the information on nonresponders sufficient to make inference on the 
representativeness of the study population? 
Description of study period 
(e) Is the study period specified? 
Description of study population 
(f) Are important population characteristics specified? 
Internal validity 
Data collection 
(g) Are the data prospectively collected? 
Measurement instrument (questionnaire, interview, additional) 
(h) Is the strategy of screening test validated? 
(i) Is the period covered by the measurement instrument specified? 
Definition of disease 
(j) Is a definition of the disease stated? 
Reported prevalence 
(k) Are age-specific and high risks specific prevalence reported? 
(l) Are possible correlates of disease reported? 
Informativity 
(m) Is the method of data collection properly described? 
(n) Are the questions and answer possibilities stated? 
(o) Are the reported prevalence rates reproducible? 
Based on quality assessment list of systematic review of prevalence (Bishop et al., 2010) (Prins et al., 
2002).  
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Criteria for decision analytic models 
Dimension of quality Questions for criteria appraisal 
Structure  
S1 Statement of decision 
problem 
Is there a clear statement of the decision problem? 
  Is the objective of the evaluation and model specified and 
consistent with the stated decision problem? 
  Is the primary decision maker specified?  
S2 Statement of 
scope/perspective 
Is the perspective of the model stated clearly? 
  Are the model inputs consistent with the stated perspective? 
  Are the outcomes of the model consistent with the perspective, 
scope and overall objective of the model? 
S3 Rationale for structure  Is the structural of the model consistent with a coherent theory of 
the health condition under evaluation? 
  Are the sources of data used to develop the structure of the model 
specified? 
  Are the causal relationships described by the model structure 
justified appropriately? 
S4 Structural assumptions Are the structural assumptions transparent and justified? 
  Are the structural assumptions reasonable given the overall 
objective, perspective and scope of the model? 
S5 Strategies/comparators Is there a clear definition of the option under evaluation? 
  Have all feasible and practical options been evaluated?  
  Is there justification for the exclusion of feasible options? 
S6 Model type Is the chosen model type appropriate given the decision problem 
and specified causal relationship within the model? 
S7 Time Horizon Is the time horizon of the model sufficient to reflect all important 
difference between options? 
  Is the time horizon of the model, the duration of treatment and the 
duration of treatment effect describe and justified? 
S8 Disease states/ pathways Do the disease states (state transition model) or the pathways 
(decision tree model) reflect the underlying biological process of 
the disease in question and the impact of the intervention? 
S9 Cycle length Is the cycle length defined and justified in terms of the natural 
history of disease? 
Data  
D1 Data identification Are the data identification methods transparent and appropriated 
given the objective of the model? 
  Where choices have been made between data sources, are these 
justified appropriately? 
  Has the quality of the data been assessed appropriately?  
  Where expert opinion has been used, are the methods described 
and justified? 
D2 Data modelling  Is the data modelling methodology based on justifiable statistical 
and epidemiological techniques? 
 
Dimension of quality Questions for criteria appraisal 
D2a Baseline data Is the choice of baseline data described and justified? 
  Are transition probabilities calculated appropriately? 
  Has half-cycle correction been applied to both cost and outcome? 
  If not, has this omission been justified? 
D2b Treatment effects If relative treatment effects have been derived from trial data, have 
they been synthesised using appropriate techniques? 
  Have the methods and assumptions used to extrapolate short-term 
results to final outcomes been documented and justified? 
  Have assumptions regarding the continuing effect of treatment 
once treatment is complete been documented and justified? 
  Have alternative assumptions regarding the continuing effect of 
treatment been explored through sensitivity analysis? 
D2c Costs Are the costs incorporated into the model justified?  
  Has the source for all costs been described? 
  Have discount rates been described and justified given the target 
decision maker? 
D2d Quality of life weights 
(utilities) 
Are the utilities incorporated into the model appropriate? 
  Is the source for the utility weights referenced? 
  Are the methods of derivation for the utility weights justified? 
 283 
D3 Data incorporation Have all data incorporated into the model been described and 
referenced in sufficient detail? 
  Has the use of mutually inconsistent data been justified? 
  Is the process of data incorporation transparent? 
  If data have been incorporated as distributions, has the choice of 
distribution for each parameter been described and justified? 
  If data have been incorporated as distributions, is it clear that 
second order uncertainty is reflected? 
D4 Assessment of uncertainty Have the four principle types of uncertainty been justified? 
  If not, has the omission of particular forms of uncertainty been 
justified? 
D4a Methodological Have methodological uncertainties been addressed by running 
alternative versions of the model with different methodological 
assumptions? 
D4b Structural Is there evidence that structural uncertainties have been addressed 
via sensitivity analysis?  
D4c Heterogeneity Has heterogeneity been dealt with by running the model separately 
for different subgroups? 
D4d Parameters Are the methods of assessment of parameter uncertainty 
appropriated? 
  If data are incorporated as point estimates, are the ranges used for 
sensitivity analysis stated clearly and justified? 
 
Dimension of quality Questions for criteria appraisal 
C1 Internal consistency Is there evidence that the mathematical logic of the model has 
been tested thoroughly before use? 
C2 External consistency Are any counterintuitive results from the model explained and 
justified? 
  If the model has been calibrated against independent data, have 
any differences been explained and justified? 
  Have the results of the model been compared with those previous 
models and any differences in results explained? 
Questions may be answered with “yes”, “no” or “non-applicable” Based on quality assessment (Philips et al., 
2006) 
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Appendix IV: PIRSMA checklist of items to include when 
reporting a systematic review   
 
Criteria of items to include when reporting a systematic 
review 
Section/topic  Check list item 
TITLE   
Title 1 Identify the report as a systematic review, meta-analysis, or both 
ABSTRACT   
Structured summary 2 Provide a structure summary including , as applicable;  background; objective; 
data sources; study eligibility criteria, participants and interventions; study 
appraisal and synthesis methods; results; limitations; conclusions and 
implications of key findings, systematic review registration number.   
INTRODUCTION   
Rational 3 Describe the rational for the review in the context of what is already known. 
Objective 4 Provide an explicit statement of questions being addressed with reference to 
participants, interventions, comparisons, outcomes, and study design (PICOS) 
METHODS   
Protocol and registration 5 Indicate of a review protocol exists, if and where it can be accessed ( e.g., Web 
address), and , if available, provide registration information including 
registration number.  
Eligibility sources 6 Specify study characteristic (e.g., PICOS, length of follow-up) and report 
characteristic (e.g., years considered, language, publication status) used as 
criteria for eligibility, giving rationale. 
Information sources 7 Describe all information sources (e.g., databases with date of coverage, 
contact with study authors to indentify additional studies), in the search and 
date last searched.  
Search 8 Present full electronic search strategy for at least one databases, including any 
limits used, such that it could be reported. 
Study selection 9 State the process for selection studies (i.g., screening, eligibility, included in 
systematic review, and if applicable, included in the meta-analysis). 
Data collection and process 10  Describe method of data extraction from reports (e.g., piloted forms, 
independently, in supplicate) and any processes for obtaining and confirming 
data from investigators 
Data items 11 List and define all variables for which data were sought (e.g., PICOS, funding 
sources) and any assumptions and simplifications made. 
Risk of bias in individual 
studies 
12 Describe methods used for assessing risk of bias of individual studies 
(including specification of whether this was done at the study or outcome 
level), and how this information is to be used in any data synthesis. 
Summary measures 13 State the principle summary measures (e.g., risk ratio, difference in means) 
Synthesis of the results 14 Describe the methods of handing data and combining results of studies, if 
done, including measures of consistency (e.g.,I2) for each meta-analysis. 
Risk of bias across studies 15 Specify any assessment of risk of bias that may affect the cumulative evidence 
(e.g., publications bias, selective reporting with studies). 
Additional analysis 16 Describe methods of additional analyses (e.g., sensitivity or subgroup 
analyses, meta –regression), if done, indicating which were pre-specified. 
RESULTS   
Study selection 17 Give numbers of studies screened, assessed for eligibility, and including in the 
review, with reasons for exclusions at each stage, ideally with a flow diagram. 
Study characteristics 18 For each study, present characteristic for which data were extracted (e.g., 
study size, PICOS, follow-up, period) and provide the citations. 
Risk of bias with in studies 19 Present data on risk of bias of each study and , if available, any outcome-level 
assessment (see item 12) 
Results of individual studies 20 For all outcomes considered (benefits or harms), present, for each study: (a) 
simple summary data for each intervention group and (b) effect estimates and 
confidence intervals, ideally with a forest plot. 
Synthesis of results 21 Present results of each meta-analysis done, including confidence intervals and 
measures of consistency. 
Risk of bias across studies 22 Present results of any assessment of risk of bias across studies (see item 15). 
Additional analysis 23 Give results of additional analyses, if done (e.g., sensitivity or subgroup 
analyse, meta-regression (see item 160). 
DISCUSSION   
Summary of evidence 24 Summarise the main findings including the strength of evidence for each main 
outcome; consider their relevance to key groups (e.g., health care providers, 
users, and policy makers). 
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Limitations 25 Discuss limitations at study and outcome level (e.g., incomplete retrieval of 
identified research, reporting bias). 
 26 Provide a general interpretation of the context of other evidence, and 
implications for future research. 
FUNDING   
Funding 27 Describe sources of funding for the systematic review and other support 9e.g., 
supply of data); role of funders for the systematic review. 
Based on The PRISMA Statement for reporting systematic reviews and meta-analyses of studies the 
evaluated health care intervention: explanation and elaboration (Liberati et al., 2009) 
 
 
 
 
Section/topic # Prevalence of GDM: Systematic  
review 
Cost analysis and cost-
effectiveness analysis: 
Systematic review 
  Sec Page  Sec Page  
TITLE        
Title 1 - - - - -  
ABSTRACT        
Structured summary 2 - - - - -  
INTRODUCTION        
Rational 3 5.1 106  6.1 124  
Objective 4 5.1 106 Para 
3
rd
 
6.1 124 Para 
1
st
 
METHODS        
Protocol and registration 5 -   -   
Eligibility sources 6 5.2.2 107  6.2.2 125  
Information sources 7 5.2.1 107  6.2.1 125  
Search 8 App I 272  App I 272  
Study selection 9 5.3  Figure 5.1 110  6.3 127  
Data collection and process 10  5.2.3 108  6.2.3 126  
Data items 11 Table 5.5 122  Table 6.4 
Table 6.6 
134, 
141 
 
Risk of bias in individual studies 12 5.2.5 109  6.2.5 127  
Summary measures 13 5.2.5 109  6.2.5 127  
Synthesis of the results 14 5.2.5 109  6.2.5 127  
Risk of bias across studies 15 5.2.5 109  6.2.5 127  
Additional analysis 16 -   -   
RESULTS        
Study selection 17 5.3 110  6.3 127  
Study characteristics 18 5.5 111  6.5,6.6 131, 
141 
 
Risk of bias with in studies 19 5.4 111  6.4 129  
Results of individual studies 20 Table 5.4, 5.5 
Figure 5.2,5.3, 
5.4 
113,122, 
114,115, 
116 
 Table 6.4 
Table 6.6 
134, 
141 
 
Synthesis of results 21 5.5 111  6.5,6.6 131, 
135 
 
Risk of bias across studies 22 -   -   
Additional analysis 23 -   -   
DISCUSSION        
Summary of evidence 24 5.6 116  6.7 143  
Limitations 25 5.6.4 120  6.7.4 149  
Conclusions 26 5.7 121  6.8 149  
FUNDING        
Funding 27 - - - - - - 
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Appendix V: Economic modelling of screening test for 
GDM (Chapter 6) 
 
NICE (2008) 
 
Figure 1 NICE basic decision tree model 
 
Round et al., (2011) 
 
Figure 2 Round et al basic decision tree model 
 
False +ve Diet/treat Metformin Hospitalisation Birth outcomes
No GDM Hypoglycaemia
True -ve Diet fail insulin No hospitalisation
No hypoglycaemia
glibenclamide
Screen/ DX
and treat Jaundice
Nerve palsy
True +ve Diet Bone fracture
induction Shoulder dystocia
GDM Neonatal death
Pregnant woman False -ve Healty life birth
Diet Still birth
No screen
No induction
False +ve  (+) SPC
No GDM Hospitalisation
True -ve No SPC
Screen Hypoglycaemia SPC
False -ve Outpatient treatment
GDM Diet 'fail' Insulin No SPC No SPC
True +ve Treat(diet)
SPC Hypoglycaemia
Pregnant woman Diet Control No SPC
NO GDM No SPC
No screen SPC
GDM
No SPC
SPC= Serious perinatal complication
[+] sub-tree callapsed but identical to treat-diet
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Lohse et al., (2011) 
 
Figure 3 Lohse et al., basic decision tree model 
 
Werner et al., (2012) 
 
Figure 4 Werner et al., basic decision tree model 
 
T2DM in child
T2DM in mother
Intervention
No perinatal AE death-baby No T2DM in child
No perinatal AE death-mother No T2DM in mother
Intervention No intervention
True+ Perinatal AE death-baby
GDM Perinatal AE death-mother
Pregnant OGCT False- No intervention
w omen OGTT
True+
No GDM
False -
AE=Adverse events
True +ve
GDM
IADPSG FPG True +ve T2DM in mother
False -ve Postpartum intervention
75 g OGTT Moternal/neonatal AC
False -ve Intervention No T2DM in mother
No GDM True +ve No intervention
No mothernal/neonatal AC
True +ve 100g OGTT
False -ve
Pregnant no  Current GDM 50 g OGTT
GDM/DM screening False -ve
No GDM
No screening 
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Mission et al.,(2012) 
 
Figure 5 Mission et al., basic decision tree model 
 
Marseille et al.,(2013) 
This study was developed to assess the cost and health impact and cost-effectiveness 
of screening tests for GDM based on Lohse and colleagues 2011 model (Lohse et al., 
2011). The same settings (India and Israel) and the decision tree model from Lohse’s 
study were used, as showed in Figure 3.  
Stillbirth
Untreated Permanent
No GDM for GDM Brachial plexus
by 1h GCT Group 2 Transient NICU admit
3h OGCT Maternal death Hypoglycemia
1h GCT Group 3 NICU admit
Pregnant Group 1 Hyperbilirubinemia
Treated No macrosomia Cesarean Stillbirth
w omen No GDM for GDM Preeclampsia No complication
by 1h GCT Group 2 No Brachial plexus injury
3h OGCT Macrosomia Maternal death
Group 3 No preeclampsia Shoulder Dystocia Hypoglycemia
2h OGTT Group 1 Veginal delivery
No Hyperbilirubinemia
No
No complication
Group1: diagnosis by the 1hGCT, Group2: diagnosis by the 2h OGTT, Group3: Normal glycemic level
AE=Adverse events
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Appendix VI: CHEERS checklist 
Consolidated Health Economic Evaluation Reporting Standards (CHEERS) 
checklist – Items to include when reporting economic evaluation of health 
interventions 
Section/Item Item 
no 
Recommendation Reported 
on page 
no. /line 
no 
Title and abstract    
 Title 1 Indentify the study as an economic evaluation, or use more specific 
terms such as “cost-effectiveness analysis and describe the intervention 
compared 
 
 Abstract 2 Provide a structured summary of objective, perspective, setting, methods 
(including study design and inputs), results (including base-case and 
uncertainty analyses) and conclusions. 
 
Introduction    
 Background and objective 3 Provide an explicit statement of the broader context for the study. 
Present the study question and its relevance for health policy or practice 
decisions.   
 
Methods    
 Target population and 
subgroups 
4 Describe characteristics of the base-case population and subgroups 
analysed including why they were chosen. 
 
 Setting and location 5 State relevant aspects of the system(s) in which the decision(s) need(s) 
to be made. 
 
 Study perspective 6 Describe the perspective of the study and related this to the cost being 
evaluated. 
 
 Comparators 7 Describe the interventions or strategies being compared and state why 
they were chosen. 
 
 Time horizon 9 State the time horizons(s) over which costs and consequences are being 
evaluated and say why appropriate. 
 
 Discount rate 9 Report the choice of discount rate(s) used for costs and outcomes and 
say why appropriate. 
 
 Choice of health outcomes 10 Describe what outcomes were used as the measure(s) of benefit in the 
evaluation and their relevance for the type of analysis performed. 
 
 Measurement of effectiveness 11a Single study-based estimates: Describe fully the design features of the 
single effectiveness study and why the single study was a sufficient 
source of clinical effectiveness data. 
 
  11b Synthesis-based estimates: Describe fully the methods used for the 
identification of included studies and synthesis of clinical effeteness data. 
 
 Measurement and valuation of 
preference based outcomes 
12 If applicable, describe the population and methods used to elicit 
preference for outcomes. 
 
 Estimating resources and 
costs 
13a Single study-based evaluation: Describe approaches used to estimate 
resource use associated with the alternative interventions. Describe 
primary or secondary research methods for valuing each resources item 
in terms of its unit cost. Describe any adjustments made to approximate 
to opportunity costs. 
 
  13b Model-based economic evaluation: Describe approaches and data 
sources used to estimate resource use associated with model health 
states. Describe primary or secondary research methods for valuing 
each resource item in terms of its unit cost. Describe and adjustments 
made to approximate to opportunity costs.  
 
 Currency, price date, and 
conversion 
14 Report the dates of the estimated resources quantities and unit costs. 
Describe methods for adjusting estimated unit costs to the year of 
reported costs if necessary. Describe methods for converting costs into a 
common currency base and the exchange rate. 
 
 Choice of model 15 Describe and give reasons for the type of decision-analytic model used. 
Providing a figure to show model structure is strongly recommended.   
 
 Assumptions 16 Describe all structure or other assumptions underpinning the decision-
analytic model. 
 
 Analytic methods 17 Describe all analytic methods supporting the evaluation, This could 
included methods for dealing with skewed, missing or censored data; 
extrapolation methods; methods for polling data; approaches to validate 
or make adjustments (e.g., half-cycle correction) to a model; and 
methods for handing population heterogeneity and uncertainty. 
 
Results    
 Study parameters 18 Report the value, range reference, and if used, probability distributions 
for all parameters. Report reasons or sources for distributions used to 
represent uncertainty where appropriate. Providing a table to show the 
input values in strongly recommended. 
 
 Incremental costs and 
outcomes 
19 For each intervention, report mean values for the main categories of 
estimated cost and outcomes of interest, as well as mean difference 
between the comparator groups. If applicable, report incremental cost-
effectiveness ratios.  
 
 Characterizing uncertainty  20a Single study-based evaluation: Describe the effects of  sampling 
uncertainty for estimated incremental cost, incremental effectiveness, 
and incremental cost-effectiveness, together with the impact of 
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methodological assumptions (such as discount rate, study perspective) 
  20b Model-based economic evaluation: Describe the effects on the results of  
uncertainty for all input parameters, and uncertainty related to the 
structure of the model and assumptions 
 
 Characterizing heterogeneity 21 If applicable, report differences in costs, outcome, or cost-effectiveness 
that can be explained by variations between subgroup of patients with 
different based line characteristics or other observed variability in effects 
that are not reducible by more information. 
 
Discussion    
 Study findings, Limitations, 
generalisability, and current 
knowledge 
22 Summarise key study findings and describe how  they support the 
conclusions reached. Discuss limitations and the generalisability of the 
finding and how the findings fit with current knowledge 
 
Other    
 Source of funding 23 Describe how the study was funded and the role of the funder in the 
identification, design, conduct, and reporting of the analysis. Describe 
other nonmonetary sources of support. 
 
 Conflicts of interest 24 Describe any potential for conflict of interest among study contributors in 
accordance with journal policy. In the absence of a journal policy, we 
recommend authors comply with International Committee of Medical 
Journal Editors’ recommendations. 
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Section/Item Item 
no 
Case identification Short term 
complications 
Long term complicaitons 
  Reported on Reported on Reported on 
Title and abstract  Sec Page Sec Page Sec Page 
 Title 1       
 Abstract 2       
Introduction        
 Background and objective 3 7.3 152 7.3 152 7.3 152 
Methods        
 Target population and 
subgroups 
4 7.3.2 153 7.3.2 153 7.3.2 153 
 Setting and location 5       
 Study perspective 6 7.3.1 153 7.3.1 153 7.3.1 153 
 Comparators 7 7.3.2 153 7.3.2 153 7.3.2 153 
 Time horizon 9 -  8.3 189 8.4 217 
 Discount rate 9 -  8.3 189 8.4 217 
 Choice of health outcomes 10   8.3.5 200 8.6 225 
 Measurement of 
effectiveness 
11b 7.5.1 163 8.3.5 200 8.6 225 
 Measurement and 
valuation of preference 
based outcomes 
12 -  8.3.5 200 8.6 225 
 Estimating resources and 
costs 
13b 7.5.2 169 8.3.4 198 8.5 223 
 Currency, price date, and 
conversion 
14 7.5.2 169 7.5.2  169 7.5.2 169 
 Choice of model 15 7.4 157 8.3.1, 
8.3.2 
190, 192 8.4.1, 
8.4.2 
218, 219 
 Assumptions 16 7.5.2 169 8.3.5 200 8.4.3, 8.7 220, 226 
 Analytic methods 17 7.6 171 8.3.8 213 8.7.3, 
8.7.4 
230, 231 
Results        
 Study parameters 18 7.5.1 136 8.3.3 193 8.4.3 220 
 Incremental costs and 
outcomes 
19 7.7.3 178 9.2.1 233 9.2.2 236 
 Characterizing uncertainty  20b 7.7.4, 
7.7.5 
180,   
180 
9.3.1 240 9.3.2 240 
 Characterizing 
heterogeneity 
21 -  -  -  
Discussion        
 Study findings 22 7.8 182 9.4.1 241 9.4.2 242 
 Current knowledge 22 7.8 182 9.6.1 251 9.6.2 253 
 Limitations  22 10.4 265 10.4 265 10.4 265 
 Generalisability 22 10.5 266 10.5 266 10.5 266 
Other        
 Source of funding 23 - - - - - - 
 Conflicts of interest 24 - - - - - - 
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